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Abstract 
INTRODUCTION: First, the region of interest (ROI) studies identified diffuse as well as 
circumscribed structural brain alterations in schizophrenia. However, ROI method has a 
number of limitations that are surpassed by a recent development in automatic structural 
image processing, voxel-based morphometry (VBM). The main advantage of VBM is that it 
allows identification of structural alterations throughout the entire brain. Second, structural 
alterations in schizophrenia have been found to be associated with cognitive deficits by ROI 
studies. Moreover, ROI studies noted differences in structure/neurocognition relationship 
between schizophrenia patients and normal controls. However, there was no previous 
investigation of the association between VBM identified alterations and cognitive deficits 
using a comprehensive neuropsychological assessment, and no formal testing of the possible 
alteration in structure/function relationship in schizophrenia. Third, cognitive deficits are 
gaining priority as a target for treatment, since they are better predictors of functional 
outcome than symptomatology. Novel or atypical antipsychotics have greater efficacy over 
conventional antipsychotics in improving cognitive functioning in schizophrenia. The 
structural predictors of atypical antipsychotic drug response in terms of cognitive 
functioning, however, were not previously investigated. AIMS: The thesis aims were: i) to 
identify the pattern of structural alterations in schizophrenia patients (n = 47) relative to 
normal controls (n = 45), utilising VBM technique (Study 1); ii) to characterise the pattern 
of cognitive deficits in the present cohort (Study 2); iii) to investigate the 
structure/neurocognition relationships in patients, contrasting them with those of controls 
(Study 3); and iv) to explore the predictive value of structural alterations to the 6-week 
treatment response with atypical antipsychotics as assessed with neurocognitive measures 
(Study 4). RESULTS: The patients showed a significant reduction in global grey-, white-, and 
total brain volumes, as well as localised alterations specific to the left hemisphere, including 
grey matter reductions in the inferior frontal gyrus (IFG), superior temporal gyrus and 
lingual gyrus, white matter reductions in the posterior and occipital lobes, and grey matter 
increases in the putamen and the precuneus (Study 1). Cognitive deficits were observed on 
all measures, with the most pronounced deficits in the domains requiring verbal function, 
including verbal memory and learning, verbal fluency, and verbal working memory (Study 
2). Reduction in global brain tissue was associated with the lower general intellectual ability 
and cognitive deficits that were found to be dependent on IQ, whereas local structural 
alterations were associated with specific cognitive deficits in schizophrenia patients (Study 
3). The structure/neurocognition relationships that dissociated patients and controls most 
clearly were between verbal memory and larger IFG volume in controls but larger volume of 
the precuneus in patients. Larger precuneus in patients was also associated with more 
recurrent form of the illness (Study 1). Further, verbal memory and learning, verbal working 
memory and dexterity showed clear improvement after 6 weeks of treatment with atypical 
antipsychotics, which could not be attributed to the practice effect (Study 4). Greater 
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improvement in verbal memory and learning was predicted by smaller volume of the IFG 
and precuneus (Study 4). CONCLUSIONS: The present cohort of schizophrenia patients is 
characterised by the structural alterations specific to the language dominant hemisphere and 
the corresponding differential cognitive deficits of language dependent functions. The 
pattern of structure/neurocognition associations implicates a greater significance of a 
posterior brain area, the precuneus, in memory function in patients, which might be related 
to the pathogenesis and the course of schizophrenia. Furthermore, poorer memory at the 
baseline and an improvement in immediate verbal memory following the atypical 
antipsychotic treatment in patients with 'normal' precuneus suggests that the increased 
precuneus might play a compensatory role in memory function. Overall, the findings 
highlight the emerging role of the precuneus in the course, cognitive functioning, and 
treatment response in schizophrenia and press the need for further studies with concurrent 
use of multiple structural and functional MRI techniques to obtain a better understanding of 
brain structure-function relationships in this population. 
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MRI-BASED VOLUMETRICS AND SCHIZOPHRENIA 
Magnetic Resonance Imaging (MRI)-based brain volumetrics is an established 
domain of brain science, which has been applied to understanding developmental 
changes in the brain (e. g. Giedd et al., 1996; Caviness et al., 1996; Huppi et al., 
1998), recognition of neurodegenerative diseases (e. g. Jernigan et al., 1991; 
Aylward et al., 1994; Mori et al., 1997), and has substantially contributed to the 
search for structural correlates of disorders with uncertain pathogenesis, such as 
schizophrenia (e. g. Andreasen et al., 1986; Suddath et al., 1989; Wilke et al., 
2001). 
The theoretical foundation underlying the proposition that brain volumetrics is 
usefully pursued as a science is based on both theoretical and observational thesis 
that volume is an evolutionarily and developmentally regulated fundamental 
property of brain tissue and its structures (e. g. Armstrong, 1983; Ringo, 1991). 
The volume of a neural structure is the direct reflection of its size, shape, as well as 
the pattern of arrangement and densities of its cellular components (Caviness et 
al., 1999). Consequently and plausibly, the volume is thought to relate in some 
regular way to the information processing capacity of the structure. The optimum 
information processing capacity of the structural component will relate in some 
regular way to its volume relative to that of other brain components of the 
distributed neural system. From the evolutionary perspective, the volume of the 
brain and its components will reflect its optimisation within the framework of 
constraints imposed by body anatomy and physiology (Gerhart and Kirschner, 
1997). From the ontogenetic perspective, the volume of the brain and its 
components will be relatively uniform among individuals of species, reflecting the 
constraints of cell and molecular biological processes, dominated by cell internal 
controls and modulated by cell external mechanisms (Caviness et al., 1999). In the 
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neuropathological conditions, such as schizophrenia, the neurodevelopmental 
and/or neurodegenerative processes affecting the cells will reflect on the volume of 
the brain and its structures. Therefore, the MRI-volumetric study of schizophrenia 
is based on the notion that the structural volume is in some way related to the 
tissue integrity, which in turn is related in some regular way to its information 
processing capacity. By this token, the volume of the brain and its structural 
components will relate to the individual's cognitive ability. Atypical (novel) 
antipsychotic drugs are known to produce improvement in cognitive functioning in 
schizophrenia (Meltzer and McGurk, 1999). However, it is presently unclear 
whether the 'baseline' brain volume and the volume of its structural components 
are related to the responsitivity to antipsychotic treatment in terms of cognitive 
improvement. 
The present investigation poses the questions: "How is the volume disturbed in 
schizophrenia? "; "What is the relationship of volumetric alterations to cognitive 
deficits in schizophrenia? "; and "Does the extent of volumetric alteration relate to 
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CHAPTER 1. SCHIZOPHRENIA: GENERAL INTRODUCTION 
The aim of this chapter is to provide a general introduction to the concept of 
schizophrenia: its origin; its evolution; a debate that the concept provoked since its 
first formulation; operational criteria for schizophrenia diagnosis and other 
classificatory approaches; epidemiology; and aetiology of the disorder. The 
objective is to acknowledge, but not to discuss in depth, the main issues 
surrounding the concept of schizophrenia, as well as to introduce the terms and 
definitions that are used throughout the thesis. 
1.1. The origin of the concept 
Before the 1 gth century, there was little differentiation between the kinds of 
insanity. German psychiatrist Emil Kraepelin (1856-1926) advanced the first 
classificatory system for severe psychological disorders. One of the disorders he 
described in his Psychiatrie in 1896 was dementia praecox, borrowing the term 
from Morel (dementia precoce - dementia of early life) (Colp, 1995). Kraepelin 
used the term to refer to different processes that were unified by the fact that they 
all involved disturbances in thought and behaviour, but in different ways. Thus, he 
described four sub-types: 
i) simple, marked by slow social decline, social withdrawal and apathy; 
ii) paranoid, distinguished by persecutory delusions and fear; 
iii) hebephrenic, characterised by emotional disturbances inappropriate to 
context; 
iv) catatonic, notable by the increased muscle tone, preservation of posture 
and expression. 
In fact, these four types of mental and behavioural disturbances were described as 
different `disorders' by other psychiatrists before Kraepelin. Falvet in 1851 
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described Folie circulaire or cyclic madness, corresponding to simple sub-type of 
Kraepelin. Hecker in 1871 coined the term Hebephrenia or a silly, undisciplined 
mind after Hebe, goddess of youth and frivolity. Kalbaum in 1874 described 
Catatonia and Paranoia. Thus, Kraepelin, whether auspiciously or misfortunately, 
pulled these various concepts under the single disease entity. By doing so 
Kraepelin, inadvertently, initiated a debate, which continued through the 1st 
century of schizophrenia and into this century, regarding the core symptoms of the 
disorder, its boundaries, its different subtypes and their aetiologies, its course and 
outcome, and so on. 
As reflected by the chosen term, Kraepelin defined dementia praecox as 
characterised by a sudden onset of symptoms early in adulthood and followed by a 
progressive deterioration, or dementia. In addition to a sudden symptom onset, 
Kraepelin held that there was "... a group of patients in whom already from 
childhood upwards a considerable degree of psychic weakness existed" (cited in 
O'Connell et al., 1997). The core features of dementia praecox in Kraepelin's 
definition included i) affective disturbances, such as emotional responses that are 
inappropriate to the context; ii) avolition; iii) anhedonia; iv) stereotyped motor 
behaviour; v) attentional impairment, vi) sensory experiences in the absence of 
appropriate stimuli, i. e. hallucinations; and vii) beliefs sustained in spite of 
overwhelming contrary evidence, i. e. delusions. As reflected by sub-typing, these 
symptoms are not present in all individuals with the `disease'. 
Swiss psychiatrist Eugene Bleuler in 1908 disputed the term 'dementia praecox' on 
the grounds that progressive deterioration of function was not present in all cases, 
and the complete or partial recovery was evident in at least a third of the 
individuals. He coined an alternative term Schizophrenia, derived from Greek 
'schizo' for split and 'phreno' for mind. Bleuler's choice of the term reflects his 
conceptualisation on the nature of schizophrenia as a splitting of thought and 
emotion, leading to the loosening of the associations. This, in turn, results in 
disintegration of the normal experience of reality, both external and internal. 
Bleuler identified four fundamental symptoms of schizophrenia, four'A's: 
i) blunted Affect (diminished emotional response to stimuli); 
ii) loosening of Associations (disturbed patterns of cognition); 
iii) Ambivalence (inability to make decisions, presumably due to a deficit in the 
integration and processing of information relevant to the context); 
iv) Autism (withdrawal into oneself). 
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Bleuler regarded hallucinations and delusions as 'accessory' symptoms, resulting 
from the more fundamental disintegration of higher cognitive faculties (Andreasen, 
1997). 
Overall, Kraepelin and Bleuler agreed on the set of symptoms that define 
schizophrenia. However, unlike Kraepelin, Bleuler did not hold early onset and 
progressive deterioration to be the only course of the disorder. He recognised that 
the disorder was chronic in some cases, but he also asserted that the recovery was 
possible. Despite these differences, both Kraepelin and Bleuler believed that 
schizophrenia was a brain disease. These two pioneering scientists initiated the 
search for a biological basis of schizophrenia. 
At around the same time, Adolf Meyer (1866-1950), a brain pathologist, took a 
completely different approach to understanding the origins of schizophrenia. In 
Meyer's view, there were no fundamental differences between individuals with 
schizophrenia and normal people in either biological or psychological make up. 
Instead, he maintained that schizophrenia was a product of abnormal early 
learning, leading to the acquisition of maladaptive habits or "adjustive 
insufficiency". 
Thus, even at the genesis of schizophrenia as a clinical entity, two opposing (or 
complementary) approaches co-existed in clinical practice and scientific research. 
While Bleuler and Kraepelin founded a biological tradition in schizophrenia 
research, Meyer gave an impetus to a tradition that focuses on learning and social 
processes as being central to understanding cognitive and behavioural 
disorganisation associated with schizophrenia. 
Although the subject of the present investigation is conceptually embedded within 
the biomedical tradition of schizophrenia research, the author acknowledges the 
importance of environmental and societal factors in shaping schizophrenia 
phenotype. 
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1.2. Controversy surrounding the concept of schizophrenia 
There has not been a moment in the history of schizophrenia when its nature and 
even its existence have not been disputed. Some of the issues that have been 
debated in the course of the 2 0th century include: 
i) Does schizophrenia exist? 
ii) Is schizophrenia separate from or coexistent with affective psychosis? 
iii) Is schizophrenia a 'disease entity' as originally conceived by Kraepelin 
and Bleuler? 
iv) What are the boundaries of schizophrenia? 
i) The first issue is primarily of philosophical and ethical character, as it mainly 
questions the value of schizophrenia diagnosis and the meaning of the words 
'normality' and 'disease', rather than the existence of the schizophrenic phenomena 
per se. Proponents of this movement, which have risen in the 1960s and 1970s, 
posited important ethical questions and expressed general dissatisfaction towards 
the orthodox psychiatry of those times in its ability to explain and treat severe 
psychiatric conditions (Scheff, 1966; Szasz, 1976; Laing, 1967; Laing and 
Esterson, 1970). Although clinical and scientific validity and utility of 
schizophrenia concept have not been permanently 'shaken' by the movement, it 
nevertheless made subtle, but important contributions towards the gradual change 
in the attitudes with which individuals diagnosed with schizophrenia are treated in 
clinical practice and in the society at large. The questioning of the value of 
schizophrenia as a clinical diagnosis in terms of its practical and clinical utility has 
been recently reopened in the work of van Os (2003). 
ii) The second issue goes back to Kraepelin. In his early writings, Kraepelin 
(1896) has distinguished between schizophrenia and affective disorders that he 
grouped together as manic-depressive psychosis. The distinction was made on the 
basis of the course and outcome of the symptoms, with dementia praecox leading 
to a progressive deterioration following the onset of the symptoms, while affective 
psychosis leading to a partial or full recovery. However, Kraepelin eventually came 
to the view that dementia praecox and affective psychosis could coexist and thus a 
possibility of unitary psychosis cannot be ruled out (Kraepelin, 1920). Bleuler, 
although separating manic-depressive psychosis, maintained that affective 
symptoms might coexist with schizophrenia. 
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The mainstream clinical practice adopted Kraepelin's initial dichotomy between 
schizophrenia and affective psychosis for the majority of the 20th century. 
However, the dichotomy has been subjected to a considerable debate and empirical 
scrutiny. Different multivariate statistical techniques have been employed in order 
to resolve the question of whether schizophrenia and bipolar disorder may be 
validly demarcated on the basis of the symptoms assigned to each condition. Most 
recent factor analytic studies of individual symptoms that included first episode 
psychotic patients of various diagnoses (i. e. not just schizophrenia and manic 
depression) have isolated schizophrenia, mania and depression as separate factors 
despite varying in the overall number of factors (from 4 to 10) that provided the 
best solution (Kitamura et al., 1995; McGorry et al., 1998; van Os et al., 1999; 
Rosenman et al., 2000; Cuesta and Peralta, 2001; McIntosh et al., 2001; Serretti 
et al., 2001). However, the studies also found a considerable overlap in the 
symptoms associated with different factors. The results of cluster analytic studies 
are less compelling (International Pilot Study of Schizophrenia, WHO, 1973; Lorr et 
al., 1966; Everitt et al., 1971) with schizophrenia diagnosis being found across the 
identified clusters. Kendler and colleagues (1998) used latent class analysis, a 
type of cluster analysis, in a study of epidemiologically based sample and have 
found that six-class solution provided the best fit. Although schizophrenia and 
major depression were easily identifiable as two separate classes, remaining four 
classes contained patients presenting with a mixture of schizophrenic and affective 
symptoms. However, cluster analysis assumes mutual exclusivity of the clusters, 
which does not make it an ideal technique when dealing with "fuzzy sets' such as 
psychiatric diagnoses. Perhaps the most compelling argument in favour of the 
distinction between schizophrenia and manic-depressive psychosis comes from the 
study that have employed discriminant function analysis, a statistical technique 
ideally suited to deal with the nature of psychiatric data. Thus, discriminant 
function analysis carried out as part of the IPSS (WHO, 1979) revealed unequivocal 
bimodal distribution when schizophrenia was examined separately versus mania 
and versus depression. Kendell and Gourlay (1970) failed to find bimodal 
distribution in the initial study of 292 patients diagnosed with schizophrenia and 
affective disorders, but the results changed to a clear dichotomy in the follow-up 
study of 128 of these patients when outcome information was taken into account 
(Brockington et al., 1979). 
Another line of inquiry to address this debate is the examination of genetic risk of 
schizophrenia and affective disorders. Early genetic studies suggested that there is 
no clear segregation between families that carry schizophrenic or affective 
genotype. Thus, Rudin (1916) reported that although the risk for schizophrenia for 
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an individual was high (6.2%) if they had a close relative with schizophrenia, it was 
higher if the ill relative had a non-schizophrenic (mostly affective) psychosis 
(8.2%). He also found almost equal numbers of relatives with affective disorder 
and relatives with schizophrenia in the families of his schizophrenic probands. On 
the other hand, among the psychotic relatives of Odegaard's (1972) manic- 
depressive probands, 19% were diagnosed as schizophrenic, indicating that the co- 
occurrence may run in both directions. 
Finally, Adler and Strakowski (2003) have recently evaluated the evidence for and 
against treating schizophrenia and manic-depressive disorders as separate 
syndromes. They concluded that whereas schizophrenia and bipolar disorder might 
be indistinguishable on the levels of phenomenology, cognitive disturbances, and 
aetiology, there are clear distinctions between two illnesses on the levels of 
epidemiology and pathophysiology. 
Overall, empirical evidence seems to suggest that although schizophrenia and 
affective disorders might exist in `clear' forms in some individuals, a considerable 
proportion of patients exhibit mixed schizoaffective symptoms. Furthermore, as 
noted first by Kraepelin and as the current data suggests, schizophrenia and 
affective disorders are best demarcated in terms of long-term outcome, as they 
can be almost symptomatically indistinguishable at first presentation. Thus, it 
seems that Kraepelin's distinction stands up when the outcome and overall 
functional disability of the patients is taken into account. Bleuler's argument is also 
valid as the studies found, time after time, a substantial proportion of patients 
presenting with both schizophrenic and affective symptomatology. This has led to 
the definition and inclusion of Schizoaffective disorder into clinical diagnostic 
manuals to account for the condition, which manifests a mixture of schizophrenia- 
like and mood disturbances. Research into schizoaffective disorder suggests that 
patients falling into this diagnostic category tend to have much more favourable 
outcome and less functional disability then patients with schizophrenia (e. g. 
Benabarre et al., 2001). The fact that Bleuler had included individuals presenting 
with the mixture of psychotic and affective symptoms into his definition of 
schizophrenia might explain why he held that poor outcome and progressive 
deterioration are not a necessary feature of the disorder. 
iii) The third issue is an extension of the first and second debates. The question at 
hand is whether schizophrenia (or any other psychiatric diagnosis for that matter) 
has validity as a categorical disease entity or whether psychosis is better 
understood as a continuum with normality, where 'normal' and 
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'psychopathological' manifestations represent quantitative variations along this 
continuum. Similarly, different 'pathological' manifestations (e. g. sub-types) might 
represent different degrees of illness severity, or alternatively, progressive stages 
in the longitudinal course of the same illness (Goldberg and Weinberger, 1995). 
Bleuler held a continuum position, writing on latent schizophrenia: personality 
deviation, developing slowly over time, but never reaching a picture of full-blown 
schizophrenia (Bleuler, 1911). Rado (1953) coined a term `schizotypy' to refer to a 
schizophrenia phenotype, characterised by anhedonia, perceptual deviations 
(particularly perceptual distortions of bodily schema), motivational deficit, and 
inability to organise goal-directed activities, presumably casued by a genetic 
predisposition. Meehl (1962,1990) conceptualised schizotypy in a similar way, 
highlighting innate neural or biochemical defect (schizotaxia) as the basis for 
schizotypal personality, which in some cases may lead to the complete picture of 
schizophrenia as a consequence of maladaptive learning and under the influence of 
environmental factors. Menninger and colleagues (1958) re-introduced the concept 
of a `unitary psychosis', which existed prior to Kraepelin's categorisation of mental 
illnesses. The above mentioned approaches to the continuum between schizotypy 
and schizophrenia have been characterised as quasi-dimensional (Claridge, 1985; 
Claridge and Beech, 1995), since they focuse on the variations within the illness 
domain, taking the 'ill' state as a reference point and constuing dimensionality as 
degrees of expression of a disease process. Claridge (1985,1987) advanced a 
'fully' dimensional position, holding that schizotypal behavioural and psychological 
traits fall within the normal, broadly healthy, domain. Crow (1990) proposed that 
schizophrenia genotype is linked to the emergence of language in human species, 
and hence is normally distributed within the population, varying from benign to 
moderate, and to malignant. 
iv) The debate as to what is and what is not schizophrenia has been also fuelled by 
the fact that the symptoms defining schizophrenia are not pathognomonic, i. e. 
observed in other conditions. Thus, psychomotor symptoms such as akinetic 
mutism, catatonia and abulia that are present in some individuals with 
schizophrenia, also occur in a wide range of psychiatric conditions, including 
dementia, the autistic spectrum disorders, as well as in patients with brain lesions. 
Psychotic symptoms, such as hallucinations and delusions can also be observed in 
other psychiatric and neurological conditions, including post-traumatic stress 
disorder, obsessive-compulsive disorder, dementia, velo-cardio-facial syndrome 
(VCFS), temporal lobe epilepsy and others. Prescription medication as well as drugs 
of abuse can also induce symptoms characteristic of schizophrenia. The solution to 
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this problem in contemporary clinical practice is to rule out these alternatives 
before assigning schizophrenia diagnosis, i. e. a differential diagnosis. 
1.3. Diagnosis and classification of schizophrenia 
1.3.1. The operational criteria for schizophrenia diagnosis 
Due to the factors discussed in the preceding section, the definition of 
schizophrenia evolved over time. The most recent diagnostic tool that is most 
widely applied in clinical as well as in research settings is the Diagnostic and 
Statistical Manual, forth version (DSM - IV), which was offered in 1994 by the 
American Psychiatric Association (APA) (see Table 1.1). It is important to note 
that DSM-IV criteria does neither imply nor intend to state that schizophrenia has 
empirical validity as a disease entity. The intention of the DSM-IV is to provide a 
tool for a reliable diagnosis for the purposes of treatment and scientific research. 
TABLE 1.1. DSM-IV criteria for schizophrenia diagnosis 
Diagnostic criteria 
A. Characteristic symptoms: Two (or more) of the following, each present for a significant portion of 
time during a 1-month period (or less, if successfully treated): 
1) Delusions 
2) Hallucinations 
3) Disorganised speech 
4) Grossly disorganised or catatonic behaviour 
5) Negative symptoms, i. e. affective flattening, alogia, or avolition 
B. Social/occupation dysfunction 
C. Duration: Continuous sings of the disturbances for at least 6 months, which may include the 
prodromal or residual periods 
D. Schizoaffective and mood disorder exclusion 
E. Substance/general medical condition exclusion 
F. Relationship to a pervasive developmental disorders: If there is a history of autistic disorder or 
another pervasive developmental disorder, the additional diagnosis of schizophrenia is made only if 
prominent delusions or hallucinations are also present for at least a month (or less, if successfully 
treated). 
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The DSM-IV diagnosis of schizophrenia includes substantive and temporal criteria. 
The substantive criteria include gross impairment of reality testing, involving 
incorrect inferences about reality and inaccurate evaluation of one's own thought 
process, i. e. psychosis. Psychosis implies substantial departure from the range of 
normal tendency to under- or over-value one's abilities and to maintain one's belief 
in the face of contradictory evidence. The disturbances must affect at least two of 
several psychological processes, including thought, perception, emotion, 
communication, and psychomotor behaviour. The temporal criteria are the 
duration of symptoms for at least six months, leading to marked deterioration from 
the individual's previous levels of social, vocational and self-care functioning 
induced by those symptoms. 
The disturbances of thought processes are called delusions, while perceptual 
disturbances are called hallucinations. Delusions are false beliefs that resist all 
argument and are sustained in the face of evidence that normally would be 
sufficient to destroy them. Hallucinations are sensory experiences with the 
compelling sense of reality in the absence of external stimulation of the 
corresponding sensory modality. Auditory hallucinations are most prevalent, but 
visual, tactile or olfactory hallucinations also occur. 
To reflect the fact that the symptoms of schizophrenia overlap with other 
psychiatric conditions, DSM-IV includes a number of exclusion criteria that have to 
be made in order to rule out other causes for the observed symptoms. 
1.3.2. DSM-IV sub-types 
There are four sub-types of schizophrenia according to DSM-IV criteria: paranoid, 
disorganised, catatonic and residual. Paranoid sub-type is characterised by 
delusions of persecution and/or grandeur, typically auditory hallucinations and by 
either intensely emotional or very formal behaviour during social interaction. 
Disorganised sub-type is characterised by body-centred delusions and/or 
hallucinations and, most markedly, idiosyncratic and incoherent behaviour, such as 
grimaces, giggles or bursts of laughter without an apparent stimulus. Catatonic 
sub-type is distinguished by delusions centred on death and destruction as well as 
very excited or, on the contrary, 'frozen' behaviour. Residual sub-type typically 
does not involve delusional or hallucinatory content, but characterised by 'flat' or 
blunted affect, and in some cases impairment of hygiene and/or peculiar 
behaviour. 
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In the present thesis, the term `schizophrenia' is taken to refer to a broad range of 
phenomena covered by the DSM-IV operational criteria for schizophrenia diagnosis. 
The expression 'schizophrenia patient' (or `patient with schizophrenia') is employed 
to refer to anyone with a diagnosis of schizophrenia according to DSM-IV 
operational criteria or other accepted diagnostic methods, such as International 
Classification of Diseases, 9th or 10th revision (ICD 9, ICD 10). 
1.3.3. Other classifications of schizophrenia 
In addition to the criteria and sub-types of schizophrenia offered in DSM-IV, other 
ways of classifying schizophrenia have been proposed. One of the approaches was 
to characterise schizophrenia according to the onset and progression of the 
symptoms. Acute vs. chronic distinction has been made (Andreasen and 
Carpenter, 1993). Acute schizophrenia is characterised by a rapid and sudden 
onset of florid symptoms. Frequently, the onset would be precipitated by a specific 
factor, such as a stressful life event (Arieti, 1974) or high expressed emotion in the 
family (Bebbington et al., 1993; Butzlaff and Hooley, 1998), in which case a 
'reactive' type of schizophrenia would develop. In contrast, chronic sub-type would 
manifest as a gradual and prolonged history of withdrawal, with no apparent 
triggers, in which case 'process' schizophrenia would be present. In clinical 
practice, the acute-chronic distinction is made on the basis of the number of 
episodes a person has had and the length of hospitalisation. The first episode that 
results in hospitalisation for less than a year or several episodes with very brief 
hospitalisations leads to an acute classification. Hospitalisation for two years and 
over results in chronic classification. However, these criteria have low reliability of 
classification as it becomes difficult to distinguish between acute and chronic 
presentations in persons who require more than a year but less than two years of 
hospitalisation. 
Another approach is based on aetiology, namely familial aggregation. Patients with 
familial history of schizophrenia are assumed to have a genetic basis, whereas 
patients without such history are thought to be affected by environmental factors. 
The review of the research into familial vs. non-familial cases of schizophrenia, with 
familial assumed to represent more severe form of the disorder with poorer 
prognosis, have concluded that there are no ascertainable differences in 
symptomatology, age of onset, premorbid functioning, outcome and treatment 
response (Roy and DeVriendt, 1994). 
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Other approaches to classifying schizophrenia capitalised on heterogeneity in terms 
of the outcome and treatment response. A proportion of people with 
schizophrenia responds well to antipsychotic medication, i. e. 'responders', and are 
able to maintain work and social interaction, whereas approximately one quarter to 
one third of patients remain treatment refractory with classic neuroleptics, i. e. 
'non-responders', and are often socially isolated and service dependent (Vaillant, 
1964; Stephens et al., 1966). However, this picture is changing with the advent 
of novel atypical antipsychotics (Smith et al., 1996; Campbell et al., 1999). 
Crow (1980) has proposed a classification that combines different forms of 
heterogeneity in schizophrenia to derive two sub-types, Type I and Type II. He 
combined such variables as the symptom type or cluster, response to 
antipsychotic medication, cognitive functioning and pathophysiological markers. 
Thus, Type I schizophrenia is acute; characterised by positive symptoms, such as 
delusions, hallucinations and positive thought disorder; treatment responsive; 
cognitively intact; and involves dopamine dysfunction. Type II schizophrenia is 
chronic; characterised by negative symptoms, such as flat affect, poverty of 
speech, and loss of volition; treatment refractory; cognitively impaired; and 
involves structural brain abnormalities such as an enlargement of lateral and third 
ventricles. 
Crow's typology brought the positive-negative symptoms dichotomy into the 
forefront of schizophrenia research. It was supported by other investigators (e. g. 
Andreasen and Olsen, 1982). However, whereas Crow's model (1980) implied the 
existence of distinct sub-types of categories, Andreasen (1985) argued that these 
symptom clusters are better viewed as dimensions, which are continuous and 
additive, and has shown that most patients have a considerable overlap of positive 
and negative symptoms. 
Liddle (1987a) has extended the positive/negative duo of symptom clusters by 
adding a third syndrome of psychomotor poverty. This tertiary syndrome structure 
of symptoms characteristic of schizophrenia has since been supported by a number 
of investigators (e. g. Arndt et al., 1991; Brown and White, 1992). Each syndrome 
was found to be associated with a specific pattern of neuropsychological and 
pathophysiological alterations (Liddle, 1987b): i) psychomotor poverty being 
associated with deficits in abstract thinking, long-term memory and left-sided 
prefrontal hypofunction; ii) disorganisation (negative syndrome) with deficits in 
concentration, short-term memory, learning and decreased perfusion in the right 
ventral prefrontal cortex and insula, and increased perfusion in the right anterior 
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cingulate; iii) reality distortion (positive syndrome) with poor figure-ground 
perception and left medial temporal lobe hyperfunction and left lateral temporal 
lobe hypofunction. 
1.3.4. One disease or many? 
The heterogeneous clinical presentation of schizophrenia led some to argue that in 
order to establish its aetiology and pathophysiology, it should not be treated as one 
disorder. Instead, homogeneous sub-types should be established, the aetiology 
and pathophysiology of which can than be traced. All different ways of classifying 
schizophrenia reviewed in the preceding section have been initially advanced as the 
potential sub-types of schizophrenia, along with sub-types delineated in DSM-IV. 
However, none has proved to be fully reliable. Goldberg and Weinberger (1995) 
have presented a case against sub-typing in schizophrenia, arguing that: (i) 
subtypes have only modest stability, with patients manifesting distinct classes of 
symptoms at different stages of illness; (ii) different syndromes co-occur in the 
same patient at the same time point; (iii) studies showing differences between 
presumed sub-types in pathophysiology, neuroanatomy, or neurocognition can be 
interpreted as showing different degrees of illness severity. They thus concluded 
that a simple model of schizophrenia in which patients vary along severity 
dimension should be favoured for the sake of parsimony. For the purposes of the 




Prevalence is defined as the number of cases (per 1000 persons at risk) in a 
population at any given time (point prevalence) or over a defined period of time 
(period prevalence). Prevalence rates for schizophrenia found in the studies with 
the least methodological problems vary depending on the diagnosis used, as well 
as the population studied, and range from 1.4 to 4.6 cases per 1000 population 
(review, Jablensky, 1995). 
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1.4.2. Incidence 
The incidence rate is defined as annual number of new cases in a defined 
population per 1000 individuals at risk, and is more representative of the morbidity 
(i. e., the probability of disease occurrence at a point in time) than the prevalence 
rates. The World Health Organisation (WHO) 10-country investigation (Sartorius et 
al., 1986; Jablensky et al., 1992) has found a rate of between 0.16 and 0.35 per 
1000 cases when ICD-9 criteria for schizophrenia was used, which includes broader 
range of cases, and the rate of between 0.07 and 0.14 when a 'narrow' diagnosis of 
schizophrenia was used (as defined by the Schneiderian first-rank symptoms: 
auditory hallucinations, delusions, thought broadcasting/insertion/withdrawal, and 
passivity phenomena). 
1.4.3. Morbid risk (disease expectancy) 
The probability of a single individual developing a disease if he/she survives 
through the entire period of risk for that disease defines the morbid risk. As most 
studies have produced morbid risk estimates in the range of 0.50-1.60% 
()ablensky, 1995), the often quoted morbid risk of schizophrenia is about 1%. 
1.4.4. Spatial distribution 
There are comparable rates of schizophrenia in developing countries and 
industrialised societies (Torrey, 1980). However, there might be a greater 
prevalence of schizophrenia amongst the poor inhabitants of the large urban areas. 
Some American studies have found the rate of schizophrenia being eight times as 
high in the lower classes than it is in the middle or upper social classes (e. g. 
Saugstad, 1989). This phenomenon is known as 'downright shift' hypothesis of 
schizophrenia, which postulates that persons who become schizophrenic drift down 
a social class from that of their parents through a process of social selection. In 
addition, the prevalence of schizophrenia might be higher amongst immigrants, as 
has been found in a few studies from different countries (e. g. Haasen et al., 2001; 
McGrath et at., 2001; Cantor-Graae et al., 2003). This later finding indicates that 
social causation, perhaps due to social isolation and stress associated with adapting 
to a new culture, has a role in schizophrenia aetiology. 
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1.4.5. Antecedents, course and outcome 
At least some individuals who later in life receive a diagnosis of schizophrenia differ 
from their peers from very early in life. Delays in reaching developmental 
milestones, neuromotor and visuo-motor anomalies, cognitive deficits, and 
prolonged impairment in social functioning are apparent throughout the premorbid 
history of schizophrenia patients (Jones and Tarrant, 2000). About three quarters 
of individuals experiencing the first psychotic episode show a prodromal phase of 
about five years. In 68 % of the cases the pre-phase (the time between the first 
positive symptom and the climax of positive symptoms) exceeds one year, in 15% 
of the cases the onset is sub-acute (the pre-phase of four weeks to one year), and 
in 18 % of the cases the onset is acute (the pre-phase of under four weeks) 
(Hafner & Nowotny, 1995). 
About 40% of individuals presenting first psychotic episode will have a chronic 
course of the disorder with persistent or re-current symptomatic episodes 
accompanied by profound and lasting social and occupational dysfunction. 
Approximately 25% of individuals will experience only one episode with total 
recovery, while about 35% will have several episodes with subsequent remission 
and minimal social impairment. In most cases, the course appears to be 
established within the first five years following the onset (Frangou & Murray, 
1996). 
Factors that are predictive of outcome include premorbid adjustment (Bailer et al., 
1997), the type of onset (Jablensky et at., 1992), marital status (Childers and 
Harding, 1990), supportive social relationship (Nuechterlein et al., 1992), symptom 
typology (Andreasen et al., 1990) and cognitive function (Green, 1996). Thus 
persons with an insidious onset, who show poor premorbid adjustment, the 
absence of extended social network, manifest predominantly negative symptoms 
and have poor cognitive abilities will have the worst prognosis clinically and 
functionally. 
There might be gender differences in terms of the premorbid history, age of onset, 
lifetime risk, and prognosis. Women generally show better premobrid adjustment, 
a higher percentage of remitting illness episodes and shorter hospital stays, higher 
survival rate, and better functional outcome (WHO, 1979; Childers and Harding, 
1990; Jablensky et at., 1992). There are well-established differences in the mean 
age of onset between two sexes. WHO 10-country study has found the mean age 
of onset for men at 25.3 years and for women at 28.9 years (Hambrecht and 
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Hafner, 1992). Furthermore, men and women show different age-incidence 
curves. For men, the risk of developing schizophrenia picks between the ages of 
20-24 years with the subsequent low and stable incidence rate, whereas women 
show much lower risk at this age range, with the sharply increasing incidence in 
age groups older than 35. However, the life-time risk for developing schizophrenia 
might be higher in women (Bojholm and Stromgren 1989; Helgason and 
Magnusson, 1989), when the cases with the late-onset schizophrenia and late 
paraphrenia (late-onset paranoid psychosis) are included. A protective, 
neuroleptic-like effect of oestrogen on central dopaminergic neurotransmission 
(Seeman and Lang, 1990), an earlier maturation of the central nervous system in 
women (Saugstad, 1989) and genetic factors (DeLisi, 1992) have been proposed to 
account for these gender differences in the age of onset and incidence curves. 
1.5. Aetiology 
In this section, the genetic, neurochemical, and functional neural dysfunction 
causes of schizophrenia will be overviewed. The pathophysiological account, 
namely structural brain alterations, will be reviewed in detail in the following 
chapter (Chapter 2). 
1.5.1. Genetics 
The role of genetic factors is well established in schizophrenia. The study of 
monozygotic twins suggests that genetic contribution to schizophrenia aetiology is 
about 42% (Shields and Gottesman, 1972). The concordance rates of 
schizophrenia for dyzogotic twins is about 9%, suggesting that it is unlikely that 
the same uterine environment is the reason for the 42% association in identical 
twins. Adoption studies also provide support for unambiguous, albeit moderate, 
genetic influence. Heston (1966) found that adopted children of schizophrenic 
mothers were five times more likely to be diagnosed with schizophrenia than those 
of normal mothers. Finally, first-degree relatives of schizophrenia probands are 18 
times more likely to be diagnosed with a schizophrenia spectrum disorder (Kendler 
et al., 1985). 
Identification of relevant genes is a much more arduous task than simple 
establishment of a genetic contribution to schizophrenia aetiology. At the present, 
there are as many candidates to schizophrenia susceptibility genes as there are 
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sources of schizophrenia heterogeneity. One of the earliest `suspects' was a cluster 
of genes on chromosome 5 (Sherrington et al., 1988); however, subsequent 
studies did not find this cluster to be associated with susceptibility to schizophrenia 
(Crowe et al., 1991). The most robust evidence to date exists for the genes 
encoding D-3 dopamine and 5-HT2a receptors, as well as a deletion of 
chromosome region 22q11 to be associated with a small rise in susceptibility to 
schizophrenia (review, McDonald and Murphy, 2003). 
One of the promising lines of inquiry into genetics of schizophrenia was opened 
recently by Weinberger and his collaborators. Their approach is based on taking 
well-characterised functional and neuropsychological deviances in schizophrenia as 
a departure point and mapping these known factors to particular genetic 
polymorphisms via the use of functional magnetic resonance imaging (fMRI). For 
example, abnormal prefrontal information processing is one of the characteristics 
of schizophrenia phenotype, and is found in unaffected individuals who are 
genetically at risk. Weinberger and colleagues (2001) have found that catechol-o- 
methyl transferase (COMT) genotype, which affects enzyme activity and appears to 
uniquely impact prefrontal dopaminergic neurotransmission, predicts performance 
on prefrontal executive and working memory tasks. They have also found, through 
family-based association studies, that excessive transmission of the COMT valine 
(val) allele to schizophrenia offspring is related to poorer prefrontal function. 
Taken together, these findings suggest that the COMT val allele increases risk of 
schizophrenia by virtue of its effect on dopamine-mediated prefrontal information 
processing. 
Overall, the search for schizophrenia susceptibility genes is taken on many 
different directions. As there is a growing awareness that both schizophrenia 
patients and their relatives have cognitive impairments (discussed in Chapter 2), 
the genetic projects attempting to link different genetic polymorphisms with 
specific cognitive processes might be a valid and fruitful approach to discovering 
genomes that produce susceptibility to mental illness in general and schizophrenia 
in particular. 
1.5.2. Neurochemistry 
Neurochemical imbalances in schizophrenia have been one of the central 
aetiological factors to be studied since the discovery of antipsychotics in the 1950s 
and their ameliorating effects on positive symptoms. Almost all known 
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neurotransmitters of the central nervous system have been implicated since than, 
including serotonin (Wooley and Shaw, 1954), noradrenaline (Stein, 1971), GABA 
(Roberts, 1972), and glutamate (Kim et al., 1980), with the dopamine hypothesis 
giving the first impetus to and dominating the neurochemical studies of 
schizophrenia. 
According to the dopamine theory in its simplest form, schizophrenia, or more 
precisely its psychotic symptoms, is the result of sub-cortical dopaminergic 
hyperfunction (e. g. Carlsson et al., 1988). Dopaminergic neurotransmission 
mediates the rewards mechanisms in the brain, and seems to modulate the 
salience of the stimuli, either external or internal. The increased, to the point of 
overwhelming, salience of the stimulus, which would be considered trivial in the 
`normal' state of mind, is central to the phenomenal quality of a psychotic state 
(Hemsley, 1994; 1998). A few models of psychosis pathogenesis have been 
advanced, all of them featuring the effects of increased dopamine activity in ventral 
striatum and its effect on the function of cortico-striato-pallido-thalamic circuitry 
(Buchsbaum, 1990; Carlsson and Carlsson, 1990; Grace, 1991; Gray, 1995; 1998; 
Csernansky and Bardgett, 1998; O'Donnell and Grace, 1998). 
The dopamine hypothesis emerged from four related tenets. First, the common 
denominator of the first generation of antipsychotic drugs is the blockade of D2 
receptors (Carlsson and Lindqvist, 1963). Second, the side effects of conventional 
antipsychotic drugs are similar to the symptoms of Parkinson's disease, a condition 
associated with low levels of dopamine, which is improved through the use of L- 
dopa. Third, the agents that are dopamine receptor agonists, such as 
amphetamine, can induce psychotic states similar to those observed in 
schizophrenia (Angrist et al., 1974). Forth, dopamine agonists aggravate the 
symptoms in schizophrenia patients (Meltzer and Stahl, 1976). 
However, there are some important caveats to the DA hypothesis as based on this 
evidence. First, these pharmacologically based facts implicate dopamine only 
indirectly. One of the predictions based on this evidence is that people with 
schizophrenia would have an increased density of DA2 receptors. The systematic 
positron emission tomography (PET) studies of DA receptor densities in drug-naive 
schizophrenia patients did not observe the density increase (review, Nordstrom et 
al., 1993). However, in more recent years it has been demonstrated that drug- 
naive schizophrenia patients show increased synthesis (e. g. Hietala et al., 1994) 
and elevated release of dopamine (e. g. Laruelle et al., 1996), and that the elevated 
release correlates with the induction of positive symptoms (e. g. Breier et at., 
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1997). Second, only about a third of the patients respond to treatment with 
antidopaminergic drugs, with patients having predominantly negative symptoms 
showing a poor response, despite having high levels of D2 blockade (Pilowsky et al., 
1993). Third, dopamine-agonist induced psychosis can only mimic one sub-type of 
schizophrenia, namely paranoid, and even with this limitation, there are differences 
between, for example, amphetamine induced psychosis and paranoid 
schizophrenia, such that amphetamine psychosis is not accompanied by affective 
blunting and the formal thought disorder. Non-paranoid forms of schizophrenia, 
with predominantly negative symptomatology, are best mimicked by phencyclidine 
(PCP, Luby et al., 1962), which predominantly acts antagonistically on the 
glutamatergic N-methyl-D-asparate (NMDA) receptors (Lodge and Anis, 1982). 
Finally and importantly, it takes several weeks for antipsychotic treatment to 
alleviate schizophrenic symptoms whereas the effects of the drugs on 
neurotransmitter systems occur within hours. 
Therefore, it has been suggested (Laruelle et al., 1996) that abnormalities could 
reside in the control of dopamine function rather than dopaminergic 
neurotransmission per se. Subsequently, greater emphasis was put into 
understanding the systems modulating or acting on dopamine neurons and their 
mutual interactions, cortically and sub-cortically (e. g. Carlsson and Carlsson, 1990: 
glutamatergic and monoaminergic interactions; Joyce, 1993: dopaminergic, 
serotonergic and noradrenergic limbic interactions; Yamamoto et al., 1994: 
noradrenergic and dopaminergic interactions; Carlsson, 1995, Carlsson et al., 
1997: dopaminergic, glutamatergic, GABAminergic, noradrenergic, serotonergic 
and acetylcholine systems). With the introduction of the atypical antipsychotics, 
which have a close affinity for several receptors besides the D2 dopaminergic, 
including D1, D3, D4,5-HT2, and NMDA, making them efficacious in reducing not 
only positive but also negative and cognitive symptoms, it became clear that many 
other receptor sites apart from D2 are likely to be involved in the pathogenesis of 
schizophrenia (Seeman, 1992; Kerwin and Taylor, 1996). (A more detailed 
discussion of atypical antipsychotics and the mechanisms of their efficacy is 
presented in Chapter 3). 
To conclude, dopamine hypothesis rests on fairly strong pharmacological and 
psychopathological evidence. The antagonism of D2 receptors still remains a 
prerequisite for a drug to have an ameliorating effect on psychotic symptoms. 
However, it is unlikely that the dysfunction of dopaminergic system alone can 
account for the wide spectrum of symptoms and cognitive dysfunction 
characteristic of schizophrenia. Moreover, since a primary disturbance in one 
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neurotransmitter function will inevitably influence other systems, it seems 
unreasonable to expect that the neurochemical aetiology of schizophrenia can be 
deduced with confidence. Finally, different sub-types of schizophrenia might have 
different primary neurochemical aetiologies. 
1.5.3. Functional brain abnormalities 
A disturbance of functional neural circuitry, possibly as a result of morphological 
and neurochemical alterations, was proposed to play a causal role in schizophrenia 
(e. g. Andreasen et al., 1998; Friston et al., 1999). The first reports of abnormal 
brain function as demonstrated by brain imaging techniques were of 
'hypofrontality' in schizophrenia patients at rest, as measured by the regional 
cerebral blood flow (Ingvar and Franzen, 1974). However, in studies of patients at 
rest, 'hypofrontality' has been an inconsistent finding, since resting is 
physiologically and psychologically variable event (review, Weinberger and 
Berman, 1996). 
Hypofrontality has been linked with executive dysfunction in schizophrenia. 
Weinberger et al. (1986) demonstrated attenuated activation of the dorsolateral 
prefrontal cortex during performance on the Wisconsin Card Sorting test (WCST) in 
unmedicated patients. More recently, Riehemann et al. (2001) have replicated this 
finding. In subsequent studies, Weinberger and colleagues demonstrated that the 
DLPFC hypoactivation during WCST was correlated with reduced dopaminergic 
activity (Weinberger et al., 1988) and reduced hippocampal volume (Weinberger et 
al., 1992). These findings suggest that structural and neurochemical alterations 
underlie disrupted brain function in schizophrenia. 
Cognitive activation paradigms have shown prefrontal hypofunction in 
schizophrenia patients during working memory (e. g. Perlstein et al., 2003), 
sustained attention (e. g. Barch et al., 2001), selective attention (inhibition of 
preportent response) (Rubia et al., 2001), but these results have been challenged 
as artefacts of poor performance. Furthermore, some studies failed to find 
hypofrontatlity during cognitive task performance (e. g. Honey et al., 2002), and 
some even observed hyperfrontality (e. g. Callicott et al., 2000; Manoach et al., 
2001; Ramsey et al., 2002). 
Interestingly, fMRI studies demonstrated altered patterns of activations in patients 
on the tasks of higher cognitive functions in which their performance was on the 
level of normal controls. Thus, Ramsey et al. (1999) found reduced activation of 
40 
the left frontal cortex in the absence of set-shifting deficit. Similarly, Goodman et 
al. (1999) observed abnormal brain activation during normal performance level on 
a working memory task. Mitchell and colleagues (2001), reviewing the findings of 
fMRI studies in schizophrenia, suggested that schizophrenia might be associated 
with functional reorganisation during brain development. 
Abnormal co-activation between different brain regions has been also observed in 
schizophrenia during higher cognitive processing. Yurgelun-Todd and colleagues 
(1996) observed lower activation of frontal but increased activation of temporal 
cortex during word production in schizophrenia patients relative to normal controls. 
Volz and colleagues (1997) observed a lack of prefrontal activation and a trend 
towards increased left temporal activation during WCST performance in patients 
relative to normal controls. In addition, Liddle and colleagues (1999) found that 
patients failed to suppress left temporal response during working memory task, 
and proposed abnormal coordination of activity between frontal and left temporal 
cortices underlying higher cognitive (dys)functioning in schizophrenia. 
Abnormal neuronal activity in schizophrenia has been also observed on the tasks of 
basic information processing. Wible and colleagues (2001) reported underactivation 
of superior temporal gyrus in patients relative to normal controls at the earliest 
stages of sensory input as measured by an auditory mismatch negativity paradigm 
(identification of deviant tones from a string of standard tones). Braus et al. (2002) 
found reduced activation of higher association cortices, including prefrontal and 
parietal, during simple sensory processing paradigm. Kumari and colleagues 
(2002a) observed reduced activation of a functional network involved in procedural 
learning, including the thalamus, the striatum, the precuneus, the cingulate gyrus 
and the premotor cortex. Reduced thalamic and basal ganglia activation was seen 
during deficient prepulse inhibition of the startle response, a measure of 
sensorimotor gating, in schizophrenia (Kumari et al., 2003a). These data point to 
widespread functional neural dysfunction in schizophrenia affecting sensory and 
association cortices, as well as subcortical structures. 
Functional neuroimaging studies have linked clinical features of schizophrenia to 
the disordered neural function. Negative symptoms have been linked to prefrontal 
hypofunction (e. g. Andreasen et al., 1992), auditory hallucinations to the activation 
of temporal lobe, particularly its anterior pole (e. g. Kurachi et al., 1985), whereas 
visual hallucinations have been shown to associate with the activation of 
extrastriate visual cortices (ffytch et al., 1998). 
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CHAPTER 2. SCHIZOPHRENIA: STRUCTURAL ALTERATIONS, 
COGNITIVE DEFICITS, AND THEIR INTER-RELATIONSHIPS 
In this chapter, structural alterations in schizophrenia will be overviewed, followed 
by the evaluation of the pattern of the cognitive deficits and their current place in 
schizophrenia research. These will be followed by a detailed up-to-date review of 
the literature on the structure/cognition relationship in schizophrenia. 
2.1. Introduction 
Kraepelin (1919) and Bleuler (1911) were the first to propose that schizophrenia 
might be a brain disease. They were also the first to observe and to study 
cognitive dysfunction in the patients they were treating. Both Kraepelin and 
Bleuler viewed cognitive dysfunction as a core feature of schizophrenia, with 
hallucinations and delusions being secondary or 'accessory' symptoms. However, 
despite these early conceptions of schizophrenia aetiology, the study of brain 
abnormalities, cognitive deficits and their possible inter-relationship took almost a 
century to establish itself as one of the primary lines of inquiry in schizophrenia 
research. 
Since the seminal Computer Topography (CT) study by Johnstone and colleagues 
(1976) that reported lateral ventricular enlargement in schizophrenia patients and 
cognitive deficits associated with the enlargement, there were a number of MRI 
studies that have studied neuropsychological correlates of structural brain 
alterations in schizophrenia. However, there has not been a comprehensive 
review of MRI/neuropsychological studies since the publication by Gur in 1992. 
The aim of this chapter is to introduce the issues of structural alterations and 
cognitive deficits in schizophrenia and to review the findings of the magnetic 
resonance imaging (MRI) studies that have examined their inter-relationships. 
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2.2. Structural Alterations 
2.2.1. Methods of quantifying structural alterations 
Two methods currently employed for the study of volumetric brain alterations 
include a region of interest (ROI) approach, which is historically older and is 
considered to be the Gold Standard, and the Voxel Based Morphometry (VBM) 
(Ashburner and Friston, 2000), which was first applied in 1995 by Wright and 
colleagues to the study of schizophrenia. 
The ROI method involves manual outline of the regions of interest on a structural 
image, pixel by pixel, and is therefore susceptible to inter-rater bias and variations 
in landmark identification. It is also extremely time consuming, positing limits on 
the number of brain regions measured, and thus preventing the comprehensive 
identification of regional alterations in any given sample. 
The VBM is an automatic technique, which allows the comparison of grey (or white) 
matter tissue availability between the groups on the voxel-by-voxel basis through 
the entirety of the brain and identifies differences of highly spatially localised 
nature. It therefore overcomes the limitations posited by the ROI technique by 
being objective and comprehensive. The VMB allows the examination of two tissue 
availability indices: concentration and volume (Ashburner and Friston, 2000). The 
concentration within the VBM context is understood as a proportion of a measured 
tissue type relative to other tissue types within a region (the size of which is 
determined by the size of the smoothing kernel applied during the image pre- 
processing, usually 12 mm). The volume is an absolute amount of a measured 
tissue type within a region in relation to the rest of the brain. (A more detailed 
account of the VBM method is provided in Chapter 5, Method). 
2.2.2. The pattern and the nature of structural alterations 
2.2.2.1. ROI studies 
The volumetric alterations identified with ROI approach are subtle but widespread, 
including an array of cortical and sub-cortical brain regions (review, Shenton et al., 
2001). However, not all of the brain pathological findings are consistently 
replicable, perhaps due the heterogeneity of schizophrenia illness, its gender 
dimorphic manifestation, as well as possible non-static presentation of the 
condition (see Shenton et al., 2001 for more details). 
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Amongst the most robust findings is the ventricular enlargement. The enlargement 
of lateral ventricles (LV) in individuals with schizophrenia has been the most 
replicable finding in the history of psychiatry. It is found in 80 % of the studies 
that measured this structure (Shenton et at., 2001). The enlargement is present in 
20% to 40% of patients with chronic schizophrenia (Shelton and Weinberger, 
1986) and seems to be more pronounced on the left side of the brain (Losonczy et 
al., 1986), especially in the region of the temporal horn (Becker et al., 1990; 
Shenton et at., 1992). It has been noted in the unaffected siblings and relatives of 
schizophrenia patients as compared to healthy subjects (Sharma et al., 1998; 
McDonald et al., 2002). Although some studies have found the LV size to be stable 
over time, there are reports of progressive enlargement with the duration of the 
illness, with the rate of change greater on the left (DeLisi et al., 1995,1997). 
Enlargement of the third ventricular size has been found in 73% of the studies that 
measured this structure (Shenton et al., 2001). 
The ventricular enlargement has been interpreted as an indirect evidence of the 
grey matter loss of the structures immediately adjacent to the lateral and/or the 
third ventricles, including amygdala, hippocampus, and thalamus. Indeed, one of 
the most replicable findings of MRI studies (74% of 49 studies) is the reduction in 
the size of the medial temporal lobe structures such as amygdaloid/hippocampal 
complex in chronic schizophrenia patients relative to healthy controls (Shenton et 
al., 2001). A reduction of this region is also reliably found in first episode patients 
(Bogerts et al., 1990; Lawrie et al., 1999; Copolov et al., 2000). The reduction of 
the thalamus is not found as reliability, 42% of the studies (Shenton et al., 2001), 
but this might be due to the difficulty in delineating thalamus with the ROI method. 
Other grey matter reductions found in schizophrenia include (in the order of 
replicability): superior temporal gyrus (100% of the studies); whole temporal lobe 
(61%); frontal lobe (60%); parietal lobe (60%); occipital lobe (44%); cerebellum 
(31%); and whole brain volume (22%) (Shenton et al., 2001). Grey matter 
increases are found in the basal ganglia structures (caudate, putamen, and globus 
pallidus) by 65% of the studies (Shenton et al., 2001), although three studies 
observed grey matter reduction of the caudate (Mion et al., 1991; DeLisi et al., 
1991a; Rossi et al., 1994), which might be associate with tardive dyskenisia (Mion 
et al., 1991). Abnormalities in white matter volume have also been reported 
(Cannon et al., 1998; Wolkin et al., 1998), but not as consistently as those for the 
grey matter (review, Lawrie and Abukmeil, 1998). Lack of normal hemispheric 
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asymmetry in schizophrenia patients has also been found (Bilder et al., 1994, 
Sharma et al., 1999). 
In terms of the magnitude of the volumetric abnormalities, meta-analysis of 58 
studies (published before August 1998) by Wright and colleagues (2000) revealed 
an absolute cerebral volume reduction of 2%, with greater relative reductions in 
the volume of grey (2%) rather than white (1%) matter. Ventricular volumes 
were increased by 26%, with the body of the lateral ventricles being increased by 
16% bilaterally and the left temporal horn of the lateral ventricles being increased 
by 10% relative to the absolute ventricular volume increases. Frontal lobes were 
reduced by 2% relative to the absolute cerebral volume reduction. A reduction of 
temporal lobe volume did not exceed overall cerebral volume differences; except 
for the left anterior superior temporal gyrus with 7% relative reduction. Medial 
temporal lobe structures showed a substantial volume reduction relative to the 
global cerebral differences, with amygdala being reduced by 6% bilaterally; 
amygdaloid/hippocampal complex by 6% on the left and 5% on the right; 
hippocampus by 2% on the left and 3% on the right; and parahippocampal gyrus 
by 7% on the left and 5% on the right. Relative volumes of the thalamus were 
also reduced by 4% for the left and 3% for the right. Basal ganglia volumes were 
increased relative to the global cerebral volumes: left caudate by 4%, right caudate 
by 2%, putamen by 6% bilaterally, left globus pallidus by 21%, and right globus 
pallidus by 24%. Gender differences for volume changes were observed only for 
total ventricular volume increases with 30% for the male and 16% for the female 
patients. 
2.2.2.2. VBM studies 
The studies utilising VBM methodology have recently converged on most of these 
findings, plus added to the list of local brain tissue alterations in the regions that 
have not been previously measured by the ROI studies, such as grey matter 
reductions in the middle temporal gyrus (Job et al., 2002), insula (Wright et al., 
1999; Wilke et al., 2001; Kubicki et al., 2002), precentral (Anath et al., 2002; Job 
et al., 2002) and postcentral gyri (Anath et al., 2002), fusiform gyrus (Anath et al., 
2002), uncus (Job et al., 2002), inferior parietal lobule (Anath et al., 2002), 
peristriate visual cortex (Anath et al., 2002), and right middle occipital gyrus 
(Ananth et at., 2002), as well as the reductions of the white matter of the right 
superior occipitofrontal fasciculus (Suzuki et at., 2002), bilateral anterior limbs of 
the internal capsule (Suzuki et al., 2002), and the lateral optic radiation (Ananth et 
al., 2002). The increases in local brain tissue have also been reported, including 
the grey matter of the left insula (Wilke et al., 2001), right putamen (Wilke et al., 
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2001), right paracentral lobule (Suzuki et al., 2002), precuneus (Suzuki et al., 
2002), bilateral cuneus (Suzuki et al., 2002), superior parietal lobule (Suzuki et al., 
2002), bilateral declive and the right culmen of the cerebellum (Wilke et al., 2001). 
The VBM studies highlight the widespread pattern of structural alterations through 
the cortical and sub-cortical areas in any given cohort of schizophrenia patients. 
Moreover, although some of the findings appear to be replicable, other findings 
might be specific to the population of patients studied, and might be related to the 
differences in clinical features, symptomatology, and neurocognitive deficits. 
2.2.3. The aetiology of structural alterations: neurodevelopmental, 
neurodegenerative and `the three hit' models 
At least three competing types of pathophysiological models have been proposed to 
account for structural brain alterations in schizophrenia. Neurodevelopmental 
models proposed by Murray and Lewis (1987) and Weinberger (1987) have stemed 
from the observations of premorbid abnormalities (e. g. Erlenmeyer-Kimling and 
Cornblatt, 1992), as well as high incidence of pre-natal and birth complications in 
individuals who later develop schizophrenia (e. g. Jones and Cannon, 1998). 
Essentially, neurodevelopmental theories maintain that an earlier lesion due to 
intra-uterine viral infection especially during late second or third trimester of 
gestation, or head trauma during birth, or some other event early in brain 
development interacts with later brain maturation with the net result of 
developmental pathology. The second type of models concentrates on peri- 
adolescent development attempting to account for the adolescent or early 
adulthood onset of schizophrenia. For example, Feinberg (1982) proposed that 
brain pathology in schizophrenia might be a result of excessive pruning during 
adolescence, the time when brain undergoes substantial changes, due to a faulty 
genetic programming. The third type of models posits neurodegenerative course of 
schizophrenia due to an active morbid process, of which acute psychosis is a 
reflection (Kraepelin, 1919; Loebel et al., 1992). All of these models have support 
from the empirical research, although evidence for neurodegenerative model is 
more controversial than for the other two models (see Heckers, 1997 for a review). 
Specifically, the evident lack of gliosis in post-mortem studies of schizophrenia 
patients is usually cited against the neurodegenerative model of schizophrenia. 
However, studies of the effect of N-Methyl-D-aspartate (NMDA) blockade in the rat 
showed that when a high percentage of the neuronal population in the posterior 
cingulate cortex is destroyed by treatment with NMDA antagonist drugs, which 
induce neurotoxic excitation in the cerebral and limbic cortices if administered 
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chronically, there is a transient increase in the markers of two types of glia, but 
these return to normal after some time (Fix et al., 1995). Thus, the common 
finding that structural reductions in schizophrenia are not associated with evidence 
for gliosis might mean either developmental abnormalities early in life or 
neurotoxic degeneration in adulthood, with these alternatives not being mutually 
exclusive (Olney, Newcomer and Farber, 1999). 
Keshavan (1999) has advanced a `three hit' model of schizophrenia pathogenesis, 
which integrates three alternative models: pre-natal neurodevelopmental, peri- 
natal/adolescent neurodevelopmental, and neurodegenerative. This model 
synthesises evidence for adverse events and markers at different time points in 
brain development and after the illness onset in individuals manifesting 
schizophrenia. It posits that there are critical 'windows of vulnerability' in brain 
development, and that adverse events during the first of them, i. e. pre-natal brain 
genesis, may lead to a cascade of abnormal events in brain maturation that would 
result in early dysplasia, abnormal pruning during adolescence, and further 
neurodegenerative processes related to the disease progression. 
2.3. Cognitive Deficits 
Discovery of antipsychotics in the 1950s revolutionised the treatment of 
schizophrenia and shifted the emphasis from cognitive deficits onto positive 
symptoms, which conventional antipsychotics so dramatically reduce. However, by 
the 1960s it became obvious that reduction in positive symptoms did not lead to 
recovery from schizophrenia and did not improve functional outcome significantly 
(Hegarty et al., 1994). The understanding of what is a fundamental deficit in 
schizophrenia made a full circle, with acceptance once again of what Kraepelin and 
Bleuler suggested at the dawn of the 20th century. Cognitive deficits are a core 
feature of schizophrenia, which i) precipitate the psychotic and negative symptoms 
in the aetiology of the disease (e. g. Weickert and Goldberg, 2000); ii) relatively 
stable over time with progressive deterioration after the age of 65 in some patients 
(e. g. Friedman et al., 2001); iii) persist upon the remission of psychotic symptoms 
(e. g. Heaton et al., 2001); iv) are related to but separate from negative symptoms 
(e. g. Harvey et al., 1996; Hughes et al., 2003). Most importantly, cognitive 
deficits are of a greater importance than positive or negative symptoms in 
predicting functional outcome, such as work status, activities of daily living, 
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community outcome, social problem solving and skill acquisition (review, Green, 
1996). 
Schizophrenia is considered to be one of the most expensive psychiatric disorder to 
treat (Capri, 1994; Knapp, 1997). Functional impairment is one of the greatest 
contributors to the cost of the illness (Kenny and Meltzer, 1991). Cognitive 
domains that were linked to different aspects of functional outcome are working 
memory, executive function, attention, verbal learning and memory, verbal 
fluency, and fine motor function (Green, 1996; Green et al., 2000). 
2.3.1. Working memory 
2.3.1.1. The definition of working memory 
Working memory function is hypothesised to be sustained by a network of 
temporary (as opposed to long-term) memory systems. It plays a crucial role in 
many cognitive tasks such as reasoning, learning and understanding. Working 
memory refers to the ability to hold the stimuli of different sensory origin, either of 
external or internal origin (e. g. sensory input or imagery), 'on line' for a short 
period of time (a few seconds) and then either to use it directly after a short delay 
or to process and/or manipulate it mentally in some way before use in order to 
solve cognitive and behavioural tasks of different complexity. Thus, working 
memory involves active rehearsing, processing and manipulation of information. It 
is most engaged when the information is new or not well learned or the task to be 
solved is novel with hight cognitive demands and has not reached the level of 
automaticity. 
2.3.1.2. Working memory models 
The classic model of working memory was described by Baddeley (1986). In this 
model, working memory refers to a single limited-capacity system that consists of 
three elements: two 'slave' systems that retain and process the stimuli and an 
attentional system that supervises and coordinates two 'slave' systems. The 'slave' 
systems are the articulatory or phonological loop, which processes speech-based 
stimuli, and visuospatial sketchpad, which processes visuospatial stimuli. 
Others have argued against the notion of a single system and proposed instead the 
existence of relatively independent subsystems for different sensory modalities and 
the tasks of different nature (e. g. Allport, 1980; Barnard, 1985). Although the 
theoretical debate is not relevant for the present purposes, it is interesting to note 
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that whatever theory one considers, the process that is referred to as central 
executive in Baddeley's model is common to all and seems to depend on the 
function of prefrontal cortex (PFC) (Goldman-Rakic, 1995). The abnormal function 
of the PFC will affect the working memory function, whether it is sustained by a 
single system or a network of subsystems, as they all converge on the PFC at some 
point along the process for attentional/controlling aspect. 
2.3.1.3. The nature of working memory dysfunction in schizophrenia 
The PFC, especially the dorsolateral part, is implicated in working memory (e. g. 
Goldman-Rakic, 1999). The pattern of activation of this region in schizophrenia 
patients during complex working memory tasks is suggestive of a system that is of 
more limited capacity than in normal individuals (review, Manoach, 2003; new 
evidence, Jansma et al., 2004). 
Neuropsychological studies that assessed working memory function in 
schizophrenia patients have observed an impairment of each component of the 
working memory system, i. e. the phonological loop, the visuo-spatial sketchpad 
and the central executive (e. g. Stuss et al., 1982; Keefe et al., 1995,1997; 
Pantelis et al., 1997). Although the relative degree of the impairment of each 
component is unclear, the crucial pattern is that the tests that involve more than 
one component and/or more complex produce differentially greater severity of 
impairment in patients relative to normal controls. This pattern of results confirms 
the findings from imaging studies suggestive of a working memory system that is 
of more limited capacity than in healthy individuals. 
Patients with schizophrenia were found to be more impaired on working memory 
function than patients with frontal or temporal lobe lesions, matched for age, sex, 
and premorbid intellectual ability (IQ) as measured by National Adult Reading Test 
(NART) (Pantelis et al., 1997). Schizophrenia patients have showed worse use of 
strategies on working memory task as compared to other patients, suggesting that 
the impairment in executive function (see below for a definition) may underlie the 
working memory impairment in schizophrenia. However, one might argue that if 
the central executive capacity of the working memory system is more limited in 
individuals with schizophrenia than in other populations, this will impede the 
successful use of strategies on a working memory task even if there is no 
dysfunction in executive function per se. Thus, it is not always easy to distinguish 
between two alternatives to account for poor working memory, i. e. the system of a 
more limited capacity vs. inadequate use of strategies. The evidence points to the 
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impairment of both; therefore, it is likely that both factors contribute to working 
memory deficit in schizophrenia. 
Working memory deficit is more severe than the deficits in some aspects of long- 
term memory in schizophrenia patients. Performance on verbal working memory 
was found to be 4 SDs below the normal mean, while the performance on long- 
term memory as measured by recognition was only 1 SD below the normal mean 
(Sullivan et al., 1997). Recognition memory does not require any strategic 
processing of the information. This finding might mean that although passive 
learning can be relatively preserved in schizophrenia, more complex learning that 
requires active and strategic processing of the information might be impaired due 
to the deficit in working memory function. In fact, it was found that deficits in 
strategic long-term memory (free recall, memory for temporal order and self- 
ordered pointing) could be accounted for by the deficits in working memory (Stone 
et al., 1998). The fact that working memory deficits can cause impairment in long- 
term memory will have an implication for the learning of new and complex skills 
and have a consequence for the functional outcome. 
2.3.1.4. Relationship between working memory and symptoms 
The working memory impairment is thought to associate with formal thought 
disorder. As monitoring one's own speech is one of the functions of working 
memory, the individual with gross impairment in this function might find it difficult 
to remember the original intention of the sentence one has just spoken. The 
speech of such an individual might be potentially filled with loose associations and 
derailment (Rochester, 1978). Indeed, visuo-spatial working memory impairment 
has been found to significantly correlate (r = 0.52) with formal thought disorder 
(Spitzer, 1993). 
One of the functions of working memory is to keep track and retain the information 
about the origin of the stimuli, i. e. external vs. internal. Frith and Done (1989) has 
put forward an interesting suggestion that some of the positive symptoms of 
schizophrenia might be due to the failure to monitor the initiation of self-generated 
thoughts. These positive symptoms might include thought insertion, delusions of 
control, auditory and visual hallucinations. Empirical findings suggest that this 
indeed might be the case. It was found that schizophrenia patients are worse than 
healthy people in monitoring the source of self-generated information, but similar 
to normal people at monitoring the information perceived from visual or auditory 
sources. Moreover, patients with auditory hallucinations were more impaired on 
source monitoring than patients without these symptoms (Keefe et al., 2001). 
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Keefe (1998) has hypothesised that working memory deficit might underlie one's 
inability to identify self-generated mental content, referred to as 'autonoetic 
agnosia'. However, the relationship between working memory deficit, autonetic 
agnosia and positive symptoms has not been studied directly. 
Working memory is also associated with negative symptoms. The pattern of the 
findings suggests that the dysfunction of working memory might cause some of the 
negative symptoms such as lack of motivation, rather then other way around. 
Thus, in the study of working memory that used pupil size as a measure of effort 
put into a performance on the task, it has been concluded that working memory 
deficit can not be accounted for by reduced motivation (Granhoim et al., 1996). 
2.3.2. Executive function 
2.3.2.1. The definition of executive function 
Executive function refers to a set of cognitive abilities that are required for a goal- 
directed behaviour and adaptation to a range of environmental changes and 
demands (Loring, 1999). These include the ability to plan and to anticipate 
outcomes; to use abstract concepts in order to work out and to execute the 
strategies for problem solving whilst monitoring one's actions and their impact, and 
to adjust one's responses according to feedback. Executive skills are most 
important for dealing with novel and/or complex situations. In essence, executive 
function is involved in controlled and goal-oriented behaviour as opposed to 
reflexive or automatic one. Physiologically, executive function is linked to frontal 
lobes but is not confined to them, as there is a growing awareness of the 
importance of cortical-subcortical circuits in frontal functions (e. g. Cummings, 
1993; Jones, 1997; Pantelis et al., 1997). 
There is a conceptual overlap between the central executive of working memory 
model and executive function. However, these two concepts are separate, although 
closely interlinked. Executive function refers to the temporally more extended 
process than the central executive. The central executive refers to the ability to 
hold and manipulate information on-line for the short periods of time, whereas 
executive function refers to one's ability to solve problems and conduct goal- 
directed behaviour over extended periods of time. Although theoretical differences 
between two concepts are apparent, both processes depend heavily on attention 
resources. This led some researchers to argue that it is very difficult to distinguish 
between two processes in reality. In fact some of the tasks, such Tower of London, 
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Wisconsin Card Sorting Task (WCST), or Trail Making form B, have been used to 
measure working memory or executive function processes by different researchers 
(e. g. Goldberg et al., 1990; Braff et al., 1991; Pantelis et al., 1997; Moritz et al., 
2002; Pukrop et al., 2003). 
2.3.2.2. Tests of executive skills 
There are many tasks that are used to measure executive function, such as Trail 
Making Test, the Category Test, the Stroop Colour Word Test, Tower of 
London/Hanoi/Toronto tasks and WCST mentioned earlier. These tests measure 
different executive skills. Trail Making Test, form B (Reitan and Wolfson, 1993) 
tests, amongst other skills, the ability to rapidly switch between processing two 
types of stimuli (mental flexibility). The Category Test (Reitan and Wolfson, 1993) 
requires the ability to think abstractly, derive hypotheses and test them while 
adjusting one's performance in response to the feedback. The Stroop Colour Word 
Test (Stroop, 1935) requires the inhibition of pre-potent automatic response, which 
is considered to be one of the roles of the executive function in controlling 
behaviour. Tower tasks test planning ability for the optimal rout to reach the goal 
by holding different options in mind and choosing the best one by comparison. 
Finally, WCST (Heaton, 1993) is similar in its demands to the Category Test by 
requiring subject to form abstract concepts in regard to the stimuli, to generate 
hypotheses for the problem solving and to shift strategies in response to the 
feedback. 
2.3.2.3. The nature of executive dysfunction 
As early as Kraepelin, it was recognised that schizophrenia involves disturbances in 
executive function skills. Since executive dysfunction in schizophrenic patients 
resemble certain aspects of behavioural problems of people with 'frontal lobe' 
syndrome, schizophrenia was even considered to be a frontal lobe disorder. 
Schizophrenia patients show deficits on most measures of executive function when 
compared to healthy individuals (e. g. Fey, 1951; Goldberg et al., 1990; Braff et al., 
1991; Perlstein et al., 1998). This suggests that the executive skills that are 
tapped by the tasks either: (i) are not developed to the same extent as in healthy 
controls and thus might present a neurobiological vulnerability; or (ii) have been 
damaged by the disease process and/or medication. 
Long-term treatment with typical antipsychotics have not been found to have 
either beneficial or detrimental effect on executive function (e. g. Cassens et al., 
1990) and in lower doses was found to have beneficial affect on attentional aspect 
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of executive function as measured by the Stroop test (Harris et al., 1997). These 
findings suggest that in chronic patients treated with neuroleptics over a period of 
time deficits in executive function cannot be attributed to the effect of medication. 
The studies that attempted to discriminate between the alternatives (i) and (ii) 
have produced inconclusive results. Some of the investigators have found deficits 
in executive function (usually measured by WCST) in first-degree relatives (e. g. 
Franke et al., 1992; Sharma et al., 1999) or those with schizotypal personality 
disorder (Trestman et al., 1995), suggesting that the deficits in executive function 
might be a neurobiological factor rather than the consequence of the illness. 
However, the evidence to support this conclusion is not robust at the present, since 
others have not corroborated these findings (Battaglia et al., 1994; Stratta et al., 
1997). It is likely that there is a state (associated with symptoms, medication, 
etc. ) as well as a trait (residual deficit even after effective treatment, and as found 
in unaffected relatives) component to the executive dysfunction in schizophrenia. 
2.3.2.4. Relationship between executive dysfunction and symptoms 
The degree of executive dysfunction is associated with some symptoms, but not 
others. Positive symptoms, such as hallucinations and delusions, have almost no 
correlation with the severity of executive dysfunction (Franke et al., 1992; Morris 
et al., 1995; Voruganti et al., 1997), whereas the severity of negative symptoms, 
such as affective flattening, alogia, social withdrawal or avolition, correlate with 
poor performance on executive function measures (e. g. Rossi et al., 1997; 
Voruganti et al., 1997). However, one study of unmedicated young acute females 
with schizophrenia (Parellada et al., 2000) has found WCST performance deficits to 
associate with both positive and negative symptoms. 
Performance on WCST has also been found to correlate with the lack of insight of 
illness (e. g. Young et al., 1993; Voruganti et al., 1997). Unawareness of illness 
has been shown to correlate with poor medication compliance (Garavan et al., 
1998), self-injurious behaviour (Meltzer, 2001), and with the risk of violence 
directed towards others (Arango et al., 1999). Several studies have suggested 
that unawareness of illness may be specifically linked with executive impairments 
and not with other cognitive deficits such as attention or memory (e. g. Lysaker et 
al., 1998; Rossell et al., 2003; but see Marks et al., 2000). Thus, executive 
dysfunction can lead to a poor outcome by predisposing an individual with 
schizophrenia to the failure to comply with the treatment as well as violent 
behaviour towards oneself and others. 
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2.3.3. Attention 
2.3.3.1. The definition of attention 
Attention refers to a set of operations that enable the organism to detect, 
recognise, and identify relevant stimuli in the environment. Selective attention 
refers to the ability to focus on the stimulus ignoring the rest of the sensory input 
as well as internally generated content. Sustained attention (or vigilance) refers to 
the ability to focus on the stimulus over a period of time or until the processing of 
it is complete. 
2.3.3.2. The nature of attention deficit 
Both Kraepelin and Bleuler have emphasised disturbances in attention as a core 
deficit in schizophrenia. Inability to sustain attention over a period of time 
(distractibility) as well as inability to attend selectively to one stimulus while 
reducing the salience of others (overinclusiveness) can lead to sensory overload 
and predispose one to the experiences that patients with schizophrenia describe. 
The phenomenological descriptions of these experiences by patients often have 
reference to being overwhelmed by the environment where every stimulus has a 
perceptual and/or emotional salience, importance and meaning. It has been 
hypothesised that this overwhelming sense of importance and meaning about even 
most banal events can lead to a development of delusions, the purpose of which is 
to make sense of these subjective experiences (Hemsley, 1998). 
Some contemporary researchers identify deficits in attention and information 
processing as 'central' to the disorder (e. g. Braff, 1985). Indeed, deficits in 
attention theoretically can underlie deficits in other higher cognitive functions such 
as working memory and executive function. There have been a multitude of studies 
investigating attentional processes, both controlled and automatic, in schizophrenia 
using neuropsychological and psych ophysiologicaI (e. g. pre-pulse inhibition of the 
startle response (e. g. Kumari et al., 1999,2000,2002b, in press), eye movements 
(e. g. Solomon et at., 1987) methods. 
The pattern of the findings in schizophrenia patients suggests that poor 
performance on the measures of attention is not due to the failure to allocate 
attention, indicating that the executive control of attentional function is not 
impaired. For example, while patients with schizophrenia deteriorate more than 
healthy individuals when asked to perform multiple cognitive tests in divided 
attention studies, they appear to utilize normal processing strategies. 
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Furthermore, the findings suggest that the attention deficits are related to 
sustained and selective attention processes and are not simply due to excessively 
slow processing (review, Cadenhead and Braff, 2000). 
Perhaps more than any other aspect of cognitive functioning, attentional deficits 
are strong candidates as markers of vulnerability. Attentional deficits were shown 
to be persistent in patients with schizophrenia who were largely in remission of 
their symptoms (e. g. Nuechterlein et al., 1986). Children and unaffected relatives 
of schizophrenia patients, as well as individuals with schizotypal personality 
disorder show deficits in both sustained and selective attention widely replicated 
across studies (e. g. Cornblatt and Erlenmeyer-Kimling, 1985; Erlenmeyer-Kimling 
et al., 1989; Green et al., 1997; Young et al., 1998). 
2.3.3.3. Relationship between attention deficits and symptoms 
Attention deficits have been found to associate with deficit syndrome and its 
persistent (primary) symptoms, such as restricted affect, diminished emotional 
range, poverty of speech, curbing of interests, diminished sense of purpose, and 
diminished social drive (e. g. Thaker et al., 1988; Ross et al., 1997). Schizophrenia 
patients who are highly distractable (i. e., have poor ability to focus and sustain 
attention) have been found to have higher levels of formal thought disorder (e. g. 
Cornblatt et al., 1985; Perry and Braff, 1994; Solomon et al., 1987). The 
association between attentional dysfunction and positive symptoms (hallucinations 
and delusions) has also been demonstrated (Cornblatt et al., 1985). The 
relationship of attentional dysfunction with all three- symptom dimensions 
reinforces the view that attentional impairment is at the core of schizophrenia. 
2.3.4. Learning and memory 
2.3.4.1. The definition of learning and memory 
The human memory system is complicated and multifaceted. There are many 
components of this system, with many different ways to conceptualise memory 
performance. The common subdivisions of the memory system focus on both the 
type of information to be learned and remembered, e. g. general knowledge vs. 
autobiographical facts, as well as the duration of storage of the information, e. g. 
short-term vs. long-term. Short-term memory concept is intrinsically linked with 
the concept of working memory, discussed earlier in the chapter. In this section, 
the function of long-term memory and learning will be discussed. 
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2.3.4.2. The nature of memory and learning impairment 
Deficits in memory and learning are not homogeneous and differ in their severity 
across different components of memory system. Some of the impairments are so 
severe that they have been said to present a differential deficit, while other 
memory and learning functions have been found to be relatively preserved as 
compared to healthy people and to be least impaired as compared to other 
cognitive domains deficient in schizophrenia. 
Episodic memory, the ability to learn and recall information from previously 
experienced events (Tulving, 1983) has been proposed to present a differential 
deficit in schizophrenia (e. g. Gold et al., 1992). One study (Saykin et al., 1991) of 
medication free and medication naive patients used a profile analysis of the 
cognitive impairment and demonstrated that memory function was more severely 
impaired than other cognitive functions such as attention, executive function, 
language, spatial abilities, sensory and motor functions. This pattern of findings 
was confirmed with a sample of first-episode neuroleptic-naive patients (Saykin et 
al., 1994), showing that this differential memory impairment cannot be accounted 
by the effect of neuroleptic or anticholinergic medication. More recently, 
Toulopoulou and colleagues (2003) reported differential impairment in verbal 
memory as measured by the recall on Logical Memory tasks, both immediate and 
delayed, in both schizophrenia patients and their relatives, suggesting that 
dysfunction in verbal memory might present familial, presumed genetic, liability to 
schizophrenia. 
It is noteworthy that in the study by Saykin et al. (1994) the only other area of 
severe impairment was sustained attention as measured by the CPT. Theoretically, 
attention and memory are very closely interlinked. Failure in selecting the stimuli 
for further processing and storage will inevitably lead to poor learning of the 
information and thus failure of memory. Equally, executive component of working 
memory might play an important intermediate role in the process of information 
acquisition. Poor encoding strategies will lead to attentional overload and thus to 
the disruption of the encoding of the information, which subsequently will result in 
poor learning and memory. Thus, although memory impairments can be 
differentially severe in schizophrenia, this does not undermine the significance of 
the impairment in other domains, as different domains are intimately interlinked. 
Therefore, even a modest disruption in one can lead to a relatively greater 
disruption in the others. 
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Indirectly confirming this theoretical notion is the fact that memory problems in 
schizophrenia are not due to rapid forgetting, but due to encoding and retrieval 
deficits, since recognition deficits in patients are mild (e. g. Paulsen et al., 1995), 
suggesting that the information storage in schizophrenia is relatively intact. 
Furthermore, schizophrenia patients have been directly shown to be impaired in 
the encoding of the information (e. g. Gold et al., 1992). When read a story or a 
list of words, they learn less than healthy individuals even after the presentation is 
repeated, showing a reduced "learning curve". On the retrieval side, schizophrenia 
patients appear to recall less information than healthy individuals when they are 
asked simply to reproduce the information previously learned without cues or 
prompts (free recall) (e. g. Paulsen et al., 1995). This recall failure remains even 
when the reduced learning rate is accounted for. Furthermore, schizophrenia 
patients benefit less from prompted and cued recall than healthy individuals. They 
are also less able to use semantic structure embedded in the information to aid the 
encoding and the retrieval of the information (e. g. Kareken et al., 1996). This is 
not simply due to the lack of strategy use. Even when patients are instructed to 
cluster the information (e. g. by categories), they still do not benefit from the 
embedded structure in the information to be recalled. This failure to utilise a 
clustering strategy was found to be the primary explanation of encoding and 
retrieval problems (e. g. Iddon et al., 1998) and has been attributed to impaired 
executive aspects of working memory (Goldman-Rakic, 1994). 
The failure to use encoding strategies has been also linked to the disruption of 
semantic system functioning, which might be the consequence of the learning 
process where the information is acquired without any organisational structure at 
the time of encoding and storage. Impairment of semantic memory has been 
repeatedly reported in schizophrenia patients (Kareken et al., 1996; McKay et al., 
1996; Aloia et al., 1998; Goldberg et al., 1998). The level of semantic memory 
deficits in schizophrenia was found to match that of the patients with Alzheimer's 
dementia (McKay et al., 1996). 
This semantic memory impairment may have a consequence for the information 
access. Thus, one of the tasks used to assess semantic memory requires a subject 
to generate a list of word using first a phonological principal (i. e. words starting 
with 'F') and then semantic principle (i. e. words belonging to the category 
'animals'). In healthy individuals, semantic fluency exceeds the phonological 
fluency, i. e. they give more responses to a semantic cue rather than a phonological 
one. In subgroup of patients with schizophrenia these pattern is reversed and this 
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lack of semantic fluency is associated with the presence of sever formal thought 
disorder (Goldberg et al., 1998). 
Studies that used other methods of assessing semantic memory in schizophrenia, 
such as word associations, priming effect and analysis of the verbal output have 
also found abnormalities in the structure of semantic memory in schizophrenia 
patients as compared to normal controls (review, Spitzer, 1997). As has been 
discussed above, this structural impairment of semantic memory may have 
consequences for both encoding and retrieval of knowledge. 
Other aspects of learning and memory are not impaired to the same extent as 
semantic or episodic memory. Thus, deficits in procedural learning, the ability to 
learn skills and motor acts, are relatively mild (e. g. Goldberg et al., 1993). There 
is some uncertainty as to what extent the impairment in procedural learning is 
inherent to the disease process and to what extent it is impaired by the treatment, 
since it has been shown to be affected by the treatment with neuroleptic 
medication (Bedard et al., 1996,2000). Studies indicate that both might have play 
a role, as patients with schizophrenia on conventional antipsychotics show slower 
rates of motor learning than medication-naive patients (Purdon et al., 2003), while 
medication-naive patients show poorer procedural memory than normal controls 
(e. g. Scherer et al., 2003). 
2.3.4.3. Relationship between memory & learning and symptoms 
Goldberg and colleagues (1993) examined different aspects of memory and 
learning, including semantic, episodic and procedural, in monozygotic twins 
discordant for schizophrenia and found an inverse relationship between verbal 
episodic memory (memory for stories) and negative as well as positive symptoms. 
Heydebrand and colleagues (2004) studied correlates of cognitive deficits in first 
episode schizophrenia patients and observed the relationship between the severity 
of negative symptoms and general psychopathology symptoms and memory 
impairment, as measured by a summary index which included scores on both 
verbal and non-verbal episodic memory tasks. Bruder et al. (2004) have reported 
that patients with deficits in both verbal and spatial memory had greater negative 
symptoms severity than patients with only verbal memory deficit. Rushe and 
colleagues (1999), however, observed no relationship of either negative or positive 
symptoms with verbal or non-verbal episodic memory and learning in chronic 
schizophrenia patients. Finally, both verbal and non-verbal memory deficits were 
58 
found to be associated with greater severity of thought disorder (Nestor et al., 
1998). 
2.3.5. Psychomotor function 
2.3.5.1. The definition of motor function 
Psychomotor function is defined as pertaining to the motor effects of psychological 
processes. Psychomotor tests are tests of motor skill which depend upon sensory 
or perceptual motor coordination. The most widely used measures of psychomotor 
function in schizophrenia research are the tests of fine motor function, such as 
finger tapping test (FTT) and grooved peg board (GPB). FIT assesses psychomotor 
speed, whereas GPB assesses dexterity. 
2.3.5.2. The nature of psycomotor dysfunction 
Compared with other cognitive processes, relatively less attention has been 
focused on psychomotor functioning in schizophrenia (Walker et al., 1999), even 
though some of the earlier precursors of schizophrenia spectrum disorders are 
disturbances in motor functioning (e. g. Fish et al., 1992; Neumann and Walker, 
1995; McNeil and Cantor-Grace, 2000). Dysfunctions in motor functioning, 
particularly psychomotor speed and dexterity, are consistently seen in adults with 
schizophrenia (e. g. Saykin et al., 1994; Bilder et al., 1995). Cannon et al (1999) 
found that motor dysfunction at the age of 4 was a significant predictor of an adult 
schizophrenia diagnosis. It is unlikely to be of genetic origin, since it is one of the 
deficits differentiating monozygotic twins discordant for schizophrenia (Golderg et 
al., 1990; Suddath et al., 1990). There is a growing body of literature suggesting 
that motor dysfunction in schizophrenia is associated with social and emotional 
disturbances (e. g. Fish et al., 1992; Dworkin et al., 1993; Neumann et al., 1995; 
Walker et al., 1996). It is also associated with the deficits of higher cognitive 
processes. D'Reaux et al. (2000) found the motor functioning assessed with the 
finger-tapping test (FTT) was strongly positively correlated with attention/working 
memory performance in healthy adults and patients with schizophrenia. More 
recently, Silver and Shlomo (2001) observed an association between motor 
functioning and the ability to identify facial emotional expressions in schizophrenia 
patients. Finally, motor function, particularly dexterity, has been found to predict 
rehabilitation success in patients (Weaver and Brooks, 1964). Licher and 
Cummings (2001) proposed that motor, cognitive, and emotional disturbances in 
schizophrenia arise due to subcortical basal ganglia dysfunction. In summary, 
psychomotor dysfunction is a prominent feature of schizophrenia, which is 
associated with other cognitive, social, and emotional disturbances. 
59 
2.3.5.3. Relationship between motor function and symptoms 
Psychomotor dysfunction is consistently associated with negative symptoms. There 
are a strong positive correlation between motor deficits and withdrawn behaviour 
(Baum and Walker, 1995) and an inverse correlation with anxiety/depression 
(Dworkin et at., 1993; Neumann and Walker, 1995; Walker et al., 1996). Slower 
finger tapping was associated with an increase in disorganized symptoms in a 
longitudinal study of cognitive function in first-episode and recent-onset 
schizophrenia patients by Gold et al. (1999). The presence of motor dysfunction 
early in the illness is associated with the emergence of tardive dyskenisia later in 
the disease process (Cliquiri and Lorh, 1994). 
2.3.6. Summary of cognitive deficits 
Patients with schizophrenia show deficits across a large number of neurocognitive 
domains. Overall performance deficit can be between 1.5 and 2 SDs below the 
normal population mean (Bilder et al., 1995). Some of the cognitive domains tend 
to differentiate between patients and healthy controls more reliably than others. 
These include working memory, learning and memory, executive function, 
language skills, attention, and psychomotor function (e. g. Bilder et al., 1994; 
Saykin et al., 1991,1994; Riley et al., 2000). Amongst these domains, verbal 
learning and memory might present a differential impairment with up to 3 standard 
deviations below the normal performance levels (Saykin et al., 1991; 1994). The 
impairment of verbal learning and memory has been linked to the disruption of 
normal semantic system structure in schizophrenia, the indirect evidence of which 
has been repeatedly observed in schizophrenia patients (Kareken et al., 1996; 
McKay et al., 1996; Aloia et al., 1998; Goldberg et al., 1998). Overall, 
schizophrenia patients show much more severe impairments on the tests of higher 
cognitive function that require cognitive control and active information processing 
for the optimal performance. Tests of perceptual discrimination, implicit memory, 
procedural learning or recognition memory do not reliably differentiate patients 
with schizophrenia from healthy individuals (e. g. Goldberg et al., 1993; Bilder et 
al., 1995). 
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2.4. Theories Relating Structural Alterations to Cognitive 
Dysfunction in Schizophrenia 
Cognitive deficits characteristic of schizophrenia are generally conceived to be a 
manifestation of brain pathology. Kraepelin proposed that schizophrenia is a 
disease of the frontal lobes (Kraepelin, 1919). The integrity of the frontal lobes 
and particularly prefrontal cortex is associated with higher cognitive functions such 
as executive control, planning, decision making, goal-directed behaviour, selective 
attention, working memory; all of which have been shown to be disrupted in 
schizophrenia (review, Elvevag and Goldberg, 2000). 
The most influential model linking frontal lobe abnormality to psychopathology and 
cognitive deficits in schizophrenia was proposed by Goldman-Rakic (1995; 1999; 
Goldman-Rakic and Selemon, 1997). The model considers the prefrontal cortex to 
be the primary site of schizophrenia pathology that would affect working memory 
in particular. According to the model, the failure of working memory might 
underlie negative symptoms, behavioural disorganisation, formal thought disorder 
and cognitive deficits such as executive function, conceptual thinking and memory 
formation. 
Pearlson and colleagues (1996) proposed that schizophrenia is a disease of 
heteromodal association cortex. They suggested that dynamic interrelationships 
between the regions of heteromodal association cortex, including dorsolateral 
prefrontal cortex, heteromodal regions of superior temporal gyrus, inferior parietal 
lobule, limbic system and basal ganglia, as well as normal neocortical left/right 
asymmetry might be neurodevelopmentally disrupted in schizophrenia leading to 
its cognitive and symptomatic features. 
Crow (1989,1990,1995) has stressed decreased left/right asymmetry in the 
temporal lobe of schizophrenia patients and proposed that this developmental 
abnormality has a genetic component related to the evolution of language in the 
human species. The failure to develop normal brain asymmetries is hypothesised 
to underlie schizophrenia phenotype and lead to cognitive (particularly that of 
language) and symptomatic disturbances characteristic of schizophrenia. 
Other models concentrate on inter-connections and inter-relationships of function 
between the prefrontal cortex, temporo-limbic cortex (particularly hippocampus), 
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and the ventral striatum, as well as dopaminergic transmission within the ventral 
striatum to account for schizophrenia phenotype (Buchsbaum, 1990; Carlsson and 
Carlsson, 1990; Grace, 1991; Gray, 1995; 1998; Csernansky and Bardgett, 1998; 
O'Donnell and Grace, 1998). Models that have implicated fronto-striatal and limbic- 
striatal networks vary in detail but have one common feature. All of these models 
draw on reduced glutamatergic input from prefrontal cortex and hippocampus to 
the ventral striatum, which results in changed dopaminergic transmission in 
nucleus accumbens. While abnormalities in hippocampus and prefrontal cortex are 
proposed to account for cognitive disturbances, dopaminergic upregulation within 
nucleus accumbens is suggested to lead to the emergence psychotic features of 
schizophrenia. Some of the researchers extended their models to include 
ventrostriatal-thalamic and thalamo-cortical circuits that would be disrupted as a 
consequence of the primary abnormalities in glutamatergic and dopaminergic 
transmission within ventral striatum (Gray, 1995; O'Donnel and Grace, 1998). 
Jones (1997) proposed that the cell loss in the thalamus itself, either as a primary 
pathology or as secondary to cortical or other subcortical pathology, could lead to 
disintegration of thought processes due to the failure of the thalamus to induce 
oscillation of large ensembles of cortical and thalamic neurons necessary for the 
binding of the brain states in functionally integrated manner. 
Weinberger and Lipska (1995) stressed the importance of prefrontal-temporolimbic 
communication for understanding the nature of schizophrenia phenomenology. 
According to this model, nucleus accumbens is important in schizophrenia only 
within the context of being a site of convergence between prefrontal and 
hippocampal regions. Prefrontal-hippocampal intra-cortical projections as well as 
Papez circuit (Papez, 1937) are two other main routes of prefrontal-temporolimbic 
connections. Dysfunctional prefrontal-temporolimbic connectivity along any of 
these three main routes will result in `noisy' or `missinformed' communication 
between prefrontal and limbic cortices leading to disintegration of normal function. 
Dopaminergic transmission might not be abnormal per se, but rather will be 
evoked in exaggerated and/or contextually inappropriate manner leading to 
increased reaction to stress and vulnerability to psychosis. 
Graybiel (1997) proposed a model that focuses on basal ganglia and parallel 
neuronal circuits that connect them with the neocortex, including efferents from 
prefrontal cortex to caudate nucleus, motor cortex to putamen, and limbic cortex 
to nucleus accumbens. The primary role of the basal ganglia in behaviour is the 
generation of cognitive patterns or templates for action that involve thought, 
movement and emotion within these three cortical-basal circuits respectively. 
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Dysfunction of basal ganglia due to a structural and/or neurochemical abnormality 
would lead to the disturbance of these processes, resulting in cognitive, negative 
and psychotic features of schizophrenia due to an abnormal function of caudate, 
putamen or ventral striatum respectively. 
Andreasen and colleagues (1996; 1998) proposed the 'cognitive dysmetria' model 
of schizophrenia, which concentrates on connectivity between prefrontal cortex, 
thalamic nuclei, and the cerebellum. This cortico-cerebellar-thalamo-cortical 
circuitry (CCTCC) was proposed to have a role in the coordination of both motor 
and cognitive processing (Schmahmann, 1991; 1997; Middleton and Strick, 1994). 
A disruption in the function of this circuitry would result in deficient processing, 
prioritising, retrieval, coordination, and responding to information, i. e. 'cognitive 
dysmetria', which according to this model is the fundamental deficit of 
schizophrenia underlying its broad variety of symptoms. 
To summarise, most of the theoretical models of brain pathology in schizophrenia 
implicate the prefrontal cortex as one of the areas that underlie cognitive and 
clinical features of schizophrenia. However, the prefrontal cortex does not function 
in isolation, and thus all models emphasise the role of the neuronal circuitry 
connecting prefrontal cortex with other cortical and sub-cortical structures to 
account for the multitude of disrupted cognitive processes in schizophrenia. 
Moreover, the prefrontal cortex does not have to be structurally altered in order to 
exhibit functional disruption, as primary abnormalities in other brain regions might 
result in hypofrontality as a secondary pathology. 
2.5. Review of the Studies Investigating Structure/Cognition 
Relationships 
A literature search, using the PubMed electronic journal engine, and manual library 
search for the relevant publications since 1990, as well as searching the reference 
lists of the retrieved articles, revealed 36 MRI studies examining 
structure/neurocognition relationships in first-episode and chronic schizophrenia 
patients, using ROI approach and utilizing methods of image processing and 
analyses that became available in the early 1990s. Most studies used volumetric 
measurements, whereas other studies (Raine eta I., 1990; Colombo et al., 1993; 
Di Michele 1992; Raine et al., 1992; Rossi et al., 1994; Woodruff et al., 1997a) 
used area or/and width measurements. Since area or width of a structure is a 
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reflection of its volume, these studies were also included in the review. One study 
(Saldago-Pineda et at., 2003) has applied VBM to investigate the relationship 
between regional grey matter concentration and the performance on sustained 
attention task (CPT), in addition to the manual ROI volumetric measurement of the 
thalamus and its association with sustained attention deficit. Since concentration 
and volume in the VBM context measure different indices of regional brain tissue 
availability (see section 2.2.1. Methods of quantifying structural alterations for 
more detail), only the findings pertaining to the volumetric ROI part of the analysis 
are included in the review in the relevant section (i. e. Thalamus) to make the 
results of the reviewed studies comparable with one another. The coverage of the 
tissue concentration/neurocognition findings is postponed until Chapter 7 
(Experimental Study 3). 
Most studies had a control group. All studies adopted a correlational design, with 
the exception of three early studies, two of which investigated whether the certain 
structures were altered in the group of patients with specific cognitive deficits 
(Raine et al., 1992; Colombo et al., 1993), and one study (Raine et al., 1990) 
which examined structural and function characteristics of the corpus callosum, but 
did not correlate structural and neurocognitive variables (see Table 2.1 for the 
summary of the main findings). 
One way to structure this review would be by cognitive function. However, as 
different studies have used different neuropsychological tests to measure the same 
cognitive domain, and, conversely, the same tests were used to measure different 
domains, this approach seemed cumbersome, requiring arbitrary decisions about 
attributing neuropsychological measures to cognitive domains. The review, 
therefore, is organized by brain structures, with the view of a particular structure in 
terms of the 'node' within the distributed functional neuronal network(s). In order 
to address two distinct but related issues, namely i) which structural abnormalities 
are associated with cognitive deficits in schizophrenia; and ii) whether 
structure/function relationships seen in normal individuals are altered in 
schizophrenia patients, the findings on the integrity of the structural volumes in 
patients for each brain region, where they were available, are presented in addition 
to examining and comparing the structure/function relationships in patients and 
controls (the information on cognitive deficits can be found in Table 2.1). Not only 
the studies that have found structural volumes to be altered have been included, 
but all studies that have investigated structure/function relationship. The reason 
for this is that if the relationship existed in the absence of statistically significant 
morphological differences between the groups, the exclusion of these findings will 
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result in the loss of information, since the differences might still pertain to at least 
a sub-group of patients. 
The review commences with whole brain volume, followed by ventricular size, 
frontal lobe, temporal and medial temporal lobes, planum temporale, parietal and 
occipital lobes, basal ganglia, cerebellum, midbrain, and brain asymmetries. Almost 
all studies, unless testing a very specific hypothesis, have measured more than one 
region of interest, and thus appear in more than one section, with cross-references 
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TABLE 2.2. Reviewed studies clustered by structure 
Whole Brain Volume Flaum et al., 1994; Gur et al., 1999; Karenken et 
al., 1995; Maher et al., 1995; Seidman et al., 
1994; Torres et al., 1997; Zipursky et al., 1998 
LV & 3rd V Bornstein et al., 1992; DeLisi et al., 1991a; Hoff 
et al., 1992; Goldberg et al., 1994; Maher et al., 
1995; Vita et al., 1995 
PFC Baare et al., 1999; DeLisi et al., 1991 a; Gur et al., 
2000 (a); Maher et al., 1995; Manschreck et al., 
2000; Nestor et al., 2002; Raine et al., 1992; 
Sanfilipo et al., 2002; Seidman et al., 1994; 
Sullivan et al., 1996; Vita et al., 1995; Zuffante et 
al., 2001 
TL DeLisi et al., 1991a; Di Michele et al., 1992; 
Flaum et al., 1994; Gur et al., 2000 (b); Hoff et 
al., 1992; Jeste et al., 1998; Krabbendam et al., 
2000; Maher et al., 1995; Nestor et al., 1993, 
2002; Raine et al, 1992; Sanfilipo et al., 2002; 
Seidman et al., 1994; Sullivan et al, 1996; Torres 
et al., 1997; Vita et al., 1995 
STG Gur et al., 2000 (b); Nestor et al., 1993,2002; 
Sanfilipo et al., 2002; Vita et al., 1995 
Hippocampus/Amygdala Bilder et al., 1995; DeLisi et al., 1991a; Di 
Michele et al, 1992; Flaum et al., 1994, Goldberg 
et al., 1994; ; Gur et al., 2000 (b); Hoff et al., 
1992; Krabbendam et al., 2000; Nestor et al, 
1993; Sanfilipo et al., 2002; Szeszko et al., 2000, 
2002; Tones et al., 1997 
PHG DeLisi et al., 1991 a; Di Michele et al., 1992; Hoff 
et al., 1992; Krabbendam et al., 2000; Nestor et 
al., 1993,2002; Sanfilipo et al., 2002 
Parietal, Parieto/occipital Raine et at., 1992; Sullivan et al., 1996 
Basal Ganglia 
DeLisi et al., 1991a; Flaum et al., 1994; Jeste et 
at., 1998; Levitt et al., 1999; Maher et at., 1995; 
Manschreck et al., 2000; Stratta et al., 1997 
Thalamus Jeste et at., 1998 
Midbrain Nopoulos et al., 2001 
Cerebellum Levitt et al., 1999; Nopoulos et al., 2001 
Corpus Callosum Raine et al., 1990; Hoff et al., 1994; Woodruff et 
al., 1997a; Rossell et al., 2000 
Brain asymmetry Hoff et al., 1992; DeLisi et al., 1997a 
73 
2.5.1. Whole brain volume 
2.5.1.1. Introduction 
Whole brain volume reduction in patients with schizophrenia is found in only 22% 
of the studies (Shenton et al., 2001). Studies that have carefully matched 
patients and normal controls on parental educational levels have failed to find 
reduced brain volumes in patients (DeMyer et al., 1988; Andreasen et al., 1990; 
Pearlson et al., 1991). One study has observed an excess of both smaller and 
larger head size, suggestive of dysmorphic crania in schizophrenia patients rather 
than a systematic decrease in head or brain size (Green et al., 1989). Thus, the 
notion of reduced brain size in schizophrenia remains controversial. 
There is a relationship between brain size and general intelligence in normal 
subject that goes beyond the differences in body and head size (Van Valen, 
1974). The correlation of 0.38 between brain size and full scale IQ as measured 
by Wechsler Adult Intelligence Scale (WAIS-R, Wechsler, 1981) was found in 
healthy normal control subjects (Andreasen et al., 1993). It is not clear whether 
this relationship between brain size and general intelligence is present in 
schizophrenia. 
2.5.1.2. Relationship of whole brain volume to cognition 
Eight studies have investigated the relationship between the whole brain volume 
(WBV) and cognitive function, six studies with a control group (Colombo et al., 
1993; Flaum et al., 1994; Kareken et al., 1995; Torres et al., 1997; Zipursky et 
al., 1998; Gur et al., 1999), and two without (Seidman et al., 1994; Maher et al., 
1995). Of those six studies with a control group, two studies (Flaum et al., 1994; 
Torres et al., 1997) did not compare patients and controls on the WBV. 
Two studies that compared patients and controls matched on parental socio- 
economic status found reduced whole brain grey matter volume in first-episode 
(FE) patients (Zipursky et al., 1998) and chronic patients, particularly women 
with schizophrenia (Gur et al., 1999). White matter volume was found to be 
unchanged in both studies. The third study (Colombo et al., 1993) that compared 
patients and controls on WBV did not segment the brain tissue into grey and 
white matter compartments and observed no WBV alterations in schizophrenia 
patients. Thus, alterations in overall brain tissue availability in schizophrenia 
might be limited to grey matter. Alternatively, reduction in WBV might be limited 
to a specific sub-group of schizophrenia patients, as found by Kareken et al. 
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(1995), who reported WBV reduction in deficit, but not in non-deficit, patients 
relative to normal controls. 
Almost all measures of cognitive functioning were found to correlate with the 
WBV, and particularly total grey matter, indicating `bigger brain-better 
performance' relationship in controls as well as in patients, with the most reliable 
associations found for the measures of general intellectual ability and composite 
cognitive processes such as language, abstraction/flexibility, and verbal and 
spatial reasoning (Seidman et al., 1994; Kareken et al., 1995; Gur et al., 1999). 
The relationship between WBV and memory was not as consistent, with Gur and 
colleagues (1999) reporting a positive association in both patients and controls, 
whereas other studies finding no relationship of immediate and delayed memory 
to WBV either in patients (Colombo et al., 1993; Maher et al., 1995; Torres et al., 
1997) or in controls (Torres et al., 1997). 
There were findings for both patients and normal controls that did not fit into 
'bigger brain-better performance' pattern. Firstly, Flaum and colleagues (1994) 
found a normal relationship between WBV/IQ in female, but not in male, patients. 
Secondly, healthy controls failed to show a WBV/IQ association, when such a 
relationship existed in first episode (FE) patients of mixed gender, with a 
significant difference in the strength of grey matter/IQ correlations between the 
groups (Zipursky et al., 1998). And finally, there were points of convergence and 
divergence in the WBV/cognition relationship amongst the predominantly male 
controls, deficit and non-deficit patients (Kareken et al., 1995), such that 
significant positive correlations existed between WBV and i) language for all 
groups; ii) abstraction/mental flexibility for controls and deficit patients; iii) 
attention, visuo-spatial memory and visuo-spatial perception for controls only; 
and iv) verbal memory for deficit patients only. 
Summary: WBV has a non-specific relationship with cognition, associating with 
the level of general intelligence as well as with more specific cognitive abilities in 
both patients and controls. The magnitude of WVB/IQ association in patients 
appears to be reflecting a normative relationship (r = 0.39, Seidman et al., 
1994). However, some of the findings point towards a more complex, and, 
perhaps, non-linear relationship between brain size and cognitive abilities in male 
patients. 
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2.5.2. Ventricular size 
2.5.2.1. Introduction 
Enlargement of lateral ventricles (LV) is found in 80% of the studies, while the 
third ventricle is found to be enlarged in 73% of the studies (Shenton et al., 
2001). Ventricular enlargement is present at the onset of the illness and is 
associated with poor premorbid adjustment (Weinberger et al., 1980; DeLisi et 
al., 1983), more severe negative symptoms (Andreasen et al., 1982; Pearlson et 
al., 1984; Kemali et al., 1985), and is generally predictive of poor outcome in 
schizophrenia (DeLisi et al., 1983). 
The enlargements of the LV and of the third ventricular cavity might indicate 
morphometric abnormalities in the structures of the temporo-limbic complex and 
thalamus that are part of cortico-temporo-limbic-cortical and cortico-striato- 
thalamo-cortical circuits respectively. Consequently, the enlargement of the 
ventricles might be associated with disrupted performance on tests of higher 
cognitive functions that are subserved by these circuits. These might include 
verbal learning and memory as well as attention and concentration. 
2.5.2.2. Relationship of ventricular size to cognition 
Six studies have investigated the relationship between the ventricular size and 
cognitive deficits, four with a comparison group (Bornstein et al., 1992; Hoff et 
al., 1992; Goldberg et al., 1994) or groups (DeLisi et al., 1991a), and two without 
(Maher et al., 1995; Vita et al., 1995). 
Two studies did not find any associations between an absolute size of lateral 
ventricles (LV) and cognitive performance in patients (DeLisi et al., 1991a; Hoff et 
al., 1992), despite the increased LV size in FE and chronic patients relative to 
neurological controls, with greater prominence on the left side in the DeLisi et al. 
study. The latter study has also measured the size of the third ventricle, finding 
no size differences or relationship with cognitive function. In the study by Hoff et 
al. (1992), almost all cognitive domains inversely correlated with LV size in 
normal controls, with smaller left LV being associated with better 
concentration/speed and sensory/perception, and smaller right LV being 
associated with better executive function, concentration/speed, 
sensory/perception, a global performance scale, verbal memory and a left 
hemisphere scale. (The association of right LV size with the left hemisphere scale 
might be due to the mixed handedness sample. ) When a sub-sample of patients 
was reassessed on neuropsychological measures 2 years later, there was 
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significant improvement on the domains that were most impaired at the time of 
the initial assessment, that is, executive function, concentration/speed, global 
scale, and, at the trend level, sensory/perceptual scale. Noteworthy, these are 
the scales that were found to correlate with the LV size in normal controls. It is 
possible that the severity of cognitive impairment was partly related to 
symptomatic state at the time of the first assessment in this sample of FE 
patients. However, the relationship between symptoms rating and cognitive 
function was not reported. The possibility that the pattern of correlations similar 
to that of controls between cognitive scores and LV size would have been found in 
these patients at 2-year follow-up is intriguing; however, there are no data 
available on follow-up relationship between cognitive and LV measures. 
A counter-intuitive relationship of enlarged absolute LV size and less 
perseveration has been found in the study of 15 pairs of monozygotic twins 
discordant for schizophrenia (Goldberg et al., 1994). Affected twins also showed 
an enlargement of the LV temporal horn and of the third ventricle, but these did 
not associate with cognitive deficits. Another study (Vita et al., 1995) measured 
the segments of LV, including frontal, body, temporal, and occipital, in chronic 
patients and found a significant enlargement of the LV body, but this was 
unrelated to language function. 
The absence of correlations between the ventricular size and cognitive deficits in 
schizophrenia patients in the studies reviewed might be due to the use of 
absolute volume measurements. Since patients with schizophrenia might have 
smaller as well as larger than average cerebrums (Green et at., 1989), relative 
measurements of ventricular size might be more appropriate. Indeed, a study 
(Bornstein et al., 1992) that calculated ventricle to brain ratio (VBR) has found 
enlarged lateral VBR to associate with worse forward Visual Span 
(attention/concentration), as well as finger tapping task using the non-dominant 
hand (psychomotor speed) in female schizophrenia patients. However, these 
associations were attenuated in affected men. Third VBR was also enlarged in 
men and women with schizophrenia relative to healthy counterparts, and 
inversely correlated with the tests of abstraction/categorization (Verbal Concept 
Formation Test, WCST categories completed) and attention/concentration 
(Seashore Rhythm, Digit Span). Surprisingly, in normal controls, larger lateral 
VBR and third VBR were associated with better cognitive performance, including 
larger lateral VBR with verbal IQ; and third VBR with verbal fluency and verbal 
concept formation. These positive correlations in controls are difficult to 
interpret. Fewer correlations between VBR and cognitive measures in controls 
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overall might be due to almost negligible variability in VBR, presumably due to 
the linear relationship between ventricular and brain sizes. In patients, on the 
other hand, the mean values for the third VBR were twice the magnitude of those 
found in controls with substantial variability, indicating disproportionately larger 
third ventricle in relation to brain size on average. In the final study employing 
VBR measurements (Maher et al., 1995, see also Whole brain volume), which 
examined neural correlates of short-term memory in schizophrenia, neither 
absolute nor relative LV size correlated with context-free or context-aided free 
recall. 
Summary: Four main points emerge regarding the relationship of ventricular 
size to cognition: (1) the relationship between ventricular size and cognitive 
function is complex, with both larger LV (in normal controls and female patients; 
Hoff et al., 1992) and smaller LV (in controls; Bornstein et al., 1992; and in male 
patients; Goldberg et al., 1994) being associated with better cognitive 
functioning; (2) the relationship between LV size and cognitive functioning might 
be disrupted in affected men (Hoff et al., 1992), paralleling the findings observed 
for WBV and IQ; (3) the abnormality of ventricular size and its association with 
cognitive measures are more reliably found when the measures of relative, as 
opposed to absolute, size are used; and (4) the size of the third ventricle might 
be more illuminating as to the nature of the cognitive disturbances in 
schizophrenia, as third ventricular enlargement might indicate the pathology of 
the thalamus, which is immediately adjacent to the third ventricle. This putative 
thalamic abnormality might cause disruption of cortico-striatal-thalamo-cortical as 
well as cortico-cerebellar-thalamo-cortical circuitry, resulting in deficient 
abstraction/flexibility and attention/concentration (Bornstein et al., 1992). 
2.5.3. Frontal lobe 
2.5.3.1. Introduction 
Only 60 % of the studies reported abnormality of the frontal lobe in schizophrenia 
patients (Shenton et al., 2001). However, the frontal lobe is a large area, 
comprising 30 % of human cerebral cortex and consisting of highly differentiated 
(both cytoarchitectonically and functionally) regions. Studies that examined 
subregions of frontal lobe, such as dorsolateral prefrontal cortex (DLPFC), 
dorsomedial prefrontal cortex (DMPFC) and orbito-frontal cortex (ORFC) have 
consistently noted abnormalities in DLPFC structure (Shenton et al., 2001). 
However, the differences found are small. 
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As prefrontal cortex sends efferents and receives afferents from all other cortical 
and almost all subcortical brain regions (Fuster, 1980), the dysfunction of 
prefrontal cortex and cognitive processes associated with it may potentially arise 
due to the abnormal structure and/or function of any region it connects with. 
There is a growing awareness that impaired performance on frontal lobe tasks in 
schizophrenia might result due to an abnormality of subcortical structures such as 
striatum (Robbins, 1990; Stratta et al., 1997) or limbic cortex (Weinberger, 
1987; Szeszko et al., 2002). Therefore, in this section, it is of particular interest 
if frontal lobe functions are associated with the structural alterations of PFC. 
The studies that examined the whole frontal lobe (FL) are reviewed first, followed 
by the studies that parcellated prefrontal lobe into sub-regions. 
2.5.3.2. Whole FL 
Seven studies have investigated neuropsychological correlates of total FL volume, 
six with a control group (DeLisi et al., 1991a; Vita et al., 1995; Sullivan et al., 
1996; Baare et al., 1999; Sanfilipo et al., 2002) or groups (Raine et al., 1992), 
and one without (Nestor et al., 2002). 
Only two of these studies found reduced FL volume in patients relative to normal 
(Raine et al., 1992; Sanfilipo et al., 2002) and psychiatric (Raine et al., 1992) 
controls, which might be limited to grey matter (Sanfilipo et al., 2002). Baare et 
al (1999) observed smaller GMV and WMV in patients, but had low power to 
detect significance. 
Two studies with a control group observed differences in structure/function 
relationships for patients and controls. Sanfilipo and colleagues (2002) found 
greater prefrontal GMV to be associated with better performance on Digit Symbol 
task in controls, but not in patients. On the other hand, a positive relationship 
existed between prefrontal WMV and cognitive flexibility in patients, but not in 
normal controls. In the second study (Baare et al., 1999), relative PFC volume 
was associated with verbal fluency and immediate recall for verbal and visual 
material in patients, and with delayed recall for visual stimuli in controls. These 
differences in associations between patients and controls might be due to the 
relative difficulty of the tasks. As suggested by the authors, delayed visual recall, 
being a more demanding task, could produce more variability in controls, and 
thus correlate stronger with PFC volume. By the same token, in patients, this 
task might produce a 'floor' effect and hence low variability, resulting in a weak 
correlation with PFC volume. 
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Two studies without a control group have reported a relationship between FL 
volumes and the performance on the so-called frontal lobe tasks. Nestor and 
colleagues (2002), using partial least square analysis, found an association 
between greater GMV and WMV and better working memory in patients. Raine 
and colleagues (1992) investigated a sub-group of patients with an impaired 
performance on frontal, but not non-frontal, measures, and found bilateral PFC 
reductions when compared with normal and psychiatric (predominantly major 
depressive disorder) controls (Raine et al., 1992). 
Other studies did not find any relationship between prefrontal volumes and 
cognitive abilities in patients, perhaps due to an approximate definition and 
measurement of the ROIs corresponding to anatomical brain regions and an 
arbitrary construction of cognitive domains (Sullivan et al., 1996), as well as a 
lack of grey and white matter segmentation in two early studies (DeLisi et al., 
1991a; Raine et al., 1992). 
Summary: Total FL volume is associated with executive functioning, working 
memory, verbal fluency, and immediate memory in schizophrenia. There were 
differences in the pattern of structure/function relationship between patients and 
controls, which might be due to different degrees of variability in performance 
depending on the relative difficulty of the task (Baare et al., 1999), as well as the 
volumes of prefrontal brain tissue, with patients being more variable in prefrontal 
WMV, and controls being more variable in prefrontal GMV (Sanfilipo et al., 2002). 
Additionally, similar volumes of prefrontal grey matter in schizophrenia may not 
result in similar levels of cognitive performance to that of controls; for example, 
due to disrupted connectivity between PFC and other regions involved in the 
cognitive processes engaged by the task, or due to the lack of strategy use, 
prohibiting an optimal utilization of available prefrontal grey tissue. 
2.5.5.3. Regions of PFC 
Seven studies have examined neuropsychological correlates of the PFC sub- 
regions: four (Maher et al., 1995; Baare et al., 1999; Manschreck et al., 2000; 
Gur et al., 2000a) studied dorsolateral prefrontal cortex (DLPFC), dorsomedial 
prefrontal cortex (DMPFC), and orbito-frontal cortex (OFC); one (Seidman et al., 
1994) investigated DLPFC and OFC; one (Szeszko et al., 2000) examined the 
superior frontal gyrus, anterior cingulate and OFC; and one (Zuffante et al., 
2001) focused on Brodmann area 46. All, but three studies (Seidman et al., 
1994; Maher et al., 1995; Manschreck et al., 2000) had a control group. 
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Of the two studies with a control group exploring DLPFC, DMPFC, and OFC, one 
study (Gur et al., 2000a) observed alterations in all three sub-regions. Gur and 
colleagues (2000a) reported a reduction i. n DLPFC volume in both male and 
female patients, a greater DMPFC volume reduction in males than females, and 
OFC reduction only in females. These reductions were limited to grey matter. 
The GMVs of the sub-regions were examined in relation to six cognitive domains 
(abstraction/flexibility, attention, verbal and spatial memory, and verbal and 
spatial abilities), predicting correlations with abstraction/flexibility and attention. 
Correlations with other domains were exploratory and were adjusted for multiple 
comparisons (p < . 01). In accordance with the prediction, greater GMV of DLPFC 
correlated with better performance on abstraction/flexibility, and greater GMV of 
DLPFC and DMPFC correlated with better attention in healthy men. For healthy 
women, greater GMV of DLPFC and DMPFC correlated with better 
abstraction/flexibility. For male patients, correlations between the GMV of DLPFC 
and cognitive domains of interest were attenuated, and the only positive 
correlation was found between DMPFC and attention. For female patients, greater 
GMV of DLPFC was associated with better attention; greater GMV of lateral and 
medial OFC with better spatial memory; greater GMV of lateral OFC with spatial 
abilities; and greater GMV of medial OFC with better verbal memory. These 
findings are in line with functional and lesion data, which suggests that dorsal PFC 
is associated with executive function, while ventral PFC is involved in memory 
(Miller and Cohen, 2001). 
In another study (Maher et al., 1995; see Ventricular size), contextual memory, 
but not rote memory, correlated positively with the relative frontal volume in 
schizophrenia patients (mostly male), with the main contribution of DLPFC to this 
relationship. According to the authors, this finding suggests the DLPFC is 
associated with redundancy utilization during verbal memory tasks, presumably 
by facilitating the encoding of information through the use of context. 
In a later study from the same laboratory (Manschreck et al., 2000), the authors 
tested the hypothesis that motor synchrony, a task requiring redundancy 
utilization for optimal performance, would be associated with PFC volume and 
with context-aided verbal memory in a group of predominantly male patients with 
schizophrenia or schizoaffective disorder. Greater volumes of OFC were found to 
associate with poor motor synchrony. As suggested by the authors, this result 
might be artifactual in a sense that greater OFC volume might simply reflect 
smaller volume of DLPFC, which was positively correlated with context-aided 
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memory in the earlier study (Maher et al., 1995). However, this does not explain 
why neither absolute nor relative DLPFC volumes were found to correlate with 
motor synchrony in Manschreck's et al. study. Alternatively, the authors further 
commented, this association might reflect the role that OFC plays in organizing 
repetitive behavior. This, however, does not explain why larger OFC volume 
would be associated with poorer motor synchrony. A possible interpretation of 
this association might be related to the fact that OFC, by the virtue of its 
connections with limbic and olfactory cortices, plays a role in affective processing. 
Larger volumes of OFC might result in heightened affective salience of the stimuli 
in individuals with schizophrenia -a feature of cognitive processing that would be 
detrimental for utilization of redundancies in the stream of stimuli. In fact, one of 
the phenomenological features of schizophrenic experience is that every event is 
perceived as salient or meaningful (Hemsley, 1994). However, as no normal 
control group has been used in the study, it is not known whether OFC volumes 
were in fact enlarged in this patient group. 
Seidman and colleagues (1994) examined the relationship of DLPFC and OFC 
volumes with verbal and performance IQ, verbal and spatial memory, and 
executive function in a predominantly male group of chronic schizophrenia 
inpatients. Greater total DLPFC volume was associated with higher IQ, as well as 
better performance on WCST and delayed Logical Memory. Hemisphere specific 
associations were also found, such that greater left DLPFC volume was associated 
with higher IQ, better WCST, Similarities, immediate and delayed Logical 
Memory, and immediate Visual Reproduction performance, whereas greater right 
DLPFC was associated with fewer errors on the Continuous Performance Task 
(CPT). OFC did not correlate significantly with any neuropsychological measures. 
Szeszko et al. (2000) measured grey and white volumes of superior frontal gyrus 
(SFG), anterior cingulate (AC), and OFC in order to test the hypothesis that the 
dorsal 'archicortical' (SFG and AC), but not ventral 'paleocortical' (OFC), PFC 
would be associated specifically with executive and motor function in FEP 
patients. Tests of language, attention, memory, and visuo-spatial function were 
used as control variables to examine the specificity of findings. Their hypothesis 
was confirmed in male, but not in female, patients: larger AC volume correlated 
with better executive function, and this association was significantly stronger than 
with other cognitive domains and general IQ. This finding is in agreement with 
the results of Seidman et al. (1994) study (reviewed above), in which 
archicortical, but not paleocortical, PFC volume associated with executive function 
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in a cohort of predominantly male patients. However, the part of the archicortex 
associated with executive function was different in two studies, which might be 
due to different methodology, with Szeszko and colleagues (2000) using gyral 
landmarks for measuring the volume of the sub-region, whereas Seidman and 
colleagues (1994) calculated volume from a single slice. The difference might 
also be due to the tests employed, with Szezsko and colleagues using the 
measures of executive and inhibitory motor control, which are associated with AC 
function (Braver et al., 2001), while Seidman and colleagues used the measures 
of abstraction/flexibility, categorization and sustained attention, which are most 
robustly associated with DLPFC function (Garavan et al., 2002). Nevertheless, 
both studies have found an involvement of the archicortex in executive cognitive 
and motor function, but not of the paleocortex, which is associated with guiding 
emotional aspects of cognition (Fuster, 1980). 
The last study (Zuffante et al., 2001) to be reviewed here tested a very specific 
hypothesis. The authors measured Brodmann area (BA) 46 and working memory 
in 23 male schizophrenia patients and 23 male healthy controls to investigate 
whether compromised working memory in schizophrenia is associated with BA 46 
volume, an area known to be associated with working memory function in 
primates (Goldman-Rakic, 1987) and healthy humans (McCarthy et al., 1994). 
The patients did not show BA 46 volume alterations, but had impaired 
performance on spatial and non-spatial working memory tasks, which was not 
independent of lower general intelligence. There was no association between 
working memory performance and BA 46 volume in patients. These findings 
might imply that working memory impairment could arise due to several 
possibilities, including: i) structural abnormalities in other PFC regions supporting 
working memory, such as BA 9 and BA 40, or other cortical regions, including 
anterior cingulate, premotor and supplementary motor areas, and posterior 
parietal cortex (Smith and Jonides, 1998), ii) disrupted connectivity (i. e. white 
matter abnormalities) within the working memory network; iii) inefficient function 
of BA 46 in the face of structural integrity. In controls, larger left BA 46 volume 
was associated with poorer spatial working memory, but this association was 
insignificant with Bonferroni correction. 
Summary: Overall, it appears that the archicortical PFC correlates most 
consistently with the tasks of executive function (Seidman et al., 1994; Szeszko 
et al., 2000), attention (Gur et al., 2000a), and verbal (Seidman et al., 1994; 
Maher et al., 1995; Gur et al., 2000a) and visual (Seidman et al., 1994) memory 
in schizophrenia, reflecting a normal pattern of structure/function relationships. 
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However, in the individual studies, the pattern of correlations between structural 
and functional measures appears to be different for patients and controls (Gur et 
al., 2002a), for men and women (Szeszko et al., 2000; Gur et al., 2002a), and 
might be attenuated in affected men (Gur et al., 2002a). There is also an 
indication of differential hemispheric involvement in the type of function, with left 
DLPFC being associated with abstraction/flexibility, categorization and non-verbal 
immediate memory, and right DLPFC being associated with sustained attention 
(Seidman et al., 1994). The paleocortex (OFC) appears to have a complex 
relationship with examined cognitive domains, perhaps due to an interaction 
between the nature of the task and the gender of the subjects (Seidman et al., 
1994; Manschreck et al., 2000; Gur et al., 2000a). 
Importantly, not all frontal functions seen to be impaired in patients were found 
to correlate with reduced total and regional PFC volumes in the reviewed studies 
(Gur et al., 2000a; Baare et al., 1999). Conversely, not all studies have found 
abnormal PFC volumes, while observing deficits in frontal function (Zuffante et 
al., 2001; Baare et al., 1999). Abnormalities in other brain regions might be 
contributing to the impaired performance on so called frontal measures in 
schizophrenia, as PFC function depends on the integrity of other cortical and sub- 
cortical structures that together constitute distributed functional networks, as has 
been noted in the introduction to this section. 
2.5.4. Temporal Lobe 
2.5.4.1. Introduction 
Lateral structures of the temporal lobe include the superior temporal gyrus (STG), 
the middle temporal gyrus (MTG) and the inferior temporal gyrus (ITG). Medial 
temporal lobe structures include limbic structures such as the 
hippocampus/entorhinal cortex and amygdala, and paralimbic structures such as 
the parahippocampal gyrus (PHG). 
Abnormalities in temporal lobe and deficits in memory observed in schizophrenia 
were linked together by Kraepelin (1919), who also considered temporal lobe to 
be a site of auditory hallucinations. Anatomical abnormality of left STG is indeed 
found in schizophrenia patients with auditory hallucinations (Barta et al., 1990), 
although not consistently (DeLisi et al., 1992). Overall, 67 % studies have found 
STG volume reduction in schizophrenia (Shenton et al., 2001), but this statistic 
goes up to 100% (10 studies) if only reductions in GMV are considered. 
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Reduction of the volume of hippocampal/amygdaloid complex is amongst the 
most replicable findings in schizophrenia research with 74 % replicability 
(Shenton et al., 2001) and is present in chronic as well as FE patients (Bogerts et 
al., 1990; Lawrie et al., 1999). None of the studies reviewed have looked at MTG 
or ITG, which are involved in auditory and visual processing respectively. 
The studies that examined the whole temporal lobe (TL) are reviewed first, 
followed by those studies investigating the superior temporal gyrus (STG) and 
medial temporal lobe structures. 
2.5.4.2. Whole Temporal Lobe 
Thirteen studies measured the volume of the whole TL, ten with a control group 
or groups (DeLisi et al., 1991a; Di Michele et al., 1992; Hoff et al., 1992; 
Colombo et al., 1993; Flaum et al., 1994; Vita et al., 1995; Torres et al., 1997; 
Krabbendam et al., 2000; Gur et al., 2000b; Sanfilipo et al., 2002), and three 
without (Nestor et al., 1993; Seidman et al., 1994; Maher et al., 1995). 
Only one study (Sanfilipo et al., 2002) found total TL volume reduction in patients 
relative to controls, which was limited to grey matter. Other studies did not 
observe TL reductions, perhaps due to the lack of segmentation into grey and 
white matter, or the insensitivity of the measurements in the earlier studies 
(DeLisi et al., 1991a; Di Michele et at., 1992; Hoff et al., 1992; Colombo et at., 
1993; Vita et at., 1995; Sullivan et al., 1996), which used thick (5-6mm) slices. 
Two studies observed positive associations between TL volume and cognitive 
functioning that were specific to schizophrenia (i. e. not seen in controls), 
including picture naming accuracy in chronic patients (Vita et al., 1995; also seen 
for the STG, see section 2,4.2. ) and concentration/speed in FE patients (Hoff et 
al., 1992). Association with picture naming might be specific to the TL, as it has 
not been observed for the PFC (Vita et al., 1995). 
One study (Flaum et al., 1994, see Whole brain section) reported a disrupted 
TL/cognition relationship in affected men, with greater bilateral TL volume 
associating with higher IQ in female patients and controls of both sexes, but not 
in male patients. 
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Other studies (DeLisi et al., 1991a; Di Michele et al., 1992, Seidman et al., 1994; 
Maher et al., 1995; Sullivan et al., 1996; Sanfilipo et al., 2002) reported no 
relationship between TL volume and specific deficits in schizophrenia, such as 
attention, abstraction/flexibility, verbal and nonverbal memory. In addition, 
Torres et al. (1997) did not find any difference in TL between patients who scored 
high or low on verbal and non-verbal memory tasks. There were no volume 
differences for high and low scoring controls either. Finally, Colombo and 
colleagues (1993) did not find TL size to be abnormal in patients with severe 
short-term memory and attention/concentration impairments. It is possible that 
deficits in abstraction/flexibility, memory and attention/concentration in 
schizophrenia are due to the PFC volume alterations, as reviewed earlier 
(Seidman et al., 1994; Szeszko et al., 2000; Gur et al., 2000a). Alternatively, 
more specific regions of TL might associate stronger with some of these cognitive 
processes, including learning and memory, and abstraction/flexibility, as reviewed 
further. 
2.5.4.3. Superior Temporal Gyrus 
Four studies have measured STG volume, three with a control group (Vita et al., 
1995; Gur et al., 2000b; Sanfilipo et al., 2002), and one without (Nestor et al., 
1993). Two studies (Gur et al., 2000b; Sanfilipo et al., 2002) have found 
reduction of STG grey matter in men, but not in women (Gur et al., 2000b). Vita 
et al. (1995) did not segment the STG into grey and white matter, which might 
explain their negative finding. 
Greater left STG volume was associated with better verbal fluency and picture 
naming accuracy specifically in patients (Vita et al., 1995). In another study 
(Nestor et al., 1993), greater GMV of left and right posterior STG correlated with 
better abstraction/categorization, and greater GMV of left posterior STG with 
learning of verbal paired associations in male patients. The posterior STG, which 
includes Wernicke's area, is involved in language comprehension and semantic 
processing. Therefore, one interpretation of these findings, as suggested by the 
authors, is a dysfunction of the semantic system, which might underlie deficits in 
abstraction/categorization, picture naming, and semantic verbal fluency in 
schizophrenia. Sanfilipo et al. (2002), however, did not find either GMV or WMV 
of STG to associate with verbal fluency in the face of differential impairment of 
this function in their cohort of patients. 
Other STG/cognition associations seem to be specific to controls. Greater STG 
volume was associated with greater processing speed (Sanfilipo et al., 2002), and 
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with spatial memory in healthy women and attention in healthy men (Gur et al., 
2000b). It is possible that greater integrity/efficiency of semantic system 
associated with posterior STG volume would have a positive effect on cognition, 
particularly processing speed. 
2.5.4.4. Medial Temporal Lobe 
Parahippocampal gyrus (PHG) was measured in four studies, three with a control 
group (Krabbendam et al., 2000; Sanfilipo et al., 2002) or groups (DeLisi et al., 
1991a), and one without (Nestor et al., 1993). None of the studies reported 
abnormal PHG volumes in patients. Hoff et al. (1992) measured the total volume 
of amygdala, hippocampus and PHG as a limbic complex and did not find it to be 
abnormal in FE patients. 
Greater PHG volume was associated with higher verbal intelligence in both FE and 
chronic patients (DeLisi et al., 1991a) and in a separate sample of FE patients of 
mixed gender (Hoff et al., 1992). However, an inverse relationship between right 
PHG volume and verbal intelligence was found in male chronic patients (Sanfilipo 
et al., 2002). The later finding might reflect a disrupted relationship between 
structure and neurocognition in affected men, observed for other brain regions. 
Alternatively, larger right PHG volume might be indicative of the alteration of the 
normal, language related left-larger-than-right asymmetry of the posterior 
temporal lobe, manifesting as an inverse association between right PHG and 
verbal IQ in these male patients. Whatever the direction of this association, it 
seems to be specific to schizophrenia, as no relationship was found between PHG 
volume and verbal intelligence in normal controls in any of the studies. Other 
findings include an association of greater PHG volume with better performance on 
the color-word part of the Stroop test in chronic patients (Krabbendam et al., 
2000); abstraction/categorization in male chronic patients (Nestor et al., 1993); 
associative learning in a mixed group of FE and chronic patients (DeLisi et al., 
1991a); and memory for stories in FE patients (DeLisi et al., 1991a). None of 
these relationships were observed in healthy controls. Thus, it appears that, 
although not volumetrically abnormal, PHG has a number of associations with 
cognitive functions specific to schizophrenia. 
The studies investigating the relationship between the hippocampus and 
amygdaloid/hippocampal complex and cognitive deficits outnumber the studies of 
any other specific brain region reviewed in this paper. One of the reasons for this 
interest is that the anatomic and functional affiliations of the limbic cortex in 
general, and the hippocampus in particular, can theoretically contribute to 
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clinical, psychophysiological and cognitive abnormalities observed in 
schizophrenia (Stevens, 1973; Torrey and Peterson, 1974; Weinberger and 
Lipska, 1995; Bilder and Szeszko, 1996). Moreover, animals with hippocampal 
lesions mirror the course and manifestation of schizophrenia with remarkable 
precision (reviews, Schmajuk, 1987; Lipska and Weinberger, 2002). 
Ten studies measured hippocampus (DeLisi et al., 1991a; Colombo et al., 1993; 
Flaum et al., 1994; Nestor et al., 1993; Bilder et al., 1995; Torres et al., 1997; 
Gur et al., 2000b; Krabbendam et al., 2000; Szeszko et al., 2002; Sanfilipo et al., 
2002). Out of six studies with a control group (DeLisi et al., 1991a; Colombo et 
al., 1993; Torres et al., 1997; Krabbendam et al., 2000; Gur et al., 2000b; 
Sanfilipo et al., 2002), only one has found reduction in the hippocampal GMV in 
affected men and women (Gur et al., 2000b). However, as hippocampal 
reduction might be limited to grey matter, other studies might have failed to find 
hippocampal abnormality due to the lack of segmentation. Also, the evidence for 
the hippocampal reduction is not as strong in FE patients as it is in chronic 
patients (DeLisi et al., 1991b). 
Although not altered in most studies, hippocampal volume associated with 
different aspects of memory in patients, as well as in controls. In a study of 
monozygotic twins discordant for schizophrenia (Goldberg et al., 1994), greater 
left hippocampal intra-pair volume difference was associated with greater intra- 
pair difference in memory for stories. Gur and colleagues (2000b) have found 
greater bilateral hippocampus to be associated with better verbal and spatial 
memory in both men and women regardless of diagnosis. In contrast, Sanfilipo et 
al. (2002) have observed dissociation in the direction of correlations between 
patients and controls, such that left and right hippocampal volumes positively 
correlated with verbal memory in patients, whereas an inverse relationship 
between right hippocampal volume and verbal memory existed in controls. This 
finding is difficult to reconcile, especially considering that greater right 
hippocampal volume has also associated with better verbal fluency and Digit 
Symbol task performance in controls. These latter relationships were not present 
in the patient group, despite differential deficit of verbal fluency. Amongst 
negative findings in regards to memory function is the lack of any association 
between hippocampal volume and either verbal or visual memory in FE and 
chronic patients studied by DeLisi et al. (1991). Additionally, Torres and 
colleagues (1997) did not find hippocampal volume difference between patients 
differentiated by high and low ability of delayed memory, or between high and 
low performing controls. 
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Hippocampal volume has also been found to associate with the functions 
commonly attributed to the integrity of frontal lobes, supporting the notion that 
the deficits of higher order cognitive functions in schizophrenia might be due to 
the disruption of frontal-limbic circuitry (Lipska and Weinberger, 1995). Thus, 
two studies from the same laboratory (Bilder et al., 1995; Szeszko et al., 2002; 
the later study included a sub-sample of patients from the first study) reported 
positive correlations between anterior hippocampus and executive and motor 
functions in FE patients. In the earlier study (Bilder et al., 1995), correlations of 
hippocampal volume with executive, but not motor function, were significantly 
stronger than with full scale IQ. Also, there was no correlation of these cognitive 
domains with either posterior hippocampus or amygdala, suggesting the 
specificity of the observed association. There was no difference in the magnitude 
of this association between male and female patients. A later study (Szeszko et 
al., 2002) had a larger sample, and has observed significant differences in the 
strength of correlations between men and women with FE psychosis. In affected 
males, larger anterior hippocampus was associated with better executive and 
motor function, and significantly stronger than with memory or language. In 
affected females, no significant correlations were found, although there was a 
trend for an association between anterior hippocampus and memory. 
Nestor et al. (1993) did not find any association between hippocampal volume 
and executive function in male chronic patients. This study measured abstraction 
and categorization aspects of executive function, whereas Bilder et al. (1995) and 
Szeszko et al. (2002) measured perseveration and inhibitory control. Thus, it is 
possible that only those measures of executive function that are indices of 
'projectional control' are associated with hippocampal volume. 
Finally, the amygdala was measured as a separate structure only by Gur and 
colleagues (2000b), who found reduced volume of the amygdala in men and 
increased volume in women with schizophrenia, but this was not associated with 
cognitive functioning either in patients or in controls. 
Summary: The total TL volume is associated with picture naming (Vitta et al., 
1995) and concentration/speed (Hoff et al., 1992). These associations might be 
specific to the TL and to schizophrenia. The GMV of the posterior STG might be 
associated with abstraction/categorization and verbal learning (Nestor et al., 
1993), but the specificity of this association remains unclear. Hippocampal 
volume is associated with memory function in both patients and normal controls 
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of both genders (Gur et al., 2000b, but see DeLisi et al., 1991a). Finally, 
executive function requiring inhibitory control of behavior might be related to 
anterior hippocampal volume in schizophrenia (Bilder et al., 1995), particularly in 
affected men (Szeszko et al., 2002), whereas abstraction and categorization 
might be related to the volume of PHG (Nestor et al., 1993). PHG volume is also 
associated with a range of cognitive processes that might require access to a 
semantic system and this association might also be specific to schizophrenia 
(DeLisi et al., 1991a; Nestor et al., 1993; Krabbendam et al., 2002). 
2.5.5. Posterior-occipital region 
2.5.5.1. Introduction 
The posterior part of the brain includes parietal and occipital lobes. The occipital 
lobe is dedicated to visual information processing, while the parietal lobe is a part 
of the heteromodal association cortex. Parietal association cortex is richly and 
reciprocally interconnected with PFC, temporal lobe and limbic cortex, forming 
cortico-cortical and cortico-subcortical functional networks with these regions 
(Mesulam, 1990,1998). There are distinctly separate areas within the parietal 
lobe that are associated with different cognitive functions. In a very general 
sense, these include three main areas and functions. The postcentral gyrus 
contains primary somatosensory cortex, which is concerned with the initial stages 
of tactile and proprioceptive sensory processing. The inferior parietal lobule, 
usually of the left hemisphere, is involved in the language comprehension 
together with the posterior part of the temporal lobe. The remainder of the 
parietal cortex subserves complex aspects of spatial awareness and perception 
(Mesulam, 1998). 
Shenton and colleagues (2001) identified 15 MRI studies that measured parietal 
lobe, 60% of which have found abnormal volume of this region. The 
abnormalities of subregions within the parietal lobe have also been reported, 
including reduced supramarginal gyrus (Goldstein et at., 1999), and inferior 
parietal lobule (Schaepfer et al., 1994). Only nine MRI morphological studies have 
measured occipital lobe, with 44 % of the studies reporting volume reduction in 
schizophrenia (Shenton et al., 2001). 
2.5.5.2. Relationship of parieto-occipital region to cognition 
Only one study (Sullivan et al., 1996, see also FL and TL sections) investigated 
functional correlates of the posterior brain regions. This study measured the 
volumes of parietal and parieto-occipital regions in 34 men with schizophrenia 
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and 47 healthy men. There were no significant differences either in GMV or WMV 
of these regions between the groups, and no significant correlations with four 
cognitive domains, which included executive function, verbal fluency, short-term 
memory, declarative memory and motor ability. Since the sub-regions of parietal 
lobe are functionally differentiated, global measurements of the posterior brain 
regions might have masked any specific associations with examined cognitive 
domains. 
2.5.6. Basal Ganglia 
2.5.6.1. Introduction 
Basal ganglia (BG) is constituted by caudate nuclei (CN), nucleus accumbens 
(NA), putamen (Pu), globus pallidus (GP), substantia nigra (SNr) and subthalamic 
nucleus. CN and Pu are the sites of the input to BG from the multiple cortical 
regions, whereas GP and SNr are the sites of BG output. The interest in BG 
structures in relation to schizophrenia exists for the following reasons. First, the 
action of antipsychotic drugs primarily targets dopaminergic receptors that 
extensively innervate BG, particularly CN, NA and Pu. Second, there is a striking 
similarity between the symptoms observed in patients with nigral lesions and 
unmedicated first-episode schizophrenia patients, who frequently display 'soft' 
neurological signs, including: deficits in smooth pursuit eye movements and 
saccadic dysmetria; affective disturbances such as emotional blunting; altered 
perceptions such as hallucinations; and cognitive deficits (Middleton and Strick, 
2000). Third, the role of BG in sensory, cognitive and motor functions in the 
context of fronto-striatal circuitry is important for understanding cognitive and 
clinical features of schizophrenia (Tekin and Cummings, 2002). 
The kind of cognitive dysfunction that might be caused by abnormalities in BG 
structures might include executive function as well as learning and memory. 
Pantelis and colleagues (1997) have demonstrated that the nature of executive 
function in patients with schizophrenia resembles that of patients with frontal lobe 
lesions or basal ganglia dysfunction (Parkinson's patients), providing support for 
the notion that the nature of executive dysfunction in schizophrenia suggests the 
disturbance of fronto-striatal circuitry. Some memory and learning deficits in 
schizophrenia might also be due to fronto-striatal abnormalities (Beatty et al., 
1993). This can be particularly the case with serial word-list learning, which was 
found to be impaired in patients with striatal dysfunction (e. g. Parkinson and 
Huntington disease) (Pillon et al., 1994). In fact, while normal subjects employ 
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the strategy of semantic clustering on word-learning tasks, both Parkinson and 
schizophrenia patients tend to depend on learning of serial word sequence 
(Shihabuddin et al., 1998). This serial learning strategy might depend more on 
striatal function than on hippocampal function (Poldrack and Packard, 2003). 
Most studies (68%) report increases in the volumes of BG structures (Shenton et 
al., 2001). However, studies of FE patients have demonstrated volume decreases 
in CN and lenticular nuclei (LN = Pu + GP) (DeLisi et al., 1991a). Treatment with 
neuroleptics has been found to alter the volume of BG (Chakos et al., 1994). 
Shihabudin and colleagues (1998) have found smaller CN in never medicated 
patients and larger CN in previously medicated patients relative to normal 
controls. Moreover, while exposure to neuroleptics leads to the increased size of 
BG, treatment with atypical antipsychotic medication is shown to reverse this 
effect (Corson et al., 1999). Therefore, it is important to evaluate the effect of 
prior exposure to antipsychotic medication as well as medication type in the 
studies investigating BG abnormalities and their neuropsychological correlates. 
2.5.6.2. Relationship of basal ganglia to cognition 
Five studies have investigated cognitive correlates of BG. Three studies (DeLisi et 
al., 1991a; Flaum et al., 1994; Stratta et al., 1997) had a control group or groups 
while two did not (Maher et al., 1995; Manschreck et al., 2000). 
In the most recent study, Stratta and colleagues (1997) investigated the 
hypothesis that executive dysfunction and disruption of goal-oriented behavior in 
schizophrenia is associated with striatal abnormalities. The total BG volume, the 
volume of the caudate nucleus (CN), and the joint volume of the putamen (Pu) 
and nucleus accumbens (NA) were measured in chronic patients and healthy 
controls (separate volumes of Pu and NA were only available for a sub-sample of 
patients). Patients were divided into poor and good performers based on their 
WCST categories completed score. No differences in age, duration of the illness 
or sex were found between poor and good performers. As hypothesized, poor 
performers had significantly smaller volumes of the BG structures, with the 
reduction of the total right striatum and left CN and Pu relative to normal 
controls, and left Pu and bilateral Pu-NA complex relative to good WCST 
performers. Good performers did not significantly differ from controls and, in 
fact, exhibited a trend for larger volumes of Pu and Pu-NA complex bilaterally. 
Striatal volumes in both good and poor performers were not related to the dosage 
of neuroleptic medication, which is known to alter the volume of BG structures 
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(Chakos et al., 1994). In patients, volumes of the left BG and Pu-NA complex 
positively correlated with the number of categories completed. In addition, 
unique errors on WCST inversely correlated with left Pu, NA, and Pu-NA complex. 
Perseverative errors did not significantly correlate with striatal volumes. As has 
been discussed in TL section, perseveration in schizophrenia might be related to 
the disruption of fronto-limbic circuitry (Bilder et al., 1995; Szeszko et al., 2000). 
It is unclear whether the found associations are specific to schizophrenia, as no 
correlations between WCST variables and striatal volumes were performed for the 
control group. Nevertheless, Stratta et al. (1997) provided support for the notion 
that the ability to organize goal-directed behavior is positively related to striatal 
volume in schizophrenia. 
Flaum and colleagues (1994; see also Whole brain, FL, and TL sections) examined 
the volumes of CN and Pu in relation to the full scale IQ. The only association 
between the striatal volumes and IQ was the correlation of larger left Pu with 
higher full scale IQ in female patients, but not in male patients or normal 
controls. In fact, this correlation was the only one to significantly differentiate 
affected women from healthy controls. 
DeLisi and colleagues (1991) measured the volumes of CN and the lenticular 
nuclei (Pu + globus pallidus) in FE and chronic patients, and neurological controls. 
Chronic patients had the largest CN volumes, while FE patients had the smallest, 
but neither group differed significantly from neurological controls. No significant 
correlations were found between the striatal volumes and cognitive measure, 
which included WCST and serial word learning, amongst others. 
Two studies from the same laboratory (Maher et al., 1995; Manschreck et al., 
2000; see also Ventricular size, FL and TL volumes) investigated the relationship 
between striatal size and the redundancy utilization ability, and observed an 
inverse correlation between striatal size and context-aided memory (Maher et al., 
1995), but not motor-synchrony (Manschreck et al., 2000). It is possible that 
larger striatal volumes in Maher et al. study were associated with greater 
neuroleptic exposure, which, in turn, might be related to greater disease severity 
and hence poorer learning and memory, however no information was available on 
life-time neuroleptic exposure. 
Finally, Jeste and colleagues (1998) investigated the relationship of structural and 
neuropsychological variables to the age of onset of schizophrenia (AOS). Although 
the structure/function examination was not the primary goal of the study, the 
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findings are interesting and relevant. Earlier AOS was associated with poorer 
abstraction/categorization, larger volumes of CN and LN, and smaller volumes of 
the thalamus. Despite the inter-domain correlations of neuropsychological and 
structural variables, there were no significant cross-domain correlations. When 
the authors performed a series of stepwise regressions with two-, three-, and 
four-variable models to predict the AOS in schizophrenia, they found that out of 
seven significant models, the model that accounted for the most variance 
(27.5%) included poorer learning, smaller thalamic and larger LN volumes as 
predictors. However, when the duration of illness, current age and current 
neuroleptic dosage were controlled for, the only model that remained significant 
included poorer abstraction/cognitive flexibility, smaller thalamus and larger CN. 
Summary: There is some evidence for an association between striatal size and 
executive function in schizophrenia (Stratta et al., 1997; but see DeLisi et al. 
1991; Jeste et al., 1998). However, there is no evidence for the positive 
association between striatal size and learning and memory from the studies 
reviewed, and in fact the inverse relationship might exist (Maher et al., 1995). 
Moreover, enlarged LN and poor learning might be associated with earlier disease 
onset (Jester et al., 1998). More studies are needed to investigate cognitive 
correlates of BG pathology, taking into account gender differences and exposure 
to neuroleptics. In particular, there is a lack of studies investigating the output 
site of BG, the globus pallidus. The function of globus pallidus interna might play 




The thalamus is a gateway to the cerebral cortex. It is a part of remarkably large 
number of pathways: all sensory pathways relay in the thalamus, and most of the 
anatomical circuits connecting neocortex with cerebellum, basal ganglia, reticular 
system and limbic structures path via thalamus. These various systems relay at 
the distinct locations of the thalamic nuclei. Due to this exceptional role as the 
relay station within the central nervous system, abnormality in the thalamus 
results in the information processing deficits. Some theories of schizophrenia 
aetiology concentrated on the dysfunction of thalamus and its role as a 'filter' for 
gating the sensory input as being at the core of symptomatology and cognitive 
deficits characteristic of schizophrenia (e. g. Jones, 1975, Frith and Done, 1989). 
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Several post-mortem studies have reported abnormalities in thalamic nuclei 
(reviewed by Heckers, 1997). MRI investigation of the thalamus in schizophrenia 
has been problematic in the past due to the difficulty in differentiating thalamic 
nuclei mass from the surrounding white matter. Nevertheless, there were at 
least 12 MRI studies of the thalamic volume in schizophrenia, 42% of which have 
found decreased volume and 58 % observed no differences between patients with 
schizophrenia and healthy subjects (Shenton et al., 2001). Reduced thalamic 
volume might be related to earlier onset of schizophrenia symptoms (Corey- 
Bloom et al., 1995; Jeste et al., 1998). In addition, smaller thalamic volumes 
were found to correlate with reduced volume of prefrontal white matter in 
schizophrenia patients (Portas et al., 1998). 
2.5.7.2. Relationship of thalamus to cognition 
Despite the theoretical and empirical implications of the thalamus as one of the 
sites of schizophrenia pathology, only one recent study (Saldago-Pineda et al., 
2003) has examined the volume of the thalamus and found that reduction of left 
and right thalamic volumes did not correlate with the sustained attention deficit in 
patients (despite the association between the reduced thalamic grey matter 
concentration and sustained attention deficit; see Experimental study 1: 
Introduction for more detail). No correlation between thalamic volume and 
sustained attention performance in normal controls was observed either. 
2.5.8. Cerebellum 
2.5.8.1. Introduction 
The cerebellum has been shown to be involved in higher cognitive functions, 
including learning and memory, planning, and language, amongst others (Leiner 
et al., 1991). The cerebellum receives input from the limbic lobe via 
hypothalamus and reticular nucleus, as well as neocortical areas via red nucleus 
and pontine nuclei. Cerebellar outputs project back to the limbic lobe via 
hypothalamus and reticular nucleus; and to motor cortex (areas 4 and 5), PFC 
(areas 8 and Broca's areas 44 and 45) as well as posterior lobe via thalamus 
(Leiner et al., 1991). On the basis of the connectivity between the posterior lobe, 
cerebellum and Broca's area, Leiner and colleagues (1989) proposed that the 
cerebellum might represent a link between the posterior (Wernicke's) and frontal 
(Broca's) language areas and contribute not only to the motor processes 
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necessary for the speech production, but also to the cognitive processes 
necessary for the choice of an appropriate word to express an idea. Support for 
this notion comes from the recent imaging studies that have shown striking 
activation in cerebellum during performance of mental tasks that require 
language processing (Peng et al., 2003; Xiang et al., 2003). 
Schmahmann and Sherman (1997) have reported that lesions of cerebellum 
involving its posterior lobe and vermis were associated with impairments of 
working memory, planning, set shifting, verbal fluency, abstract reasoning, 
perseveration, visual-spatial disorganisation, visual memory deficits, logical 
sequencing as well as blunt or inappropriate affect. All these cognitive and 
affective disturbances are conspicuously characteristic of individuals with 
schizophrenia. 
The evidence for the overall abnormality of the cerebellum is not very strong, 
with 31% reporting positive findings (Shenton et al., 2001). However, there is 
indication of abnormalities in the specific regions within the cerebellum such as 
reduced anterior vermis (Nopoulos et al., 1999; Levitt et al., 1999), posterior 
superior vermis (Okugawa et al., 2002) in male patients with chronic 
schizophrenia as well as decreased vermis-to-brain ratio in male patients 
compared to female patients (Rossi et al., 1993). The vermis is connected with 
the limbic cortex, including hippocampus and amygdala (Schmahmann, 1997), 
and thus might play a role in learning and memory. 
Cerebellar abnormality might be limited to white matter. Two studies (Levitt et 
al., 1999; Seidman et al., 2000) have reported increases in cerebellar white, but 
not grey, matter volumes. As pointed out by Shenton and colleagues (2001), this 
increase in white matter might be the result of neuroleptic treatment, as there 
are findings of axonal sprouting in rats exposed to neuroleptic medication (Benes 
et al., 1983). Alternatively, this might represent a developmental abnormality. 
There is not enough evidence at present to discriminate between these 
alternatives. Finally, there is an evidence of progressive reduction in cerebellar 
hemispheric volume in schizophrenia patients (DeLisi et at., 1997b). 
2.5.8.2. Relationship of cerebellum to cognition 
Four studies (Flaum et al., 1995; Nopoulos et al., 1999; Levitt et al., 1999; 
Szeszko et al., 2003) have investigated cerebellar volume and its sub-regions and 
their relation to cognitive functioning in schizophrenia. All studies had a control 
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group, but two studies (Flaum et al., 1995; Szeszko et al., 2003) did not report 
on between-group morphological differences. 
The total cerebellar volume was found to be unaltered in men with schizophrenia 
(Nopoulos et al., 1999; Levitt et al., 1999), but there was greater left-than-right 
cerebellar asymmetry of grey matter (Levitt et al., 1999). Cerebellar vermis, on 
the other hand, might be abnormal in affected men. Nopoulos and colleagues 
(1999) reported reduced volume of the anterior vermis, which was associated 
with lower full scale and verbal, but not performance, IQ. Levitt and colleagues 
(1999) reported increased vermal white matter, which was associated with poorer 
immediate memory for stories (Logical Memory). These associations between 
altered vermal volumes and cognition were specific to schizophrenia. 
Other studies (Flaum et al., 1994; Szeszko et al., 2003) have observed a lack of 
cerebellum/cognition relationships in men with schizophrenia when such were 
found in normal controls. Flaum and colleagues (1994; see also Whole brain, TL 
and BG sections) found greater left and right cerebellar volume to be associated 
with higher IQ in normal men and women as well as in women with 
schizophrenia, but not in affected men, with this difference significantly 
differentiating affected men. Similarly, Szeszko and colleagues (2003) reported a 
positive correlation between total cerebellar volume and global 
neuropsychological functioning, visuo-spatial, and memory scales in healthy but 
not affected men, with the strength of the correlations being significantly different 
between the groups. 
Summary: Men with schizophrenia might have cerebellar abnormalities that are 
limited to the anterior vermis (Nopoulos et al., 1999) and an increase of white 
matter (Levitt et al., 1999), which are associated with lower general and verbal 
ability and the dysfunction of narrative memory respectively. Total cerebellar 
volume does not seem to be altered and does not associate with cognitive ability 
in affected men. In healthy people (Flaum et al., 1994; Szeszko et al., 2003) and 
women with schizophrenia (Flaum et al., 1994), on the other hand, total 




The midbrain is of a particular interest in schizophrenia as it contains the source 
nuclei of three dopaminergic pathways in the human brain: the nigrostriatal 
pathway, originating in SNr; the mesolimbic pathway and the mesocortical 
pathway, both originating in the ventral tegmentum. Due to the association with 
dopaminergic pathways and the mediatory position of the midbrain between the 
cerebrum and the cerebellum, midbrain abnormality would be expected to have 
an implication for a range of cognitive functions as well as affective processing 
related to the dopamine transmission. 
Despite this significance of the midbrain in schizophrenia, there has been only 
one morphometric study (see below) investigating this brain region. One 
histological study (Bogerts et al., 1983) has found a significant decrease in the 
volume of the nigrostriatal system due to the reduced volume of glial nuclei, as 
well as a decrease in the number of nerve cells in the mesolimbic system in 
never-medicated schizophrenia patients. In addition, Minabe and colleagues 
(1990) described a case of a 40-year-old woman who had developed a syndrome 
consistent with schizophrenia diagnosis following midbrain tegmental lesion. 
2.5.9.2. Relationship of midbrain to cognition 
Nopoulos and colleagues (2001) investigated midbrain volume and its relationship 
with IQ. The midbrain, as well as pons and medulla as control regions, were 
measured in 50 men with schizophrenia and 50 healthy men. Midbrain volume, 
but not pons or medulla, was significantly smaller in affected men, but the 
volume reduction was not associated with lower IQ. 
2.5.10. Corpus Callosum 
2.5.10.1. Introduction 
The corpus callosum (CC) is a bundle of white 
hemispheres. It allows the integration of cerebi 
cognitive function (review, Hoptman and 
interhemispheric communication mediated by 
information processing deficits characteristic 
Serafetinides, 1990). 
matter tracts that connects two 
-al hemispheric activity for higher 
Davidson, 1994). Defective 
CC was proposed to underlie 
of schizophrenia (Coger and 
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An initial finding of a thicker CC in post-mortem study of schizophrenia patients 
(Rosenthal and Bigelow, 1972) led to the surge of interest in this structure with 
the advent of in vivo imaging techniques. Following the initial replication of the 
findings with MRI (Nasrallah et al., 1986), subsequent studies produced 
conflicting results, reporting no abnormality or a reduction of the CC area (meta- 
analysis, Woodruff et al., 1995). Overall, 63% (17 out of 27) of the studies 
reported abnormal corpus callosum in schizophrenia, with the variability in 
measuring methods being the strongest possible contributor to the inconsistency 
of the findings (Shenton et al., 2001). 
2.5.10.2. Relationship of corpus callosum to cognition 
Four studies investigated the relationship between CC and cognitive functioning in 
schizophrenia (Raine et al, 1990; Hoff et al., 1994; Woodruff et al., 1997a; 
Rossell et al., 2001), all with the control group or groups. 
Raine and colleagues (1990) investigated structural and function characteristics of 
the CC in schizophrenia patients, psychiatric controls and normal controls. They 
have measured the total area and length of the CC as well as thickness of its 
anterior, middle and posterior segments. Dimorphic gender presentation of the 
anterior and posterior callosal thickness was evident in schizophrenia patients, 
such that normal male controls had thicker callosi than female normal controls, 
whereas this gender difference was reversed in the patient groups. There was, 
however, no difference between two groups in the inter-hemispheric function 
thought to be mediated by the CC. 
Hoff and colleagues (1994) used a comprehensive neuropsychological battery to 
investigate the relationship between the CC size and domains of higher cognitive 
function in first episode schizophreniaform patients and normal controls. They 
observed smaller total CC area in female patients relative to female controls and 
male patients. Total CC size positively correlated with executive functioning, 
verbal memory, speed of information processing, sensory/perceptual function, 
right hemisphere function, and the global function in normal controls with similar 
correlation strength observed for men and women. However, these CC/function 
relationships were disrupted in FE patients, with negative non-significant 
correlations. 
Woodruff et al. (1997a) studied the relationship between total CC area and four 
CC segments and inter-hemispheric function as measured by the modified version 
of the Stroop task (Philips et al., 1996). They did not observe any significant 
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differences in total CC or its sub-areas between chronic schizophrenia patients 
and normal controls. Patients, however, showed less interference on the task. 
Both bilateral facilitation and bilateral interference performance indices correlated 
with the posterior CC segment at a trend level in schizophrenia patients, such 
that better performance was associated with larger posterior CC area. However, 
these relationships were much weaker in controls. 
Finally, Rossell et al. (2001) investigated the relationship of total CC area and 
length, as well as the areas of four CC segments, to the performance on dichotic 
listening and finger tapping tasks in chronic schizophrenia patients with and 
without the history of auditory verbal hallucinations and normal controls. There 
was no difference between the groups on any of the CC measurements. Both 
patient sub-groups performed significantly worse than normal controls on finger 
tapping task. There was no relationship between CC measurements and 
neuropsychological performance in either patient or controls. 
Summary: The findings pertaining to the relationship between structure and 
function of the CC are inconsistent in both schizophrenia patients and healthy 
individuals. Three studies investigated the relationship between CC and inter- 
hemispheric transfer, with two observing no relationship either in patients or 
controls (Raine et at., 1990; Rossell et al., 2000), and one study noting a trend 
association specific to patients (Woodruff et al., 1997a). The study using 
standard neuropsychological tests of presumably lateralised higher cognitive 
functions (Hoff et al., 1994) observed a reverse pattern, such that larger CC had 
a positive effect on cognition in healthy individuals, but not in patients with 
schizophrenia, for whom larger CC size was associated with worse performance. 
2.5.11. Brain asymmetry and cognitive function 
2.5.11,1. Introduction 
In addition to the evidence of the altered whole brain volume and specific brain 
regions and the relationship of these alterations to cognitive deficits in 
schizophrenia, there is also an issue of altered brain asymmetry in schizophrenia 
and its bearing on cognitive processes. 
Although not a uniquely human characteristic (Rosen, 1996), brain asymmetries 
tend to associate with lateralisation of specific functions across species (Harris et 
al., 1996). One cognitive function that is specifically human is language. 
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Language in humans has been linked to the left hemisphere since the time of 
Broca (1861), who reported that left hemispheric lesion leads to speech 
disturbances. Overall, there is right-left (right larger than left) hemispheric 
asymmetry in normal human brain. However, for the area that has been linked 
to language function, Planum Temporale (PT), which lies at the posterior border 
of STG, the reverse asymmetry is observed. Thus, there is left - right (left larger 
than right) asymmetry in 65 % of the normal human brains, while 35 % have 
equal or larger right than left PT (Geschwind and Levitsky, 1968). Other normal 
brain asymmetries in humans include right-left asymmetry of the frontal lobe and 
left-right asymmetry of the occipital lobe (Galaburda et al., 1978). 
Brain asymmetry is modulated by gender (McGlone, 1997) and handedness 
(Annet and Alexander, 1996). It has been hypothesised that formation of normal 
human brain asymmetries has genetic underpinnings (Geschwind, 1978) and that 
schizophrenia might be a result of an abnormal formation of language related 
cerebral asymmetries (Crow, 1989,1990,1993,1995). At least some patients 
with schizophrenia show the reverse asymmetry of language related areas, with 
five out of 10 studies reporting larger right than left PT (Shenton et at., 2001). 
Abnormalities in PT asymmetry are found to associate with clinical features, such 
as suspiciousness/persecution subscales of the Positive and Negative Symptom 
Scale (Kay et al., 1987) and formal thought disorder (Rossi et at., 1994; Petty et 
al., 1995). The evidence for disrupted asymmetries of frontal and occipital lobes 
in schizophrenia is more modest. As reviewed by DeLisi and colleagues (1997), 
one study out of five, which compared the width asymmetries of frontal and 
occipital lobes of patients with schizophrenia with that of controls, has observed 
the reversed frontal asymmetry (Lee et al., 1985), whereas another study 
(Luchins et al., 1979) reported reversed occipital asymmetry in schizophrenia. 
The authors of the later study have subsequently failed to replicate this finding 
(Luchins and Meltzer, 1983). However, in both studies by Luchins and 
colleagues, altered occipital asymmetry was associated with greater 
psychopathology on measures of quality of interview, incomprehensibility, and 
auditory hallucinations. 
2.5.11.2. Relationship of brain asymmetry to cognitive function 
Two studies (Hoff et al., 1992; DeLisi et al., 1997a) have directly investigated the 
effect of disrupted brain asymmetries on cognition in schizophrenia. 
Hoff and colleagues (1992, also see Ventricular size and TL sections) measured 
the length of the lateral sulcus (LS), which corresponds to the length of the 
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planum temporale (PT) (posterior area associated with language) in a mixed 
gender sample of FE patients and normal controls. A lack of normal left/right LS 
asymmetry was found in female, but not male, patients. Surprisingly, a sub- 
group of patients with the lack of normal asymmetry demonstrated better global, 
executive, verbal and spatial memory functions than the sub-group with normal 
asymmetry. Language functioning, however, was not related to the degree of LS 
asymmetry in patients. For the control group, there were no differences in 
cognitive performance between the abnormal and normal asymmetry sub-groups. 
DeLisi and colleagues (1997) assessed neuropsychological correlates of the 
frontal, temporal, and occipital asymmetries, as well as the segments of sylvian 
fissure (anterior, horizontal, and vertical) in FE patients and normal controls. 
Both male and female patients had reduced left/right asymmetry of the temporal 
and occipital lobes. Surprisingly, the degree of left/right occipital asymmetry was 
inversely correlated with the complexity of expressive language. A trend for a 
reduction of left hemisphere length as well as reduced left/right asymmetry of the 
horizontal segment of SF (overlying PT) was also observed. However, the degree 
(reversed, reduced, or normal) of laterality of this region, hypothesized to be 
crucial for language, did not associate with language disturbances, but related to 
vigilance (sustained attention). Vigilance was also positively correlated with the 
degree of left/right asymmetry of the anterior sylvian fissure. Normal subjects 
exhibited a different and an extensive pattern of correlations between the degree 
of brain asymmetries and cognition. Left/right asymmetry of the horizontal 
sylvian fissure segment correlated positively with receptive language performance 
in a noise distraction condition, but inversely in a quiet condition. In addition, 
greater asymmetry of this region associated with better nonverbal memory. 
Greater posterior frontal and anterior sylvian fissure asymmetries associated with 
better phonological verbal fluency. Greater right/left anterior frontal asymmetry 
associated with better verbal memory and non-verbal ability. Finally, greater 
left/right temporal asymmetry associated with better verbal memory. None of 
these relationships survived a correction for multiple comparisons either in 
patients or in controls. 
Summary: The current evidence points towards reduced asymmetry of the 
language related areas in FE patients, but does not support its hypothesized 
association with language disturbances. In healthy individuals, normative 
asymmetry of language related areas appears to associate with a range of 
cognitive domains, including language. 
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2.6. Summary of the main findings and patterns 
There has been some consistency in structure/function relationships in both 
schizophrenia patients and healthy individuals. In general, total brain volume 
tends to have a non-specific relationship with cognition, with bigger brains 
associating with better performance. Similarly, measures of general cognitive 
ability, such as IQ, tend to correlate with a number of brain regional volumes, 
including left and right cerebral hemispheres, hippocampus, and cerebellum in 
normal controls and female patients, but these relationships might be disrupted in 
men with schizophrenia (Flaum et al., 1994). Since the frontal lobe has a unique 
involvement in higher cognitive processing and behavioral control, the volume of 
dorsal PFC, particularly its grey matter, is positively correlated with a range of 
cognitive processes in both patients and controls, including abstraction, attention, 
verbal memory, and psychomotor speed (Gur et al., 2000a; Sanfilipo et al., 
2002). 
A number of associations appear to be specific to schizophrenia. Greater 
cognitive flexibility in patients associated with greater GMV and particularly WMV 
of the PFC (Nestor et al., 2002; Sanfilipo et al., 2002), as well as smaller 3rd 
ventricle VBR (Bornstein et al., 1992). These associations indirectly implicate the 
role of fronto-thalamic circuitry in cognitive flexibility in schizophrenia. Other 
specific associations suggest that the dysfunction of language, as well as higher 
cognitive processes that require verbal endowment and abstraction/categorization 
of verbal information, might be associated with the volumes of STG and PHG 
(DeLisi et al., 1991a; Hoff et al., 1992; Nestor et al., 1993; but see Sanfilipo et 
al., 2002). 
Reviewed findings suggest that executive dysfunction in schizophrenia might be 
associated with the volumes of several distributed structures apart from the PFC. 
Executive tasks normally engage a number of distinct processes and abilities: i) 
identification and categorization of information relevant to the task, ii) 
development of a strategy or acquisition of a rule necessary for the task 
performance; and iii) inhibition of pre-potent yet redundant responses. The data 
from the reviewed studies suggest that the first ability might be related to the 
volumes of PHG and STG and the function of semantic system associated with 
these regions (Nestor et al., 1993). Second ability might be related to 
the 
integrity of the striatum (Stratta et al., 1997). In fact, recent modeling work 
suggests that hierarchical updating and the sequencing of actions may 
involve 
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interactions between the PFC and the basal ganglia (Houk and Wise, 1995). 
Finally, the third ability might be dependent on the integrity of the anterior 
hippocampus (Szeszko et al., 2002) and the AC (Szeszko et al., 2000). 
Abnormality in this fronto-hippocampal circuitry might result in a failure of error 
detection/inhibition in schizophrenia, leading to perseveration. Possible thalamic 
abnormality and deficits in "set shifting' associated with fronto-thalamic 
interaction might also disrupt the third ability (Bornstein et al., 1992). All these 
neuronal circuits have been implicated in the models of schizophrenia 
pathophysiology (see section 1.3. ). It must be acknowledged, however, that 
these functional distinctions mapped onto different neuronal circuits are only 
heuristics. 
Discrepancies between patients and controls in the pattern of structure/function 
correlations were present in most studies. These differences might represent 
statistical artifacts, altered structure/function relationship in schizophrenia, or an 
interaction of both. For example, relative task difficulty and relative structural 
volume variability would produce different ranges of scores and volumes in two 
groups for the same set of structural/functional variables, resulting in correlations 
of a different strength. In order to account for this possibility and to aid the 
interpretation of the findings, future studies should report on structural and 
functional differences between the groups and examine relative variability of 
performance and volumetry before proceeding towards the examination of 
structure/function relationship. In other cases, however, differences in 
structure/function relationship between patient and controls might reflect a 
genuine finding. However, only few studies have tested whether such between- 
group correlation differences were significant, with other studies leaving the 
implications of their findings unclear. Future studies should not only investigate 
the relationship between structural alterations and cognitive deficits but also 
ascertain whether there is an altered structure/function relationship in 
schizophrenia. 
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CHAPTER 3. SCHIZOPHRENIA: TREATMENT AND THE PREDICTION 
OF TREATMENT RESPONSE 
In this chapter, the pharmacological treatments of schizophrenia will be 
introduced, namely typical and atypical antipsychotics. The distinction between 
two groups of antipsychotics in terms of their pharmacology as well as their 
clinical, side-effects, and cognitive profiles will be made. These will be followed 
by the presentation of differences within the atypical antipsychotic group in terms 
of their pharmacological properties, and the putative mechanisms underlying 
superiority of atypical action on symptoms and cognition in schizophrenia. 
Further, the empirical evidence for the clinical and cognitive superiority of the 
atypical antipsychotics under investigation will be presented. The chapter is 
concluded with the issue of predicting antipsychotic drug response. 
3.1. Pharmacological Treatments of Schizophrenia: Typical and 
Atypical Antipsychotics 
Conventional, or typical, antipsychotics were discovered in the 1950s and 
immediately became a first line of treatment for schizophrenia. Their ability to 
reduce positive symptoms gave them the name `anti psychotic'. Recently, a new 
generation of drugs was developed which rapidly became preferred treatment in 
first-episode psychosis as well as in treatment-resistant schizophrenia. 
Newer antipsychotic drugs were developed in response to problems with typical 
antipsychotics (see next section 3.1.1. ). These drugs were referred to as 'atypical' 
as they did not produce catalepsy in rodents as all conventional, typical, 
antipsychotics do, while still having antipsychotic effects (Pilowsky, 2001). The 
ability to induce catalepsy was used as a screening tool for antipsychotic drugs 
and was believed to be necessary for a drug to have an antipsychotic effect. 
Thus, initially, atypical antipsychotics were defined as those antipsychotic agents 
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which produce fewer extrapyramidal symptoms (EPS) at clinically effective 
antipsychotic doses than the typical antipsychotics (Meltzer et al., 1999). 
However, this definition of an atypical antipsychotic drug is still controversial 
(Gerlach & Casey, 1996). Various authorities have suggested that the term is to 
be changed to "novel anti psychotics', while others suggested for the definition to 
be broadened to include features beyond lower EPS, such as multireceptor 
affinity, efficacy in treatment-resistant schizophrenia, and ability to improve 
negative as well as cognitive symptoms (see Kinon and Lieberman, 1996 for a 
critical discussion). 
Clozapine is the first prototype of an atypical antipsychotic drug and has been 
shown to have all of the above-mentioned characteristics (e. g., Arnt and 
Skarsfeldt 1998; Remington and Kapur, 1999). It became a drug of choice for 
treatment resistant schizophrenia. However, it has serious side effects such as 
agranulocytosis, which limits its applicability in the treatment of psychosis. 
Therefore, there was a need for developing other atypical antipsychotic agents 
with similar efficacy, but without serious life-threatening side effects. Olanzapine, 
Risperidone and Quetiapine are atypical antipsychotics that have been developed 
to address these demands. The following discussion of atypical antipsychotics is 
going to be restricted to these three brands, since they are the most commonly 
used in current clinical practice. 
3.1.1. Typical Antipsychotics 
Discovery of neuroleptics revolutionised the treatment of schizophrenia and 
brought an emphasis on the positive symptoms, which the typical antipsychotics 
so dramatically reduce. Treatment with typical antipsychotics led to the closing of 
hospitals for most chronic psychiatric patients and offered much hope for the 
patients to be reintegrated into the society. However, by the 1960s it became 
obvious that reduction in positive symptoms did not lead to recovery from 
schizophrenia. Although typical antipsychotics were effective in treating positive 
symptoms, they lack the ability to improve cognitive impairment (e. g. Medalia et 
al., 1988) and thus produce poor functional outcome (Meltzer & McGurk, 1999). 
Moreover, typical antipsychotics have further problems such as lack of efficacy in 
one third of the patients (Friedman et al., 1999), lack of improvement and even 
worsening of negative symptoms (Sharma, 1999), and troublesome adverse 
106 
effects, especially EPS and tardive dyskinesia. The most common treatment of 
EPS is co-administration of drugs with strong anticholinergic properties. These 
agents cause further problems for patients with schizophrenia by impairing their 
already compromised cognitive functions (e. g., Strauss et al., 1990; Kumari et 
al., 2003b; Ettinger et al., 2003), and thus reducing the prospects for positive 
functional outcome (Green, 1996). 
Conventional antipsychotics are non-selective dopamine antagonists with mainly 
D2 receptor affinity. The ability of conventional antipsychotics to block D2 
receptors in the mesolimbic pathway such as nucleus accumbens and olfactory 
tubercle appears to be the basis for their effect on positive symptoms (Meltzer & 
Stahl, 1976). Blockade of D2 receptors in the striatum appears to be the basis 
for the EPS (Meltzer & Stahl, 1976). 
3.1.2. Atypical Antipsychotics 
The class of drugs refered to as atypical antipsychotics includes drugs with 
heterogeneous pharmacological makeup. However, as a class, atypical 
antipsychotics differ from typical ones on one crucial property: their limbic- 
specific dopamine D2 receptor binding and high ratio of serotonin 5-HT 2 receptor 
binding to D2 binding (Arnt and Skarsfeld, 1998). 
Despite the controversies in defining the atypical drug, there is a general 
agreement that three features differentiate the atypical antipsychotics from the 
conventional ones, and that these features may arise from the dopamine - 
serotonin antagonism which most of the atypical antipsychotics share (Meltzer & 
McGurk, 1999). The first of these differentiating features, as mentioned above, is 
that the atypical antipsychotics show little or no propensity to cause EPS or 
tardive dyskinesia, which are the most troublesome side effects of the 
conventional antipsychotics. 
The mechanism by which atypical antipsychotics spare the motor function is 
related to the reciprocal relationship between serotonin and dopamine in 
nigrostriatal pathway that projects from substantia nigra to the striatum and 
regulates movement. The nature of this relationship is such that serotonin 
inhibits dopamine release (Meltzer, 1991). Thus, serotonin antagonism of 
atypical antipsychotics in nigrostriatal pathway disinhibits dopamine neurones. 
The dopamine released through disinhibition competes with the atypical drug for 
107 
the D2-receptors and thus does not lead to their total inhibition, as it is the case 
with the conventional antipsychotics. Thus, serotonin blockade reverses D2 
blockade in the striatum, which is the cause of little or no extrapyramidal effects 
and tardive dyskinesia with atypical medication (Kapur & Remington, 1996). 
The lower affinity of atypical antipsychotics to striatal D2 dopamine receptors is 
another possible reason for the low EPS incidence with these newer drugs as 
compared with conventional antipsychotics (Pilowsky, 2001). The lower 
occupancy of striatal D2 receptors allows for dopamine to compete with the 
atypical drug at the D2 receptor sites, while occupancy of D2 receptors with 
conventional antipsychotics can be as high as 80 % (Stahl, 1998) resulting in 
complete inhibition of the D2 receptor neurons and thus to the EPS. 
Second differentiating feature of atypical antipsychotics is that some of them do 
not raise prolactin levels, which every conventional antipsychotic does (Kapur & 
Remington, 1996). This property of atypical antipsychotics might be due to 
reciprocal relationship of serotonin and dopamine in tuberoinfundibular pathway 
that projects from hypothalamus to the pituitary (Stahl, 1998). Dopamine 
inhibits prolactin secretion in the pituitary (Kapur & Remington, 1996). D2 
antagonism of conventional drugs leads to the blockade of the D2 receptors, 
which results in increased prolactin levels. In contrast to dopamine, serotonin 
stimulates prolactin secretion, when it occupies 5HT-2 receptors and excerpts an 
indirect action on dopamine, by preventing dopamine release. 5HT-2 antagonism 
of atypical antipsychotics leads to the blockade of 5HT-2 receptors and thus 
reverses the effects of blocking D2 - receptors, leading to the release of 
dopamine and allowing for the dopamine inhibition of prolactin secretion to take 
place (Bouloux & Grossman, 1987). This makes serotonin-dopamine antagonists 
better tolerated than conventional antipsychotics, which may have an indirect 
effect on cognitive improvement (Meltzer & McGurk, 1999). 
Finally, most atypical antipsychotics reduce negative symptoms of schizophrenia 
and have positive effects on cognitive deficits to a greater extent than the 
conventional antipsychotics (e. g. Hagger et al., 1993; Hoff et al., 1996; Green et 
al., 1997; Rossi et al., 1997). Also, there is some evidence for atypical 
antipsychotics to be superior to conventional antipsychotics in improving 
automatic information processing deficits as assessed by pre-pulse inhibition 
(PPI) of the startle response in schizophrenia (Kumari et al., 1999,2000,2002b; 
Leumann et al 2002). 
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The mechanism by which atypical antipsychotics have ameliorating effect on 
negative symptoms and cognitive impairments may be related (Arnt et al., 1999). 
The revised dopaminergic hypothesis of schizophrenia proposes the coexistence 
of a hyperdopaminergic state in the mesolimbic pathway, underlying positive 
symptoms, along with hypodopaminergia in the mesocortical tract (Davis et al., 
1991; O'Donnell and Grace, 1998; Weinberger, 1987). Primary deficiency of 
dopamine in the mesocortical pathway, which projects from midbrain ventral 
tegmental area to limbic cortex, is a hypothetical cause of negative symptoms 
and some of the cognitive symptoms. Secondary deficiency of dopamine in the 
mesocortical pathway as a result of serotonin excess is another hypothetical 
cause of negative and cognitive symptoms in schizophrenia (Goldberg & 
Weinberger, 1996). Serotonin-dopamine antagonists, but not conventional 
antipsychotics, can increase dopamine release and decrease levels of serotonin 
selectively in the mesocortical pathway by blocking 5-HT2 receptors (Fischman et 
al., 1996). This theoretically explains the improved efficacy of atypical 
antipsychotics over conventional antipsychotics in the treatment of negative and 
most of the cognitive symptoms of schizophrenia (Friedman et al., 1999). 
3.1.3. Pharmacological profile of atypical antipsychotics 
Atypical antipsychotics have the most complex mixture of pharmacological 
properties in psychopharmacology (Stahl, 1998). These agents act on multiple 
DA receptors (D1-4), serotonin receptors (5-HT -1A, 2A, 1D, 3,6,7) and 
serotonin reuptake inhibition, noradrenergic system (alpha 1 and alpha 2 
blockade), cholinergic system (muscarinic blockade and norepinephrine reuptake 
inhibition), and histamine (H1) receptors. 
TABLE 3.1. Pharmacological profile of olanzapine, risperidone and quetiapine 
Olanzapine: Risperidone: Quetiapine: 
D1-4 D2 D2 






H1 H1 (? )* H1 
al aland cc 2 alanda2 
* See text 
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Table 3.1 presents the pharmacological profile of the atypical drugs most 
commonly used in clinical practice. As can be seen from the table, olanzapine has 
the most diverse repertoire of neuroreceptor affinity. It antagonises dopamine 
receptors D1-4, four subtypes of serotonin receptors, 5-HT -2a, -2c, -3 and -6, 
muscarinic receptor M1, histamine receptor H1 and has affinity to al-adrenergic 
receptor. Risperidone differs from olanzapine in that it has affinity to only D2 
dopamine receptor, two serotonin receptor subtypes, 5-HT 2a and -7, and a1 and 
a 2- adrenergic receptors. Different studies and reviews are inconsistent in regard 
to risperidone's affinity to H1 histamine receptors. It does appear, though, that 
its action on these receptors is not as potent as that of olanzapine and 
quetiapine. Risperidone does not have affinity to muscarinic receptors. 
Quetiapine is very similar to risperidone in its pharmacological profile. The only 
additional property is antagonism of serotonin 5-HT6 receptor subtype. 
Recent PET studies of D2 and 5-HT2a blockade by olanzapine, risperidone (Kapur 
et al., 1999) and quetiapine (Kapur et al., 2000) have revealed that quetiapine 
has the lowest affinity to these receptors and shortest half-life then the other two 
atypical antipsychotics. Risperdone and olanzapine were found to have similar 
affinities to D2 and 5-HT2 receptors, with risperidone having a slightly higher 
occupancy of D2 receptor then olanzapine at clinically relevant doses. These 
pharmacological differences may account for differential clinical and side-effect 
profiles of these atypical antipsychotics (Remington and Kapur, 2000) and will be 
discussed in the following sections. 
3.1.4. Atypical antipsychotics: Effects and putative mechanisms of action 
on symptoms and cognition 
As discussed above, one mechanism for their superior effect on cognitive deficits 
is serotonin-dopamine antagonism that all atypical antipsychotics share. 
Serotonin-dopamine action in mesocortical pathway can have direct ameliorating 
effect on cognitive deficits by mediating dopamine and serotonin transmission in 
prefrontal cortex (Meltzer and McGurk, 1999). Also, serotonin-dopamine action 
of atypical antipsychotics can play an indirect role in cognitive enhancing effects 
as compared with conventional antipsychotics through greater reduction in 
primary and secondary negative symptoms, adverse side effects, such as EPS and 
hyperprolactinemia, and increased tolerability (Keefe et al., 1999). 
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Other receptor-binding properties may be involved in efficacy of atypical 
antipsychotics on cognitive impairments in schizophrenia. The combination of 
simultaneous actions may be required to explain the mechanism of enhanced 
efficacy of atypical drugs on cognitive functions as compared to conventional 
antipsychotics. Thus, some of the beneficial effects of serotonin antagonism of the 
atypical drugs may be mediated through the effect of serotonin neurones on 
cholinergic neurones (e. g., Decker and McGaugh, 1991). 5-HT antagonists have 
been shown to alter the detrimental effects of muscarinic cholinergic antagonists 
on learning and memory (Keefe et al., 1999). Anticholinergic properties of 
conventional antipsychotics have been shown to worsen learning and memory in 
patients with schizophrenia in many studies (review, Heaton and Crowley, 1981). 
Olanzapine has anticholinergic properties, but does not seem to affect learning 
and memory (Keefe et al., 1999). This may be due to its high affinity to both 
cholinergic and serotonergic neuroreceptors, as serotonin antagonism may cancel 
out the detrimental memory effects of cholinergic antagonism (Keefe et al., 
1999). 
3.1.5. Atypical antipsychotics: Preliminary evidence of clinical and 
cognitive superiority 
3.1.5.1. Clinical efficacy 
Overall, there is consistent evidence that olanzapine, risperidone and quetiapine 
are at least as effective and, in the case of non-responders, superior to 
conventional medication in the treatment of positive symptoms in schizophrenia 
(Mortimer, 2001). Also, these drugs have been found to be more effective than 
conventional medication for the treatment of both primary and secondary 
negative symptoms at clinically effective doses, although the evidence is stronger 
for olanzapine than either risperidone or quetiapine (review, Remington and 
Kapur, 2000). 
Olanzapine, risperidone and quetiapine have a record of better tolerability in 
terms of side-effects such as EPS, tardive dyskinesia and hyperprolactinemia, 
although there are higher incidence of these side effects with risperidone than 
with olanzapine or quetiapine (Remington and Kapur, 2000). However, as 
discussed by Kapur et al. (1999), these differences might have emerged due to 
the clinical doses of risperidone used that produce higher D2 receptor occupancy 
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then the doses used for olanzapine or quetiapine, and thus higher levels of EPS 
and hyperprolactinemia were found for risperidone in the previous studies. It is 
also possible that the higher incidence of EPS and hyperprolactinemia with 
risperidone is due to lower 5-HT2/D2 ratio as compared to olanzapine or 
quetiapine, as the D2 receptor affinity has been reported to be higher for 
risperidone then for olanzapine or quetiapine (Kapur et al., 2000), while 5-HT2 
receptor affinity of risperidone and olanzapine has been reported to be similar 
(Kapur et al., 1999). 
3.1.5.2. Cognitive efficacy 
The atypical antipsychotics have been shown to produce greater improvement in 
cognitive deficits when compared with conventional drugs (review, Meltzer & 
McGurk, 1999, Keefe et al., 1999, Sharma, 1999). When compared as a group 
with conventional antipsychotics in meta-analysis of data from 15 studies (Keefe 
et al., 1999), atypical antipsychotics were found to be superior in their cognitive 
enhancing effects in at least one cognitive domain in two of three double-blind 
studies and in seven of the 12 open-label investigations. 
In the review of cognitive effects of atypical antipsychotics by Meltzer and McGurk 
(1999), risperidone has been found to improve performance on measures of 
attention, executive function, working memory, verbal learning and memory, 
motor function and perceptual/motor processing, but not verbal fluency or motor 
learning. Olanzapine has been found to have significant effect on some measures 
of reaction time, executive function, verbal learning and memory, and verbal 
fluency. The magnitude of this effect for olanzapine was greater than that 
previously found for clozapine or risperidone (Meltzer and McGurk, 1999). 
In a recent 6-months study of cognitive effects of risperidone and olanzapine in 
the group of 38 partially responsive outpatients with schizophrenia, atypical 
antipsychotics were associated with significant differential improvement over time 
in attention, verbal memory and executive function as compared to conventional 
antipsychotics. No improvement has been found on measures of verbal fluency, 
spatial memory and visuo-motor abilities (Cuesta et al., 2001). Risperidone and 
olanzapine had differential effect on measures of cognitive function, with 
risperidone being superior on measures of executive function (Wisconsin Card 
Sorting Task) and olanzapine having greater effect on selective attention (Stroop 
test). 
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In a recent independent, randomised, double-blind study (Purdon et al., 2001), 
quetiapine has been found to improve verbal fluency and immediate recall. In 
another larger, randomised, double-blind trial of 41 stable outpatients, quetiapine 
was found to be superior than haloperidol on tests of executive function and 
verbal memory (Velligan et al., 1999). 
3.2. Prediction of Treatment Response 
Patients with schizophrenia vary considerably in their response to antipsychotic 
medication. Only one third will be responsive to the treatment with conventional 
antipsychotics, with higher percentage of responders to novel atypical drugs. 
Since it became evident that schizophrenia is characterised by global as well as 
regional structural volume alterations, the question has arisen as to how the 
degree of structural alterations is related to drug response. Crow (1985) initially 
hypothesised when defining Type I and Type II schizophrenias that patients with 
Type II illness will have enlarged ventricles and will be characterised by the poor 
response to antipsychotic drug treatment. Subsequent studies relating 
ventricular size to treatment response yielded inconsistent results: whereas some 
studies confirmed larger ventricular size to result in poorer drug response 
(Nasrallah et al., 1980; Weinberger et al., 1980; Luchins et al., 1983,1984; 
Williams et al., 1985; Pandurangi et al., 1989), others have not observed such an 
association (Nasrallah et al., 1983; Naber et al., 1985; Losonczy et al., 1986) and 
even reported reverse findings (i. e. larger ventricles predicting better response) 
(Boronow et al., 1985; Smith et al., 1985). 
There is a paucity of studies investigating the relationship between global or local 
tissue volumes and the neuroleptic drug response, with only one MRI study up to 
date examining the possibility of such a relationship. Zipursky and colleagues 
(1998) studied structural correlates of drug response in first episode patients and 
reported that the severity of cortical grey matter reduction was inversely 
associated with the degree of treatment response, as measured by the 
improvement in positive and negative symptoms after one week of treatment. 
As has been noted above, patients that do not respond to conventional 
antipsychotics can benefit from the treatment with atypical antipsychotics. Only 
one study up to date has examined the predictive validity of structural alterations 
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for the atypical antipsychotics response. Friedman and colleagues (1991) 
compared patients who were non-responders, moderate responders, and good 
responders to atypical drug clozapine, as measured by the change in Brief 
Psychiatric Rating Scale (BPRS) scores after 6 weeks of treatment, on prefrontal 
sulcal prominence (PSP), and found a linear trend for PCP, with non-responders 
having highest, moderate responders an intermediate degree, and good 
responders the least PSP. The degree of PCP was also a significant predictor of 
treatment response at 6 weeks as assessed by multiple linear regression, 
suggesting that the effect of clozapine on psychopathology is associated with 
prefrontal structural integrity. 
To the present date, no studies have assessed the validity of structural alterations 
in predicting the degree of cognitive improvement with atypical antipsychotic 
treatment. As has been discussed in Chapter 2, cognitive deficits are better 
predictors of functional outcome in schizophrenia than psychopathology. The 
identification of cognitive response predictors is therefore an important practical 
issue in schizophrenia. From a broader prospective, identifying structural 
markers of drug response can lead to better sub-typing of schizophrenia. As has 
been discussed in Chapter 1, schizophrenia is heterogeneous, and the work is still 
ongoing in defining different sub-types with greater precision for the purposes of 
diagnosis, treatment and research. In view of controversy surrounding the sub- 
typing of schizophrenia and schizophrenia diagnosis per se, one of the approaches 
to sub-typing schizophrenia might be on the basis of pathophysiology. Such 
pathophysiological variables as neuroanatomical abnormalities and treatment 
response might potentially provide a framework for categorising schizophrenia 
and determining its subtypes, resulting in greater reliability and validity of the 
diagnosis, which is necessary for the success of treatment and research. 
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CHAPTER 4. AIMS AND OBJECTIVES 
In this chapter, the broad outline of aims and objectives will be given first, 
followed by the more detailed presentation of the plan of investigation and 
hypotheses of the experimental studies. 
4.1. Aims and Objectives 
The pioneering scientists of schizophrenia Kraepelin and Bleuler both believed it 
to be a brain disease, with its behavioural and cognitive features being 
manifestations of brain pathology (Chapter 2: General Introduction). Since the 
advent of imaging techniques it became well established that schizophrenia 
patients have subtle but wide-spread pattern of structural alterations (Chapter 2: 
Structural alterations), some of which appear to relate to cognitive (dys)function 
(Chapter 2: Structure/Cognition Relationships). Cognitive (dys)function, in its 
turn, has been shown to be of primary importance for the functional outcome 
(Chapter 2: Cognitive deficits), and is rapidly taking over the symptomatology as 
the primary target for treatment. Novel or atypical antipsychotic drugs show 
promise in ameliorating cognitive dysfunction, becoming the first treatment 
choice in first episode psychotic patients as well as chronic patients non- 
responsive to conventional antipsychotics (Chapter 3). The superior cognitive 
efficacy of atypical antipsychotics is presumed to rise due to their simultaneous 
action on dopaminergic and serotonergic receptors (Chapter 3). Currently, it is 
unclear whether structural alterations play a role in predicting response to 
treatment with atypical antipsychotics in terms of cognitive functioning (Chapter 
3). Historically, the main approach to the study of structural alterations was the 
region of interest method. Being an extremely labour intensive and time 
consuming technique, its application precludes the identification of the 
comprehensive pattern of structural alterations in any given sample. With the 
advent of automatic processing techniques, Voxel Based Morphometry (VBM) is 
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gaining the momentum, primarily due to its power to map the pattern of 
structural alterations comprehensively by examining between group differences 
on a voxel-by-voxel basis throughout the entire brain, cortically and sub- 
cortically. 
The main aims of the present investigations are: (i) to utilise this novel method 
for the identification of structural alterations in schizophrenia patients; (ii) to 
investigate the relationship of the identified global and local structural alterations 
to cognitive deficits most characteristic of schizophrenia; and (iii) to explore the 
predictive validity of structural alterations for treatment response to atypical 
antipsychotics in terms of cognitive improvement. 
4.2. Plan of Investigation 
The thesis contains four experimental chapters: 
Study 1 (Chapter 5): Structural Alterations 
Study 2 (Chapter 6): Cognitive Deficits 
Study 3 (Chapter 7): Relationship between Structural Alterations and Cognitive 
Deficits 
Study 4 (Chapter 8): Structural Alterations as Predictors of Treatment Response. 
A sample of patients conforming to the DSM-IV diagnosis of schizophrenia and 
schizophrenia spectrum disorders was recruited for the investigation of structural 
alterations (Study 1), cognitive deficits (Study 2) and their inter-relationships 
(Study 3). All, but four, patients were stable on neuroleptic medication. A sub- 
group of these patients was subsequently switched to atypical medications, 
quetiapine, risperidone, or olanzapine, and re-assessed on clinical and 
neuropsychological measures after 6 weeks of treatment. This sub-sample 
constitutes the experimental group of Study 4. 
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PART II 
STUDY 1: STRUCTURAL ALTERATIONS IN SCHIZOPHRENIA 
STUDY 2: COGNITIVE DEFICITS IN SCHIZOPHRENIA 
STUDY 3: RELATIONSHIPS BETWEEN STRUCTURAL 
ALTERATIONS AND COGNITIVE DEFICITS 
STUDY 4: STRUCTURAL ATLERATIONS AS PREDICTORS OF 
TREATMENT RESPONSE 
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CHAPTER S. STRUCTURAL ALTERATIONS IN SCHIZOPHRENIA: A 
VOXEL-BASED MORPHOMETRY STUDY 
5.1. Introduction 
Earlier efforts to identify brain abnormalities in post-mortem studies of 
schizophrenia patients led to conflicting findings and were flawed by irresolvable 
methodological issues (Plum, 1972). As a result, the idea of identifying brain 
neuropathology in schizophrenia was abandoned by the mid-1970s. Since the 
finding of lateral ventricular enlargement in schizophrenia by Johnstone and 
colleagues in 1976 with the help of CT, and subsequent multiple replications of 
this finding by CT and later by MRI studies (e. g. reviews by Shelton and 
Weinberger, 1986; Buckley, 1998), there was a resurge of interest in identifying 
neuroanatomical pathology in schizophrenia. 
There is currently a substantial body of evidence to reaffirm the initial proposals 
by Kraepelin and Bleuler that schizophrenia involves brain pathology. However, 
the understanding of the nature of this pathology has shifted in recent decades. 
Whereas the initial search was directed towards identifying gross circumscribed 
lesions, perhaps in the frontal and/or temporal lobes, as originally hypothesised 
by Kraepelin (1919), it is becoming increasingly clear that schizophrenia is more 
likely to be characterised by subtle and diffuse alterations in neuronal circuitry, 
both cortically and sub-cortically. 
The Gold Standard of brain volumetry, ROI method, was extensively applied to 
the study of structural pathology in schizophrenia (most recent review by 
Shenton et al., 2001 includes 193 peer reviewed studies published between 1988 
and 2000), resulting in the implication of almost all cortical and sub-cortical 
structures. However, it must be emphasised, that this of course does not imply 
that any given individual or sample of schizophrenia patients bears all or even 
some of these alterations. This brings to the forefront the most serious limitation 
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of ROI method - being extremely laborious and time consuming it inhibits the 
identification of the pattern of structural alterations comprehensively in any given 
sample of patients. 
The improved resolution of structural MRI scans and the development of 
sophisticated image processing tools have led to the emergence of automatic 
morphometric techniques. Amongst the most widely used are voxel-based 
morphometry (VBM), allowing a voxel-wise comparison of spatially normalised 
images; deformation-based morphometry (DBM), allowing the identification of 
differences in relative positions of brain structures; and tensor-based 
morphometry (TBM), allowing the detection of local shape differences. The 
discussion will be limited to a VBM approach for the present purposes. 
Generally, VBM refers to a class of techniques that are applied to some scalar 
function of the spatially normalised (i. e. transformed into the same stereotactic 
space) images (whereas DBM and TBM are applied to the information coded in the 
deformation field obtained when spatially normalising an image in non-linear 
fashion). The most commonly used VBM technique involving statistical 
comparisons of tissue partitions (e. g. grey or white matter) has been described 
by Ashburner and Friston (2000) and is implemented in SPM software developed 
by Karl Friston and colleagues at the Wellcome Department of Institute of 
Neurology, London (http: //www. fil. ion. ucl. ac. uk/spm/). The SPM software is a 
suite of MatLab (Matrix Laboratory, MathWorks, Natick, MA) functions and 
subroutines implementing Statistical Parametric Mapping, based on General 
Linear Model. SPM was originally written to organise and interpret functional 
neuroimaging data. The latest version of the SPM software at the time of the 
data analysis for the present thesis was SPM99. Therefore, the VBM approach 
described in this thesis refers to the VBM as implemented in SPM99. 
Since the pioneering study by Wright and colleagues (1995), VBM is more and 
more widely applied in schizophrenia research, as well as in the study of brain 
pathology in other psychiatric and neurological conditions with promising results 
for its power to characterise and quantify local alterations in brain tissue 
availability with high spatial precision. From the very beginning, application of the 
VBM method revealed new areas of altered brain tissue, such as insula, that have 
previously received no attention from schizophrenia researchers due to the 
aforementioned limitations of the ROI approach. 
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As has been discussed in chapter 2, the VBM method allows identification of two 
indices of brain tissue alteration: concentration and volume. (Some researchers 
use the term `density' instead of `concentration'. However, the term `density' is 
misleading in the VBM context, since it does not imply the same as when it is 
used in cytoarchitectonic studies, namely the density of neurones in neuropil. 
Therefore, the term 'concentration' will be used throughout the thesis to avoid 
this misleading connotation. ) 
To understand the difference between these tissue indices, one needs to consider 
what is involved in pre-processing of the images for VBM analysis. In its 
simplest, pre-processing requires three steps. First, the whole brain images are 
spatially normalised to the same stereotactic space by registering them to the 
same whole brain template, by minimizing the residual sum of squared 
differences between the images and the template. This is achieved using 12- 
parameter affine (linear) transformation (Ashburner et al., 1997) to correct for 
differences in brain size and orientation, followed by the non-linear 
transformation using a set of cosine basis functions to correct for differences in 
global brain shape (Ashburner and Friston, 1999). It should be noted that spatial 
normalisation does not attempt to match all brain features exactly. If the spatial 
normalisation was perfect, then all the images would be identical and no 
differences would be detected. Instead, spatial normalisation corrects for global 
brain shape differences, with VBM analysis directed towards identification of local 
scale differences over and above global shape variations. Second, the normalised 
images are segmented into grey matter, white matter, cerebrospinal fluid (CSF), 
and three other background classes by using a-priori classification for each voxel 
via registering a brain image to prior probability maps of grey matter, white 
matter and CSF, and applying mixture model cluster analysis technique 
(Ashburner and Friston, 1997) to classify the voxels into different tissue types. 
Finally, the segmented images are smoothed by convolving with an isotropic 
Gaussian kernel, usually of the size 12-mm full width at half maximum (FWHM). 
This last step is performed i) to make the data conform to the Gaussian field 
model, underlying the statistical inferences implemented in SPM99; ii) to render 
the data more normally distributed to ensure the validity of the parametric tests 
employed by SPM99; and iii) to reduce the effects of individual variation in 
sulcal/gyral anatomy (Ashburner and Friston, 2000). The smoothing also makes 
the subsequent voxel-wise analysis comparable to ROI approach, since the 
resulting intensity in each voxel of smoothed tissue segment is a locally weighted 
average of tissue availability from a region of surrounding voxels (Ashburner and 
Friston, 2000). The size of the region is defined by the size of the smoothing 
120 
kernel. Because of the non-linear transformation during spatial normalisation, the 
volumes of some brain regions will grow (i. e. new voxels will be added), whereas 
others will shrink (i. e. some voxels will be removed) in order to compensate for 
differences in brain shape between the individual image and the template. 
However, a relative amount of a certain tissue type to other tissue types in the 
normalised image will remain unchanged, since all tissue types will go through 
the same transformation. Consequently, a comparison of the resulting brain 
tissue segments with VBM will show the differences in the relative amount or 
concentration of a tissue type, i. e. the proportion of a tissue type relative to other 
tissue types within a region. In order to preserve the original amount of a tissue 
type within each structure, a further processing step was introduced, which 
involves the multiplication of the normalised tissue segment by the Jacobian 
determinants of the deformation field containing the information about image 
transformations during spatial normalisation. This procedure has the effect of 
preserving the total amount of a tissue signal in the normalised image (Goldszal 
et al., 1998). With this adjustment for volume change, VBM compares the 
absolute amount or volume of a tissue type in each region between groups of 
subjects (Ashburner and Friston, 2000). 
Two formal protocols for pre-processing structural images have been described 
and applied in peer-reviewed publications: so called standard and optimised. The 
standard protocol, as originally introduced by Ashburner and Friston (2000), has 
been described in the previous paragraph and involves spatial normalisation, 
segmentation, and smoothing for the comparison of tissue concentration; plus 
modulation (i. e. multiplication with the Jacobian determinants), which is 
performed prior to smoothing, for the comparisons of tissue volumes. 
The optimised protocol has been devised and validated more recently by Good et 
al. (2001). The main theoretical and practical underpinning of the optimised 
procedure proposed by Good and colleagues is that the spatial normalisation is 
improved by matching grey matter to grey matter prior probability template, due 
to the exclusion of voxels representing non-brain tissues (e. g. skull, dura matter) 
from the estimation of the spatial warps, which have an influence when matching 
whole head images to a whole head template. The low frequency basis functions 
employed during spatial normalisation are not good at modelling high frequency 
variability in skull thickness, head shape, etc. Another component of the 
optimised procedure is that it incorporates a few automated morphological 
operations at different stages of pre-processing to remove non-brain tissue that 
otherwise gets misclassified as grey matter. The complete optimised procedure 
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will be described in the Method section. For the purposes of the introduction, it 
suffices to say that it involves many more pre-processing steps, which makes it 
substantially more time consuming and computer intensive. 
The standard VBM technique has been validated with ROI measurements (e. g. 
Vharga-Khadem et al., 1998; Job et al., 2002; Maguire et al., 2003; Saldago- 
Pineda et al., 2003), as well as with the phantom-lesion detection approach (e. g. 
Wright et al., 1999). The optimised VBM technique has been validated with an 
independent automated segmentation technique and ROI measurements in 
groups of elderly healthy subjects and patients with Alzheimer's disease and 
semantic dementia (Good et al., 2001). 
Although theoretically, optimised protocol should yield superior segmentation of 
the brain into its constituting tissue types, i. e. grey, white, and CSF, it has not 
been tested directly in a clinical population whether optimised protocol presents 
an advantage over more concise and hence less time consuming standard 
protocol. Therefore, the aims of this study were twofold: 
1) To identify a pattern of structural alterations in schizophrenia population 
using VBM method. 
2) To compare standard and optimised VBM protocols in schizophrenia 
population in terms of tissue segmentation accuracy. 
It was hypothesised: 
1) Based on the results of the previous research, with both ROI and VBM 
approaches that have been outlined in Chapter 2, patients with 
schizophrenia would have global (i. e. whole brain and grey matter) as well 
as regional structural volume alterations. The local alterations were 
expected in the areas that are most consistently found in the ROI and VBM 
studies (Chapter 2: Structural Alterations), and have been implicated most 
strongly in the pathophysiology of schizophrenia (Chapter 2: Relationship 
between structural alterations and cognitive deficits), including: 
Grey matter volume reduction of: 
- Prefrontal cortex as has been observed 
by ROI studies, localised to the 
Inferior Frontal Gyrus (IFG) by previous VBM studies; 
- Superior Temporal Gyrus 
(STG), as has been observed in all ROI studies 
measuring grey matter volume of this structure as well as more recently 
by some (but not all) VBM studies; 
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- Hippocampal complex, as has been observed in 74 % of the ROI studies 
and some (but not all) VBM studies; 
Grey matter volume increases of: 
- Basal Ganglia structures, including caudate and putamen, possibly due to 
neuroleptic medication exposure. 
Further alterations were expected in cortical regions understudied with ROI 
approach, such as parietal and occipital lobes. Global white matter was predicted 
to be unchanged in patients, since total white matter volume reduction is not 
found as reliability as that of total grey matter volume (review, Lawrie and 
Abukmeil, 1998). No predictions were made as to local white matter availability. 
2) An optimised protocol would result in superior tissue segmentation compared 
with standard protocol. 
The absolute local tissue alterations were of interest to make the findings of this 
study directly comparable with the existing literature using ROI method. 
Therefore, the volume rather than concentration of grey and white matter was 
compared between patients and healthy individuals. 
A further aim of the study was to investigate the inter-relationships of structural 
volume alterations in schizophrenia patients. Although many MRI studies reported 
more than one morphological abnormality in schizophrenia patients as a group, 
little is known about the associations between the alterations in the volume of 
different brain regions. Previously, Wible and colleagues (1995) reported left 
prefrontal grey matter volume to correlate with volume reductions in the left 
amygdala-hippocampal complex, left STG, and left parahippocampal complex in 
schizophrenia patients. Correlations between these brain regions were not 
observed in controls. In an exploratory study of structural brain volume 
relationships in schizophrenia patients and normal controls using factor analysis, 
Tien et al. (1996) observed the disrupted relationship between dorsolateral 
prefrontal and superior temporal volumes in schizophrenia patients that was 
present in normal controls. Subsequently, Woodruff and colleagues (1997b), who 
investigated associations between several brain regions in male schizophrenia 
patients, also reported disrupted frontal-temporal volume relationship in patients 
relative to normal controls. Finally, Bullmore and colleagues (1998) re-assessed 
the data reported by Woodruff et al. (1997b) using statistical methods based on 
information theory and principal component analysis, and also showed reduced 
dependencies between frontal and temporal lobe volumes in schizophrenia. 
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Therefore, the present study wished to further investigate the inter-relationships 
between brain regions that are altered in schizophrenia patients, and compare the 
associations found in patients with those in controls. 
Finally, structural volume alterations in patients were investigated in relation to 
their clinical characteristics. 
5.2. Method 
5.2.1. Participants 
5.2.1.1. The inclusion criteria 
The inclusion criteria for the patients were i) no neurological conditions; ii) no 
additional (to schizophrenia) diagnosis of DSM IV axis-I-disorder (First et al., 
1996a); iii) no concomitant diagnosis of drug or alcohol abuse; and iv) no 
previous experience with the neuropsychological measures used in the study. 
The inclusion criteria for healthy volunteers were i) no personal history of DSM-IV 
Axis I and II disorders (First et al., 1996a); ii) no familial history of psychosis (as 
determined by the Family Interview for Genetic Studies (FIGS), Gershon and 
Guroff, 1984); iii) no neurological conditions; iv) no drug or alcohol abuse; and v) 
no previous experience with the neuropsychological tests. 
Both patients and controls had English as their first language. 
5.2.1.2. Overall sample 
50 in- and out- patients in the category of DSM-IV schizophrenia or 
schizophrenia-related disorders and 48 healthy controls, right handed, age 
between 18-65 years, were recruited for the investigation. Diagnoses were 
ascertained by experienced psychiatrists of the Section of Cognitive 
Psychopharmacology, Institute of Psychiatry, using the structured Clinical 
Interview for DSM-IV Axis I disorders Research Version (SCID-I; First et al., 
1996b). All participants gave informed consent prior to the participation. Five 
patients were excluded: three females due to the MRI motion artefact and two 
males due to brain tumours as revealed upon the examination of the structural 
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MRI scans. Three controls were excluded due to the MRI motion artefact: two 
females and one male. 
5.2.1.3. Final Sample 
Forty five schizophrenia patients, 27 male and 18 female, and 43 healthy 
controls, 25 male and 18 female, have met all of the above criteria, as well as 
passed the stringent quality control of the MRI scans, and thus constitute the final 
sample (see Table 5.1 for demographic characteristics). The groups were closely 
matched on sex, ethnicity and parental socio-economic status (SES). The 
schizophrenia patients were significantly older (Mean = 40.49, sd = 11.67, range 
18-61) than the controls (Mean = 33.72, sd = 12.37, range 19-65) [p=. 01]. This 
group difference was due to significantly older female patients (Mean=42.33, 
sd=12.47, range 21-61) relative to female controls (Mean=30.72, sd=12.70, 
range 20-65) [p=. 008], which resulted from the exclusion of two younger female 
patients and two older female controls due to the reasons stated above. Male 
participants were closely age matched, with male patients having the mean age 
of 39.26 years (sd=11.18, range 18-61) and male controls having th mean age of 
35.88 years (sd=12.28, range 19-60) [p=. 304]. 
Parental SES is closely associated with the level of educational achievement in 
normal population (e. g. Okpala, Okpala, and Smith, 2001; Bradley, 2002). 
Individuals with schizophrenia often achieve lower level of education that would 
be predicted from their social class (e. g. Isohanni et al., 2001). This might be 
due to cognitive problems experienced very early in life (e. g. Isohanni et al., 
2004). The current sample confirms this pattern. Although the patients closely 
matched controls on parental SES, their level of educational achievement was 
substantially lower (patients' mean=11.93, sd=3.08; controls' mean=16.31, 
sd=3.44) [p<. 0001]. This was true for both male (patients' mean=12.19, 
sd=3.45; controls' mean=16.38, sd=3.40) [p<. 0001] and female (patients' 
mean=11.56, sd=2.45; controls' mean=16.22, sd=3.59) [p<. 0001] sub-groups. 
Table 5.2 lists clinical characteristics of the patients, including the diagnosis, 
illness type, familial history, age of onset, age of first hospitalisation, duration of 
illness, number of previous episodes, and symptom ratings using the Positive and 
Negative Syndrome Scale (PANSS, Kay et al., 1987). 
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TABLE 5.1. Demographic Characteristics of the Final Sample 
Characteristic Patients (N=45) Controls (N=43) 
Mean (SD) [Range] Mean (SD) [Range] 
Male/Female 27/18 25/18 
Age: Group 40.49 (11.67) [18-61] 33.72 (12.37) [19-65] 
Male 39.26 (11.18) [18-61] 35.88 (12.28) [19-60] 
Female 42.33 (12.47) [21-61] 30.72 (12.70) [20-65] 
Education: Group 11.93 (3.08) [5-22] 16.31 (3.44) [11-25] 
Male 12.19 (3.45) [5-22] 16.38 (3.40) [11-25] 
Female 11.56 (2.45) [7-17] 16.22 (3,59) [11-24] 
Ethnicity: Caucasian 37 36 
African 4 3 
South-East Asian 2 2 
Mixed Race 1 1 
Other 1 1 
Parental SES: (N=41) (N=43) 
Professional 5 6 
Intermediate 13 13 
Skilled: non-manual 1 3 
manual 10 8 
Semi-skilled manual 7 8 
Unskilled manual 5 5 
Statistics 
XZ = . 
03 1; p=. 859 
T86 = 2.60; p=. 01 
Tso = 1.039; p=. 304 
T34 = 2.824; p=. 008 
T86 = -6.302; p<. 0001 
Tso = -4.408; p<. 0001 
T34 = -4.552; p<. 0001 
X2 = . 
526; p=. 640 
X'=. 008; p=. 930 
TABLE 5.2. Clinical Characteristics of Patients 
Characteristic First Episode (n=4) Chronic (n=41) Total (n=45) 
Diagnosis: N/A Total (VF) 
Schizophrenia, paranoid 28(20/8) 
Schizophrenia, undifferentiated 3 (1/2) 
Schizophrenia, residual 9 (5/4) 
Schizoaffective disorder 1(1/-) 
Family history: 
Yes 12 (10/2) 
No 28(16/12) 
Missing data 41 (1/-) 
Mean (SD) [Range] Mean (SD) [Range] Mean (SD) [Range] 
Age at onset of first symptoms: 27.25 (4.79) [21-31] 25.15 (9.17) [15-59] 25.33 (8.85) [15-59] 
Number of previous episodes: N/A 4.41 (4.62) [1-20] 
Age at first hospitalisation: 27.25 (4.79) [21-31] 22.46 (12.21) [0-59] 22.89 (11.78) [0-59] 
Previous psychiatric hospitalisations: N/A 3.71 (4.02) [0-20] 
Duration of illness since first symptoms 
(years): N/A 16.88 (11.69) [1-39] 
N=38 N=42 
PANSS Positive symptoms: 27.75 (2.22) [25-30] 17.11 (7.12) [7-32] 18.15 (7.50) 
[7-32] 
PANSS Negative symptoms: 21.50 (5.07) [17-28] 17.83 (8.08) [7-52] 18.20 
(7.86) [7-52] 
PANSS General Psychopathology: 57.75 (5.12) [53-65] 37.27 (9.82) [13-55] 39.27 (11.25) [13-65] 
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All but ten patients received conventional antipsychotics, either orally or as a 
depot injection (chlorpromazine equivalents mean = 283.76, sd = 254.96, range 
31.25-1000 mg/day). Fifteen patients were receiving adjunctive anticholinergic 
medication (procyclidine, mean = 5.9, sd = 2.93, range 2.5-15 mg/day). 
5.2.2. MRI Data Acquisition 
Structural images were acquired using a 1.5 Tesla GE NV/i MR Signa system 
(General Electric, Milwaukee WI, USA) at the Maudsley Hospital, London, with 
routine daily quality control, using an automated procedure (Simmons et al., 
1999). A high-resolution 3-D inversion recovery prepared spoiled GRASS pulse 
sequence was used to acquire a T1-weighted volume in the axial plane (TR=12.2 
ms, TE=5.3 ms, TI=300 ms, flip angle=20°, in-plane resolution=. 94 mm, matrix 
dimensions 256 x 256), yielding 124 contiguous slices of 1.5 mm thickness. Head 
movement was limited by foam padding and a restraining band across the 
forehead. 
5.2.3. MRI Data Pre-processing 
Structural images were converted into ANALYZE format (ANALYZE software, BRU, 
Mayo Foundation, Rochester, MN; Robb, 1990) and pre-processed using SPM99, 
running in MATLAB 6.1 (MathWorks, Natick, MA). A manual determination of the 
anterior commissure was performed for all images in preparation for the 
processing. Patients and controls did not differ on intra-scanner movement 
(rotations no larger than 1 degree or translations no greater than 1 mm), using a 
group (patients vs controls) x movement dimension (x, y, z, pitch, roll, yaw) 
ANOVA (p<. 345). The images were then pre-processed following the standard 
and optimised VBM protocols. 
5.2.3.1. Standard Protocol 
First, images were spatially normalised to the standard SPM99 T1 whole brain 
template. The standard SPM99 whole brain template for T1-weighted images is 
an average of 152 MRI scans of young healthy brains from the Montreal 
Neurological Institute, which has been adopted as an international standard by 
the International Consortium of Brain Mapping and is known as ICBM152. The 
images were normalised using 12-parameter linear transformation followed by 
non-linear iterations using 7x8 x7 basis functions as integrated in SPM99. The 
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normalised images were written down with lxlxl mm voxel size to reduce the 
partial volume effect aiding the segmentation. Second, the normalised images 
were segmented into grey matter, white matter, CSF and non-brain tissue using 
prior probability maps of different tissue types inherent to SPM99. Third, the 
segmented images were modulated by multiplying with Jacobian determinants of 
the deformation fields to correct for volume changes introduced during non-linear 
transform. Finally, the images were smoothed with 12-mm FWHM isotropic 
Gaussian kernel. The width of the smoothing kernel determines the scale at 
which morphological changes are most sensitively detected, since smoothing 
creates a local weighted average of the surrounding pixels. The use of 12-mm 
kernel was recommended by Ashburner and Friston (2000) to insure the validity 
of the following statistical tests and has been accepted as a `Gold Standard' by 
researchers. Smoothing kernels of smaller sizes might not be sufficient to render 
the data normally distributed, making analyses susceptible to false-positive 
errors. 
5.2.3.2. Optimised Protocol 
The original structural images were re-processed following the optimised protocol 
devised by Good et al. (2001). 
Creation of Customised Templates 
As the first step, study specific (customised) whole brain template and prior 
probability maps were created to improve the spatial normalisation. Since the 
standard SPM99 templates were created from the images of the young healthy 
individuals, they might not be suitable for normalising brains of the population 
with deviant brain features, such as enlarged ventricles, biasing their 
normalisation. Customised whole brain templates as well as grey-, white- matter, 
and CSF prior probability maps were therefore created from the images 40 
patients (25 male and 15 female) and 40 controls (25 male and 15 female) of the 
present sample matched as closely as possible on demographic variables. 
For the whole brain template, the images were spatially normalised to T1- 
weighted template (ICBM 152 standard, inherent to SPM99), using 12-parameter 
affine transformation only (Ashburner et al., 1997); smoothed with 8 mm full 
width half maximum (FWHM) isotropic Gaussian kernel; and averaged. For 
customised probability maps, images were segmented into grey-, white- matter, 
and CSF compartments using grey-, white- matter, and CSF probability maps 
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inherent to SPM99. The resultant tissue segments were automatically cleaned to 
remove non-brain tissue; smoothed with 8-mm FWHM isotropic Gaussian kernel; 
normalised using customised whole brain template with 12-parameter affine 
transformation; and finally averaged to derive grey-, white- matter, and CSF 
probability maps. Templates were created with 1xix1 mm voxel size to reduce 
the partial volume problem and to ensure optimal tissue segmentation. 
Deriving and Applying Optimised Normalisation Parameters 
The first step involved a segmentation of the original images in native space, 
registering to the customised tissue probability maps and correcting for image 
inhomogeneity, followed by the automatic brain extraction and cleaning 
procedure to remove non-brain tissue. Second step entailed spatial normalisation 
of the original images to the customised whole brain template using 12- 
parameter linear and 7x8x7 discrete cosine transform basis function non-linear 
transformations (Ashburner and Friston, 1999), with parameters determined from 
the images derived from the first step; and resliced to 1xix1 mm voxel size to 
yield more accurate subsequent tissue segmentation. The spatially normalised 
images were then segmented into three tissue compartments, using the 
customised grey-, white- matter, and CSF templates. Brain extraction and 
cleaning procedures were re-applied to the segmented normalised grey matter 
images to further remove extraneous brain tissue. The cleaned grey matter 
images were modulated, i. e. the voxel values of each segment were multiplied by 
the Jacobian determinants of the deformation matrix derived during the spatial 
normalisation step. The modulation 'restores' the original volume of each grey 
matter segment, as the volume of some brain regions may shrink or expand as a 
result of non-linear spatial normalisation. Finally, grey and white matter 
segments were smoothed using 12-mm FWHM isotropic Gaussian kernel. 
5.2.4. Data Analysis 
5.2.4.1. VBM model specification and parameter estimation 
The model and parameters for SPM voxel-wise comparisons of the images 
processed with standard and optimised protocols were identical. 
First, global tissue availability indices, global grey-, white- matter, and whole 
brain volumes (global grey + global white) were calculated using an integral 
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function (SPM list archives, http: //www. jiscmail. ac. uk/lists/spm. html) applied to 
the original structural images. The values (in litres) for total grey and white 
matter volumes were used in voxel-wise comparisons to control for individual 
variations in tissue availability. The correction for differences in total tissue 
volumes decreases the rate of false positive errors in VBM (Ashburner and 
Friston, 2000). Further, the total volumes were entered into SPSS version 10 and 
compared using analysis of covariance (ANCOVA), controlling for age and sex for 
their known influence on brain morphology (Coffey et al., 1998), to investigate 
whether there were alterations in global tissue volumes in patients. 
To compare the groups on the regional volumes of grey and white matter voxel- 
by-voxel, the grey/white matter segments of patients and controls were 
proportionally scaled to total grey/white matter volume with the global mean of 
100, adjusting for the confounding effects of age and sex. Therefore, each 
region of group difference represents the difference in the proportion of total 
grey/white matter volume in that region between the groups. 
The predicted values (y' adjusted = y' fitted + error) for the percentage of total 
grey/white matter volume at the maxima voxel of all the regions of between- 
group differences were extracted for each participant for the analyses of the 
inter-relationships between altered regions, as well as their relationship with 
clinical variables in SPSS. 
5.2.4.2. Statistical comparisons 
For the statistical comparisons of regional volumetric differences between the 
groups normalising for whole grey/white matter volumes and covarying for the 
effects of age and sex, SPM proceeds through the following steps: 
i) performs a statistical analysis for each voxel independently; 
ii) calculates at statistic from the results of this analysis for each voxel; 
iii) calculates az score equivalent for the t statistic; 
iv) estimates ap value for at statistic at each voxel independently; 
v) estimates a corrected p value adjusted for multiple comparisons performed for 
the entire brain. 
For the steps i) to iv), SPM uses General Linear Model (GLM), where 
-a voxel value for each scan 
is an observation; 
- data for all the scans 
for one voxel (i. e. all the observations) is a 
dependent variable (a response); 
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-a diagnosis is an independent variable (a predictor), covariate for the 
effects of age and sex. 
To solve the multiple comparison problem (step v), SPM uses random field theory 
(RFT). (Since the brain voxels are spatially correlated, Bonferroni correction is 
too conservative as it assumes independent tests. ) The RFT correction is based 
on the number of resels in the image and Euler characteristic (EC) of the image. 
A resel is a "resolution element" and is defined as a block of pixels of the same 
size. The size of the pixels in its turn is determined by FWHM of the image 
smoothness. As the images were smoothed with 12mm FWHM kernel, one resel is 
a 12 x 12 pixel block. The number of resels is conceptually similar to the number 
of independent observations in the image, but it is not equivalent to it. The EC of 
an image is a property of the image after it has been thresholded, which means 
that all pixels with z scores below or equal to the threshold value will be set to 
zero and all pixels with z scores above the threshold value will be set to one. 
The RFT correction proceeds through determining the number of resets in the 
image, uses the resel count to work out the expected EC of the image at various 
thresholds, and finally calculates the alpha (the rate of false positives) for the 
results observed at the set threshold from the expected ECs. 
For all comparisons in SPM99, the threshold for statistical parametric maps was 
set at T=3.20, p<. 001 uncorrected. The spatial extent threshold was set at 25 
contiguous voxels, since clusters of smaller size are more likely to arise by chance 
(Wilke et al., 2001). The results were considered to be statistically significant at 
p<. 05 voxel level corrected for multiple comparisons throughout the entire brain. 
For the predicted regions (see Introduction), small volume corrections (SVC) were 
used when adjusting for multiple comparisons to reduce the search-volume to the 
regions of interest. Further, since the multiple comparisons correction procedure 
in SPM99, which was originally designed for the analysis of functional data, is 
overly strict when applied to the structural data (Sowell et al., 1999), the 
unpredicted regions of differences that did not reach 5% level after multiple 
comparisons correction but exceeded T=4.00 (p<. 00001 uncorrected) were 
considered to be a trend and, therefore, of interest for the investigation of 
structure/neurocognition associations of Study 3. 
SPM99 displays the results as a statistical parametric map and uses Talairach and 
Tournoux system of coordinates (i. e. x=0, y=0, z=0 at the anterior 
commissure, and with the anterior / posterior commissural line defining the plane 
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where z= 0). Since the MNI templates in SPM99 are larger (i. e. higher, deeper 
and longer) than the brain pictured in the Talairach and Tournoux atlas (1988), 
with differences at maximum in the order of 10mm, MNI Xyz coordinates of 
significant and of interest voxels were converted to Talaraich and Tournoux space 
using a non-linear transform (Brett, 1999). The voxel locations were then 
identified using the Talairach and Tournoux atlas (1988) and the Ta/airach 
Daemon software (Lancaster et al., 2000). 
5.3. Results 
5.3.1. Global tissue alterations 
Patients had decreased global grey matter, white matter, and whole brain 
volumes (in litres). The grey matter volume was reduced by 9% (patients' mean 
= . 659, sd = . 007; controls' mean = . 725, sd = . 008) [F (1,84) = 13.956, 
p<. 0001], beyond the significant confounding effects of age [p=. 001] and sex 
[p<. 0001]. The white matter volume was reduced by 7% (patients' mean = 
. 384, sd = . 006; controls' mean = . 414, sd = . 005) [F (1,84) = 8.554, p= . 004], 
beyond the significant effect of sex [p < . 0001] (but not age [p = . 234]). The 
whole brain volume was reduced by 9.5% (patients' mean = 1.043, sd = . 118; 
controls' mean = 1.138, sd = . 129) [F (1,84) = 13.498, p <. 0001], beyond the 
significant effects of sex [p < . 0001] and a trend effect of age [p = . 065]. 
5.3.2. Local Tissue Alteration 
5.3.2.1. Standard Protocol 
The pre-processing with the standard protocol resulted in the mis-registration of 
the images and a faulty segmentation, such that at least some of the grey matter 
voxels were misclassified as white matter. This became apparent when the white 
matter segments of patients and controls were compared. The SPM revealed a 
cluster of increased volume with the voxel of the maximum difference at x= -26, 
y= -14, z=8. When the SPM was overlaid on the average image of patient 
group, the cluster fell onto the putamen (Figure 5.1. ). 
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FIGURE 5.1. The cluster of presumably increased white matter (maxima voxel: x= -26, y 
= -14, z= 8) in schizophrenia patients overlaid on mean patient structural image, 
demonstrating misregistration with the standard VBM protocol 





5.3.2.2. Optimised Protocol 
The optimised pre-processing appeared to have yielded accurate normalisation 
and segmentation. The results of the optimised protocol were therefore treated 
as final and are reported in this chapter (see Table 5.1. ). 
TABLE 5.3. Structural Alterations in Schizophrenia Patients 
Brain Region Brodmann Cluster size Maxima voxel T value p uncorrected p corrected 
Area (# voxels) x, y, z 
Inferior Frontal Gyrus BA 45/47 3947 -33 28 -8 4.72 <. 0001 . 025 
Lingual Gyrus BA 17 4213 -22 -89 -6 4.34 <. 0001 . 05 
Superior Temporal BA 38 4290 -36 22 -31 4.27 <. 0001 . 105 
Gyrus -50 14 -34 4.08 <. 0001 . 179 
Putamen - 637 -29 -7 9 4.19 <. 0001 . 132 
Precuneus BA 7 1052 -13 -76 35 4.05 <. 0001 . 157 
Superior Fasciculus - 3578 -28 -38 26 4.18 <. 0001 . 126 
Longitudinalis 
Occipital White Matter - 851 -15 -86 -1 4.07 <. 0001 . 
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Reductions 
The grey matter volume was significantly reduced in two left hemisphere regions: 
the inferior frontal gyrus [IFG, BA 45/47, centred at the voxel x= -33, y= 27, z 
= -8, t (84) = 4.72, p= . 025], and the 
lingual gyrus [LG, BA 17, x= -22, y=- 
86, z= -9, t (84) = 4.34, p= . 05]. 
In addition, two voxels in the left anterior 
superior temporal gyrus (STG) showed trend significance [BA 38, voxel 1: x=- 
36, y= 20, z= -27, t (84) = 4.27, p= . 105, and voxel 2: x= -50, y= 
12, z=- 
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z= 6mm Z= 8mm 
29, t (84) = 4.08, p= . 179] after correction 
for multiple comparisons through the 
entire brain (see Figure 5.2). After the SVC was applied to STG, as it was one of 
the hypothesised regions, restricting the search volume to the temporal lobe (box 
with the dimensions: x= 50mm, y= 60mm, z= 40mm), the difference in STG 
regions became significant [p = . 012 and p= . 021 respectively]. 
FIGURE 5.2. Regions of grey matter volume reductions in patients (LEFT/RIGHT of the 
images correspond to LEFT/RIGHT of the brain): a) statistical parametric map (p<. 001 
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ABBREVIATIONS: IFG = Inferior Frontal Gyrus; LG = Lingual Gyrus; STG = Superior Temporal Gyrus. 
The white matter volume was reduced at a trend level in the posterior lobe (in the 
region of the superior fasciculus longitudinalis) [SFL, x= -28, y= -36, z= 26, t 
(84) = 4.18, p= . 126], and occipital 
lobe (OL) in the primary visual cortex [x =- 
15, y= -86, z= -1, t (84) = 4.07, p= . 172] (see Figure 5.3). 
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FIGURE 5.3. Regions of reduced white matter volume in patients (LEFT/RIGHT of the 
images correspond to LEFT/RIGHT of the brain): a) statistical parametric map (p<. 001 






FIGURE 5.4. Regions of increased grey matter volume in patients (LEFT/RIGHT of the 
images correspond to LEFT/RIGHT of the brain) : a) statistical parametric map (p<. 001 
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Patients had more grey matter relative to controls in two left-hemispheric regions 
(see Figure 5.4): posterior putamen [x = -29, y= -6, z=9, t (84) = 4.19, p= 
. 029 after the SVC with the search volume restricted to basal ganglia (sphere of 
40 mm radius) and the precuneus [BA 7, x= -13, y= -72, z= 35, t (84) = 4.05, p 
= . 157] which, although not significant after correcting for multiple comparisons, 
showed T>4.00, p<. 0001 uncorrected, and thus was considered of interest to 
the present investigation. 
There were no local volumetric increases of the white matter. 
5.3.3. Inter-relationships between Local Tissue Volumes 
In patients, there were a number of inter-relationships between altered regional 
volumes (see Table 5.2. ). Grey matter reduction of IFG was associated with the 
grey matter reduction of STG (voxel 1) [r = . 335, p <. 05] and LG [r = . 344, p 
<. 05]. Reduced grey matter of LG was associated with the reduction of white 
matter in OL [r = . 450, p <. 01]. Grey matter reduction in two STG regions was 
strongly associated [r = . 705, p <. 001]. Grey matter increase in putamen was 
inversely associated with white matter reduction in SFL [r = -. 483, p <. 01]. The 
associations between these brain regions were also present in controls; except for 
the inverse relationship between putamen and SFL, which was significantly 
stronger in patients [p = . 03]. 
There was also attenuation or lack of associations in patients that were significant 
in controls (see Table 5.2). Particularly, grey matter volume of STG 1 was 
significantly positively correlated with grey matter volume of LG [r = . 346, p 
<. 05], white matter volume of OL [r =. 364, p<. 05], and inversely with white 
volume of SFL [r = -. 303, p<. 05] in controls, differentiating them from patients 
with 82%, 98% and 91% probability respectively. In addition, precuneus grey 
matter volume inversely correlated with SFL white matter volume in controls [r = 
-. 324, p<. 05], but not in patients, differentiating the groups with 88% 
probability. 
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TABLE 5.4. Partial r correlation coefficients, adjusted for age and sex, expressing the inter- 
relationships between regional volumes in patients and controls. The r coefficients in two 
groups are compared using Fisher z transformations with the p values shown in brackets. 
LG STG1 STG2 Pu Prec SFL RO 
P/C P/C P/C P/C P/C P/C P/C 
(p value) (p value) (p value) (p value) (p value) (p value) (p value) 
IFG . 
344*/. 130 . 
335*/. 371 * 
. 
228/. 351 * -. 263/-. 232 . 
054/. 277 -. 040/-. 078 . 
088/. 101 
(. 30) (. 84) (. 55) (. 88) (. 29) (. 87) (. 95) 
LG . 






(. 18) (. 35) (. 81) (. 37) (. 13) (. 12) 
STG1 . 704**/. 665** -. 154/-. 390** . 056/. 007 . 067/-. 303* . 024/. 364* (. 65) (. 24) (. 83) (. 09) (. 02) 
STG2 -. 067/-. 088 -. 010/. 033 -. 027/-. 132 -. 198/. 274 
(. 92) (. 92) (. 63) (. 03) 
Pu . 
037/. 224 -. 483 * */-. 046 . 
103/-. 064 









* Significant at the 0.05 level (2-tailed) 
** Significant at the 0.01 level (2-tailed) 
ABBREVIATIONS: IFG = inferi or frontal gyrus; LG = lingual gyrus; P/C = Patients/Con trols; Prec = 
precuneus; Pu = putamen; STG = superior temp oral gyrus; SFL = superior longitudinal fascicules. 
5.3.4. Relationships between Structural Alterations and Clinical 
Characteristics of Patients 
Significant associations between structural alterations and medical history were 
observed for: i) smaller LG and greater number of previous psychotic episodes [r 
= -. 376, p<. 05]; ii) smaller SFL and greater number of previous psychotic 
episodes [r =-. 321, p<. 05] and hospitalisations [r =-. 323, p<. 05]; and iii) larger 
precuneus and greater number of previous psychotic episodes [r =. 444, p<. 01] 
and hospitalisations [r =. 402, p<. 01](see Table 6.3. ). In addition, patients with 
familial history of schizophrenia had significantly smaller grey matter of the 
anterior STG 2 than patients with no familial history [F 1,36 = 3.696, p= . 05]. 
Finally, since enlarged striatum has been shown to associate with neuroleptic 
exposure (Chakos et al., 1994), the putamen volume was investigated in relation 
to current neuroleptic dose, but no relationship has been found (r = -. 034, p= 
. 852). Precuneus increase was also unrelated 
to current neuroleptic dose (r =- 
. 039, p =. 827). 
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Structural alterations were also associated with psychopathology, including: i) 
smaller total grey matter volume and higher PANSS positive symptoms [r =-. 362, 
p<. 05]; ii) larger putamen and lower PANSS positive symptoms [r =-. 510, 
p<. 01] and general psychopathology [r =-. 432, p<. 01]; and iii) smaller SFL and 
lower PANSS general psychopathology [r =. 362, p<. 05] (see Table 5.3). 
TABLE 5.5. Partial r correlation coefficients, adjusted for age and sex, between 
structural alterations and clinical characteristics of the schizophrenia patients 
Whole brain volume None 
Total grey matter 
PANSS positive syndrome -. 362* 
Total white matter None 
Inferior Frontal Gyrus, BA 47/45 None 
Lingual Gyrus, BA 17 
Number of previous episodes -. 376* 
Superior Temporal Gyrus 1, BA 38 None 
Superior Temporal Gyrus 2, BA 38 None 
Putamen 
PANSS positive syndrome -. 510** 
PANSS general psychopathology -. 432* 
Precuneus, BA 7 
Number of previous episodes . 
444* 
Number of previous hospitalisations . 
402 
Superior Fasciculus Longitudinalis 
PANSS general psychopathology . 
362* 
Number of previous hospital isations -. 323* 
Number of previous episodes -. 321 * 
White matter of OL None 
* Correlation is significant at the 0.05 level (2-tailed) 
** Correlation is significant at the 0.01 level (2-tailed) 
5.4. Discussion 
Towards achieving the primary aim of this investigation, i. e. identification of 
structural volume alterations in schizophrenia patients throughout the brain, the 
structural data were initially processed according to the standard VBM protocol. 
However, it has resulted in the segmentation fault, such that some of the sub- 
cortical grey matter voxels were misclassified as white. This became apparent 
when SPM map showing regions of increased white matter volume was overlaid 
on the structural image representing the averaged brain of the patient group. A 
presumed sub-cortical region of increased white matter had fallen onto the 
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posterior putamen. This registration error was rectified with optimised VBM. 
Therefore, only the results of the optimised VBM were reported and are discussed 
next. 
The optimised protocol revealed global and regional structural volume alterations 
in patients. Global alterations encompassed reductions in the volume of both grey 
(by 9%) and white matter (by 7%), and, consequently, that of the whole brain 
(by 9.5%). The present finding adds to the weight of evidence for reduced white 
matter availability in schizophrenia patients as compared to healthy individuals, 
since previous studies did not find the white matter reduction as consistently as 
that of the grey matter (Lawrie and Abukmeil, 1998). 
Regional alterations observed in the present sample were confined to the left 
hemisphere (although statistical parametric map displayed a right hemisphere 
reduction of IFC volume, it was not significant according to the criteria specified 
in the Method section). Regional alterations included significant grey matter 
volume reductions of IFG (BA 47/45), LG (BA 17), and STG (BA 38; significant 
with SVC), and significant (with SVC) grey matter volume of the putamen. 
Additionally, few reductions were significant at less than 1% level uncorrected, 
but did not survive multiple comparisons correction, including white matter 
volume of the posterior and occipital lobes, as well as increased grey matter 
volume of the precuneus (BA7). 
Most of these findings are in agreement with other recent VBM studies. The left 
IFG and OL white matter volume reductions are in line with the findings of Ananth 
and colleagues (2002), who were the first to employ optimised volumetric VBM 
protocol, although the region of maximal effect for IFG in their study was more 
superior (BA 46) [x yz= -45 15 36], bordering the middle frontal gyrus (BA 9). 
The reduction of the IFG grey matter concentration has also been observed with 
VBM (Wright et al., 1999; Wilke et at., 2001; Suzuki et al., 2002). One ROI study 
(Buchanan et al., 1998) reported reduced volume of both left and right IFG. 
The patients had reduced grey matter volume of the LG (BA 17). Selemon and 
colleagues (1995) reported increased neuronal density (a marker of neuronal 
atrophy) in BA 17 in post-mortem brains of schizophrenia patients. Reduction of 
the grey and white matter in the primary visual cortex was recently reported to 
associate with poor-outcome schizophrenia patients (Mitelman et al., 2003). Four 
earlier ROI studies measuring the occipital lobe as a whole have reported a 
reduction of this region (Andreasen et al., 1994; Bilder et al., 1994,1999; 
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Zipursky et al., 1992). One VBM study (Job et al., 2002) observed grey matter 
concentration reduction in the cuneus, which is immediately adjacent to the area 
of reduced volume in the present cohort. The findings of the present study 
suggest that greater LG volume reduction might be associated with more severe 
form of the illness, as it positively correlated with the number of previous 
psychotic episodes. This, in fact, replicates the finding by Mitelman et al. (2003) 
of poor clinical outcome in patients having a greater reduction of the primary 
visual cortex. 
STG grey matter volume reduction has 100% replicability using ROI approach 
(Shenton et al., 2001), with the reduction of the anterior part found more 
consistently than that of the posterior part (Rajarethinam et al., 2000). VBM 
concentration studies have found left STG grey matter volume reductions specific 
to the anterior part (Wright et al., 1999; Wilke et al., 2001; Kubicki et al., 2002). 
The anterior STG grey matter reduction might also be specific to schizophrenia, 
since it was one of the areas to differentiate patients with schizophrenia and 
bipolar depression (Pearlson, 1997). Recently, Kasai and colleagues (2003) 
reported progressive changes in both anterior and posterior STG grey matter 
volume in first-episode patients 1.5 years following the initial hospitalisation. The 
present investigation, however, did not observe an association between STG grey 
matter volume and illness duration. What was observed is smaller STG volume in 
patients with family history of schizophrenia than in patients with no family 
history. It is possible that in patients with genetic loading STG volume reduction 
might represent a neurodevelopmental anomaly with possible further 
degeneration following the illness onset. 
Putamen enlargement has been observed in schizophrenia with both ROI (Gur et 
al., 1998; Hokama et al., 1995) and VBM (Wilke et al., 2001; Saldago-Pineda et 
al., 2003) methods. The putamen increase might be associated with neuroleptic 
exposure (e. g. Gur et al., 1998); however, the present study did not observe 
such an association. It must be noted that the use of chlorpromazine equivalents 
may result in a distorted estimate of the current neuroleptic exposure, and thus 
the possibility of the putamen increase being due to the neuroleptic use cannot be 
completely discounted. Buchsbaum and colleagues (2003) have recently reported 
increased putamen size in good, but not in poor, outcome schizophrenia patients, 
which was not related to either current or accumulative neuroleptic exposure, and 
suggested that larger putamen might simply represent a physiological correlate of 
neuroleptic responsiveness. The observed association of larger putamen with less 
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severe positive and general psychopathology symptoms in the present cohort 
provides an indirect support for this notion. 
The increase in the grey matter concentration of the precuneus (bilaterally) was 
previously observed in female, but not male, patients with VBM (Suzuki et al., 
2002). Another VBM study (Wilke et at., 2001) reported the bilateral reduction of 
CSF concentration above the precuneus. The present study provides further 
evidence for the grey matter increase in the precuneus, now with the volumetric 
approach and regardless of gender, and suggests that larger left precuneus is 
associated with more recurrent form of psychosis, by positively correlating with 
the number of previous psychotic episodes and hospitalisations. However, two 
VBM studies that used in-house processing techniques rather than protocols 
implemented in SPM, reported reduction in grey matter concentration of the 
precuneus on the left (Shapleske et al., 2002) as well as bilaterally (Hulshoff Pol 
et al., 2001). The regions within the precuneus implicated in these studies were 
more ventro-medial than the ones observed in this study (which was bodering 
parieto-occiptial sulcus) and other VBM studies using SPM. 
To the best of author's knowledge, the present study is the first to observe white 
matter volume reduction in the white matter region that includes the fibres of the 
posterior extent of SFL in schizophrenia. SFL is a long association tract and is the 
most important one for language function, as it establishes communication 
between area triangularis of the inferior frontal lobe, BA 22 in the temporal lobe, 
and the angular and supramarginal gyri in the parietal lobe. A severing of a part 
of this tract known as the arcuate fasciculus in the dominant hemisphere 
disconnects the anterior speech area (Broca's area) from the posterior language 
area (Wernicke's area), resulting in conduction aphasia (inability to repeat what is 
heard). Reduced volume of the posterior SFL, near the inferior parietal lobule, 
might have implication for language function. 
The present study did not observe predicted reductions of hippocampal complex. 
It could be argued that the VBM might not be sensitive enough to identify these 
abnormalities, due to the difficulty in differentiating grey and white matter in 
these areas (Velakoulis et al., 1999; Ashburner and Friston, 2000). In addition, 
12mm smoothing kernel creates local weighted volumes that are larger than the 
size of the hippocampus, thus potentially hampering the detection of possible 
abnormalities in hippocampal complex. Therefore, the lack of findings in this area 
might be due to the limitations of the VBM method and the choice of the 
smoothing kernel size. However, previous VBM studies have been able to detect 
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abnormalities in the medial temporal lobe structures, including reduction of the 
right amygdala (with 12mm smoothing kernel; Wright et al., 1999; Job et al., 
2002), parahippocampal gyrus (with 12mm, Job et al., 2002), left hippocampus 
(with 6mm, Kubicki et al., 2002), and bilateral hippocampus (with 12mm, Suzuki 
et al., 2002). To ascertain that the lack of the hippocampal finding is not due to 
the selection of 12 mm kernel, the data were re-analysed with 10mm and 6mm 
smoothing kernels; however, no differences were observed in the hippocampal 
complex even at the most liberal threshold of p<. 05 uncorrected. 
The present study did not observe any alterations of some regions that have been 
relatively consistently replicated in VBM studies. One such region is insula, which 
was neglected by ROI studies, and has emerged due to the VBM approach as the 
area implicated in schizophrenia neuropathology. Three VBM studies (Wright et 
al., 1999; Wilke et al., 2001; Kubicki et al., 2002) have reported grey matter 
concentration reduction of the insula. However, Ananth et al. (2002) who applied 
volumetric VBM did not observe insula alteration. Therefore, the reduction of 
insula might be limited to grey matter concentration, i. e. to the amount of grey 
matter relative to other brain tissues in this region. Another region that has been 
replicated by three VBM concentration studies (Job et at., 2002, Kubicki et al., 
2002; Suzuki et al., 2002), but not VBM volume study (Ananth et al., 2002) is 
anterior cingulate (AC). The present study did not observe AC volume reduction, 
suggesting that AC reduction might also be limited to the concentration. Third 
region showing relative consistency in being implicated is orbito-frontal cortex 
(OFC), which was observed with both concentration (Wilke et al., 2001) and 
volume (Ananth et al., 2002) measurements. Overall, the pattern of structural 
alterations identified by different VBM studies differs and sometimes substantially. 
Factors such as differences in the patient populations and sample compositions 
(e. g. gender of the patients, age, etc), variations in the pre-processing steps, the 
choice of covariates (e. g. total grey matter, whole brain volume, intra-cranial 
volume) amongst possible others are all contributing factors to variations in 
findings. The pattern of the structural alterations of the present study is generally 
consistent with the previous literature. 
Contrary to the prediction and to the findings of the previous studies (Tien et al., 
1996; Woodruff et al., 1997b; Bullmore et al., 1998), the volumes of the frontal 
and temporal cortices were found to be associated in schizophrenia patients to a 
similar extent as in normal controls. The present study investigated the 
relationship between much more specific areas and specific tissue compositions, 
than studies that observed fronto-temporal dissociation in schizophrenia patients 
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(Tein et al., 1996; Woodruff et al., 1997b; Bullmore et al., 1997). The only other 
study (Wible et al., 1995) to look at separate tissue compositions have observed 
relationship between the volume of left PFC grey matter and reduced volume of 
STG in schizophrenia patients; however, the difference between patients and 
controls was not assessed formally and, therefore, it is not clear whether the 
finding was specific to schizophrenia. Interestingly, Woodruff and colleagues 
(1997b) observed no association between the volume of ventrolateral PFC, which 
included IFG, and the volume of STG either in patients or controls. It is possible 
that the association might be specific to grey matter volume, as found in the 
present study. Alternatively, the dissociation might be specific to male patients 
(Woodruff et al., 1997b; Bullmore et al. 1997). However, in the present study the 
effects of age and gender were controlled for at all stages of the analysis, and 
thus the association between these two regions existed regardless of gender. 
Finally, in the previous studies the patients did not differ from the controls on the 
volume of the ROI that were found to be associated in controls but dissociated in 
patients. The present study was specific to investigating the inter-relationships 
between regions which volumes were altered relative to normal controls. 
Basolateral frontal cortex is connected with anterior temporal cortex through a 
thick bundle of relatively short white matter fibers called fascisu/us uncinatus. 
The IFG and the anterior STG show functional correlation in the tasks requiring 
semantic processing and memory (e. g. Binder et al., 1997; Rao et al., 1997; 
Mummery et al., 1999). The co-reduction in the volumes of these regions 
(independent of total grey matter volume) suggests structurally compromised 
neural network involved in language and meaning related processing in at least 
some patients (the correlations between the volumes of these regions were 
modest). Shergill et al. (2000) reported functional disconnection between IFG and 
STG in patients prone to auditory hallucinations, presumably resulting in impaired 
verbal self-monitoring. 
The IFG volume reduction in patients was also positively associated with that of 
LG. This association was much weaker in controls. Curiously, although the grey 
and white matter volume reduction of the occipital lobe were correlated, IFG grey 
matter volume reduction was associated with only grey matter volume of LG. 
Other positive inter-relationships between altered tissue volumes in patients were 
observed between spatially related regions, including two regions of STG grey 
matter volume, and grey and white matter volumes of the occipital lobe. These 
associations were also strong in normal controls. Further, larger putamen volume 
was associated with smaller white matter volume of SFL, with this volume inter- 
relationships being specific to schizophrenia (i. e. significantly differentiating the 
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groups). On the other hand, patients lacked 'normal' inter-relationships between 
larger precuneus and smaller SFL, as well as larger STG grey matter and larger 
OL white matter volumes. The findings pertaining to these volume inter- 
relationships are open to interpretation. Not much is known about the cortical 
volume inter-development and inter-relationships in normal or affected 
populations. A relative lack of strong and consistent inter-relationships between 
structural volume alterations in the patients, except for the spatially related areas 
such as LG grey matter and OL white matter, and two voxels of the STG, 
suggests that there is a considerable variability in the pattern of structural 
alterations amongst the patients, with individual patients presenting with some 
but not all of the observed alterations. For example, based on the observed 
correlations, increased precuneus cannot be said to represent a compensatory 
feature, since its volume did not significantly correlate with the reduction in other 
regions. 
Some structural alterations were associated with the severity of psychopathology. 
First, the severity of positive symptoms was associated with global grey matter 
reduction, but not with any regional reduction, suggesting that positive 
symptomatology might be a manifestation of the widespread alteration in grey 
matter tissue availability. Alternatively, the use of positive symptom scale rather 
than individual symptoms for correlations potentially may mask any specific 
region/symptoms associations. For example, auditory hallucinations were found 
to associate with the anterior STG reductions (Barta et al., 1990), whereas 
delusions with the posterior STG reduction (Menon et al., 1995). Positive 
syndrome score derived from PANSS contains other items apart from 
hallucinations, which might have masked the relationship between STG volume 
and hallucinatory experiences. However, when hallucination ratings were 
correlated with the anterior STG volume (not reported in the results section), the 
correlations observed, although in the right direction, were not significant (r =- 
. 166 and -. 137; p= . 282 and p= . 376). Second, increase 
in the putamen 
volume was associated with less severe positive symptoms and general 
psychopathology ratings. As has been discussed earlier, a possible interpretation 
of this association is that larger putamen allows better neuroleptic 
responsiveness. Third, greater reduction of SFL white matter was associated with 
lower ratings on general psychopathology. This is a counter-intuitive association, 
which is open to interpretation, as this area in relation to schizophrenia 
psychopathology is unknown. Finally, negative symptoms did not associate with 
any of the structural alterations. In previous research, the severity of negative 
symptoms was found to associate with the volumes of PFC grey matter (Chua et 
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al., 1997; Molina et al., 2003a), PFC white matter (Wible et al., 2001) and DLPFC 
CSF (Flaum et al., 1995; Molina et al., 2003b). In addition, Schroder et al. (1995) 
reported an association between negative symptoms and frontal interhemispheric 
fissure widening in chronic patients. Other studies, however, have failed to relate 
prefrontal grey matter volume reduction and negative symptoms (Wolkin et al., 
1992; Gur et al., 2000; Molina et al., 2003b). It appears from these findings that 
PFC CSF increase is found to be associated with negative syndrome more 
consistently than PFC grey matter reduction, which might be indicative of 
degenerative rather than developmental processes as the basis for negative 
symptomatology. Alternatively, different methodologies and patients' 
characteristics might explain the inconsistency in findings. For example, Chua et 
al. (1997) observed association between psychomotor poverty, as defined by 
Liddle (1987), and ventro-medial PFC grey matter volume, whereas other studies 
have correlated PANSS- or SANS- derived negative syndrome scores with the 
variety of general and regional PFC measurements. 
What might be the reasons for a misregistration of the images with the standard 
protocol? The standard SPM99 whole brain template for T1-weighted images, 
which was used to normalised brains during the standard pre-processing, is an 
average of 152 MRI scans of young healthy brains, as has been described in the 
introduction. This template might not be optimal for normalisation of the brains 
from the populations that have substantial deviations from the normal brain 
morphology, e. g. enlarged ventricles, as presented in the case of schizophrenia 
patients. Because of the high contrast between brain tissue and CSF, the spatial 
normalisation will attempt decreasing the sizes of extra large ventricles by 
shrinking all the tissue surrounding this region, which has the effect of `pulling in' 
grey matter towards the centre of the brain (John Ashburner, personal 
communication). Therefore, the normalisation of patients' brains to the MNI 
template might have created a displacement of grey matter voxels adjacent to 
and surrounding the region of the lateral ventricles. Spatially normalising based 
only on the grey matter in the optimised procedure avoids this problem. 
Furthermore, the use of customised probability maps of grey matter constructed 
from the brains of both patients and controls during the optimised pre-processing 
should further decrease the bias in the processing of patients' brains. It is not 
possible to evaluate the relative contribution of these factors to the improved 
processing with the optimised protocol in the present study. The systematic 
investigation of the absolute and relative importance of grey matter normalisation 
and the use of customised templates for the pre-processing of brains of 
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schizophrenia patients is needed to understand the contribution of different 
processing components to segmentation accuracy. 
In fact, this issue is of great empirical importance. Wilke and colleagues (2003) 
have recently reported the results of the systematic investigation of the effect of 
different features constituting standard and optimised VBM protocols amongst 
other variables that they have manipulated on the detection of grey matter 
malformations in epilepsy. Their results revealed that the simplest protocol with 
affine transformation only during spatial normalisation was the most sensitive in 
identifying cortical malformations. The optimised protocol was inferior, `missing' a 
few regions. The results of this investigation are not directly applicable to the 
case of schizophrenia, since there are no 'gross' cortical malformations associated 
with this condition. Nevertheless, the study raises an important question as to the 
sensitivity of different methods of processing in the case of schizophrenia. Thus, 
the future work should systematically manipulate different variables constituting 
the VBM pre-processing steps. It might be the case, for example, that the use of 
the customised whole brain template with standard protocol is equivalent, if not 
superior, to the optimised procedure described by Good and applied in this study 
in the detection of structural alterations of a kind present in schizophrenia 
patients. 
The observed misregistration with standard protocol in the present study also 
raises a question as to the validity of the findings by previous VBM studies of 
schizophrenia patients that have used standard VBM protocol with MNI template 
for spatial normalisation (e. g. Suzuki et al., 2002; Kubicki et al., 2002) or 
customised templates containing information only from normal subjects (e. g. Job 
et al., 2002; Ananth et al., 2002). 
To conclude, the present study identified both global and regional volume 
alterations of grey and white tissue in schizophrenia patients. The alterations 
span all cortical lobes of the left hemisphere, and extend sub-cortically into 
putamen. These alterations were present in patients as a group regardless of 
gender or age, and were unrelated to medication exposure. They were not 
related to the duration of the illness, suggesting neurodevelopmental origin. 
Some alterations, including the reduced white matter of the primary visual cortex 
and SFL and increased grey matter of the precuneus, might be related to the 
course of the illness. The study has highlighted the need for using the pre- 
processing protocols that treat patients' brains in the unbiased way by 
normalising to grey matter as opposed to the whole brain and/or by using the 
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customised templates containing information from both patients and controls to 
avoid spatial distortions of patients' brains that might arise due to enlarged 
ventricles. Finally, it is important to view regional differences in schizophrenia 
patients detected in the present study as representing foci of maximal change, 
rather than regions that are exclusively or selectively affected, since the VBM 
technique may not be able to detect very small grey matter reductions, grey 
matter reductions in areas of hight variability in grey matter volume, or grey 
matter reductions with an inconsistent location. 
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CHAPTER 6. COGNITIVE DEFICITS IN SCHIZOPHRENIA 
6.1. Introduction 
Individuals with schizophrenia display well documented cognitive deficits 
(reviews, Elvevag and Goldberg, 2000; Kuperberg and Heckers, 2000; Sharma 
and Antonova, 2003), which i) precipitate the psychotic symptoms (Weickert and 
Goldberg, 2000); ii) are relatively stable over time with progressive deterioration 
after the age of 65 in some patients (Friedman et al., 2001); iii) persist upon the 
remission of psychotic symptoms (Heaton et al., 2001); and iv) are related to, 
but separate from, negative symptoms (Harvey et al., 1996; Hughes et al., 
2003). Most importantly, cognitive deficits are better predictors of functional 
outcome than the psychotic symptoms (Green, 1996), which have made them the 
primary target of therapeutic intervention over the past decade (Sharma, 2002). 
Delays in reaching developmental milestones, neuromotor and visuo-motor 
anomalies, and cognitive deficits are apparent throughout the premorbid history 
of schizophrenia patients (Jones and Tarrant, 2000). It is well established that 
schizophrenia is often associatied with impairment in general intellectual 
functioning (review, Aylward, Walker, & Bettes, 1984). It is not clear if impaired 
IQ represents a decline due to a disease process or a premorbid deficit. 
Retrospective and high-risk studies reported that individuals who develop 
schizophrenia have lower premorbid IQ than siblings and peers matched for 
parental socio-economic status (review, Aylward et al., 1984). The 19-year 
prospective study (Kremen et at., 1998) has found that IQ decline between the 
ages of 4 (as measured by the Standford-Binet IQ test; Terman and Merrill, 
1960) and 7 years (as measured by the abbreviated version of the Wechsler 
Intelligence Scale for Children (WISC); Wechsler, 1949) was predictive of adult 
psychotic symptoms in a community birth cohort. Therefore, it is likely that 
impaired IQ in schizophrenia might be a result of the process starting early in the 
development and presenting a risk factor for psychosis. 
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In addition to lower general intelligence, a wide spectrum of cognitive domains 
has been consistently shown to be impaired in first episode and chronic 
schizophrenia patients between one and three standard deviations below the 
mean of age-matched controls, including verbal and visuo-spatial working 
memory, learning and memory, executive function, attention, verbal fluency, 
speed of information processing and fine motor function (e. g. Nuechterlein and 
Dawson, 1984; Waddington et al., 1990; Green et al., 1992; Hoff et al., 1992; 
Braff et al., 1993; Saykin et al., 1994; Bilder et al., 1995; Hutton et al., 1998; 
Riley et al., 2000; Bilder et at., 2000). These deficits cannot be explained solely 
by the chronic administration of neuroleptic medication, since these deficits are 
also observed in neuroleptic naive first episode patients to a similar extent 
(Saykin et al., 1994). However, neuroleptic medication as well as adjunct 
cholinergic treatment has adverse effects on some cognitive functions in 
schizophrenia (Frith, 1984; Medalia et al., 1988; Spohn and Strauss, 1989; 
Cassens et al., 1990; Kumari et at., 2003b; Ettinger et at., 2003). Anticholinergic 
procyclidine is also known to impair cognitive function in healthy humans (e. g. 
Kumari et al., 2001; Zachariah et al., 2002). 
Meta-analysis (Heinrichs and Zakzanis, 1998) of 204 studies of schizophrenia 
patients relative to healthy individuals revealed moderate to large effect sizes (d 
>. 60) for 22 neuropsychological test variables, tapping the domains of general 
intelligence, verbal and nonverbal memory, motor performance, visual and 
auditory attention, spatial ability, executive function, language, and inter- 
hemispheric transfer. Although this pattern of cognitive impairment points to a 
generalised deficit, there is evidence to suggest that verbal learning and memory, 
working memory (its executive component) and attention might be specifically 
affected in the background of general cognitive impairment (review, Gur, Moelter, 
and Ragland, 2000). 
The primary aim of this study was to characterise the pattern of cognitive deficits 
in the present cohort for the subsequent investigations: Study 3 (Chapter 7): The 
relationships between structural alterations and cognitive deficits; and Study 4 
(Chapter 8): Structural Alterations as Predictors of Treatment Response following 
6-week Treatment with Atypical Antipsychotics. The nature of this study was 
replicatory. To suit the present aims, the cognitive domains and individual 
neuropsychological tests tapping the domains of interest were selected based on 
the following criteria (as validated by the previous research): 
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1. To reliably differentiate schizophrenia patients from healthy individuals 
and to be commonly used in schizophrenia research to ensure 
generalisability of findings from the present study to those of previous 
research. 
2. To be unaffected or worsened by the conventional antipsychotics. 
3. To be sensitive to improvement with atypical antipsychotics. 
4. To have relevance to functional outcome in schizophrenia. 
5. To have high test-retest reliability. 
6. To have alternative form(s) for repeated administration to minimize 
practice-effect. 
The fulfilment of the first and the second, the first and the third, or the first and 
the fourth criteria was held as obligatory for all domains/tests selected for the 
investigation. The fulfilment of any additional criterion was held as desirable, 
because not all tests that have proven useful in the study of treatment response 
and functional outcome in schizophrenia have these properties. 
The cognitive domains selected based on these criteria were immediate and long- 
term verbal memory and learning, verbal working memory, verbal fluency, 
immediate visuo-spatial memory, executive function, memory for social stories, 
selective and sustained attention, speed of information processing, and fine motor 
function. The description of individual neuropsychological tests selected to 
measure these domains and the fulfilment of the above criteria by each test is 
provided in the Method section. 
Based on the observations of previous research, it was predicted that 
schizophrenia patients would perform significantly worse on all cognitive domains, 
with specific impairments on the tests of verbal learning and memory, working 
memory and attention. Since high doses of conventional antipsychotic and 
anticholinergic treatment have an adverse effect on learning and memory, the 
severity of the impairment on this function was predicted to be associated with 




The information on patient and control groups is presented in Chapter 5. 
6.2.2. Neuropsychological Battery 
The tests comprising the neuropsychological battery described below are grouped 
a priori into cognitive domains for the presentation only based on the cognitive 
processes that these tests are considered to measure (Lezak 1995, Spreen and 
Strauss, 1998). It must be noted, however, that each neuropsychological test is 
likely to require a complex composite of cognitive operations for performance, 
involving specialised processors, as well as non-specific strategic control 
processes. Therefore, when the test is said to measure a specific domain, it is 
presumed that the test places the highest demand on this domain for the optimal 
performance; but might involve one or more of other domains. 
6.2.2.1. General Intellectual Functioning: Premorbid and Current IQ 
National Adult Reading Test, restandardised version (NART-R; Nelson and 
Willison, 1991), was used to assess premorbid intellectual ability. Premorbid IQ 
constitutes the level of intellectual ability prior to the onset of a disorder, 
psychiatric or neurological, or the occurrence of brain lesion. The NART was 
chosen since it is the most common test used in schizophrenia research to 
estimate premorbid intelligence. It requires reading 50 irregularly spelled words 
(e. g. debt, catacomb, naive) in order of increasing difficulty. The rationale for the 
irregularly spelled words is to ensure that the subject's reading is based on word 
recognition rather than phonemic decoding. The NART is assumed to measure 
premorbid intelligence since the word-reading ability is highly (0.75) correlated 
with general intelligence in healthy individuals (Nelson and McKenna, 1975) and 
is remarkably preserved in dementing patients with substantial cognitive 
deterioration (Nelson and O'Connell, 1978). The number of errors is used to 
estimate the premorbid WAIS-R Full Scale IQ. 
Some studies of neuropsychological function in schizophrenia have matched 
patients and controls on premorbid IQ in order to estimate the extent of cognitive 
dysfunction independent of premorbid general intelligence. However, most 
studies did not match patients and controls on premorbid IQ. Such matching was 
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not attempted for the purposes of the present investigation. Since IQ decrement 
in schizophrenia population might be associated with the disease aetiology and be 
a manifestation of an underlying neurodevelopmental pathology, matching groups 
on IQ would inadvertently lead to "matching fallacy' (Meehl, 1970) and create a 
sampling bias towards more intelligent non-representative schizophrenia sample. 
As described in Chapter 5, the groups were matched on parental socio-economic 
status instead, since parental social class is the best predictor of IQ in normal 
controls (Keefe, 1995). 
The Vocabulary sub-test of the Wechsler Adult Intelligence Scale, third 
version (WAIS-III, Wechsler, 1997) was used to assess subjects' current full-scale 
IQ. The Vocabulary sub-test has been traditionally held to represent the single 
best indicator of the current intellectual ability (Yates, 1954). Russell and 
colleagues (2000) in a retrospective study have found that the Vocabulary sub- 
test of WAIS-revised was the strongest index of premorbid as well as current full 
scale IQ. Based on these indicators, only the Vocabulary subtest was 
administered rather than all WAIS-III subtests to minimize the time required for 
the completion of neuropsychological assessment and hence to ensure optimal 
performance from patients in a single session. 
The test requires giving brief and precise definitions to both concrete and abstract 
words (nouns, verbs, and adjectives). The words are presented in the order of 
increasing difficulty. The test is discontinued after 6 consecutive failures to 
provide a definition. Age scaled scores were used to calculate the pro-rated full 
scale IQ. By treating the scores as the average of the 6 sub-tests constituting the 
verbal IQ of WAIS-III, verbal IQ was estimated first, from which the full IQ was 
derived using Tables A. 3. and A. 5. of the WAIS-III manual respectively. 
6.2.2.2. Executive Function 
Wisconsin Card Sorting Test (computerised version) (Heaton, 1993) 
Test description: 
The WCST assesses the ability to form abstract concepts and flexibility of 
thinking. A participant is presented with a card at the bottom of a computer 
screen and is asked to match the card to one of the four cards at the top of the 
screen. The test requires an individual to work out a sorting rule for the cards 
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that can be categorised by three dimensions: shape, colour and number of items 
on the card. After each match, a participant is given feedback whether the 
decision was right or wrong. After 10 consecutive correct matches the sorting 
category shifts to a different dimension. This requires a participant to be flexible 
in his/her responses by abandoning a previously successful sorting rule and 
learning a new one. The first sorting category is colour, which then changes to 
shape and then to number and this sequence is repeated once. 128 cards are 
administered in total in this version of the test. 
The WCST requires a number of cognitive processes for a successful performance, 
including the ability to abstract and categorise stimuli, to come up with a 
strategy, to shift mental sets (set-shifting) in response to the changed rules, and 
to inhibit an established (pre-potent) response. To characterise the WCST in 
terms of these processes, the WCST yields several scores, such as categories 
completed, number of errors, perseverative responses/errors, conceptual level 
responses and failures to maintain set. Categories completed and perseveration 
(responses or errors) are most commonly used in schizophrenia research, with 
perseverative responses being shown to be the most sensitive and specific to the 
nature of executive dysfunction observed in schizophrenia patients (Koren et al., 
1998). 
Dependent variable: 
The total number of perseverative responses was selected as the dependent 
variable on the WCST. Perseverative response occurs when the previously 
successful strategy is continually used in the face of a changed rule and hence is 
the index of the ability to inhibit a pre-potent yet redundant response and to shift 
strategy in response to environmental feedback. 
performance (i. e. greater perseveration). 
Fulfilment of the selection criteria: 
Higher score represents poorer 
This test was selected as it is the single most widely used measure of executive 
function in schizophrenia research, as well as in the general neuropsychological 
practice and research (Butler et al., 1991). The WCST performance consistently 
differentiates patients from controls. Since the initial study by Fey (1951), over 
150 studies were published implicating impaired WCST performance in 
schizophrenia (Palmer and Heaton, 2000). The WCST performance has been 
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linked to functional outcome, with perseveration index found to be predictive of 
social adjustment (Jaeger and Douglas, 1992), social competence and 
occupational functioning (Velligan et al., 2000). 
The WCST does not have high test-retest reliability in normal subjects, since it is 
susceptible to practice effects. It has been argued that once administered, the 
WCST no longer measures problem-solving ability (Lezak, 1995). This of course is 
inevitable with any true measure of executive function, since the executive 
function is by definition employed to tackle novel tasks and situations. Once a 
situation has been encountered and a strategy developed, given the subject has 
an intact memory, the retest performance will be guided by one's memory of the 
task. Schizophrenia patients treated with conventional neuroleptics do not show 
normal test-retest gains in task performance (e. g. Goldberg et al., 1987), 
presumably due to the effects of sub-cortical dopaminergic blockade on episodic 
memory inhibiting the memory-dependent improvement (Robbins et al., 1990). 
However, patients with less severe general cognitive impairment show 
improvement with repeated exposure (Green et al., 1990; Bellack et al. 1996). 
The WCST performance has been found to improve with novel antipsychotics such 
as clozapine, risperidone and olanzapine, although negative findings have also 
been reported (review, Meltzer and McGurk, 1999). Therefore, any potential 
improvement on the WCST with repeated administration after the switch to 
atypical antipsychotics (Study 4) should be interpreted with caution, since it 
might occur due to the improvement of executive function itself or episodic 
memory. 
Trail Making Test (Reitan and Wolfsonk, 1993) 
Test description: 
This test has two parts, A and B. Part A requires a subject to join the circles 
containing numbers from 1 to 25, which are scattered on the A4 sheet, in 
ascending order as quickly and as accurately as possible. Optimal performance on 
part A primarily depends on efficiency of visual scanning and psychomotor speed 
(Spreen and Strauss, 1998). Part B demands the employment of executive 
function, particularly mental flexibility, since it requires the subject to join the 
numbers in ascending order from 1 to 13 alternating with letters in alphabetic 
order from A to L that are randomly scattered on an A4 sheet. Apart from placing 
demands on visual scanning and psychomotor speed, part B also requires greater 
attention and working memory than Part A. 
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Normally parts A and B are scored separately, with the score represented by the 
time to complete in seconds. A difference score, subtracting the time on Part A 
from the time on Part B, can be used to factor out the effects of psychomotor 
speed (Buchanan et al., 1994). Although the difference score has not been as 
widely used as the scores for Part B alone, it is recommended (Palmer and 
Heaton, 2000), since it allows isolating the effects of mental flexibility deficits 
from psychomotor slowing, which can be a side effect of conventional 
antipsychotics. 
Dependent Variable: 
Following the recommendation of Palmer and Heaton (2000), the difference score 
Part B minus Part A (Part B- Part A) was used as an index of mental flexibility. 
Fulfilment of the selection criteria: 
Trail Making Test is extensively used in schizophrenia research and is consistent 
in differentiating schizophrenia patients from normal controls (e. g. Braff et al., 
1991; Franke et al., 1993; Bilder et al., 1991; 1995; 2000; Saykin et al., 1994; 
Riley et al., 2000). In the meta-analysis of 204 studies (Heinrichs and Zakzanis, 
1998), the test was found to separate more than half of the patients and control 
distributions. Trail Making performance is sensitive to treatment with atypical 
antipsychotics risperidone (Meltzer and McGurk, 1999) and quetiapine (Fleming et 
al., 1997). Olanzapine was not found to have a positive effect on Trail Making 
performance in the study of neuroleptic resistant schizophrenia patients (Meltzer 
and McGurk, 1999), however treatment resistant sub-group is not representative 
of the schizophrenia population at large. Trail Making was not found to be 
predictive of community outcome in schizophrenia patients (Goldman et al., 
1993; Buchanan et al., 1994). However, Trail Making performance might be more 
relevant to occupational outcome and skill acquisition, but these outcome 
variables have not been as yet assessed in relation to the Trail Making deficit. 
Test-retest reliability is . 98 for Part A and . 
67 for Part B in normal subjects, with 
significant practice effects only on Part A over three administrations in 6 month 
intervals. Durvasula et al. (1987) reported significant practice effects for both 
parts at 6-month testing intervals, which flattened after 5 administrations. 
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Therefore, any improvement on TMT in Study 4 will have to be interpreted with 
caution taking the practice effects into account. 
6.2.2.3. Sustained and Selective Attention 
Continuous Performance Test, Identical Pairs Version (CPT-IP) (Cornblatt 
et al., 1988) 
Test description: 
This test was designed to assess the ability to sustain attention. Subject's task is 
to identify the pairs of identical numbers within a continuously presented string of 
four digit numbers, which are flashed up on a computer screen at a rate of one 
per second with an 'on' screen time of 50 ms. Subjects are asked to hold the left 
mouse button of a computer continuously throughout the test lifting the finger up 
quickly and putting it back again when the subject spots a number which is 
identical to the one before. There are also a number of catch trials on which the 
stimulus presented is similar to the preceding one, but not identical to it. There 
are 450 numbers presented overall with 90 response targets and 90 catch trials. 
Individual performance on the CPT-IP task is based on hits (responses to target 
trials) and false alarms (responses to catch trials) yielding two signal detection 
indices: 
d'prime - representing signal to noise ratio and measuring sensitivity of the 
subject to discriminate targets from catch trials; 
beta - criterion of the subject to respond to target or catch trials, i. e. under or 
over-responding. 
Depended variable: 
d' prime was used as the dependent variable, since it is the measure of sustained 
attention. 
Fulfilment of the criteria: 
CPT - IP is the single most often used measure of sustained attention 
(vigilance) 
in schizophrenia research (Neuchterlein and Dawson, 1984), and is very sensitive 
to the attentional impairment in schizophrenia patients (e. g. Strauss et al., 1993) 
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and in individuals at high risk (e. g. Cornblatt and Keilp, 1994). CPT performance 
is impaired by acute (1-3 days) administration of conventional antipsychotics 
(Latz and Kornetsky, 1965), but shows some improvement with chronic 
administration (review, Medalia et al., 1988). However, improvement is greater 
with novel antipsychotics, including risperidone (Stip and Lussier, 1996; Rossi et 
al., 1997; Kern et al., 1998), olanzapine (review, Meltzer and McGurk, 1999) and 
quetiapine (review, Velligan et al., 2002). Attentional dysfunction as assessed by 
CPT combined with other measures of attention is predictive of different aspects 
of functional outcome, including social problem solving (Bowen et al., 1994; Penn 
et al., 1995) and skill acquisition (Bowen et al., 1994; Corrigan et al., 1994; Kern 
et al., 1992). 
CPT - IP has high test-retest reliability (ranging from . 56 to . 73 for d'prime, 
Cornblatt et al., 1988), making it ideal for the studies with repeated assessments. 
However, practice effect is also robust and has to be controlled for, although it is 
minimal for d'prime index (Cornblatt et al. 1988). 
Stroop Test (Golden, 1978) 
Test description: 
This test was designed to test the inhibition of pre-potent response that requires 
selective attention to the stimuli. A subject is presented with a list of 100 colour 
words and is given 45 sec to name as quickly as possible colours in which these 
colour words are written. The challenge lies in the fact that the words are written 
in colour ink that is incongruent with the colour for which this word stands for. 
For example, response to the word RED typed in BLUE colour should be BLUE. 
The effect of this test is understood to be due the requirement to actively inhibit a 
more automatic (and hence quicker processed) tendency to read words in favour 
of the less automatic (or slower processed) colour naming (Dyer, 1973). Two 
control tasks, reading of the colour words typed in congruent colour over 45 sec 
and naming the colours over 45 sec, are administered in conjunction with the 
main task to control for individual differences in the speed of reading and colour 
naming respectively. The number of words read and colours named at each stage 
of the test is recorded. 
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Dependent variable: 
The depended variable is the interference score, which is the difference between 
a predicted colour word (CW) score and the raw CW score. Predicted CW score is 
calculated from the following formula: Cx W/C + W, where C is the number of 
colours named in 45 seconds and W is the number of words in congruent colours 
read in 45 seconds. 
Fulfilment of the selection criteria: 
Stroop task, or as it is also called Golden Stroop, is widely used within 
schizophrenia research as a measure of selective attention or inhibition (review, 
Pearlstein et al., 1998), and it can be subsumed under a more general domain of 
executive function (Lezak, 1995; Spreen and Strauss; 1998). The interference 
score produces a large effect size (d = 1.22) in schizophrenia studies as revealed 
by meta-analysis (Heinrichs and Zakzanis, 1998). Stroop performance is 
unaffected by chronic administration of conventional antipsychotics (e. g. Killian et 
al., 1984), but shows improvement with atypical antipsychotics, such clozapine 
(Buchanan et al., 1994) and quetiapine (Velligan et al., 2002). It has been also 
found to associate at trend level with community outcome (Buchanan et al., 
1994). 
All three parts of the Stroop test show high test-retest reliability with the 
coefficients of . 90 for the word reading, . 83 for the colour naming, and . 
91 for the 
colour-word part in normal subjects (Spreen and Strauss, 1998). However, 
significant practice effect is also observed, and therefore should be controlled for. 
6.2.2.4. Verbal working memory 
Letter-Number Test (Gold et al., 1997) 
Test description: 
Letter-number test (LNT) assesses subject's ability to retain and manipulate 
mentally common verbal stimuli in working memory, and thus employs central 
executive component of working memory. A subject is presented with verbal 
strings comprised of randomly ordered numbers and letters. The task is to listen 
to the string and to repeat it back in a certain order, putting the numbers first in 
ascending order followed by the letters in the alphabetic order. Increasingly 
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longer strings are presented starting from two stimuli (one letter, one number, 
e. g. D6) and finishing with the string of seven stimuli (three numbers and four 
letters, e. g. C7G4Q1S, or four numbers and three letters, e. g. 3T4P7M9). Each 
level of complexity is comprised of 4 different strings, bringing the total number 
of strings to 24. The test is discontinued after a subject fails all four trials at a 
given string length. 
Dependent variable: 
The dependent variable is the total number of strings reproduced correctly. The 
scores range between 0 and 24, with higher score indicating better performance. 
Fulfilment of the selection criteria: 
LNT captures the essence of executive working memory component so well, that 
it has been incorporated into the most recent versions of both the Wechsler Adult 
Intelligence Scale (WAIS-III) and the Wechsler Memory Scale (WMS-3). Both 
chronic and first episode schizophrenia patients show large deficit on this task 
(e. g. Park and Holzman, 1993; Gold et al., 1997; Riley et al., 2000; Pukrop et al., 
2003). No published study was found purporting to the effects of conventional 
antipsychotics on LNT, perhaps because LNT has been relatively recently adopted 
for the study of auditory working memory in schizophrenia. Other tests of 
auditory working memory such as Digit Span forward and backward do not seem 
to be affected by either acute or chronic administration of conventional 
antipsychotics (e. g. Abrams, 1958; Castner et al., 1958; Pearl, 1962; Small et 
al., 1972; ). Auditory working memory as measured by LNS and digit span tasks 
might be improved with risperidone, but not olanzapine (review, Meltzer and 
McGurk, 1999) or quetiapine (Velligan et al., 2002). 
Letter-Number Sequencing task, which is a derivative of the LNT task adopted for 
WAIS-III and WMS-III, has high test-retest reliability (0.71) and shows minimal 
practice effects at 2 to 12 weeks retest interval. Therefore, LNT task was 
considered to have satisfactory psychometric properties for the repeated 
administration. 
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6.2.2.5. Visuo-spatial immediate memory 
Benton Visual Retention Test (Benton, 1972) 
Test description: 
Benton Visual Retention Test (BVRT) assesses visual memory, visual perception, 
and visuoconstructive abilities (Spreen and Strauss, 1998). A subject is presented 
with 10 designs of abstract shapes in the order of increasing complexity. First 
two designs contain one large central geometric figure, while the other eight 
contain two larger central and one small peripheral figure. Each picture is 
presented for ten seconds, after which it is withdrawn, and the subject is required 
to reproduce it immediately on a peace of paper (Administration A). The 
response is scored as correct, if all the figures, their size, shape and their spatial 
inter-relationships correctly reproduce the original design. 
Dependent variable: 
The dependent variable is the total number of pictures reproduced without errors. 
The scores range between 0 and 10, with higher score indicating better 
performance. 
Fulfilment of the selection criteria: 
BVRT is a popular test in clinical setting (Spreen and Strauss, 1998), but has not 
been used as widely as Visual Reproduction subtest of WMS-III in examining 
visual memory in schizophrenia. However, BVRT was considered more suitable 
for the purposes of the present investigation, because it contains three alternative 
forms (C, D, and E) of equivalent difficulty (Benton, 1972), making it ideal 
psychometrically for the repeated administration. Although not used extensively, 
BVRT has reliably produced deficient performance in schizophrenia patients (e. g. 
DeLisi et al., 1991a; Hoff et al., 1992; Silver and Geraisy, 1995; Silver and 
Shlomo et al., 2001). In a recent study (Rollnik et al., 2002) BVRT performance 
was found to improve with both typical and atypical antipsychotics, indicating that 
the test might be sensitive to antipsychotic treatment. (However, as no control 
group was used in that study, this improvement might be due to practice effect). 
Although BVRT has not been employed by any studies to date investigating the 
relationship between cognitive impairment and functional outcome, it was found 
to be predictive of facial emotion perception in chronic patients (Silver and 
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Shlomo, 2001), the deficit of which might have implications for social interaction 
and hence community outcome. 
6.2.2.6. Verbal Learning and Memory 
Hopkins Verbal Learning Test (HVLT-Revised, Shapiro et al., 1999) 
Test description: 
This measure is included to assess free recall - the index of declarative (explicit) 
memory. A subject is presented with a list of 12 nouns three times and the total 
number of words recalled after each presentation is recorded. The words 
comprising the list are drawn from three semantic categories (4 words for each 
category such as food, animals, tools, etc. ). The task also allows testing 
recognition memory, but the score for recognition was not used in the present 
investigation, since recognition memory appears to be intact in schizophrenia 
patients (review, Sharma and Antonova, 2003). 
Dependent variable: 
The dependent variable is the total number of words recalled on three trials. The 
scores range between 0 and 36, with higher score indicating better performance. 
Fulfilment of the selection criteria: 
The HVLT is similar to the California Verbal Leaning Test (CVLT, Delis et al., 
1987), which is widely used in schizophrenia research and in general clinical 
testing for the assessment of declarative memory. The HVLT was preferred to the 
CVLT due to the availability of six alternate versions, making it more suitable for 
the repeated testing. The paradigm inherent to both the HVLT and the CVLT has 
been very reliable in quantifying free recall impairment in first-episode and 
chronic schizophrenia patients (e. g. DeLisi et al., 1991a; Hoff et al., 1992; 
Kareken et al., 1996; Baare et al., 1999; Lysaker et al., 2000; Bilder et al., 
2000). Conventional antipsychotics have been consistenly shown to impair free 
recall as measured by this paradigm, possibly due to their anticholinergic action 
and the need for anticholinergic medication to reduce EPS (review, Keefe et al., 
1999). Atypcial antipsychotics, such as olanzapine, risperidone and quetiapine 
have been found to improve free recall as measured by the CVLT (review, Meltzer 
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and McGurk, 1999). Since the HVLT has similar psychometric properties, it was 
assumed that it would also be sensitive to potential improvement with atypical 
antipsychotic treatment in the present investigation. Verbal memory as 
measured by HVLT was found to positively associate with all measures of 
functional outcome assessed in the study by Velligan and colleagues (2000), 
including social and occupational functioning, level of independent living, work 
and productivity, and social competence. 
Buschke Selective Reminding Test (BSRT, Buschke, 1973) 
Test description: 
This test was included to assess learning by means of measuring recall 
consistency. Recall consistency has been found to be very sensitive to 
anticholinergic effects (e. g. Thal and Fuld, 1983). The BSRT is a multi-trial list- 
learning test. After a list of 16 unrelated nouns has been presented to a subject 
and the subject has recalled as many words as possible, only the words that were 
not recalled on this trial are read to the subject on the next trial. On each trial 
the subject has to recall as many words as possible from the list, including the 
ones recalled on the previous trial. The test stops after 7 trials or after the 
subject has recalled all the words without a reminder. 
Dependent Variable: 
The BSRT allows calculating different indices of learning and memory, including 
total recall, long-term memory storage and retrieval, short-term retrieval, 
consistent long-term retrieval and random long-term retrieval. A single index may 
adequately quantify learning as measured by BSRT, given high intercorrelation of 
the scores and hence their redundancy (Spreen and Strauss, 1998). Westerveld 
et al. (1994) and Sass et al. (1994) have recommended the use of total number 
of words recalled on all trials as a measure of learning, since it is most reliable. 
Following this recommendation, the total number of words recalled was used as 
dependent variable to measure learning in the present investigation. The scores 
can range between 0 and 112, with higher score indicating better performance. 
Fulfilment of the selection criteria: 
The BSRT is one of the most widely used paradigms for assessing leaning and 
memory function following head injury (Spreen and Strauss, 1998), and is a 
162 
predictor of the overall level of disability 1 year after the injury (Levin et al., 
1979). It has also proved useful in identifying children at risk for memory 
disorders (Snow et al., 1992). It is ideally suited for repeated testing as it 
contains alternate forms. BSRT has recently been employed in the schizophrenia 
research as a measure of learning producing impaired performance in patients 
(Sanfilipo et al., 2002). The effect of atypical antipsychotics on this test is not 
yet known. 
In normal individuals, there appears to be a non-specific practice effect with 
repeated administration of alternate forms (Clodfelter et al., 1987; Hannay and 
Levin, 1985; Loring and Papanicolaou, 1987), which might reflect the ability to 
learn how to perform a complex task. Therefore, practice effect should be 
quantified and controlled for on this test. 
Logical Memory (LM, WMS-III subtest, Wechsler, 1997) 
Test description: 
This test was used to assess memory for stories, both immediate and long-term. 
A subject is read two stories and asked to recall as many details of each story as 
possible immediately after presentation and then again 20 minutes after 
presentation. 
Dependent variables: 
Two dependent variables are derived by summing the total number of details 
recalled for both stories for immediate recall and long-term retention. Age scaled 
scores were derived from WMS-III manual. Aged scaled scores range between 1 
and 19, with higher score indicating better performance. 
Fulfilment of the selection criteria: 
The LM test has been extensively employed in schizophrenia research and 
invariably revealed deficit in both immediate and delayed performance in fist 
episode and chronic patients (e. g. Saykin et al., 1991; Goldberg et al., 1994; 
Seidman et al., 1994; Kareken et al., 1995; Torres et al., 1997; DeLisi et al., 
1997a; Levitt et al., 1999; Nestor et al., 2002; Toulopoulou et al., 2003) as well 
as in relatives of schizophrenia probands (Toulopoulou et al., 2003). Such an 
extensive interest in employing this task stems from the fact that memory for 
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stories might have more ecological validity in terms of community function, which 
is compromised in schizophrenia, than single word-list learning paradigms. 
Buchanan and colleagues (1994) observed a trend improvement on LM after 1- 
year treatment with clozapine (versus haloperidol), which was significantly 
positively associated with community outcome in patients. 
The test-retest reliability coefficient of LM is sufficiently high (. 71, Mittenberg et 
al., 1992) for repeated testing. 
6.2.2.7. Verbal Fluency 
Two aspects of verbal fluency, phonological and semantic, were assessed with 
letter and category verbal fluency tasks respectively (Milner, 1975). In letter 
fluency task, also known as FAS task, a subject is asked to produce as many 
words as possible starting from three letters: F, A, and S, excluding proper 
nouns, numbers, and the same word with a different suffix, and avoiding 
repetitions. Sixty seconds are given for responses for each letter. In category 
fluency task, a subject is asked to produce as many words belonging to three 
categories: animals, fruits and vegetables, avoiding repetitions. Sixty seconds are 
given for each category. 
Dependent variables: 
The dependent variables are the total number of words produced for three letters 
as a measure of phonological verbal fluency and the total number of words 
produced for three categories as a measure of semantic verbal fluency. 
Fulfilment of the selection criteria: 
Language skills in schizophrenia patients are most commonly assessed with 
verbal fluency tasks. Although many versions of the verbal fluency paradigm 
exist, the letter and category tasks selected are the most commonly used in both 
neuropsychological and neuroimaging investigations and are reliable in producing 
deficient performance in patients (e. g. DeLisi et al., 1991a; Bornstein et al., 
1992; Vita et al., 1995; Baare et al., 1999; Sanfilipo et al., 2002). Verbal fluency 
as measured by category fluency task has been found to improve with clozapine 
(vs haloperidol) after 10-week of treatment, and to correlate with improved 
quality of life (Buchanan et al., 1994). Olanzapine, but not risperidone, has been 
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shown to produce improved performance on VF tasks (review, Meltzer and 
McGurk, 1999). Thus, VF tasks are sensitive to augmentation with atypical 
antipsychotics, although different brands might have differential effect. 
Test-retest reliability is high (. 88) after 19-42 days of testing in healthy adults 
(desRosiers and Kavanagh, 1987), indicating that the test is suitable for repeated 
testing. Short-term practice effects have not been previously reported (Spreen 
and Strauss, 1998). 
6.2.2.8. Speed of Information Processing 
Word Reading and Colour Naming parts of the Stroop task (Golden, 1978) 
Test description: 
The word reading and colour naming tests are control tasks of the Stoop test, 
which was described in the section 6.2.2.3 Attention. Word reading part involves 
reading colour words written in congruent colour ink as quickly as possible. Colour 
naming part involves naming the colour in which symbols XXXX are printed as 
quickly as possible. 45 seconds are given for each part. 
Dependent variables: 
Speed of word reading: the total number of words read in 45 seconds. 
Speed of colour naming: the total number of colours named in 45 seconds. 
Fulfilment of the selection criteria: 
The use of performance on word and colour parts might be unorthodox in 
schizophrenia research and in general clinical testing, but there are good reasons 
for utilising these timed tasks as measures of speed of information processing in 
the present investigation. First, there is an inverse relationship between age and 
performance on Stroop word reading and colour naming parts in healthy adults 
attributed to age-related decline in processing speed (Uttl and Graf, 1997). 
Second, factor analytic studies (Graf et al., 1995) suggested that the speed of 
processing tasks (Digit Symbol) contribute to performance on Stroop colour 
naming part. Third, schizophrenia patients are known to perform significantly 
slower on both parts relative to healthy individuals (e. g. Hanes et al., 1996; Riley 
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et al., 2000; Krabbendam et al., 2000,2001). Fourth, test-retest reliabilities of 
both parts are high, with the coefficient of . 90 for the word reading and . 83 for 
the colour naming (Spreen and Strauss, 1998). Finally, the utilisation of these 
tests, rather than the use of more common information processing speed 
measures, allowed keeping the number of the tests as low as possible to ensure 
reasonable administration time of the battery and hence optimal performance and 
low drop out rate. 
6.2.2.9. Fine Motor Function 
Finger Tapping Task (FIT, Halstead, 1947) 
Test description: 
This test assesses psychomotor speed by requiring the subject to tap on the 
leaver as quickly as possible with the index finger of the dominant hand and then 
non-dominant hand. Five 10-second trials are given for each hand. However, if 
the performance is inconsistent, deviating by more than 5 points on one or more 
trials, additional trials are given and the scores of the deviant trial(s) are 
discarded. A maximum of 10 trials is given for each hand. 
Dependent variables: 
Two dependent variables are computed representing the average number of taps 
from (the best) five trials for each hand. 
Fulfilment of the selection criteria: 
Finger tapping task is the most popular measure of psychomotor speed and is 
often used in clinical drug trials as well as structural imaging studies of 
schizophrenia patients. Due to the dopamine blockade in the basal ganglia, 
conventional antipsychotics impair psychomotor speed as measured by FTT 
(review, Medalia et al., 1988), whereas atypical antipsychotics spare it (review, 
Meltzer and McGurk, 1999). 
Test-retest reliability was reported to be high for both dominant and non- 
dominant hands (. 80) with minimal practice effects (Morrison et al., 1979), 
making the test suitable for repeated administration. 
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Grooved Peg Board Task (GPB, Klove, 1974) 
Test description: 
This test assesses dexterity by requiring a subject to fit metal grooved pegs into 
the holes as quickly as possible using dominant hand first and then non- 
dominant hand. The holes have a random arrangement with regards to the 
groove orientation, thus the subject's task is to rotate the peg first in order to 
make the groove fit the hole. Since the pegs are small and slime, this task 
requirement puts a considerable emphasis on the finger dexterity function. 
There are 25 holes in total arranged in 5 rows of 5 holes in each. 
Dependent variables: 
Two dependent variables are the time in seconds to complete the task for each 
hand. 
Fulfilment of the selection criteria: 
The GPB was selected since it is the most popular test of manual dexterity -a 
proxy for parkinsonism. Since dopamine blockade in the basal ganglia induces 
EPS, dexterity is affected in patients treated with conventional antipsychotics 
(Medalia et al., 1988). Dexterity as measured by the GPB was found to predict 
patients with rehabilitation potential (Weaver and Brooks, 1964). Spared or 
improved dexterity is, therefore, a desirable feature of pharmacological treatment 
with atypical antipsychotics. Further, dexterity as measured by GPB was found to 
be predictive of Performance subscale of WAIS (Schear and Sato, 1989), 
emphasising the importance of dexterity in general cognitive functioning. GBP has 
not been previously used in clinical trials of atypical antipsychotics. 
Test-retest reliability for GPB is high (. 79), although the practice effect is also 
significant (McCaffrey, Ortega, and Haase, 1993). 
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6.2.3. Procedures 
The neuropsychological battery was administered to all participants, patients and 
controls, within a week of MRI scanning. The battery required approximately 1.5 
hours for completion. Patients were allowed to take breaks as required to ensure 
optimal performance. The tests were administered in the following order: 
National Adult Reading Test 
Vocabulary sub-test of WAIS-III 
Hopkins Verbal Learning Test 
Buschke Selective Reminding Test 
Finger Tapping Test 
Trail Making Forms A, B 
Continuous Performance Test 
Wisconsin Card Sorting Test 
Grooved Peg Board 
Logical Memory-I (immediate) 
Letter Verbal Fluency 
Category Verbal Fluency 
Letter-Number Test 
Stroop Test 
Benton Visual Retention Test 
Logical Memory-II (delayed)* 
* Or after 20 minutes if the tests following Logical Memory-I took longer than 20 
minutes for completion. 
For those tests with alternate forms (HVLT, BSRT, and BVRT), two different forms 
were administered to participants in each group in random order to 
counterbalance forms' presentation for repeated testing in Study 4. This was done 
to ensure that any changes in performance observed in Study 4 could not be 
attributed to the relative difficulty of the alternate forms. 
To empirically validate the right-handedness of all participants, prior to the 
administration of the battery, hand preference was assessed using Edinburgh 
Handedness Inventory, shortened version (Oldfield, 1971). The total number of 
right- and left- hand items were scored, and the laterality quotient was computed 
as (total right-total left)/(total right + total left). Thus, laterality quotients could 
range from 1.00 (all items right) to -1.00 (all items left). Laterality quotient 
greater than . 70 was taken 
to indicate strong right-hand preference. 
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6.2.4. Data Analysis 
6.2.4.1. Preliminary Data Screening 
Prior to the analysis, each variable was screened for missing values. Further, the 
variables were evaluated in relation to assumptions of the analysis of variance, 
i. e. the normality of distribution and the homogeneity of variance. The normality 
of distribution was assessed using the inspection of skewness (symmetry) and 
kurtosis (shape) coefficients as well as histograms with fitted normal curve and 
Q-Q Plots. Whenever a variable severely deviated from being normally 
distributed, either log or power transformation was performed to remedy positive 
or negative skeweness respectively. The homogeneity of variance was evaluated 
using Error bar graphs representing standard deviations of two groups for each 
variable. 
6.2.4.2. Standardisation 
Due to the differences in scales of neuropsychological test scores, each variable 
was transformed using z-transformation (a scale with the mean of 0 and the 
standard deviation of 1) in order to evaluate relative impairment on different 
neuropsychological tests of patients against normal controls. The scores in both 
groups were standardised using control's mean and standard deviation for each 
variable. 
6.2.4.3. Main analysis 
A one-way analysis of covariance (ANCOVA), with group as a between-subject 
factor and neuropsychological variable as a within-subject factor, adjusting for 
the confounding effects of age and sex, was used to compare group differences 
for each neuropsychological variable. Since all neuropsychological tests employed 
in the study were hypothesised to produce impaired performance in the patient 
group, no adjustment was made for multiple comparisons. To assess a possible 
moderating effect of premorbid IQ, further ANCOVAS, adjusting for age, sex and 
NART score, were performed. 
To investigate which of the neuropsychological variables best differentiated 
patients and controls, exploratory stepwise logistic regression (LR) with the 
diagnosis as a dependent variable and neuropsychological variables as predictors 
was performed, adjusting for gender, age, and premorbid IQ. 
LR does not require 
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the criteria of linearity, normality and the homogeneity of variance. It 
emphasizes the probability of a particular outcome for each case, given the 
person's pattern of responses on IVs. The outcome variable Y is the probability of 
having one outcome or another based on non-linear function of the linear 
combination of predictors. That is, the linear regression equitation is the natural 
log of the probability of being in one group divided by the probability of being in 
the other group. The maximum likelihood procedure is applied for the estimation 
of coefficients. The goal is to find the best linear combination of predicators to 
maximise the likelihood of obtaining the observed outcome frequencies. 
6.3. Results 
6.3.1. Preliminary Data Screening 
Table 6.1. presents information on the missing values, outliers, skewness and 
kurtosis coefficients for each neuropsychological variable. 
TABLE 6.1. Missing values, outliers, skewness and kurtosis coefficients for each 
neuropsychological variable by group 




HVLT total recall 
BSRT total recall 
Finger 
dominant 












1----. 247 -. 884 -. 634 -. 100 
(. 357) (. 361) (. 702) (. 709) 
---- . 180 . 029 -. 291 -. 
623 
(. 354) (. 365) (. 695) (. 717) 
2--- . 354 -. 323 -. 
303 -. 725 
(. 361) (. 361) (. 709) (. 709) 
6- 3b 1 a, 1b . 788 . 405 . 233 1.323 (. 378) (. 361) (. 741) (. 709) 
Taping --- 1` -. 426 -. 674 -. 659 -. 142 
(. 354) (. 361) (. 695) (. 709) 
Finger Taping -- 
1° - -. 799 -. 333 . 
215 -. 004 
non-dominant (. 357) (. 361) (. 702) (. 709) 
Trail B-A 2- 1e 38 . 152 1.749 3.336 2.987 (. 357) (. 361) (. 702) (. 724) 
CPT d'prime 21 -- . 607 . 156 -. 190 -. 575 (. 361) (. 365) (. 709) (. 717) 
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GPB dominant -- 2a 1b 1.198 3.026 1.021 4.204 
(. 354) (. 361) (. 695) (. 709) 
GPB non- -- 4a 2b 1.132 1.825 . 905 5.047 dominant (. 354) (. 361) (. 695) (. 709) 
WCST 1- 3a 2a 2.014 2.752 4.215 9.922 
perseverative (. 357) (. 361) (. 702) (. 709) 
responses 
Logical Memory 3-- - . 611 -. 433 . 220 -. 338 immediate (. 365) (. 361) (. 717) (. 709) 
Logical Memory 3-- - . 253 -. 453 -. 461 1.564 delayed (. 365) (. 361) (. 717) (. 709) 
Verbal Fluency 1-- 1b . 462 . 645 -. 184 1.937 letter (. 357) (. 361) (. 702) (. 709) 
Verbal Fluency 1-- - . 152 -. 724 -. 394 . 128 category (. 357) (. 361) (. 702) (. 709) 
Letter-Number 2-- - . 358 -. 143 -. 337 -. 388 correct (. 361) (. 361) (. 709) (. 709) 
Stroop word 32- - . 234 . 359 . 278 . 201 reading (. 354) (. 695) (. 361) (. 709) 
Stroop colour 32- - . 532 1.781 -. 593 -. 257 naming (. 354) (. 695) (. 361) (. 709) 
Stroop 32- - . 726 . 342 . 154 -. 144 interference score (. 365) (. 369) (. 717) (. 724) 
BVRT number --- 1a -. 021 -1.213 -1.028 1.937 
correct (. 354) (. 695) (. 361) (. 709) 
* Number of extreme cases outside of the range defined by a minimum score: Lower quartile - 1.5 
times inter quartile range, and a maximum score: Upper quartile + 1.5 t imes inter quartile range. 
"A measure of the symmetry of the distribution. The value of zero indicates normal distribution. High 
positive value indicates a long right tail of the distribution. High negative value indicates a long left tail 
of the distribution. As a rough guide, skewness value more than twice its standard error is taken to 
indicate a departure from symmetry. 
$A measure of the extent to which observations cluster around a central point. For a normal 
distribution, the value of the kurtosis statistic is 0. Positive kurtosis indicates that the observ ations 
cluster more and have longer tails than those in the normal distri bution and negative kurtosis 
indicates the observations cluster less and have shorter tails. 
a Low performance extreme 
b High performance extreme 
Abbreviations: se - standard error 
NART-R IQ 
There was one missing data value for a female first episode patient on NART due 
to dyslexia. Patients' NART IQ scores were normally distributed, whereas scores 
for normal controls were negatively skewed [skewness=-. 884, se= . 361]. This 
effect in the controls is due to the limited range of scores on the NART, which 
does not allow proper IQ estimation at the higher end of the distribution. No 
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transformation was performed, since the deviation from normality was not 
considered to be severe enough to invalidate the analysis of variance and was 
due to the psychometric weakness of the test, rather than deviant scores. 
WAIS-III full scale IQ 
There were no missing values for the WAIS-III IQ scale. Scores for both patients 
and controls were normally distributed, with similar variance. 
HVLT 
Two chronic patients attempted but could not complete HVLT. Their cases were 
treated as missing values in all analyses. Free recall scores for the remaining 
patients (n=43) and controls were normally distributed. 
BSRT 
Six chronic patients either refused or were unable to complete BSRT test. These 
cases will be treated as missing values in all subsequent analyses. There were 
three low performing outliers in patients' group and one low and one high 
performing outliers in the control group. However, since all outlier scores fell 
within the normal range of performance on this task, free recall scores for 
patients and controls were considered normally distributed, with comparable 
variance. 
Finger Tapping Task 
There were no missing values on FTT. Dominant hand scores were relatively 
normally distributed in both groups. An extremely high score [more than 1.5 
interquartile range from the upper quartile], indicating poor performance, existed 
in the control group, but as the score was within the normal population range of 
performance on this task, the outlier was not excluded from the subsequent 
analyses. Non-dominant hand scores were reasonably normally distributed in 
both groups. However, skewness coefficient of patients scores [skewness=-. 799, 
se=-. 357] suggests negative skewness, but since the kurtosis coefficient 
[kurtosis=. 215, se=-. 004) and the inspection of the frequency histogram 
indicated that the shape of the distribution is near normal, the variable was not 
considered to violate the normality assumption. 
Trail Task, part B-A 
There were two missing values for TTT B-A score, due to inability to complete 
part B by two chronic patients. These cases were treated as missing values in all 
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analyses. There was one low performing outlier in the patient group, and three 
low performing outliers in the control group, but these scores were within the 
normal range of performance on this test. Skewness coefficient suggested severe 
positive skeweness in control group [skewness=3.336, se=. 702]. The inspection 
of the boxplots and frequency histograms revealed that controls' score 
distribution was genuinely asymmetrical and might benefit from log 
transformation. Log transformation was therefore applied, which rendered the 
scores of both groups more normally distributed. 
CPT-IP 
There were two missing values in the patient group due to the inability to 
perform, with these cases excluded for the subsequent analyses of this variable. 
One missing value in the control group was due to the equipment failure and was 
substituted with the group mean, since the subject had an average performance 
on most other tests. Scores in both groups did not deviate from the normality 
assumption and had similar variances. 
GPB 
Scores for both dominant and non-dominant hands were positively skewed. 
Control group had an outlier. The scores of both groups were log transformed, 
which normalised the distribution and eliminated the outlier in the control group. 
WCST 
One patient refused to complete WCST; this case was treated as a missing value 
in all subsequent analyses of perseverative responses. Perseverative responses 
scores were severely positively skewed in both groups [Patients: skewness = 
2.014, se = . 357; Controls: skewness = 4.215, se = . 702], with three under- 
performing outliers in the patients group and two in the control group. Log 
transformation has rendered the scores of both groups more normally distributed 
and eliminated the outliers. The variance was similar in two groups. 
Logical Memory 
Three chronic patients were unable to perform LM task, either immediate or 
delayed. Their cases were treated as missing values in all analyses of these 
variables. The scores for both LM immediate and delayed did not deviate from the 
assumptions of normality and homogeneity of variance in two groups. 
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Verbal Fluency 
One patient refused to complete VF tasks. His case was treated as a missing 
value in all analyses involving letter and category VF scores. The remaining 
scores were normally distributed in two groups for both letter and category 
fluency, with similar variances. The test for outliers indicated a possible outlier in 
the control group for letter fluency, but since the score was within the normal 
performance range, it was not considered to disturb the homogeneity of the 
group. 
Letter-Number Test 
Two chronic patients were unable to perform on LNT. Their cases were treated as 
missing values in all analyses. The remaining scores were normally distributed in 
two groups, with similar variances. 
Stroop Test 
There were three missing values in the patient group and two in the control group 
due to the unavailability of the test form at the time of the assessment. The 
scores for these participants were interpolated from the scores of other 
participants with similar neuropsychological profile in their respective group. The 
scores for all three parts of the test were normally distributed in both groups, 
with similar variance. 
6.3.2. Main Analysis 
Table 6.2. presents means and standard deviations of the raw scores 
(unstandardised and untransformed), differences in z scores, F statistics, and p 
values for the differences in performance between patients and controls. 
TABLE 6.2. Means and standard deviations of the raw scores, differences in z 
scores and the significance of these differences, adjusted for age and sex, for 
Premorbid IQ, Current IQ, and specific cognitive functions of patients and controls 
Dependent variable 
Premorbid full scale IQ: NART 
Current full scale IQ: WAIS-III 
Patients Controls Analysis 
Mean Mean Difference 
(SD) (SD) in z scores 
100.71 114.44 -1.45 
(13.59) (9.47) 
83.24 112.12 -1.64 
(16.46) (17.55) 
Statistic P value 
F1,83 = 30.24 <. 0001 
F1,84 = 55.95 <. 0001 
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Immediate verbal memory: 
HVLT free recall 17.26 26.79 -1.95 F1,82 = 56.50 <. 0001 (5.89) (4.89) 
Immediate visuo-spatial memory: 
BVRT number correct 4.73 7.05 -1.12 F1,84 = 16.38 <. 0001 (2.30) (2.07) 
Verbal Learning: 
BSRT total words recalled 42.28 71.05 -1.72 F1,78 = 54.02 <. 0001 
(15.57) (16.65) 
Memory for Stories: 
Logical Memory immediate 7.98 13.51 -1.57 F1,81 = 42.83 <. 0001 
(3.56) (3.53) 
Logical Memory delayed 6.45 11.186 -1.48 F1,81 = 36.45 <. 0001 
(3.78) (3.19) 
Verbal Working Memory: 
Letter-Number total correct 8.33 16.40 -2.62 F1,84=128.48 <. 0001 
(4.41) (1.70) 
Sustained Attention: CPT d'prime 
. 55 1.57 -1.14 F1,82 = 38.31 <. 0001 (. 44) (. 90) 
Inhibition (Selective Attention): 
Stroop interference score -2.11 5.95 -. 889 F1,84 = 11.88 <. 001 
(8.67) (9.07) 
Speed of word naming: 
Stroop word score 84 105 -1.46 F1,84 = 30.47 <. 0001 
(17.03) (14.45) 
Speed of colour naming: 
Stroop colour score 55 78 -1.35 F1,84 = 44.54 <. 0001 
(12.55) (16.79) 
Mental Flexibility: Trail B-A* 57.79 36.12 . 95 F1,82 = 16.64 <. 0001 (30.49) (26.13) 
Set-shifting (Perseveration): 
WCST perseverative responses * 28.11 13.40 . 98 F1,83 = 16.38 <. 0001 (25.65) (14.88) 
Verbal Fluency: 
Phonological 30.39 44.23 -1.15 F1,83 = 27.92 <. 0001 
(9.99) (3.19) 
Semantic 36.93 48.40 -1.43 F1,83 = 28.01 <. 0001 
(9.95) (12.01) 
Psychomotor Speed and Dexterity: 
Finger Taping mean 41.30 48.51 -. 78 F1,84 = 10.70 <. 002 
(10.33) (9.29) 
GPB mean* 106.02 64.79 . 67 F1,84 = 18.95 <. 0001 (47.79) (10.21) 
* Higher score indicates poorer performance 
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Patients' mean premorbid IQ was 1.45 standard deviations (sd) and current IQ 
was 1.64 sd below normal controls' mean [p < . 0001]. Paired-samples t-test 
showed that patients' current IQ was significantly lower than their premorbid IQ 
[Premorbid IQ mean = 100.71, sd = 13.59; Current IQ mean = 83.24, sd = 
16.46; t= 12.566, df = 43; p<. 0001]. In addition to lower IQ, patients were 
significantly impaired on all cognitive functions, with deficits ranging from . 67 to 
2.62 sd relative to normal mean [p ranging from . 002 to . 00001, after adjusting 
for age and sex]. The average degree of impairment on neuropsychological 
measures was 1.30 standard deviation below the controls' mean. The severest 
deficits [difference in z scores greater than 1.5 sd] were observed for verbal 
working memory, verbal memory and learning, and memory for stories, both 
immediate and delayed, whereas psychomotor speed and dexterity were the least 
impaired (See Figure 6.1 demonstrating the relative impairment on different 
measures). 
FIGURE 6.1. Deficits in scores for premorbid IQ, current IQ, and specific cognitive 








* By the definition of z-transformation, the control group has a mean score of zero on each measure. 
ABBREVIATIONS: BVRT = Benton Visual Retention Test; FTT = Finger Tapping Test; GPB = Grooved 
Peg Board; HVLT=Hopkins Verbal Learning Test; LM I= Logical Memory immediate; LM II = Logical 
Memory delayed; LN = Letter-Number test; VF = Verbal Fluency; WCST = Wisconsin Card Sorting 
Test. 
Since patients had significantly lower premorbid IQ, the influence of IQ level on 
other cognitive abilities was evaluated. Using ANCOVA, premorbid IQ did not 
have any effect on Buschke Selective Reminding Test free recall or Stroop 
interference score. It had some effect on immediate and delayed Logical Memory, 
Hopkins Verbal Learning Test total recall, Letter-Number task, Continuous 
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Performance Test d'prime, Wisconsin Card Sorting Test perseverative responses, 
Stroop word and colour naming, Trail Making form B-A, as well as phonological 
and semantic Verbal Fluency, but the difference on these tests was still significant 
between groups. The deficits in Finger Tapping, Grooved Peg Board and Benton 
Visual Retention Test performance could be completely explained by lower 
premorbid IQ in patients. 
6.3.3. Relationships Between Cognitive Deficits and Clinical History 
The relationships between cognitive deficits and clinical history, such as age of 
onset, duration of illness, and number of previous episodes and hospitalisations 
were investigated using partial correlations. The correlations of cognitive deficits 
with medical history variables were controlled for sex, since women are known to 
have later age of onset than men and tend to have less recurrent form of the 
illness (Chapter 1). Additionally, correlations between cognitive deficits and 
duration of illness, number of previous episodes and hospitalisations were 
controlled for age, since these variables are related to age. 
Table 6.3 presents partial correlation coefficients for the significant relationship 
between cognitive deficits and clinical history. Earlier age of onset correlated with 
poorer immediate verbal memory (. 323), and fine motor function, both speed 
(. 376) and dexterity (-. 385). There were trend associations between greater 
number of previous psychotic episodes and poorer cognitive flexibility (. 311) and 
poorer semantic verbal fluency (-. 300). 
TABLE 6.3. Partial r correlation coefficients of cognitive deficits with clinical 
history, adjusted for age and sex 
Clinical History Cognitive Deficits Partial r coefficient p value 
Age of Onset 
Number of episodes 





* Greater score means poorer performance 
(df) 
. 323 (40) . 037 
376 (42) . 012 
-. 385 (42) . 010 
311 (37) . 054 
-. 300 (38) . 06 
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In addition, patients with family history of schizophrenia had poorer psychomotor 
speed relative to patients with no family history It (38) = 2.39, p= . 022], with the 
trend for significance remaining after controlling for age and sex [p = . 07]. 
6.3.4. Relationships Between Cognitive Deficits and Symptoms 
Partial correlations, adjusting for age and sex, revealed significant associations 
between poorer immediate verbal memory (HVLT total recalled) and greater 
severity of negative symptoms (-. 418, df = 38, p= . 009; individual items 
included blunt affect, poor rapport, and stereotyped thinking, p <. 05); and poorer 
inhibition (Stroop interferences) and greater severity of general psychopathology 
(-. 436, df = 39, p= . 004; individual items included motor retardation, 
uncooperativeness, unusual thought content, poor attention, disturbance of 
volition, poor impulse control, active social avoidance, p<. 05 ) as measured by 
PANSS. 
6.3.5. Relationships Between Cognitive Deficits and Medication 
Since high doses of typical antipsychotics and anticholinergic drugs are known to 
affect memory and psychomotor function, the degree of impairment on cognitive 
measures tapping memory and motor processes were investigated in relation to 
the current dosages of neuroleptic and anticholinergic medications. There were no 
significant relationship, but trend associations were observed between higher 
current neuroleptic dose and poorer logical memory, immediate (-. 329, df = 27, p 
= . 081) and delayed (-. 315, df = 33, p =. 096). 
In addition, patients who were on anticholinergic medication had significantly 
poorer speed of information processing, including Stroop word reading [F(1.36) _ 
11.984, p= . 001] and Stroop colour naming 
tasks [F(1.36) = 8.684, p= . 006], 
controlling for age and sex. 
6.3.6. Exploratory Analysis 
Stepwise logistic regression was performed to determine neuropsychological 
variables that had unique variance in classifying patients and controls into 
groups. Gender, age, and premorbid IQ were treated as covariates and were 
entered into the model using forced entry method. All neuropsychological 
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variables were entered into the model in a stepwise fashion using the forward 
maximum likelihood-ratio procedure. Due to the missing data, total of 33 
patients and 43 controls were included in the analysis. The model with the best 
fit had three significant predictors: Buschke Selective Reminding Test, Letter- 
Number test, and Stroop colour naming, which correctly predicted 31 of 33 
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The aim of the present study was to quantify neuropsychological deficits in 
schizophrenia patients on the cognitive domains that have been consistently found to 
be compromised in schizophrenia and shown to bare significance for functional 
outcome. The neuropsychological measures were chosen for their reliability in 
differentiating patients and healthy controls in previous research. Consequently, 
patients were found to have impaired performance on all neuropsychological 
measures selected for the present investigation. 
The deficits ranged from . 63 standard deviations below the normal mean for 
dexterity to 2.62 standard deviations for verbal working memory. The greatest 
deficits (quantified as being greater than 1.5 sd) were observed on the measures of 
memory requiring verbal processing, including verbal working memory, immediate 
verbal memory and learning, and memory for stories, both immediate and delayed. 
The severity of these deficits was disproportional to the lower premorbid IQ levels of 
patients. Numerous other studies have observed differential impairment of these 
cognitive domains in schizophrenia patients, both chronic and first episode (reviews, 
Goldberg and Gold, 1995; Kuperberg and Heckers, 2000; Gur et al., 2000; Sharma 
and Antonova, 2003). Attention, visuo-spatial memory, and executive function 
showed a moderate impairment. Attention and executive dysfunction could only in 
part be explained by IQ deficits, whereas visuo-spatial memory impairment could be 
completely accounted for by IQ levels. In line with previous research (Hutton et al., 
1998; Riley et al., 2000), the impairment of semantic verbal fluency was more 
pronounced than that of phonological verbal fluency and approached the criterion of 
a specific impairment (1.43 sd below the normal mean). Patients also showed 
considerable slowing on the speed of word reading (1.46 sd) and colour naming 
(1.35 sd) as measured by the control tasks of the Stoop test. Finally, fine motor 
dysfunction showed least impairment, which could be completely explained by IQ 
deficits. This relationship between psychomotor function and general intellegince is 
interesting, considering that psychomotor dysfunction is evident very early in life and 
is one of the most robust childhood predictors of adult schizophrenia (see Chapter 
2). Rosenbaum and colleagues (2001) recently reviewed how intellectual and motor 
skills are acquired in fundamentally similar ways and concluded that basic 
coordination and timing processes seem to be required for interellectual as well as 
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motor skills. Therefore, the association between fine motor functioning and IQ levels 
in schizophrenia patiens might be explained by the parallel development of these 
processes early in life. 
LNT, BSRT, and Stroop colour naming had a unique variance in predicting patients' 
group membership, indicating that the impairment in verbal working memory, verbal 
learning, and the speed of information processing were the 'signatures' of 
schizophrenia patients' neuropsychological profile relative to healthy individuals. 
Schizophrenia patients as a group had an average premorbid IQ (normal population 
average is a score of 100 on the NART IQ scale). However, the findings of the 
present study indicate that this average score might not reflect the 'true' potential, 
yielding support for the notion of impaired premorbid IQ in schizophrenia. As has 
been noted in the introduction, IQ is best predicted from the parental SES. Patients 
had significantly lower premorbid IQ then would be expected from their parental 
SES, since patients and controls were matched on parental SES for the present 
investigation. These findings suggest that IQ impairment might be indicative of the 
disease process early in life and might be a risk factor for schizophrenia. Further, 
current IQ as measured by the Vocabulary sub-test of WAIS-III was significantly 
lower in patients than their premorbid IQ as measured by NART-R, suggesting that 
there might be a further IQ decline associated with the disease progression. 
However, it is known that NART-R tends to overestimate IQ at the lower end of the 
distribution (Nelson and Willison, 1991). Therefore, the difference between current 
and premorbid IQ scores in the patient group might reflect psychometric properties 
of the NART-R. Russell and colleagues (2000) have found that the NART 
overestimates premorbid IQ by an average of 15 IQ points, with about 10 points for 
100-114 IQ band. In the present study, patients' current IQ was 17 points lower 
than their premorbid IQ. Further, controls' IQ scores fell within the 10-point over- 
estimation band of 100-114 score, but their scores on the measures of premorbid 
and current IQ are separated by an average of 2 points only. Thus, the difference in 
premorbid and current IQ scores in the patient group is unlikely to be completely 
explained by the psychometric limitations of the NART. 
There were a number of associations between cognitive deficits and clinical 
characteristics. Poorer immediate verbal memory as measured by HVLT was 
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associated with earlier age of onset and greater severity of negative symptoms. This 
finding replicates that of Paulsen and co-workers (1995) who observed associations 
between CVLT, which is similar in its cognitive demands to HVLT, and age of onset 
and negative symptoms in schizophrenia patients. Greater severity of fine motor 
function was also associated with earlier age of onset. In addition, poorer 
psychomotor speed distinguished patients with familial history of schizophrenia 
spectrum disorders. In the recent review of 16 high-risk (HR) studies, which followed 
up longitudinally children at high-risk for schizophrenia (i. e. at least one parent 
diagnosed with schizophrenia spectrum disorder), Niemi and colleagues (2003) 
concluded that problems in motor function and verbal immediate memory (as well as 
attention) were predictive of schizophrenia later in life. For example, in the New 
York HR study, verbal immediate memory deficits predicted 83% of the HR offsprings 
who developed schizophrenia-related psychosis (Erlenmeyer-Kimling and Cornblatt, 
1992; Erlenmeyer-Kimling et al., 2000). Recent report from the Edinburgh HR study 
of neuropsychological change in young people at HR for schizophrenia during a 2- 
year period indicated that decline in IQ and verbal memory preceded the 
development of psychotic symptoms. Taken together, the present findings and the 
findings of the previous studies suggest that deficits in verbal immediate memory 
and motor function play a role in pathogenesis of schizophrenia. Duration of illness 
did not associate with any of the cognitive deficits. This finding is in agreement with 
the longitudinal literature (review Rund 1998; Weickert and Goldberg 2000; Lewis, 
2004) of the course and stability of cognitive deficits in schizophrenia, showing that 
there is no worsening in cognitive functioning over time apart from normal effects of 
age. Finally, poorer inhibition of pre-potent response was associated with greater 
severity of general psychopathology, particularly strongly with motor retardation, 
uncooperativeness, unusual thought content, poor attention, disturbance of volition, 
poor impulse controls, and active social avoidance. These associations make good 
theoretical sense and suggest that social avoidance in schizophrenia might be 
underlined by a basic cognitive dysfunction of poor inhibition, which manifests as 
disturbances in motor, thinking and volitional processes. 
As predicted, the severity of memory deficit in schizophrenia patients was associated 
with anticholinergic treatment. The association, however, was limited to memory for 
stories, with both immediate and delayed recall being worse in patients who were 
taking adjunct anticholinergic procyclidine than in patients who were only taking 
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antipsychotics. This finding adds to the weight of evidence for the memory impairing 
effect of procyclidine in schizophrenia (Frith, 1984; Medalia et al., 1988; Spohn and 
Strauss, 1989; Cassens et al., 1990; Kumari et al., 2003b; Ettinger et al., 2003). 
To conclude, the present study confirmed the presence of generalised (IQ) and 
specific cognitive deficits in schizophrenia patients, including verbal working memory, 
learning and memory, executive function, sustained and selective attention, verbal 
fluency, speed of information processing, and fine motor function. The present 
findings suggest that deficits in verbal working memory and speed of information 
processing best differentiate patients from normal controls; whereas deficits in fine 
motor function and visuo-spatial immediate memory appear to be present due to low 
general intelligence of some patients. Finally, the findings highlight the need for 
better treatment in schizophrenia in order to avoid further impairment of verbal 
memory and learning due to the anticholinergic treatment necessary with 
conventional antipsychotics. 
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CHAPTER 7. RELATIONSHIP BETWEEN STRUCTURAL ALTERATIONS 
AND COGNITIVE DEFICITS IN SCHIZOPHRENIA 
7.1. Introduction 
With the advent of brain imaging techniques, it has become possible to investigate in 
vivo Kraepelin's idea that cognitive dysfunction in schizophrenia are the 
manifestation of the underlying brain pathology, by studying the relationship 
between structural brain alterations and cognitive deficits. 
Chapter 2 presented a comprehensive review of the Region of Interest (ROI) studies 
investigating structure/neurocognition relationship in schizophrenia. One of the 
issues that have emerged from the review is that ROI studies did not always 
distinguish between two issues: volume/neurocognitive ability relationship vs. 
structural alteration/neurocognitive deficit relationship. In other words, the studies 
investigated the relationship between the volume of measured structures and 
cognitive deficits regardless of whether the volume was altered in patients relative to 
controls, making the implication of their findings for the relationship between 
structural pathology and cognitive dysfunction in schizophrenia unclear. 
The associations between structural alterations and cognitive deficits identified by 
the ROI studies (review, Antonova et al (2004), see also Chapter 2 and Appendix I) 
included: (i) reduced total brain and grey matter volumes with low premorbid IQ 
(Zipursky et al., 1998), deficits in executive (Kareken et al., 1995; Sullivan et al., 
1996) and psychomotor (Sullivan et al., 1996) functions, verbal memory (Gur et al., 
1999), visuo-spatial memory (Kareken et al., 1995; Gur et al., 1999), and attention 
(Gur et al., 1999), (ii) reduced PFC grey matter volume with attention and memory 
dysfunction (Gur et al., 2000a); (iii) reduced hippocampal volume (Gur et al., 2000b) 
and increased cerebellar vermis white matter volume (Levitt et al., 1999) with 
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memory deficits; and finally (iv) reduced volume of left striatum and 
putamen/nucleus accumbens complex with abstraction/categorization deficits 
(Stratta et al., 1997). The only VBM study of structure/neurocognition relationship 
(Saldago-Pineda et al., 2003) has reported an association between reduced grey 
matter concentration of the thalamus, angular, supramarginal, inferior frontal, and 
postcentral gyri of the left hemisphere and sustained attention deficits in first 
episode schizophrenia patients, but not in healthy controls. 
Out of 22 ROI studies with the control group, which performed correlations for both 
patients and controls, 12 observed substantial differences in the pattern of 
structure/neurocognition relationship between the groups (Hoff et al., 1992; 
Bornstein et al., 1992; Flaum et al., 1994; Kareken et al., 1995; Sullivan et al., 
1996; DeLisi et al., 1997a; Baare et al., 1999; Levitt et al., 1999; Nopolous et al., 
1999; Krabbendam et al., 2000; Sanfilipo et al., 2002, Szeszko et al., 2003), with 
some associations being specific to schizophrenia patients (i. e. not seen in controls), 
and others lacking in patients (i. e. observed in controls but not in patients). For 
example, Sanfilipo et al. (2002) have observed positive correlation between left and 
right hippocampal volume and verbal memory in schizophrenia, but an inverse 
correlation between right hippocampal volume and verbal memory in controls. On 
the other hand, patients lacked an association between hippocampus and verbal 
fluency observed in normal controls. Further, left and right PFC white matter volume, 
which was significantly reduced in patients, was associated with cognitive flexibility 
in schizophrenia patients, but not in controls. Zipursky et al. (1998) found 
significant correlations between grey matter volume and IQ (as measured by NART 
and Quick test) in first-episode patients in schizophrenia, but not in normal controls. 
Krabbendam and colleagues (2000) observed an association between 
parahippocampal volume and information processing speed in patients, but not in 
healthy controls, despite no difference in hippocampal volume between the groups. 
Scezsko and colleagues (2003) reported the lack of 'normal' association between 
larger cerebellar volume and global as well as executive, visuo-spatial, and memory 
functions in a cohort of first-episode patients. Baare and colleagues (1999) found 
relative prefrontal volumes to positively correlate with immediate recall on verbal 
and visual memory and semantic fluency in patients, and only delayed visual 
memory in controls. For the detailed findings of other studies see Chapter 2, Table 
2.1. 
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Although many studies have observed differences in the pattern of correlations in 
patients and normal controls, only three (Flaum et al., 1994; Zipursky et al., 1998; 
Szeszko et al., 2003) have formally tested whether these differences significantly 
differentiated the groups. Flaum et al. (1994) found that the correlation between 
enlarged putamen and IQ in female patients was significantly stronger than the 
correlations between this structure and function in either normal controls or affected 
men, using Fisher z transformations (Fisher, 1921). Szeszko et al. (2003) tested the 
difference in the strength of correlation between cerebellar volume and global 
functioning using non-transformed z score difference between two correlation 
coefficients and reported significantly stronger correlation in controls than in 
patients. Finally, Zipursky et al. (1998) found significant diagnosis-by-IQ tests 
interactions on grey matter volume using ANOVA, suggesting that the relationship 
between grey matter volume and general intellectual functioning is substantially 
different in patients relative to controls. 
It is currently unclear whether these differences pertain to statistical artefacts, such 
as different range of structural volumes and neuropsychological performance 
resulting in different correlation strength, or whether they reflect altered 
structure/neurocognition relationship in schizophrenia, or perhaps both hold true in 
different cases (Antonova et al, 2004) Appendix I). 
The present study investigated whether global and regional structural alterations 
identified in Study 1 (Chapter 5) are associated with impaired IQ and cognitive 
deficits of immediate and long-term verbal memory and learning, verbal working 
memory, immediate visuo-spatial memory, attention, executive function, verbal 
fluency, speed of word and colour naming, and psychomotor speed and dexterity 
observed in Study 2 (Chapter 6). Further, the study aimed to test explicitly and 
formally the hypothesis that structure/neurocognition relationship is altered in 
schizophrenia, such that some associations would be specific to patients, whereas 
others would be lacking relative to healthy individuals, with these differences not 
simply being due to statistical artefacts. Therefore, the study presents the following 
methodological advances relative to previous research: (i) the use of VBM for its 
power to identify structural alterations throughout the whole brain; (ii) investigating 
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strictly structural alteration/cognitive deficit relationship; (iii) explicit and formal 
testing of the altered structure/neurocognition relationship in schizophrenia, 
suggested by previous studies; and (iv) exploring possible statistical reasons for the 
differences in structure/neurocognition associations between patients and normal 
controls by comparing variance of two groups on both sets of variables, structural 
and neuropsychological. 
Based on the previous literature reviewed above and in Chapter 2, it was predicted 
that reduced whole brain volume would be associated with impaired IQ and IQ- 
dependent cognitive abilities, including psychomotor speed (finger tapping) and 
dexterity (grooved peg board) (see Study 2, Chapter 6). These associations are likely 
to be due to the associations of these cognitive abilities with the grey rather than 
white matter volume. Specific regional alterations were predicted to be associated 
with specific cognitive deficits, independent of IQ. The IFG volume reduction was 
predicted to be associated with the deficits of verbal learning and memory, verbal 
fluency and sustained attention. The STG reduction was not found to associate with 
specific cognitive deficits in schizophrenia patients previously (Sanfilipo et al., 2002; 
Gur et al., 2000b), despite correlating with processing speed (Sanfilipo et al., 2002), 
spatial memory and attention (Gur et al., 2000b) in normal controls. Therefore, no 
relationship between STG reduction and cognitive deficits in patients was predicted. 
Enlarged putamen was found to associate with better WCST performance in chronic 
patients (Stratta et al., 1997). Therefore, it was predicted that enlarged putamen 
would associate with better WCST performance as measured by perseverative 
responses. The alterations of primary visual cortex, superior fascicules 
longitudinalis (SFL) and precuneus have not been studied previously in relation to 
cognitive deficits in schizophrenia. Based on the anatomical connectivity of these 
regions and their known functions from lesion and fMRI research, it was anticipated 
that LG grey and white matter reductions would be associated with impaired 
performance on measures involving visual processing, particularly with the timed 
component, including Benton Visual Retention Test and Stroop word reading and 
colour naming. SFL reduction was predicted to associate with impaired performance 
on measures involving verbal functioning, since this association tract connects 
language areas of prefrontal, temporal, and parietal cortex and thus is most 
important for language. The precuneus is known to activate during semantic 
processing and episodic memory tasks, along with left IFG, in normal individuals 
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(reviews, Cabeza and Nyberg, 2000, Binder and Price, 2001). Therefore, the volume 
of precuneus was predicted to associate with the verbal learning and memory, but 
the direction of this association was left open. Finally, it was predicted that some 
structure/neurocognition relationships would be specific to patients, whereas others 
would be lacking in patients relative to normal controls. 
7.2. Method 
7.2.1. Participants 
The information on patient and control groups is presented in Chapter 5. 
7.2.2. Measures 
7.2.2.1. Structural Variables 
The predicted values (y' adjusted = y' fitted + error) for the percentage of total 
grey/white matter volume at the maxima voxel of all the regions of between-group 
differences that were extracted for each participant in Study 1 for the analyses of the 
inter-relationships between altered regions, as well as their relationship with clinical 
variables, were used for the investigation of structural alterations with cognitive 
deficits. 
7.2.2.2. Neuropsychological Variables 
Since all neuropsychological measures were found to significantly differentiate 
patients and controls in Study 2, the standardised scores on all neuropsychological 
variables were used to investigate the relationship of structural alterations to 
cognitive deficits. 
Data reduction techniques to reduce the number of neuropsychological variables for 
the investigation of structure/neurocognition relationships were not used for both 
theoretical and practical reasons. Theoretically, since the VBM method allows the 
identification of regional differences with high spatial precision, the use of factor 
scores or a priori scales might mask any potential associations between regional 
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structural alterations and cognitive deficits through the loss of measurement 
specificity of combinatory constructs such as factors and scales. Practically, data 
reduction techniques such as factor analysis could not be meaningfully applied due to 
the insufficient sample size as well as the lack of orthogonality between the factors 
when the procedure was attempted using the principal component analysis. To 
reduce the number of variables, the mean scores for two hands on Finger Tapping 
and Grooved Pegboard tasks were used since the scores for two hands were highly 
correlated (r = . 889 and r= . 897, p <. 0001). 
7.2.3. Data Analysis 
Partial correlations, adjusting for age and sex, were run in SPSS to investigate the 
relationship between structural and neuropsychological variables. This method was 
preferred to running correlations using VBM in SPM99 with small volume corrections 
(SVC) restricted to the regions found to be altered in patients relative to controls, 
because it allows deriving partial correlations coefficients for the association between 
structural and neuropsychological variables, which can be compared between the 
groups to investigate the issue of altered structure/cognition relationship in 
schizophrenia (see below). Moreover, two methods give similar results (as was 
ascertained by the present investigator), but the preferred one (i. e. using SPSS) is 
less computer intensive and time economical. 
To minimize the chance of false positive errors due to the number of performed 
tests, the correlations were considered to be significant at p <. 025. Since the 
correlations between structural volumes and cognitive functions observed in ROI 
studies are modest (. 350-. 400 on average), more conservative p value would have 
substantially increased the risk of type II error. 
Finally, to examine the issue of altered structure/neurocognition relationship in 
schizophrenia, partial correlations r coefficients, adjusted for age and sex, for each 
significant (at p<. 025) structural predictor of a neuropsychological variable in 
patients or controls were compared with those of the other group using Fisher z 
transformations (Fisher, 1921). Fisher z transformation is applied to the test of a 
difference between two independent rs because when the population correlation 
coefficient p does not equal zero, the sampling distribution of r is not normal, and 
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becomes more and more skewed as p approaches ±1, and its standard error is not 
easily estimated. The same holds true for the difference rl - r2 (Howell, 1997). 




Then r' is approximately normally distributed around p' (the transformed value of p) 




The null hypothesis that p, - pz =0 is tested by converting each r to r' and solving for 
Z= 




where z is the test statistic (z statistic is used rather than t, since the standard error 
does not rely on statistics computed from the sample and is therefore a parameter). 
To ascertain the significance of z value at a= . 05 two tailed, the following formula 
was applied in SPSS to calculate the p value: 
p= (1-(CDFNORM(z value))*2 
where 'CDFNORM' stands for the 'cumulative distribution function', which returns the 




7.3.1. Relationships between Structural Alterations and Cognitive 
Deficits in Patients 
A number of structure/neurocognition associations were observed in patients, 
summarised in Table 6, presenting partial r coefficients for correlations between 
significant structural predictors and cognitive deficits in patients and partial r 
coefficients for the same pair of structure/neurocognition variables in controls, 
contrasted using Fisher z transformations to examine the specificity of these 
associations to schizophrenia. Reduced whole brain volume as well as white matter 
volume of the occipital lobe were associated with the deficit of phonological verbal 
fluency [r = 367, p<. 023 , and r= . 356, p <. 023, respectively]. Reduced white 
matter of the occipital lobe was also associated with slower Stroop word reading [r = 
. 437, p<. 003] and colour naming [r = . 483, p<. 001]. Reduced total grey matter 
volume was associated with lower IQ [r = . 397, p <. 012] and impaired dexterity [r = 
-. 382, p <. 014]. Finally, enlarged precuneus was associated with better verbal 
learning as assessed by BSRT total words recalled [r = . 395, p<. 012]. Two of these 
structure/neurocognition associations significantly differentiated patients from 
controls, including those between larger precuneus and better verbal learning 
[p<. 03]; and smaller OL white matter volume and poorer colour-naming speed 
[p<. 01]. 
Re-examination of significant structure/cognition relationships in patients whilst 
controlling for premorbid IQ resulted in weakening or loss of the significance of the 
correlations between global volume measurements and cognitive deficits (i. e. WBV 
with GPB), whereas the correlations between regional grey and white matter 
alterations and cognitive deficits remained essentially unchanged. 
7.3.2. Structure/Neurocognition Relationships Lacking in Patients 
Partial correlations revealed a number of significant structure/neurocognition 
associations in controls that were either attenuated or completely absent in patients, 
including larger IFG with verbal learning [r=. 391, p<. 011], immediate memory of 
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stories [r=. 358; p<. 022], delayed memory for stories [r=. 377, p<. 015], and 
memory for visuo-spatial stimuli [. 426; p<. 006]; and smaller precuneus and better 
verbal working memory [r=-. 454; p<. 003]. The associations in controls 
differentiating them from patients most clearly were between IFG volume and verbal 
learning [p<. 07], immediate memory for stories [p<. 06], and visuo-spatial memory 
[p<. 07], as well as precuneus volume and verbal working memory [p<. 04]. (See 
Table 7.1. for the correlation coefficients in patients for the same pairs of 
structural/neurocognitive variables, and Fisher z-transformed values and the p- 
values for the between-group differences). 
7.3.3. The comparison of variance on the structure/neurocognition pairs 
significantly differentiating the groups 
The examination of the ranges for the variables constituting structure/neurocognition 
pairs that significantly differentiated patients and controls revealed similar variance 
in two groups on all pairs, except for GPB scores in patients which had greater 
variance than in controls, suggesting that the differences in the strengths of 
correlations on the same pairs of structure/neurocognition variables were not simply 
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Structural alterations were predictive of some cognitive functions in patients. As 
hypothesized, the indices of global brain tissue availability showed a non-specific 
relationship to cognition, with total grey matter associating with premorbid IQ 
and dexterity, which was dependent on premorbid IQ levels. In addition, whole 
brain volume positively correlated with phonological verbal fluency in patients. 
Controls showed similar pattern, except for the association between total grey 
matter volume and dexterity. Overall, there were no significant differences in 
the pattern of structure/neurocognition relationships between global brain tissue 
availability and premorbid IQ as well as IQ-dependent cognitive function between 
patients and controls, albeit controls showed somewhat weaker associations. 
As predicted, the regional structural alterations were associated with specific 
cognitive functions in both groups. Further, supporting the prediction, some 
associations were specific to patients, whereas others were specific to controls. 
The clearest differentiation between two groups was observed for the 
relationships between regional structural volumes and learning and memory. In 
controls, IFG volume was associated with verbal and visuo-spatial memory, 
differentiating them from patients with 6% and 7% probability of this occurring 
by chance. In patients, enlarged precuneus was associated with better verbal 
learning, significantly differentiating them from controls (3% probability). Left 
IFG and precuneus are commonly activated during semantic processing and 
episodic memory tasks in normal individuals during fMRI experiments (reviews, 
Cabeza and Nyberg, 2000, Binder and Price, 2001). Left IFG (BA 45/47) is 
proposed to be involved in selecting, comparing, or deciding on information 
during mnemonic processes (Petrides, 1995). The precuneus, due to its proximity 
to the retrosplenial cortex (Vogt, 1976), which is richly connected with 
hippocampus, parahippocampus (Mufson and Pandya 1984; Suzuki and Amaral, 
1994) and anterolaterodoral thalamus (Sripanidkulchai and Wyss, 1986), is 
proposed to play a role in episodic memory encoding (de Zubicaray et al., 1998; 
Capilotti and Macquire, 2003), retrieval (Buckner et al., 1996; Krause et al., 
1999) and retrieval success (Kapur et al., 1995). Fletcher and colleagues (1995) 
suggested that the role of the precuneus in episodic memory is that of a 'mind's 
eye', imagining the learned episode, and showed that the precuneus activation 
was much stronger for imaginable than for non-imaginable words. Thus, left BA 
45/47 and the precuneus are two nodes of the functional network involved in 
mnemonic processes. The findings of the present study suggest that greater 
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volume of left ventrolateral prefrontal cortex was a determinant of better 
performance on memory and learning tasks in normal controls. In the patients, 
on the other hand, the structural volume reduction of this region appears to have 
resulted in the loss of function, as evidenced by the observed differential deficit in 
memory and learning. The larger precuneus in some of the patients appears to 
have a beneficial effect on verbal learning and memory function. However, larger 
precuneus was also associated with greater number of psychotic episodes and 
hospitalizations in patients (Study 1, Chapter 5), suggesting that enlarged 
precuneus might have implications for schizophrenia course. Interestingly, in 
controls, larger precuneus was associated with poorer verbal working memory, 
suggesting that in healthy individuals larger precuneus might be detrimental for 
on-line cognitive information processing and manipulation. The putative 
enlargement of the precuneus and its implications for psychopathology and 
cognitive functioning in schizophrenia should be investigated further, as this area 
is largely unexplored in relation to schizophrenia as well as normal cognition. It 
would be interesting, for example, to investigate whether larger precuneus in 
healthy individuals is associated with the presence of schizotypal traits. 
It is noteworthy that phonological verbal fluency performance did not associate 
with the IFG volume either in patients or controls, since BA 45/47 is commonly 
found to activate during performance on this task (e. g. Fiez, 1997; Weiss et al., 
2003). 
Other structure/function relationships that significantly differentiated patients 
from controls were that of the greater white matter volume reduction of the 
primary visual cortex and poorer speed of word and color naming. These 
associations suggest that deficits in word and color naming speed in patients 
might be due to the compromised function early in the brain's visual information 
processing hierarchy. 
In line with the prediction, STG reduction did not associate with cognitive deficits 
in patients. There were no associations between STG volume and cognitive 
function in controls either. Although anticipated, this lack of relationships between 
STG volume and cognitive function in either group is somewhat surprising. 
Anterior temporal pole is associated with the semantic system function. Anterior 
temporal pole atrophy, especially on the left, is a hallmark of semantic dementia, 
as found by two VBM studies (Mummery et al., 1999; 2000). Functional imaging 
studies of normal controls show the activation in temporal operculum during the 
tasks requiring access to semantic knowledge (e. g. Demonet et al., 1992; 
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Mummery et al., 1996; Pugh et al., 1996; Vandenberghe et al., 1996). In line 
with this functional role, one ROI study has found smaller (but not reduced! ) left 
STG volume to associate with poorer verbal fluency in schizophrenia patients 
(Vita et al., 1995). However, Sanfilipo et al. (2002) did not find such an 
association between reduced STG volume and differentially impaired verbal 
fluency. It is plausible, that, as in the case with IFG volume reduction, anterior 
STG reduction resulted in the loss of function, as evidenced by the differential 
impairment of semantic verbal fluency in patients, but no direct relationships are 
observable perhaps due to other mechanisms playing a greater role in the face of 
STG structural and functional disruption. 
The most obvious limitation of this study is the number of performed tests 
without the correction for multiple comparisons, although the chance of false 
positives was minimized by adopting a more conservative p value of . 025. The 
structure/function correlations that were observed in ROI studies are generally 
modest and rarely exceed 35%. Thus, such stringent corrections as Bonferroni 
method might result in multiple type II errors. Taken these limitations into 
account, the results of the present study should be considered as putative and 
are in need of a replication. 
To conclude, the present study is the first to investigate, to the best of author's 
knowledge, the structure/neurocognition relationships in schizophrenia patients 
with optimized volumetric VBM approach and using a comprehensive 
neuropsychological battery. Further, it is the first study to explicitly test the 
hypothesis that structure/function relationship in schizophrenia might be altered. 
The results revealed left hemisphere localized structural alterations to associate 
with specific (not general) cognitive deficits in patients. Some 
structure/neurocognition associations appeared to be specific to schizophrenia, 
and some were lacking in patients relative to normal controls. 
198 
CHAPTER 8. STRUCTURAL ALTERATIONS AS PREDICTORS OF 
TREATMENT RESPONSE TO ATYPICAL ANTIPSYCHOTICS 
8.1. Introduction 
As has been reviewed in detail in Chapter 3 of the General Introduction, atypical 
antipsychotics have greater efficacy than typical antipsychotics in improving 
cognitive deficits characteristic of schizophrenia. Three most commonly used 
atypical antipsychotics in clinical practice are olanzapine, risperidone and 
quetiapine. Although divergent in their broader pharmacological profile, all three 
drugs share one common property: serotonin-dopamine antagonism, which is, as 
discussed in Chapter 3, is thought to relate to their greater cognitive efficacy than 
typical neuroleptics, which are exclusive dopamine antagonists. The lack of need 
for anticholinergic medication as an adjunctive treatment with atypical 
antipsychotics may also contribute to better cognitive functioning of the patients 
taking atypical antipsychotics. 
Earlier comparative studies of risperidone and olanzapine with small samples 
have suggested that these drugs might have differential effect on cognitive 
functioning (Cuesta et al., 2001, unpublished pilot study in Harvey et al., 2003). 
Purdon et al. (2000) with larger sample of patients (n = 65) have reported 
olanzapine to be superior to risperidone, but as argued by Sharma (2002), this 
differential effect might be due to unjustifiably high doses of risperidone used in 
the study. Most recent comparative studies with large sample sizes and clinically 
equivalent dosages did not support the notion of differential cognitive efficacy of 
olanzapine and risperidone, reporting no significant differences in the magnitude 
of produced improvement in cognitive functions (Bilder et al., 2002; Harvey et 
al., 2003). There are presently no published studies comparing quetiapine with 
other atypical antipsychotics in cognitive efficacy. 
Patients with earlier onset schizophrenia have more marked structural brain 
alterations than adolescence- or adult- onset schizophrenia (review, Mehler and 
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Warnke, 2002). Earlier age of onset is also associated with poorer response to 
treatment (Metlzer et al., 1997) and higher dosage of typical antipsychotics 
(Dernovsek and Tavcar, 1999). The degree of enlargement of CSF spaces 
(Harvey et al., 1993; Knoll et al., 1998; Lieberman, 1999) and cortical volume 
reduction (Zipursky et al., 1998) were shown to relate to the rate of symptom 
response to typical antipsychotics. Similarly, prefrontal sulcal prominence 
(Friedman et al., 1991), temporal CSF volume (Lauriello et al., 1998), and DLPFC 
and TL grey matter volumes (Molina et al., 2003a) were found to predict 
responsiveness to clozapine in schizophrenia in terms of clinical improvement. 
Molina et al. (2003b), however, did not find the volumes of total CSF, DLPFC CSF 
and grey matter, TL CSF and grey matter, and hippocampus to be predictive of 
clinical symptom improvement with risperidone treatment. It has not been 
previously investigated whether basal structural volumes are predictive of the 
degree of cognitive improvement with atypical antipsychotics. 
The present study, therefore, sought to investigate whether the degree of 
structural brain alterations is predictive of cognitive treatment response to 
atypical antipsychotics. To this end, cognitive functioning in patients on atypical 
antipsychotics (as one class of drugs) was compared with their cognitive 
functioning whilst on typical antipsychotics. In their review and meta-analysis of 
atypical antipsychotic trials, Keefe and colleagues (1999) recommended that the 
following conditions be met for a rigorous study comparing typical and atypical 
antispychotics: i) a within-subject design; ii) 4-to 6-week period of stable 
treatment with typical antipsychotics prior to the baseline assessment; iii) low 
dosages of typical antipsychotics as a comparator; iv) the assessment of positive 
and negative symotoms, as well as side effects and movement disorders at each 
neuropsychological assessment in order to discriminate between cognitive 
enhancement vs generalised clinical change. Following these recommendations, 
cognitive functioning in schizophrenia patients was assessed at two time points in 
a within-subject design: the baseline whilst the patients were treated with 
conventional medication for a period of at least 6 weeks, and after 6 weeks of 
treatment with one of the atypical antipsychotics, olanzapine, risperidone or 
quetiapine. Low dosages of typical antipsychotics were used as a comparator, 
and the assessments of overall clinical change in terms of symptoms, side-effects 
and movement disorder was carried out. A group of healthy individuals was 
included in order to control for the test-retest practice effects. It was 
hypothesised that patients would show significant improvement on 
neuropsychological test performance after 6-week treatment with atypical 
antipsychotics due to their shared property of dopamine-serotonin antagonism; 
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and that less altered structural volumes would be predictive of greater cognitive 
improvement. 
8.2. Method 
8.2.1. Design & Procedures 
The study has a within-subject design with two groups: one experimental 
(schizophrenia patients switched from conventional to atypical anti psychotics), 
and one control (healthy volunteers). The control group was included to estimate 
normal practice effect on neuropsychological measures. 
Each participant was tested on two occasions, the baseline (as described in Study 
2) and after 6 weeks. After the baseline MRI and neuropsychological assessment, 
schizophrenia patients were randomly assigned to one of the three atypical 
antipsychotics: olanzapine, risperidone or quetiapine. Randomisation was 
undertaken in order to exclude clinical bias in switching patients to one of the 
three atypical antipsychotic. 
8.2.1.1. Randomisation Procedure 
Randomisation was achieved by creating a randomisation table, an excerpt of 
which is provided below (see Table 8.1). The table represented a matrix of 
gender by age with three different age groups: from 18 to 33; from 34 to 50; and 
from 51 to 65 years of age. Each medication type has been given a letter code, 
A, B, or C, and these letters were pseudo-randomised across the three age 
groups in the following way. The first letter sequence was A-B-C, followed by B- 
C-A, followed by C-A-B. These three sequences were repeated in this order 
across the age groups. The person responsible for randomisation was unaware of 
the results of initial screening and baseline clinical and neuropsychological 
assessment. The investigators responsible for assessments were unaware of the 
randomisation procedure. This was done in order to prevent potential biases at 
the assessment and assignment stages of the trial. 
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TABLE 8.1. Randomisation matrix for four experimental medication groups 
MALE FEMALE 
AGE 18-33 
Name Name GROUP 
1 1 A 
2 2 B 
3 3 C 
4 4 B 
5 5 C 
6 6 A 
Age 34-50 
1 1 A 
2 2 B 
3 3 C 
4 4 B 
5 5 C 
Age 51-65 
1 1 A 
2 2 B 
3 3 C 
4 4 B 
8.2.1.2. Blinding 
The study utilised a single-blind design where investigators responsible for clinical 
and neuropsychological assessments were blind to the atypical antipsychotic that 
the patients were treated with. Since there is a possibility of the differential effect 
of atypical antipsychotics on cognition, the blinding was implemented as a 
precautionary measure to exclude the possibility of the investigator bias during 
the assessments. 
Patients were aware of the type of the medication they were receiving. Although 
this method might be open to criticism due to the possibility of patients' created 
biases in their responses during the neuropsychological assessments, these are 
improbable for the following reason. Even if the patients were knowledgeable in 
regard to cognitive effects of the atypical antipsychotic, the fact that patients 
were randomised after the baseline assessment prevents them from 'holding 
back' their responses at the baseline, and then "improving' their performance at 
the follow up assessment, either consciously or unconsciously. Thus, if the 
atypical antipsychotics were to be found to improve neuropsychological 
performance from the baseline to 6-week assessment, this would be unlikely to 
arise due to the patients' created biases. 
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In regard to the assessment bias issue, the 'blinding' of investigators responsible 
for clinical and neuropsychological assessments is of a far greater importance and 
necessary measures were implemented to ensure that clinical and 
neuropsychological assessments were performed under the 'blind' conditions. 
8.2.1.3. Dosage of Atypical Antipsychotics 
Starting doses for atypical antipsychotics were according to the "Summary of 
Product characteristics" for each individual drug: 20 mg for olanzapine, 2 mg for 
risperidone, and 50 mg increasing to 400 mg over three-four days for quetiapine. 
Optimal dosage for each patient was achieved within 14 days after the switch and 
the patients were retested after having been on the optimal dose for 6 weeks. 
Adjunctive Medication 
Anticholinergic medication was permitted in the study if required together with 
atypical antipsychotic. This method was applied to avoid the increased EPS that 
may result from discontinuation of anticholinergic medication, which might have 
reflected poorly on cognitive performance at 6 weeks. Further, this method made 
the medication regime at 6 weeks comparable to the one during conventional 
antipsychotic treatment; and allowed measuring the effect of atypical 
antipsychotics above and beyond the effect of adjunctive anticholinergic 
medication. Finally, this method is more representative of actual clinical practice, 
which makes the findings of the present study directly applicable to clinical 
practice. Thus, this is an appropriate method to estimate the effects of atypical 
vs. conventional antipsychotics on cognitive functioning. However, every attempt 
was made to keep patients on monotherapy as far as possible. 
8.2.1.5. Exclusion Criteria 
Patients were excluded from the study if i) co-medication not allowed in the study 
was required for the patient along with psychotropic medication tested in the 
study (e. g. additional antipsychotic medication, mood stabilisers); ii) compliance 
with prescribed medication was lacking; or iii) no significant medication effect was 
ascertainable or serious adverse reaction to the medication had occurred (as 
judged by the treating physician). 
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8.2.2. Participants 
PATIENTS: 30 (Male/Female = 20/10) out of 41 patients on conventional 
antipsychotics who were recruited for Studies 1,2, and 3 (for sample details see 
Chapter 5: General Method) gave consent to participate in the study. Patients 
were told that they were to take part in the study of the effect of atypical 
antipsychotics on cognition, and that they would be randomly allocated to 
treatment with one of the novel antipsychotics: olanzapine, risperidone, or 
quetiapine; after which they were to repeat the neuropsychological assessment 
following 6 weeks of treatment. Patients were instructed that they could 
withdraw their consent at any time without having to provide a reason. Three 
patients (Male/Female = 2/1) allocated to atypical group withdrew their consent 
before they were switched. Two male patients switched to risperidone relapsed 
and were excluded from the study. Three patients (Male/Female = 2/1) patients 
switched to quetiapine required adjunctive depot medication due to the 
exacerbation of the symptoms and were consequently excluded from the study. 
Thus, 22 patients (Male/Female = 14/8) have constituted the experimental 
group: 9 (Male/Female = 6/3) patients on olanzapine, 6 (Male/Female = 4/2) 
patients on risperidone, and 7 (Male/Female = 4/3) patients on quetiapine. 
Table 8.2 lists clinical characteristics of the patients, including diagnosis, illness 
type, familial history, age of onset, age of first hospitalisation, duration of illness, 
number of previous episodes and hospitalisation, and symptom ratings using the 
Positive and Negative Syndrome Scale (PANSS, Kay et al., 1987). 
CONTROLS: 25 individuals from the control group of Studies 1,2, and 3 gave 
consent to participate in the study. 23 (Male/Female = 14/9) have completed the 
study, with two individuals withdrawing before 6 weeks assessment. 
Table 8.3 presents demographic characteristics of the final sample. Two groups 
were matched on age, sex, ethnicity and parental SES. Normal controls had 
significantly higher levels of education than patients, as well as premorbid and 
current IQ (p <. 001). 
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TABLE 8.2. Clinical characteristics of the patients 
Characteristic Atypical (n=22) 
Diagnosis: 
Schizophrenia, paranoid 17 
Schizophrenia, undifferentiated 2 
Schizophrenia, residual 2 





Age at onset of first symptoms: 20.72 (13.40) 
Age at first hospitalisation: 25.95 (9.98) 
Duration of illness (years): 14.68 (12.61) 
Number of previous episodes: 3.80 (3.81) 
Number of previous hospitalisations: 2.68 (2.55) 
PANSS Positive symptoms: 17.5 (6.94) 
PANSS Negative symptoms: 18.50 (9.38) 
PANSS General Psychopatholog y: 37.64 (9.62) 
Conventional antipsychotics dosage 255.88 (220.71) 
(CPZ equivalents mg) 
Anticholinergic medication: N=8 
Dosage 4.81 (. 99) 
TABLE 8.3. Demographic characteristics of the final sample 






Age 40.64 (12.46) 37.65 (13.24) T(43) _ . 778; p=. 441 
Sex: Male 14 14 XZ . 037; p=. 848 
Female 89 
Education 12.27 (3.60) 16.76 (3.98) T(43) =-3.963; p=. 0003 
Premorbid IQ (NART) 105.23 (11.72) 116.04 (11.69) T(43) = -3.099; p=. 003 
Current IQ (WAIS-III) 87.09 (14.60) 112.43 (21.54) T(43) = -4.599; p<. 0001 
Ethnicity: Caucasian 16 16 
African 42 
South-East Asian 22 X2 (4) = 3.646; p=. 456 
Mixed Race -2 
Other -1 
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continued from p. 205 
Parental SES: 
Professional 2 3 
Intermediate 6 7 
Skilled: non-manual - 2 
manual 6 3 
Semi-skilled manual 3 5 
Unskilled manual 4 3 
8.2.3. Measures 
8.2.3.1. Structural Variables 
X2(5) = 8.627; p=. 125 
The predicted values (y' adjusted = y' fitted + error) for the percentage of total 
grey/white matter volume at the maxima voxel of all the regions of between- 
group differences that were extracted for each participant in Study 1, were used 
to investigate the predictive validity of structural alterations in treatment 
response with atypical antipsychotics. 
8.2.3.2. Neuropsychological Variables 
Scores on the neuropsychological measures obtained in Study 2 were used as the 
baseline scores. The neuropsychological battery described in Study 2, excluding 
the measures of general intelligence, NART and Vocabulary sub-test of WAIS-III, 
was used to assess cognitive functioning at the 6-week assessment. Where 
available, alternate test forms were used at the follow-up assessment, including 
Hopkins Verbal Learning Test, Buschke Selective Reminding Test, and Benton 
Visual Retention Test. Alternate test forms were counterbalanced for the baseline 
and follow-up assessments. 
8.2.3.3. Clinical Variables 
PANSS (Kay et al., 1987) was re-administered by the qualified psychiatrists at the 
follow-up assessment in order to ascertain changes in symptomatology with 
atypical antipsychotics from baseline to 6 weeks of treatment. 
In order to ascertain that cognitive change with atypical antipsychotics was not 
simply the result of reduced side effects induced by conventional antipsychotics, 
extrapyramidal, neurological, and autonomic side effects were assessed at the 
baseline and at 6 weeks using Simpson-Angus Rating Scale (SARS) for 
Extrapyramidal Side Effects (Simpson and Angus, 1970), Barnes Akathisia Scale 
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(BAS, Barnes, 1989), and Abnormal Involuntary Movement Scale (AIMS, Guy, 
1976). 
8.2.4. Statistical Analyses 
8.2.4.1. Data Distribution 
The raw scores on all the variables were checked for the normality of the 
distribution at the baseline and 6 weeks. Skewed variables were transformed in 
order to meet the requirements of parametric tests. 
8.2.4.2. Missing Data 
All variables were checked for missing values. Any cases with missing values 
were excluded from the analysis per variable. 
8.2.4.3. Test-Retest Reliability of Neuropsychological Measures 
Pearon's product moment correlations between the baseline and 6 week scores 
were used to investigate normal (i. e. using control group data) test-retest 
reliability of each neuropsychological measure. 
8.2.4.4. Practice Effect 
Paired-sample t-tests were used to investigate normal (i. e. using control group 
data) practice effect on each neuropsychological measure. 
8.2.4.5. Effects of Atypical Antipsychotics on Cognitive Functioning 
Due to the possibility of differential effects of three atypical antipsychotics on a 
given cognitive function, the statistical significance of the score change from 
baseline to 6 weeks was evaluated using a mixed-model analysis of variance 
(ANOVA), with time (baseline and 6 week scores) as the within-subject factor, 
and the atypical antipsychotic type (olanzapine, risperidone, or quetiapine) as the 
between-subject factor. Bonferroni correction was applied to adjust for the 
number of performed comparisons; therefore, the main effect of time was 
considered significant at p<. 003 (a of . 05/16 comparisons). 
For those neuropsychological tests that showed significant improvement, a 
mixed-model ANOVA, with time (baseline vs. 6 weeks) as a within-subject factor, 
and group (patients vs. normal controls) as a between-subject factor, was used to 
ascertain whether the improvement observed in patients was significantly greater 
than what would be expected due to the normal practice effect. The results of 
time by group interaction were considered significant at 5% level. 
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8.2.4.6. Structural Predictors of Cognitive Improvement 
Stepwise multiple linear regressions with the 6-week score as a dependent 
variable and the global and regional structural volumes as predictors were used to 
investigate whether any global or regional structural volumes were predictive of 
the 6-week score. The baseline score was entered into the model as a covariate 
(i. e. forced entry) to account for the effect of baseline performance on the follow 
up scores. Structural predictors were considered significant at 5% level. 
8.2.4.7. Effects of Atypical Antipsychotics on Symptoms 
A mixed-model analysis of variance (ANOVA), with time (baseline and 6 week 
scores) as the within-subject factor, and the atypical antipsychotic type 
(olanzapine, risperidone, or quetiapine) as the between-subject factor was used 
to investigate the significance of the effect of atypical antipsychotics as compared 
with conventional antipsychotics on positive, negative, general psychopathology 
as measured by PANSS, as well as side-effects as measured by AIMS, BAS, and 
SARS. The results were considered significant at 5% level. 
8.2.4.8. Relationship between Cognitive and Symptomatic Improvement 
Stepwise multiple linear regressions with the 6-week score as a dependent 
variable and the change scores (expressed as the percentage change from the 
baseline score) for the measures of symptomatology and side-effects as 
predictors were used to investigate the relationship between cognitive and 
symptomatic improvement. The baseline neuropsychological score (and atypical 
antipsychotic type where appropriate) was used as a covariate (i. e. entered the 
model as a forced entry). Predictors were considered to be significant at 5% level. 
8.3. Results 
8.3.1. Preliminary Data Screening 
8.3.1.1. Data Distribution 
The raw scores for WCST perseverative responses were positively skewed in both 
groups and were log transformed, which normalised the distribution at both time 
points. 
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8.3.1.2. Missing Data 
There were a few missing values on some of the neuropsychological measures. 
One patient switched to olanzapine failed to complete CPT at the follow up. One 
patient switched to risperidone failed to complete CPT at the baseline, but found it 
possible to cope with the demanding nature of the task at 6 weeks. Both patients 
reported not being able to discriminate between the numbers despite making an 
attempt to do so. 
The cases with the missing values were excluded from the analysis per variable. 
8.3.2. Main Analyses 
8.3.2.1. Test-retest Reliability of Neuropsychological Measures 
All neuropsychological measures, excluding Hopkins Verbal Learning Task and 
Stroop interference, showed satisfactory test-retest reliability in the normal 
control group. Correlation coefficients ranged between . 546 for Grooved Pegboard 
test and . 876 for the Letter-Number test (all p<. 006). Stroop interference scores 
of the baseline and 6 weeks performances showed a correlation of . 398 (p = 
. 060). However, after the exclusion of an obvious outlier as identified by using 
the scatterplot, the correlation improved to . 475. HVLT scores correlated at . 294, 
but after the exclusion of the outlier, the correlation improved to . 552. 
8.3.2.2. Normal Practice Effect 
The normal practice effect on all measures was small and none was greater than 
0.5 sd. The practice effect in normal controls reached statistical significance at 
5% level on Logical Memory delayed recall (z = . 40, p= . 023), Trail B-A 
(z =- 
. 40, p= . 027), WCST perseverative responses 
(z = -. 44, p= . 024), CPT d'prime 
(z = . 42, p= . 028), and Stroop word reading 
(z = . 47, p= . 007). (See Table 
8.4. for the baseline and 6 weeks raw mean scores mean, sd, change in z-scores, 
and p-values). 
8.3.2.3. Effect of Atypical Antipsychotics on Neuropsychological 
Performance 
Table 8.4 presents the descriptive statistics (raw score means, sd, and mean z- 
score change) for the patients' performance on conventional antipsychotics and 
after 6 weeks treatment with atypical antipsychotics. As can be seen from the 
table, the performance on four tests improved by more than .5 sd, including 
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HVLT, BSRT, GPB, and Letter-Number test, which is greater than the practice 
effect observed in normal controls on these measures. 
TABLE 8.4. Change in neuropsychological performance from baseline to 6 weeks 
in patients treated with atypical antipsychotics and normal controls 
Mean (SD) P value 
Neuropsychological Measure Group Baseline 6 weeks 
Mean Within Time by Time by Between 
z-score group atypical group group 
change type 









Controls 26.78 (4.94) 27.65 (4.70) 
. 
18 
. 474 - 









Controls 69.39 (16.21) 68.22 (13.49) -. 01 . 696 - 























Controls 6.52 (2.43) 6.76 (2.10) . 
00 1.00 - 















Controls 44.26 (31.49) 31.65 (22.71) -. 40 . 
027 - 
WCST perseverative responses * Patients 32.82 (32.42) 24.00 (15.42) -. 19 . 
353 . 
235 -- 
Controls 15.09 (11.74) 9.50 (9.26) -. 44 . 
024 - 
CPT d'prime Patients . 
66 (. 43) . 









Stroop interference score Patients 1.30 (9.86) -1.71 (5.03) -. 32 . 
213 . 
708 -- 
Controls 3.28 (9.77) 1.63 (6.54) -. 17 . 
036 - 
Stroop word score Patients 84.95 (14.92) 81.89 (19.46) -. 16 . 
403 . 
350 -- 






















Semantic Verbal Fluency Patients 37.23 (10.69) 36.27 (6.57) -. 11 . 
591 . 
437 -- 
Controls 48.57 (9.07) 47.14 (14.94) -. 17 . 
655 - 


















Higher score indicates poorer performance 
f Significant at 5% level 
Significant with Bonferroni correction (p = . 003) 
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Hopkins Verbal Learning Test 
The improvement of . 77 sd was observed on HVLT total recall. The main effect of 
time of a mixed-model ANOVA was significant after Bonferroni correction [F(1,19) = 
13.327, p= . 002], with no significant time by atypical antipsychotic type 
medication interaction [p = . 922], suggesting the patients improved regardless of 
which atypical antipsychotic they were switched to. (See Fiqure 8.1. illustrating 
the mean change in z-scores for patients treated with olanzapine, risperidone, or 
quetiapine). 
FIGURE 8.1. Plot of HVLT performance change in mean z-scores from the baseline to 6 























Patients improved in their HVLT performance more than would have been 
expected due to the normal practice effect, as evidenced by the trend for time by 
group interaction of a mixed-model ANOVA, with time as a within-subject factor, 
and group (patients vs controls) as a between-subject factor [F(1,43) = 3.539, p= 
. 067]. There was also a significant between group main effect [F(1,43) = 38.621, p 
<. 0001]. Post hoc between-group contrasts using independent samples t-tests 
with the Bonferroni correction (2 comparisons, p= . 025) showed significant 
group differences at both baseline [t(43) _ -5.874, p< . 0001] and 6 weeks [t(43) = 
-4.645, p< . 0001], suggesting that although the patients' performance has 
improved, it was significantly below the normal level. These differences remained 
after controlling for premorbid IQ [baseline: F(1,42) = 26.845, p= . 0002; 6 weeks: 
F(1,42) = 12.720, p= . 0005]. 
Stepwise multiple linear regression with HVLT 6 week score as the dependent 
variable, and with baseline HVLT z-score as a covariate (forced entry), showed 
that smaller grey matter volume of the precuneus was predictive of higher HVLT 
score at 6 weeks in patients [ß = . -414; t=-2.600, rp = -. 512, p= . 018] 
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accounting for 16% of the variance. The regression model including the baseline 
score and the precuneus grey matter volume accounted for 53% of the variance 
in 6 weeks scores [R2 = . 532, F(1,19) = 10.805, p= . 001]. 
To ascertain that the relationship between smaller precuneus volume and greater 
HVLT performance improvement is not simply due to the ceiling effect, i. e. the 
fact that patients who did not show change in performance did not have a room 
for improvement due to scoring high at the baseline assessment, patient group 
was divided using the median split into two sub-groups: No change (n =12, mean 
change = . 12, sd = . 49) and Change (n = 10, mean change = 1.56, sd = . 75). 
Change sub-group had lower mean HVLT baseline performance than No change 
sub-group (No change: mean = -1.58, sd = 1.29; Change: mean = -2.29, sd = 
. 94), but it was not statistically significant using independent-sample t-test [t(20) 
= 1.461, p= . 160]. Further, there was a trend difference in 6-week scores 
between two sub-groups, with Change sub-group outperforming the patients who 
did not change (No change: mean = -1.46, sd = . 97; Change: mean = -. 73, sd = 
. 72; t(20) = -1.968, p= . 063), suggesting that the relationship 
between smaller 
precuneus grey matter volume and better HVLT 6 week performance could not be 
explained by the ceiling effect in the patients who did not improve. Figure 8.2 
illustrates the relative performance on HVLT by Change and No change sub- 
groups. 
FIGURE 8.2. The plot of HVLT performance in patients who showed and did not show 



















Buschke Selective Reminding Test 
An improvement of . 70 sd was observed in patients after 6-week treatment with 
atypical antipsychotics on the BSRT total words recalled. A main effect of time of 
a mixed-model ANOVA was significant after the Bonferroni correction [F(1,16) _ 
14.659, p= . 001], with a trend for time by group interaction [p = . 080], 
suggesting differential effect of atypical antipsychotics on this measure. As can 
be seen from Figures 8.3 illustrating mean change in z-scores for patients treated 
with three atypical antipsychotics, all sub-groups have shown positive change in 
scores, although olanzapine sub-group had very small increment in performance 
(Olanzapine: mean z-score change = -. 19, sd =. 73; Risperidone: mean z-score 
change = -. 78, sd = . 87; Quetiapine = -. 81, sd = 1.35). As can be seen from the 
scatterplots of the change z-scores for individual cases (Figure 8.4), olanzapine 
sub-group was most heterogeneous in terms of performance change. Post hoc 
contrasts using a mixed-model ANOVA with the Bonferroni correction (3 
comparisons, p=. 016) revealed no significant time by atypical medication type 
interactions; however, there was a trend for a greater improvement with 
quetiapine than olanzapine [F(1,11) = 4.627, p= . 055]. 
FIGURE 8.3. The plot of BSRT performance FIGURE 8.4. Scatterplot of change z-scores in 
change in mean z-scores from the baseline to GPB performance for patients treated with 
6 weeks for patients treated with olanzapine, olanzapine, risperidone, or quetiapine 
risperidone, or quetiapine 
0.0 
ö 































Since the main effect of time was significant and neither drug has produced a 
worsening of the performance, the data from patients treated with three atypical 
antipsychotics were treated as one group in the subsequent analyses. 
An improvement in patients after 6 weeks of atypical treatment in BSRT 
performance was significantly greater than what would be expected due to the 
normal practice effects, as evidenced by a significant time by group interaction of 
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a mixed-model Repeated Measures ANOVA, with the baseline and 6 weeks as the 
within-subject factor, and patients vs. normal controls as the between-subject 
factor [F(1,40) = 7.282, p= . 010]. There was also a significant between group 
main effect [F(1,38) = 18.583, p =. 0001]. Post hoc between-group contrasts using 
independent samples t-tests showed significant group differences with the 
Bonferroni correction (p = . 025) at both baseline [t(40) = -5.105, p= . 0009] and 
6 weeks [t(40) = -2.509, p= . 016], suggesting that although patients' 
performance has improved, it was still below the normal level. However, after 
controlling for difference in premorbid IQ, the difference at 6 weeks was no longer 
significant using 1-way analysis of covariance (ANCOVA) [p= . 089]. 
Stepwise multiple linear regression, with the baseline BSRT z-score and atypical 
antipsychotic type as forced entries, showed that smaller IFG grey matter volume 
was predictive of higher BSRT score at 6 weeks in patients [Q = . -466; t=-2.792, 
rp = -. 585, p= . 014], accounting for 21% of the variance in 6-week scores. The 
regression model including the baseline score, atypical antipsychotic type, and 
the IFG grey matter volume accounted for 51% of the variance in 6-week scores 
[R2 = . 506, F(1,18) = 3.799, p= . 003]. 
To ascertain that the relationship between smaller IFG volume and greater BSRT 
performance improvement is not simply due to the ceiling effect, the patients 
were divided using the median split into two sub-groups: No change (n =11, 
mean change = . 01, sd = . 47) and Change 
(n = 8, mean change = 1.60, sd = 
. 78). There was no significant difference in the 
baseline scores between Change 
(mean = -1.64, sd = . 62) and No change (mean = -1.33, sd = . 
94) sub-groups 
using an independent-samples t-test [F(1,17) = . 831, p= . 417], with a significant 
difference at 6 week (Change: mean = -. 004, sd = 1.02; No change: mean =- 
1.27, sd = . 71) [t(17) = -3.126, p =. 006]. 
Therefore, the relationship between 
smaller IFG grey matter volume and greater BSRT improvement could not be 
explained by the ceiling effect. Figure 8.5 illustrates the relative performance on 
BSRT by Change and No change sub-groups. 
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FIGURE 8.5. The plot of BSRT performance in patients who showed and did not show 
























11 no change 
11 change 
6 weeks 
An improvement of 1.57 sd was observed in patients after 6-week treatment with 
atypical antipsychotics on the measure of verbal working memory Letter-Number 
Test, which was significant after the Bonferroni correction [F(1.19) = 41.429, p= 
. 0004]. The time by atypical antipsychotic type interaction was not significant (p 
= . 419), indicating no differential effect of atypical antipsychotics on this 
cognitive function. (See Figure 8.6 illustrating the mean change in z-scores for 
patients treated with olanzapine, risperidone, or quetiapine). 
Figure 8.6. Plot of LNT performance change in mean z-scores from the baseline to 6 weeks 
in patients treated with olanzapine, risperidone, or quetiapine 
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An improvement in patients was significantly greater than what would be 
expected due to the normal practice effect, as evidenced by the significant time 
by group interaction of a mixed-model ANOVA, with the baseline and 6 weeks as 
the within-subject factor, and patients vs. normal controls as the between-subject 
factor [F(1,43) = 28.657, p= . 0003]. There was also a significant between-group 
main effect [F(1,43) = 32.094, p =. 0001]. Post hoc between-group contrasts using 
independent-samples t-tests showed significant group differences after the 
Bonferroni correction (p = . 025) at both the baseline [t(43) = -6.997, p= . 0007] 
and 6-week [F(43) = -3.085, p= . 004] assessments, suggesting that the 
performance improved but did not normalise at 6 weeks in the patient group. 
However, when the between-group difference in IQ level was controlled for, the 
difference between patients and controls was no longer significant at 6 weeks [p 
= . 117], 
but remained significant at the baseline [F(1,42) = 31.428, p= . 0002]. 
No significant structural predictors of the 6-week LNT scores were found using 
stepwise multiple linear regression, with the baseline LNT scores as a covariate. 
Grooved Peg Board 
An improvement of 1.36 sd was observed in patients after 6-week treatment with 
atypical antipsychotics on the measure of dexterity, GPB. A mixed-model ANOVA 
with time (baseline vs. 6 weeks) and atypical antipsychotic type (olanzapine, 
risperidone, or quetiapine) showed a significant main effect of time at 5% level, 
but not significant with the Bonferroni correction [F(1,19) = 6.184, p= . 023]. 
There was no significant time by atypical antipsychotic type interaction [F(l. 19) = 
1.744, p=. 203], suggesting no differential effect of atypical antipsychotics with 
the present sample size. As can be seen from Figures 8.7. and 8.8., presenting 
the graph and the scatterplot of the performance change in three sub-groups, 
the improvement was not uniform across groups, with only olanzapine sub-group 
showing improvement. However, patients treated with olanzapine had worse 
performance at the baseline, levelling up with the other two sub-groups after 6 
weeks of treatment. 
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FIGURE 8.7. The plot of GPB performance 
change in mean z-scores* from the baseline to 
6 weeks for patients treated with olanzapine, 

























FIGURE 8.8. The scatterplot of z-scores 
change* in GPB performance for patients 









* Lower mean indicates better performance 
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Quetiapine Risperidone Olanzapine 
* Lower change score indicates greater 
improvement 
An improvement in patients was significantly greater than what would be 
expected due to the normal practice effect, since there was a significant time by 
group interaction of a mixed-model ANOVA, with time (baseline vs. 6 weeks) as 
the within-subject factor, and group (patients vs. normal controls) as the 
between-subject factor [F(1,43) = 6.776, p= . 013]. There was also a significant 
between group main effect [F(1,43) = 18.353, p =. 0001]. Post hoc between-group 
contrasts using independent-samples t-tests with the Bonferroni correction (p = 
. 025) showed significant between-group differences at both baseline 
[t(43) = 
3.907, p= . 0003] and 6-week [t(43) = 3.851, p= . 0004] assessments, suggesting 
that the performance improved but did not normalise at 6 weeks in the patient 
group. The between-group differences at the baseline and 6 weeks remained 
significant after controlling for the group differences in IQ [baseline: F(1,42) _ 
6.840, p= . 012; 6 weeks: F(1,42) = 5.979; p= . 
019]. 
Stepwise multiple linear regression analysis revealed no significant structural 
brain volume predictors of 6 week GPB performance, after taking the baseline 
performance as a covariate. 
8.3.2.4. Effect of Atypical Antipsychotics on Symptoms 
PANSS Positive Symptoms 
Positive symptom ratings decreased from the mean of 17.5 (sd = 6.94) to the 
mean of 13.47 (sd = 5.25) from the baseline to 6 weeks. A mixed-model ANOVA, 
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with time (baseline vs. 6 weeks) as a within-subject factor and atypical 
antipsychotic type (olanzapine, risperidone, or quetiapine) as a between-subject 
factor, revealed a significant main effect of time [F(1,21) = 5.673, p= . 028], with 
no significant time by antipsychotic type interaction [p = . 962], suggesting that 
the positive symptoms ratings improved in patients regardless of which atypical 
antipsychotic they were treated with. 
PANSS Negative Symptoms 
There was no mean change in negative symptom ratings in patients as a group 
(baseline mean = 17.38, sd = 5.69; 6 weeks mean = 17.00, sd = 5.95). A 
mixed-model ANOVA, with time (baseline vs. 6 weeks) as a within-subject factor 
and atypical antipsychotic type (olanzapine, risperidone, or quetiapine) as a 
between-subject factor, revealed no significant main effect of time [p = . 794], 
with a trend for a time by antipsychotic type interaction [F(1,21) = 3.198; p= 
. 065], suggesting a differential effect of atypical antipsychotics on negative 
symptoms. As can be seen from Figure 8.9, only patients treated with quetiapine 
showed a reduction in PANSS negative symptoms ratings. Risperidone sub-group 
appears to have worsened, whereas olanzapine group showed no change. 
FIGURE 8.9. The plot of PANSS negative symptom ratings at baseline and 6 weeks for 
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There was a decrease in PANSS general psychopathology ratings in patients as a 
group from the baseline (Mean = 37.64, sd = 9.62) to 6 weeks (Mean = 33.05, 
sd = 7.61). A mixed-model ANOVA, with time 
(baseline vs. 6 weeks) as a within- 
subject factor and atypical antipsychotic type (olanzapine, risperidone, or 
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quetiapine) as a between-subject factor, revealed a trend for the main effect of 
time [F(1,21) = 3.868, p= . 065], with no significant time by antipsychotic type 
interaction [p = . 405], suggesting that the general psychopathology ratings 
improved in patients regardless of atypical antipsychotic type. 
AIMS 
There was a decrease in the ratings of abnormal involuntary movements as 
measured by AIMS from the mean of 2.33 (sd = 3.47) at the baseline to the 
mean of 1.14 (sd = 1.80) at 6-weeks assessment. However, the improvement 
was not statistically significant using a mixed-model ANOVA [p = . 117], with no 
significant time by antipsychotic type interaction [p =. 567]. 
Barnes Akathisia Rating Scale 
There was a slight decrease in akathisia ratings as measured by BARS from the 
mean of 3.63 (sd = 3.25) to the mean of 2.63 (sd = 2.98). However, it was 
insignificant using a mixed-model ANOVA [p = . 311], with no significant time by 
antipsychotic type interaction [p = . 242]. 
Simpson Angus Rating Scale 
There was no change in the ratings of parkinsonism as measured by SARS from 
the mean of 2.85 (sd = 2.25) to the mean of 2.89 (sd = 2.23). A mixed model 
ANOVA showed no significant main effect of time [p = . 376] and no time by 
atypical antipsychotic type interaction [p = . 730]. 
8.3.2.5. Relationship between Cognitive and Symptomatic Improvement 
Stepwise multiple linear regressions with 6-week neuropsychological scores as 
the dependent variable, and with the baseline neuropsychological score as a 
covariate (forced entry) showed that the change (expressed as the percentage of 
change with respect to the baseline ratings) in PANSS positive symptoms or 
general psychopathology ratings were not predictive of cognitive improvement 
with atypical antipsychotics. 
8.3.2.6. Relationship between Cognitive Improvement and Side-effects 
Change 
Although there was no statistically significant improvement in motor, 
neurological, and autonomic symptoms, the change on AIMS, BAS and SARS was 
evaluated in relation to cognitive improvement to ascertain that cognitive 
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improvement was not simply due to the change in side-effects. Stepwise multiple 
linear regressions with 6-week neuropsychological scores as the dependent 
variable, and with the baseline neuropsychological score as a covariate (forced 
entry) showed that the change (expressed as the percentage of change with 
respect to the baseline ratings) in AIMS, BAS, or SARS ratings were not predictive 
of cognitive improvement with atypical antipsychotics. 
8.3.2.7. Relationship Between Structural Alterations and Symptom 
Improvement 
The predictive value of structural alterations was evaluated in relation to the 
improvement in positive and general psychopathology symptoms. Stepwise 
multiple regressions with 6 weeks symptoms scores as the dependent variable 
and global and regional structural volumes as predictors, with baseline symptoms 
scores as covariates showed that greater decrease in positive symptoms was 
associated with smaller precuneus [ß = . 570; t=3.066, rp = . 586, p= . 007], 
accounting for 31% of the variance in 6-week scores. The regression model 
including the baseline score, and the precuneus volume accounted for 40% of the 
variance in 6-week scores [R2 = . 400, F(2,18) = 6.010, p= . 010]. 
8.4. Discussion 
The aim of the present study was to explore the validity of structural alterations 
as predictors of cognitive improvement with atypical antipsychotics. It was 
predicted that the patients would perform better on neuropsychological tests after 
being treated with atypical antipsychotics for a period of 6 weeks as compared 
with their performance on conventional antipsychotics. Greater cognitive 
improvement was hypothesised to be associated with less altered global and/or 
regional brain volumes. 
The improvement was observed on four cognitive domains: immediate verbal 
memory (HVLT), verbal learning (BSRT), verbal working-memory (LNT), and 
dexterity (GPB). Verbal working memory improved by more than 1.5 sd in 
patients as a group, dexterity by 1.36 sd, whereas the improvement on 
immediate verbal memory and learning was more modest: . 77 and . 70 sd 
respectively, but all were significantly greater than practice effects observed in 
normal controls. The improved performance on LNT and BSRT approached normal 
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levels, after the differences in premorbid IQ between patients and controls were 
taken into account. 
Greater improvement in immediate verbal memory was predicted by smaller 
volume of the precuneus. Although this finding is in accordance with the 
prediction that less altered structural volumes will be predictive of greater 
improvement, it is somewhat difficult to reconcile with the fact that larger 
precuneus was predictive of better verbal learning at baseline as found in Study 2 
(Chapter 7). This relationship between HVLT performance change and precuneus 
volume could not be explained by the ceiling effect. The median split into sub- 
groups of patients who did and did not improve after 6 weeks of treatment 
showed that patients who improved had worse performance at the baseline, but 
outperformed the patients who did not change at the follow up, approaching 
normal control level (see Figure 9.2). These findings suggest that although 
patients with smaller precuneus perform worse than patients with larger 
precuneus whilst treated with conventional antipsychotics, they experience 
greater benefits from atypical antipsychotics for immediate memory function. 
Interestingly, smaller precuneus was associated with greater reduction in positive 
symptoms. One of the findings of Study 1 (Chapter 5) was the association 
between larger precuneus and greater number of previous psychotic episodes. 
Therefore, it is possible that patients with larger precuneus might have treatment 
resistant positive symptoms that do not respond to either conventional or atypical 
antipsychotics. Somehow, however, larger precuneus in these patients allows 
them better episodic memory. Patients with smaller precuneus on the other 
hand, have benefited more from the atypical antipsychotic treatment, both in 
terms of psychotic symptom reduction and in terms of verbal memory 
improvement. Although psychotic symptoms and verbal memory dysfunction did 
not correlate, suggesting no causal relationships between them, they might be 
underlined by the same structural abnormality, namely precuneus enlargement, 
which, speculatively, results in greater vividness or salience of one's mental 
experiences, leading to better episodic memory, but predisposing to reality 
distortion in schizophrenia patients. 
Greater improvement in verbal learning was predicted by smaller IFG volume. 
The direction of this relationship is contrary to the expectation, and could not be 
attributed to the ceiling effect. One possible interpretation of this finding is that 
patients with smaller IFG volume had greater severity of secondary negative 
symptoms induced by conventional antipsychotics, which were elevated when 
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they were switched to atypical antipsychotics, leading to better performance at 
the follow up. However, the results do not support this interpretation, since there 
was no association between IFG volume, negative symptoms ratings, and verbal 
learning performance either at the baseline or after the switch. Previous studies 
(Friedman et al., 1991; Molina et al., 2003a) reported positive associations 
between the measures of PFC integrity and volume and symptomatic 
improvement with clozapine. It is possible that the difference in the direction of 
associations between structural and functional variables in the previous and 
present studies is due to the difference in the assessed function, i. e. symptomatic 
vs. cognitive. The measure of the symptomatology, although susceptible to the 
investigator's bias, is exempt to practice effects. Cognitive performance, on the 
other hand, is a subject to many potential confounds, such as rapport with the 
experimenter, motivation, performance anxiety, understanding of the 
instructions, etc. It is possible to speculate that patients with larger IFG volume 
have performed to the best (or near the best) of their ability at the baseline, due 
to better executive functioning affording them greater `adaptability' to the 
cognitive testing setting, and thus did not have much room for improvement at 
the follow-up. Patients with smaller IFG volume, on the other hand, might have 
had confounding factors affecting their performance at the baseline, such as 
difficulty in adjusting to the novel testing situation, understanding the 
instructions, etc. Against this suggestion, however, is the fact that IFG volume 
was not predictive of the improvement on other neuropsychological tests that 
would be dependent on its function, which would be subjects to similar influences. 
Pharmacologically, it is difficult to interpret why patients with smaller IFG volume 
would benefit from the atypical antipsychotic treatment, whereas patients with 
larger IFG volume would not. Studies are needed to replicate or refute the 
finding of the present investigation before an understanding can be reached. The 
improvement in verbal working memory (LNT) or dexterity (GPB) was not related 
to either global or regional structural brain volumes. 
The improvement in all four cognitive domains was independent of the change in 
psychopathology as measured by PANSS or side effects as measured by AIMS, 
BAS, and SARS, suggesting a direct effect of atypical antipsychotics on cognitive 
deficits in schizophrenia. 
Cognitive improvement with atypical antipsychotics in the present study was 
observed despite relatively low doses of haloperidol as a comparator. One of the 
ongoing controversies in relation to atypical antipsychotics superiority on 
cognition relative to typical antipsychotics is whether their effects can be 
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demonstrated relative to low doses of haloperidol. Traditionally high doses of 
haloperidol in clinical practice have little benefit or even a detrimental effect on 
cognitive function (Blyler and Gold, 2000). However, more recent studies 
investigating the effect of low doses of typical antipsychotics indicated that they 
might not have detrimental effects on cognition as traditional doses, with atypical 
antipsychotics showing no superiority over lower doses of typical antipsychotics 
(Green et al., 2002; Keefe et al., 2004). Therefore, cognitive superiority of 
atypical antipsychotics medication was called into question. Do atypical 
antipsychotics actually improve cognition or do they simply "afford a release from 
the deleterious effects, such as extrapyramidal symptoms (EPS), of 
inappropriately large doses of typical antipsychotics and concomitant adjunctive 
agents such as anticholinergics"? (Keefe et al., 2004; see also a debate on this 
issue between Meltzer & Sumiyoshi, 2003 and Carpenter & Gold, 2003). The 
results of the present study suggest that atypical antipsychotics effects on 
cognition could not be explained simply by the typical antipsychotic dose, since 
patients in the present study were on low doses of conventional medications, 
which were comparable to those used in Keefe et al. (2004) study. Neither they 
can be explained by the reduction in motor disorders associated with conventional 
antipsychotics, since, as discussed above, the motor side effect ratings were 
initially low and no further ascertainable change occurred. The discontinuation of 
anticholinergic medication might have played a role, since none of the patients 
required anticholinergic medication with atypical antipsychotics at 6 weeks. 
However, anticholinergic medication was only found to associate with LM 
performance in Study 2 (Chapter 6), but not with the tests that showed 
improvement in the present study. Cognitive efficacy of atypical antipsychotics is 
likely to be a combination of their pharmacological properties and release of 
typical medication deleterious effects. 
It is interesting to note that the cognitive functions that have improved the most 
with atypical antipsychotic treatment included those that differentiated most 
reliably between schizophrenia patients and normal controls in Study 2 (Chapter 
6), namely verbal working memory and learning. Both functions depend to some 
extent on the dorsolateral prefrontal cortex. Improvement in these functions 
might be due to the increased dopaminergic transmission in DLPFC attributable to 
serotonin-dopamine antagonism of atypical antipsychotics. Further, verbal 
working memory and learning are closely linked to the function of cholinergic 
system (Friedman et al., 1999). Conventional antipsychotics have consistently 
been shown to impair verbal learning due to the anticholinergic action and the 
need for anticholinergic medication to reduce EPS (Keefe et al., 1999). Previous 
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studies have found olanzapine, risperidone, and quetiapine to improve verbal 
working memory and learning, although the effect size for risperidone and 
quetiapine was found to be larger than that for olanzapine (Meltzer and McGurk, 
1999). In the present investigation, patients treated with quetiapine and 
risperidone showed greater improvement in verbal learning than patients treated 
with olanzapine, with the difference between quetiapine and olanzapine sub- 
groups approaching significance. The absence of anticholinergic properties of 
risperidone and quetiapine might account for their greater efficacy on verbal 
learning than conventional antipsychotics or olanzapine. Due to its cholinergic 
properties, olanzapine did not produce as substantial increase in verbal working 
memory and learning as compared with conventional medication, but it did not 
have a detrimental effect either due to its dual serotonin-cholinergic antagonism 
(as discussed in Chapter 3 of General Introduction, serotonin antagonism can 
alter anticholinergic effects). Thus, the limited sample of the present study 
provides further evidence that risperidone and quetiapine might have greater 
positive effect on verbal learning in schizophrenia than olanzapine. There was no 
evidence for the differential effect of three antipsychotics on other cognitive 
domains assessed in the present study. However, no firm conclusions can be 
drawn from the results of the present study in relation to the possible differential 
effect of three atypical antipsychotics on cognitive functioning in schizophrenia 
due to a very small sample size of the sub-groups. 
The patients as a group showed improvement in positive symptoms and general 
psychopathology ratings, but not negative symptoms, as compared with 
haloperidol (the baseline). The results for negative symptoms indicated 
differential effect of three drugs, with quetiapine producing an improvement, 
olanzapine having no effect, and risperidone leading to worsening relative to the 
haloperidol baseline. Previous studies of risperidone did not observe such a 
detrimental effect of risperidone on negative symptoms, generally observing 
improvement in both positive and negative symptomatology compared to 
haloperidol (e. g. Gelders et al., 1990; Claus et al., 1992; Lindstrom et al., 1995; 
Jeste et al., 1997; meta-analysis: Glick et al., 2001). One recent study observed 
no improvement (Lindenmayer et al., 2004), whereas the result of another study 
(Marder and Meibach, 1994) suggested that negative symptom improvement 
might be specific to 6mg and 16mg of risperidone. The dose of risperidone in the 
present study was 2 mg, which was not found to be more effective for negative 
symptoms than treatment with haloperidol (Marder and Meibach, 1994). In a 
recent review of clinical efficacy of atypical antipsychotics in schizophrenia, 
risperidone, olanzapine, and quetiapine were 
found to have equal effect on 
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positive and negative symptomatology (Serretti et al., 2004). Therefore, the 
results of the present study suggesting differential effect of three atypical 
antipsychotics on negative symptoms might be due to the low dose of risperidone 
as well as small sample size producing spurious findings. In addition, patients in 
olanzapine sub-group had greater severity of negative symptoms (average score 
of around 20 points as compared with 16 points for quetiapine and risperidone), 
which might have biased the assessment of the effect of olanzapine on negative 
symptoms unfavourably. 
The findings in relation to test-retest reliability of the neuropsychological 
measures in normal controls indicate that HVLT and Stroop interference might not 
have as high reliability as would be desirable for repeated testing. This finding 
casts doubts on the observed improvement on HVLT performance in 
schizophrenia patients, which might be a result of low reliability of this measure. 
It should be noted, however, that the improvement was observed in patients 
treated with three different antipsychotics to the same extent, indicating a 
systematic effect, rather than a spurious one. 
More generally, the estimation of practice effect for the neuropsychological 
measures from healthy controls may not be adequate for the evaluation of the 
cognitive efficacy of atypical antipsychotics due to the fact that practice effects 
in schizophrenia are poorly understood (Beglinger et al., 2003). Therefore, to 
exclude the possibility that the improvement on neuropsychological measures 
observed in the present study is not simply due to low performance stability in 
patients, a control group of patients on conventional medications would have 
been desirable in the present study. This would have allowed estimating practice 
effects in schizophrenia patients (albeit confounded by the use of conventional 
medication). However, there were practical limitations preculiding the use of 
such patient control group, due to difficulty in recruiting patients that are 
maintained on conventional antipsychotics. It should be noted, however, that a 
none of the tests in the present study showed negative change, and that other 
tests on which performance have improved in patients showed high test-retest 
reliability and small practice effect in normal controls. Therefore, the results of 
the present study are unlikely to be fully explained by such possible confounds. 
To conclude, the strengths of the present study were (i) within-subject design; ii) 
(ii) normal control group allowing for estimation of test-retest reliability practice 
effects; and (iii) low doses of conventional antipsychotics as a comparator. 
Improvement with atypical antipsychotics was found on the tests of verbal 
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memory and learning, verbal working memory, and dexterity. Contrary to the 
expectation, cognitive improvement on verbal immediate memory and verbal 
learning was predicted by smaller structural volumes of the precuneus and the 
IFG respectively. Improvement in verbal working memory and dexterity was not 
predicted by either global or regional structural volumes or change in 
psychopathology and/or side effects. 
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CHAPTER 9. GENERAL DISCUSSION 
9.1. Chapter Overview 
This chapter summarises and integrates the findings of the empirical 
investigations described in this thesis and attempts to place them in the context 
of the previous research. First, the aims and the theoretical underpinnings are 
reviewed, followed by the summary of the key findings. Further, the implications 
of the key findings for the schizophrenia research are outlined. Finally, 
methodological considerations and suggestions for future research are made. 
9.2. The Overview of the Aims and Hypotheses 
The main theoretical underpinning of the present investigation is that structural 
volume abnormalities characteristic of schizophrenia underlie its functional 
dysfunction, manifesting, amongst other things, as cognitive deficits, which can 
be quantified by the standard neuropsychological tests. These cognitive deficits 
are known to affect social, occupational, and personal success of individuals with 
schizophrenia and, therefore, became one of the treatment targets. Atypical 
antipsychotics are thought to have ameliorating effect on cognitive deficits as 
compared to conventional or typical antipsychotics. Therefore, the general aims 
of the present investigation were: 
1) to quantify structural volume alterations in schizophrenia using a state-of- 
the-art automatic method of voxel-based morphometry, which surpasses 
the limitations of the traditional manual region of interest approach (see 
section 2.2.1); 
2) to investigate the relationship of these structural volume alterations to 
the cognitive deficits as quantified by standard neuropsychological tests; 
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3) to explore the value of the structural volume alterations in predicting 
treatment response to atypical antipsychotics in terms of cognitive 
improvement. 
To these aims, four experimental studies were conducted. The research problem, 
the aim, and the hypotheses of each study are summarised next. 
9.2.1. Study 1: Structural Alterations in Schizophrenia: A Voxel-Based 
Morphometry Study 
The aim of the first study was to identify the pattern of structural alterations in 
schizophrenia patients using the VBM technique. Currently, there are two main 
pre-processing protocols used for VBM: `standard' and 'optimised'. The optimised 
protocol involves many more steps compared to the standard protocol, one of 
which is the construction of the study specific (i. e. based on the study's sample) 
template for the normalisation and segmentation of the brain images. Although 
theoretically optimised protocol should yield superior segmentation of the brain 
into its constituting tissue types, i. e. grey, white, and CSF, it has not been tested 
directly in a clinical population as to whether optimised protocol presents an 
advantage over more concise and hence less time consuming standard protocol. 
Therefore, the aims of Study 1 were twofold: 
1) To identify a pattern of structural alterations in schizophrenia population 
using VBM method; 
2) To compare standard and optimised VBM protocols in schizophrenia 
population in terms of tissue segmentation accuracy. 
It was hypothesised that: 
1) Patients with schizophrenia would have global and regional structural 
volume alterations. Apart from the regional alterations extensively studied 
with the ROI approach, such as STG, hippocampus, and basal ganglia 
(reviewed in Chapter 2), patients were hypothesised to have alterations of 
IFG grey matter volume, which have been relatively consistently identified 
in previous VBM studies, as well as brain regions thus far neglected by ROI 
studies, such as parietal and occipital cortex. No reduction of white matter 
volume was predicted since it is not found as consistently as that of the 
grey matter. 
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2) Optimised protocol would result in superior tissue segmentation compared 
with standard protocol. 
A secondary aim of the study was to investigate the inter-relationships 
between structural volume alterations in schizophrenia and compare them 
with controls. This research question was motivated by the suggestions of the 
previous research that normal volumetric associations between different 
regions and structures of the brain might be altered in schizophrenia. Based 
on the previous research, it was hypothesised that schizophrenia patients will 
present with fronto-temporal dissociation, such that frontal and temporal 
volumes will be positively correlated in normal controls but not in patients. 
9.2.2. Study 2: Cognitive Deficits in Schizophrenia 
The primary aim of the second study was to ascertain the presence of cognitive 
deficits in the cohort of patients recruited for the present investigation. To this 
end, a neuropsychological battery was designed. All tests selected are 
standardised neuropsychological measures that have been consistently applied to 
assess neuropsychological deficits in schizophrenia population. The choice of the 
tasks has been motivated by the need to cover those cognitive domains that: 
(i) have been shown to be central to the cognitive impairment in 
schizophrenia; 
(ii) have a direct link with function outcome; 
(iii) have been found to correlate with structural measures in the ROI 
studies; 
(iv) are known to be unaffected or worsened by conventional 
antipsychotics; and are likely to be sensitive to pharmacological 
changes induced by atypical antipsychotics; 
The battery taps into neurocognitive processes of verbal working memory, 
executive function, immediate and delayed memory and learning, immediate 
visuo-spatial memory, verbal fluency, sustained and selective attention, speed of 
information processing, and fine motor function. 
It was hypothesised that patients will have deficits on all cognitive domains, with 
the most severe impairment on the tests of verbal memory and learning, as has 
been found by the previous research (see Chapter 2). Further, cognitive deficits 
were expected to be independent of symptomatology. 
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9.2.3. Study 3: Relationships between Structural Alterations and 
Cognitive Deficits 
Chapter 2 reviewed comprehensively ROI studies investigating the relationship 
between structural and cognitive variables in schizophrenia. As has been 
discussed in the chapter, most ROI studies noted discrepancies in the 
structure/neurocognition relationships between patients and controls. The 
differences in structure/neurocognition correlations between the groups were of 
two sorts: i) those specific to schizophrenia patients (i. e. not seen in controls), 
and ii) those lacking in patients (i. e. significant in controls, but are not observed 
in patients). It is not clear, however, whether these differences pertain to 
statistical artefacts (i. e., different ranges of structural volumes and 
neuropsychological performance resulting in different correlation strength) or 
whether they reflect altered structure/neurocognition relationship in 
schizophrenia. Furthermore, only one study (Flaum et al., 1996) has formally 
tested the differences in the correlations between patients and controls 
statistically. Therefore, it is not currently clear whether the observed 
discrepancies significantly differentiate patients and controls. Finally, previous 
studies have not made an explicit distinction between the investigations of 
structural alterations/neurocognitive deficits relationships vs. 
structure/neurocognition relationships. 
Study 3 was conducted to clarify these issues. It has utilised the VBM method for 
its power to identify localised tissue availability alterations throughout the entire 
brain with the aim to investigate whether: i) structural volume alterations are 
associated with cognitive deficits that are most characteristic of schizophrenia 
patients and ii) the structure/neurocognition relationship in schizophrenia is 
significantly altered in relation to healthy individuals. Note that the aim of the 
study was to investigate specifically the role of structural alterations (not 
structural volumes per se) in cognitive deficits in schizophrenia. 
It was hypothesised that: (i) structural volume alterations identified in study 1 
would be associated with cognitive deficits identified in study 2; (ii) there would 
be structure/cognitive relationships specific to schizophrenia; and (iii) there would 
be structure/cognitive relationships lacking in patients. More specific hypotheses 
as to the relationship between structural volumes and cognitive deficits were 
made in the Method section of Study 3 where previous findings on structural 
alterations/cognitive deficits were summarised. 
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9.2.4. Study 4: Structural Alterations as Predictors of Treatment 
Response to Atypical Antipsychotics 
The first line of treatment for schizophrenia is pharmacological intervention with 
antipsychotic medication. New generation of antipsychotic drugs have greater 
efficacy in treating cognitive deficits, which, as discussed in Chapter 3, are better 
predictors of functional outcome, than conventional drugs. 
Three most commonly applied drugs in clinical practice, risperidone, qutaipine, 
and olanzapine, share the main pharmacological property, namely dopamine- 
serotonin antagonism, which seems to underlie their greater cognitive efficacy. 
The aim of this study was to investigate the validity of structural brain alterations 
(identified in Study 1) in predicting cognitive improvement after 6 weeks of 
treatment. 
It was hypothesised that greater severity of structural alterations, both global and 
local, would be predictive of poorer response to atypical antipsychotics in terms of 
cognitive improvement following 6 weeks of treatment. 
9.3. Summary of the Key Findings 
The key findings of the investigations conducted to assess the above hypotheses 
are as follows. First, optimised VBM protocol had superior registration to the 
standard one and revealed both global and regional reductions of grey and white 
matter in schizophrenia patients. Regional alterations were specific to the left 
hemisphere and included significant reduction of the IFG and STG grey matter 
volume, a trend for white matter volume reduction of parietal and occipital lobes, 
and a trend for grey matter volume increase in the putamen and the precuneus. 
Contrary to the prediction and the findings of previous studies, the patients did 
not show fronto-temporal dissociation. Second, patients displayed cognitive 
deficits on all domains assessed, with the particular impairment on the tests 
requiring verbal function, including verbal learning and memory, verbal working 
memory, and verbal fluency. Deficits of working memory and learning, and speed 
of information processing differentiated patients and controls most reliably. 
Third, there were a number of associations between structural volume alterations 
and cognitive deficits in patients, some of which were specific to patients. 
Patients also lacked a number of association observed in controls. Specifically, 
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smaller global brain volume was associated with poorer phonological verbal 
fluency; smaller grey matter volume was associated with lower premorbid IQ and 
poorer dexterity, with the later association being specific to patients. Enlarged 
precuneus was associated with better verbal learning in patients, with this 
relationship being specific to schizophrenia. The function of verbal learning as 
well as verbal and non-verbal memory was associated with the volume of IFG 
significantly stronger in controls than in patients. This dissociation between two 
groups in terms of the regional structural volume/memory and learning 
relationship was perhaps the most striking finding. Larger volume of the 
precuneus was associated with poorer verbal working memory in controls, 
significantly differentiating them from patients. The deficits in the speed of word 
reading and colour naming in patients were associated with the reduced white 
matter volume of the occipital lobe, whereas these structure/cognition 
relationships were not observed in controls. Fourth, patients showed 
improvement in verbal memory and learning, verbal working memory, and 
dexterity after 6-week treatment with atypical antipsychotics. However, contrary 
to the prediction, cognitive improvement was not associated with larger brain 
volumes. Instead, smaller IFG volume was found to be predictive of greater 
improvement in verbal learning, whereas smaller precuneus was found to be 
predictive of greater improvement in immediate verbal memory. 
9.4. Implication of the Key Findings for Schizophrenia Research 
9.4.1. Structural Alterations 
The present thesis adds to the weight of the evidence for the existence of 
structural volume alterations in individuals diagnosed with schizophrenia (e. g. 
Shenton et al., 2001, Chapter 2). Characteristically, regional alterations in the 
present cohort were restricted to the left hemisphere. There was a cluster of grey 
matter volume reduction observed in the right IFG, but it was not significant with 
the statistical criteria for the VBM method adopted in the present study and 
elsewhere (e. g. Wright et al., 1995; Wilke et al., 2000; Ananth et al., 2002). The 
observed left hemisphere alterations were present in patients as a group 
regardless of their age, gender, or global tissue volumes. The pattern of the 
alterations of the grey matter volume was widespread, affecting primarily cortical 
heteromodal association areas, such as IFG, anterior STG, and the precuneus, but 
also primary sensory area of the visual cortex, and sub-cortically putamen. 
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Patients with family history of schizophrenia were found to have smaller STG 
volume than patients with no family history. It is possible that in patients with 
genetic loading STG volume reduction might represent a neurodevelopmental 
anomaly with possible further degeneration following the illness onset. The 
possible difference in STG volume in familial and non-familial schizophrenia 
should be investigated further. 
Compared with other VBM studies, the patients of the present cohort had 
relatively few structural alterations relative to normal controls, restricted to the 
left hemisphere. Most VBM studies observed bilateral alterations of tissue 
density and volume (e. g. Wright et al., 1999; Wilke et al., 2001; Ananth et al., 
2002; Job et al., 2002). One study (Suzuki et al., 2002) observed predominantly 
left hemisphere grey matter density reductions in schizophrenia males, including 
that of medial frontal and superior temporal gyri, but right hemisphere grey 
matter density reduction in schizophrenia females, including that of superior and 
medial frontal gyrus. It is possible that right IFG reduction in the present cohort 
was mediated by gender, and therefore did not attain significance, since the 
gender was controlled for in the analysis. Although bilateral reductions were 
noted in the majority of the studies, left hemisphere tended to be affected more 
severely, with more altered regions and with the alterations having greater 
spatial extent (i. e. greater number of voxels in the cluster of altered brain tissue) 
than those observed in the right hemisphere. Many ROI studies of schizophrenia 
patients have also noted predominantly left hemisphere abnormalities in right- 
handed subjects, particularly in the lateral and medial temporal lobe structures 
(e. g. Barta et al., 1990; Bogerts et al., 1990; Shenton et al., 1992; Wible et al., 
1995; Velakoulis et al., 1999; Kwon et al., 1999). The right hemisphere, 
especially the temporal area, develops earlier than the left for a short period of 
time, which may result in it being less likely to be impaired (Gerschwind and 
Galaburda, 1985). Therefore, the period of vulnerability is more prolonged on the 
left, which could make it more prone to injuries. It is, however, unknown whether 
disturbances in the left hemisphere are related to genetic or environmental 
factors. The study by Reveley and colleagues (1987) of eleven monozygotic twin 
pairs discordant for schizophrenia and 18 control monozygotic twin pairs using CT 
revealed that the left hemisphere was less dense than the right in twins with 
schizophrenia, while the reverse was found for the co-twins and controls. These 
results suggest that left hemisphere abnormality is environmentally acquired, 
rather than a genetic trait. In any case, if there were an insult to the fetal brain 
in the process of neurodevelopment, environmental or otherwise, the left 
hemisphere would be more prone to disruption, which could possibly be related to 
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the pathogenesis of schizophrenia. It should be born in mind, however, that many 
of the key areas implicated in schizophrenia, including sub-regions of the PFC, 
lateral and medial temporal lobe structures, basal ganglia, sub-regions of the 
parietal lobe and others were found to be affected bilaterally in some studies (e. g. 
Baare et al., 1998; Wright et al., 1999; Cannon et al., 2002). 
The most pronounced reduction of the grey matter volume in the present cohort 
was observed in the IFG and anterior STG. The volume reduction of these areas 
was also correlated in patients. As has been discussed in Chapter 5, these areas 
are related structurally and functionally, representing a part of a neuronal circuit 
associated with semantic processing and memory (e. g. Binder et al., 1997; Rao 
et al., 1997; Mummery et al., 1999). The studies of language disturbance in 
schizophrenia patients showed that semantic domain is more prominently deviant 
than phonological or syntactic (review, DeLisi, 2001). Study 2 (Chapter 6) found 
the most severe performance deficits in schizophrenia patients on the tests 
requiring semantic processing, comprehension, and production. As other studies, 
the present investigation observed greater deficits in semantic than phonological 
verbal fluency. Further, patients with familial history of schizophrenia had 
significantly greater reduction of the anterior STG than patients without family 
incidences. Previous studies (e. g. Condray et al., 1992; Goldberg et al., 1995; 
Niendam et al., 2003) showed that disturbances in semantic system are also 
apparent in unaffected relatives of schizophrenia probands. Moreover, as 
discussed before (Study 1, Chapter 5), the reduction of the anterior STG volume 
distinguishes patients with schizophrenia from those with bipolar disorder 
(Pearlson, 1997). Taken together, these findings suggest that abnormal structure 
and function of the semantic system might represent an endophenotype and a 
risk factor for schizophrenia. 
As discussed in Chapter 5, previous studies investigating the inter-relationships 
between the volumes of different brain structures in schizophrenia reported 
conflicting results as to the relationship between PFC and STG. Specifically, 
whereas Wible et al. (1995) observed significant positive correlations between the 
volumes of left PFC grey matter and anterior STG (as well as anterior medial 
temporal lobe structures) in schizophrenia patients but not in normal controls, 
Woodruff et al. (1997b) reported a dissociation between the total volumes of PFC 
and STG in patients with the relationship being significant in normal controls. The 
present investigation (Study 1, Chapter 5) has found the grey matter volumes of 
IFG and anterior STG to correlate to a similar extent in both patient and control 
groups. The differences in measurements, such as total versus grey matter 
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volume, or anterior/posterior STG versus total STG volume, might contribute to 
the differences in the findings between the studies. Due to the substantive 
structural and functional connections between PFC and STG, it is likely that the 
development of these brain regions is temporary related. Inter-relationship 
between different brain regions is poorly understood in healthy as well as 
abnormal development. Establishing whether there is dissociation or increased 
association between the volumes of these brain regions in schizophrenia patients 
relative to healthy individuals might be important for understanding the 
pathogenesis of schizophrenia. For example, the primary abnormality in the 
anterior STG due to genetic factors, as suggested by the greater reduction of this 
region in patients with family history of schizophrenia, might result in abnormal 
development of the PFC regions structurally and functionally related with the STG 
by the virtue of disrupted mutual trophic influence on establishing axonal 
connections (Caviness and Takahashi, 1995) and/or programmed synaptic 
pruning (Keshavan et al., 1994). Grey matter losses throughout childhood and 
adolescence are concentrated in the frontal and parietal but not in the temporal 
and occipital cortical areas in normal brain development (Rapoport et al., 1999). 
Therefore, reductions in the IFG volume might be due to the failure to establish 
distant synaptic connections, leading to overpruning of synapses, and thus 
reduced volume. 
The present investigation did not observe alterations in the volume of the medial 
temporal lobe structures in schizophrenia patients. The abnormality of the 
hippocampal complex in particular is a central feature of many accounts of 
schizophrenia pathogenesis and pathophysiology (e. g. Torrey and Peterson, 
1974; Conrad and Scheibel, 1987; Weinberger and Lipska, 1995; Gothelf et al., 
2000). Data from schizophrenia patients (Gothelf et al., 2000) suggest that 
developmental abnormalities of the hippocampus may be aetiological. In addition, 
excitotoxic lesion of the ventral hippocampus in rodents and primates leads to 
behavioural and neurophysiologic defects similar to those seen in affected 
humans (Lipska et al., 1995; Bachevalier et al., 1999). The studies of 
monozygotic twins discordant for schizophrenia consistently demonstrate smaller 
hippocampal volume in the affected twin (Suddath et al. 1990; McNeil et al. 
2000; Baare et al., 2001), with this difference most likely being due to non- 
genetic factors such as obstetric complications (McNeil et al., 2000). Supporting 
this argument, Stefanis et al. (1999) reported hippocampal volume reductions in 
patients with no familial history of schizophrenia but with the history of obstetric 
complications relative to the patients with familial history of schizophrenia but 
without the history of obstetric complications and normal controls. In a more 
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recent study from the same laboratory Schulze and co-workers (2003) showed 
that the association between obstetric complications and hippocampal volume is 
not confined to patients with no familial history, but is also observed in patients 
with familial history. Therefore, the inconsistency of the evidence for the 
hippocampal involvement across neuroimaging (reviews, Nelson et al., 1998; 
Shenton et al., 2001) and post-mortem studies (review Dwork, 1997) might be 
due to the inclusions of the subjects with and without the history of obstetric 
complications. In the present investigation, obstetric history of the participants 
was not available. If the majority of the patients in the present cohort did not 
have obstetric complications or, alternatively, there was a similar number of 
patients and normal controls exposed to obstetric complications, these sample 
compositions might explain the negative finding in relation to the hippocampus. 
Future studies of schizophrenia pathophysiology need to include the history of 
obstetric complications as a confounding variable to control for its putative 
relationship with hippocampal volume. In addition, as discussed in Chapter 5, the 
VBM technique might not be sensitive enough to identife hippocampal changes 
due to the difficulty in differentiating grey and white matter in these areas 
(Velakoulis et al., 1999; Ashburner and Friston, 2000). However, some of the 
previous VBM studies have implicated medial temporal structures in schizophrenia 
patients using similar methodology (e. g. Wright et al., 1999; Job et al., 2002; 
Kubicki et al., 2002; Suzuki et at., 2002). 
The findings of the present thesis do not provide support for the structural 
volume pathology of either thalamus or cerebellum in schizophrenia. Andreasen 
et al. (1996; 1998; 1999) proposed that schizophrenia might be characterised by 
abnormal connectivity between prefrontal cortex, thalamic nuclei, and the 
cerebellum. This abnormal cortico-cerebellar-thalamo-cortical circuitry (CCTCC) 
will functionally manifest as cognitive dysmetria, i. e. disruption in processing, 
prioritising, retrieval, coordination, and responding to information. An attractive 
feature of the model proposed by Andreasen is that cognitive dysmetria, as a 
disorder of the CCTCC, may provide a heuristic theoretical framework for 
strategies to explore aetiology, pathophysiology, intervention, and prevention of 
schizophrenia. One of the long-lasting controversies about schizophrenia, as 
discussed in Chapter 1, is whether there is a unifying phenotype underlying the 
condition or whether it is a heterogeneous disorder. Cognitive dysmetria model 
offers a unifying framework, defining schizophrenia phenotype by a specific 
abnormality of a functional neuronal circuit, which can potentially produce a 
diversity of symptoms characteristic of schizophrenia. There is some support for 
the model from the functional imaging studies using 
both PET (e. g. Andreasen et 
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al., 1996; Wiser et al., 1998; Crespo-Facarro et al., 1999) and fMRI (e. g. 
Schlosser et at., 2003) that demonstrated disrupted function of CCTCC in 
schizophrenia patients during rest and cognitive activation paradigms. 
Morphometric MRI studies from Andreasen's laboratory have reported abnormal 
volumes of the thalamus (Andreasen et al., 1994) and the cerebellar vermis 
(Nopolous et al., 1999) in schizophrenia patients. Investigators from an 
independent laboratory (Volz et al., 2000) have confirmed thalamic and cerebellar 
abnormalities in the same sample of patients using deformation-based 
morphometry. However, only one study using VBM (Ananth et al., 2002) 
observed thalamic reduction in schizophrenia and two studies reported grey 
matter increases in the cerebellum (Wilke et al., 2001; Suzuki et al., 2002), 
which might be more prominent in affected women (Suzuki et al., 2002). The 
present investigation adds to the negative findings in relation to thalamic and 
cerebellar structural pathology in schizophrenia. However, it should be noted that 
the measurement of thalamic nuclei using either ROI or VBM approaches is 
complicated by the fact that the grey/white matter segmentation is problematic in 
this region due to the blurred boundaries between two tissue types. Magnotta 
and co-workers (2000) developed new MR pulse sequence, cortex attenuated 
inversion recovery, which increases the contrast-to-noise in MRI scans allowing 
the imaging of the individual thalamic sub-nuclei. Perhaps future studies using 
this acquisition sequence will either confirm or refute the presence of thalamic 
reduction in schizophrenia. In addition, thalamic reduction might be confined to 
the patients with earlier onset, as found by two studies (Corey-Bloom et al., 
1995; Jeste et al., 1998). Since patients of the present cohort had the average 
age of onset in early adulthood, they might not present with significantly smaller 
than normal thalami. 
Finally, the important contribution of the present thesis to the field of 
schizophrenia research is the demonstration that the standard VBM protocol using 
MNI template may not be adequate for the pre-processing of the structural 
images of individuals with schizophrenia. The present investigation could not 
determine, considering the time constraints, weather the misregistration was the 
result of the use of the MNI template or the standard protocol or the combination 
of both. The misregistration had most likely occurred due to the enlarged 
ventricles of schizophrenia patients, which led to the distortion of the grey matter 
surrounding them during the spatial normalisation. Optimised protocol with 
customised template has rectified the problem. Future research may want to 
systematically vary the parameters of the pre-processing steps to determine the 
influence of different factors on the pre-processing accuracy. This question is of 
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great practical importance, since the standard protocol is much less time and 
computer consuming. If it were to be shown that customised template including 
the sca sans from patients is the deciding factor, the application of the standard 
protocol might be the desired option for the researchers. In addition, Wilke et al. 
(2003) have shown that less manipulation of the images leads to better detection 
of the cortical grey matter malformations in the temporal lobe epilepsy. It is not 
known whether the same applies to the detection of structural alterations in 
patients with schizophrenia. 
In summary, the findings of the present investigation on structural brain 
alterations in schizophrenia provide further evidence for the reduced volumes in 
heteromodal association areas of ventrolateral prefrontal and lateral temporal 
cortices of schizophrenia patients that have long been implicated in schizophrenia 
pathophysiology. In addition, the present investigation adds evidence for the 
increased volume of recently implicated precuneus, as well as strengthens the 
evidence for the compromised integrity of the primary visual cortex. Present 
findings do not implicate medial temporal structures, thalamus, or cerebellum in 
schizophrenia, failing to provide evidence for the theories that proposed 
hippocampal complex or CCTCC circuitry to be central to understanding aetiology 
and pathophysiology of schizophrenia. The only sub-cortical structure found to be 
altered was left putamen, which was larger than normal. Finally, the present 
investigation was the first to compare standard and optimised VBM protocols in 
the same sample of schizophrenia patients, and found standard protocol to result 
in misregistration of the different brain tissues, raising important questions for 
the previous and future research. 
5.4.1. Cognitive Deficits 
The present investigation, in accordance with previous studies, has found that 
schizophrenia patients show deficits in many cognitive domains, including verbal 
and non-verbal learning and memory, verbal working memory, attention, 
executive function, verbal fluency, psychomotor processing, and speed of 
information processing. It is still poorly understood whether findings of the 
compromised function in this various domains reflect the presence of one 
underlying global cognitive deficit, or whether they each represent a discrete 
cognitive factor. If there were discrete cognitive deficits, one would expect that 
various cognitive deficits in patients occur both independent of each other and 
independent of IQ. The findings of the present investigation suggest that only 
fine motor function and visuo-spatial memory deficits could be explained by the 
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levels of general intelligence. The deficits in other cognitive functions were shown 
to be either completely independent or only partially related to IQ level. Further, 
logistic regression analyses showed that three domains, namely verbal working 
memory, verbal learning, and the speed of information processing (colour 
naming) had independently differentiated patients and controls. Krabbendam and 
co-workers (2001) have identified these three domains as familial cognitive risk 
factors in schizophrenia. They assessed neuropsychological function in 
schizophrenia patients, their first-degree relatives, and normal controls and found 
that speed of information processing, working memory, and episodic memory 
independently discriminated patients and their unaffected relatives from normal 
controls, with the degree of the impairment having a different order of magnitude 
in patients and their relatives. Therefore, these domains might represent 
cognitive vulnerability indicators underlined by genetic mechanisms. If future 
studies were to confirm the findings of Krabbendam et al. and the present 
investigation in singling out these cognitive domains as signatures of 
schizophrenia, this potentially may lead to the development of better screening 
for prodromal cases and preventive strategies, reducing the incidence rates and 
improving outcome in individuals vulnerable for schizophrenia. Furthermore, 
Lewis (2004) has argued that cognitive dysfunction should be included as a 
diagnostic criterion for schizophrenia. Tsuang et al. (2002a, 2002b) proposed 
including a new category of ""schizotaxia" in the next addition of the DSM, which is 
defined as a state of vulnerability or predisposition to develop schizophrenia. 
They proposed that DSM criteria for such a category would incorporate biological 
and neuropsychological abnormalities. The results of the present investigation 
showed that the deficits in verbal learning and memory, working memory and 
speed of information processing correctly predicted 31 out of 33 or 94% of 
schizophrenia patients. Lewis (2004) argued that the inclusion of the cognitive 
criterion may ""enhance the predictive utility of the existing non-specific DSV 
criteria for schizophrenia, particularly in early psychosis, in which it is so difficult 
to make the diagnosis based purely on psychotic symptoms and impairment of 
functioning" (p. 110). Indeed, two subjects from the patient group who were 
misclassified (using linear regression) as `normal controls' were first episode 
psychosis patients, who did not present with as severe deficits of working 
memory, verbal learning and memory, and the speed of information processing 
as other two first-episode or chronic patients. Future studies should evaluate the 
specificity of these cognitive impairments to schizophrenia by i) cross-sectionally 
comparing schizophrenia patients with those holding different psychiatric 
diagnoses, particularly affective disorders; and ii) longitudinally assessing 
whether first-episode psychosis patients with and without these cognitive deficits 
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subsequently receive schizophrenia or 'lighter' diagnosis. If reliability and 
diagnostic specificity of this triad of neuropsychological abnormalities were to be 
established by future research, its inclusion as a criterion for schizophrenia might 
indeed prove useful for the diagnosis and prevention. 
5.4.2. Structure/Cognition Relationship 
Supporting the conclusion of the review of the structure/function relationship 
(Chapter 2, Antonova et al., 2004) and the hypothesis of study 7, the findings of 
the present investigation showed that global structural alterations tend to 
associate with global cognitive deficits such as IQ and specific cognitive deficits 
that were not independent of IQ levels, whereas regional structural alterations 
tend to associate with specific cognitive deficits, that are wholly or partially 
independent of IQ levels. This pattern of associations makes good theoretical 
sense and suggests that the wide spectrum of cognitive deficits in schizophrenia 
cannot be simply explained by the global reduction of the brain tissue. It also 
argues against the notion that the deficient performance of schizophrenia patients 
on almost all cognitive domains can be simply explained by the generalised 
deficit. The data of the present thesis argue against such notion, and indicate 
that both hold true - i. e. specific cognitive deficits as manifestations of alterations 
in specific brain regions against the background of generalised cognitive deficits 
as a manifestation of global brain tissue reduction. 
However, the enthusiasm of this conclusion is dampened by the fact that 
although some specific structure/function associations were found, generally 
there was a relative lack of associations between structural alterations and 
cognitive deficits. Noticeably, the pattern of cognitive deficits is more diverse than 
the pattern of structural alterations identified in the present cohort. Cognitive 
deficits of verbal working memory, sustained and selective attention, 
perseveration, visuo-spatial memory, and psychomotor speed did not associate 
with any of the structural alterations. It is possible that individual patients have 
alterations in different `nodes' constituting the functional neural systems 
associated with these cognitive processes, making it impossible to identify the 
'source' of these deficits at the group level. Alternatively, cognitive deficits might 
result due to the abnormal neurochemical transmission (this is more likely given 
the improvement with atypical antipsychotics and rather subtle and heterogenous 
stuctural alterations in schizophrenia) and/or altered effective connectivity 
between different brain regions. Future studies should combine functional and 
structural MRI as well as receptor imaging methods for the study of cognitive 
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dysfunction in schizophrenia to disentangle these possibilities. Finally, the 
present investigation assumed linear relationship between structural alterations 
and cognitive deficits, which might not necessarily be the case. Future studies 
should investigate the possibility of more complex relationship between structural 
alterations and cognitive functioning in both affected and unaffected individuals. 
One of the most intriguing conclusions from the review of the structure/cognition 
relationship in schizophrenia presented in Chapter 2 (also see Antonova et al., 
2004) was that structure/cognition relationship might be altered in schizophrenia 
patients. This conclusion was tentative since no previous research has formally 
investigated the differences in structure/cognition associations between patients 
and normal controls. Study 3 of the present thesis has directly tested the 
hypothesis that structure/cognition relationship is altered in schizophrenia and 
has found dissociation between patients and controls in the relationship between 
brain structure and learning & memory. This finding is interesting on the 
following account. Functional imaging studies, using PET and fMRI, have 
repeatedly found that schizophrenia patients underactivate brain areas that are 
active in controls, but also activate alternative brain areas, usually called by the 
researchers 'compensatory', during performance of various cognitive tasks. For 
example, Wiser and co-workers (1998) found that although schizophrenia 
patients and controls reached a similar level of performance on a word 
recognition task, they appeared to have achieved this goal using a different 
neural network. Compared to controls, patients' frontal cortex, precuneus, 
posterior cingulate gyrus, visual cortex and cerebellum showed less of an increase 
in rCBF in response to the task, whereas the anterior cingulate, the pre-and post- 
central gyrus, the putamen, the superior and inferior temporal gyri and the 
fusiform gyrus exhibited larger increases in rCBF in response to the same task. 
Similarly, Crespo-Facorro and co-workers (1999) observed underactivation of the 
left IFG, right anterior cingulate, right bilateral cerebellum in patients during 
recall of novel and practiced word lists, but noted an increased blood flow in the 
left parietal lobe during both tasks that was not observed in controls. Kim and 
colleagues (2003) using PET observed dorsolateral prefrontal activation in healthy 
subjects, and ventrolateral prefrontal activation in the schizophrenic patients 
during a working memory task. Further, prefrontal cortex activation in normal 
controls was significantly correlated with activation in the bilateral inferior parietal 
region, but was not correlated with any regional activation in patients. Differences 
in activation patterns were also reported for the relatives of schizophrenia 
patients relative to normal controls. Thus, Spence and colleagues (2000) 
conducted a PET study of obligate-carrier relatives performing a verbal fluency 
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task and found less functional connectivity between left PFC regions (including 
IFG, BA 45/47) and the precuneus, with activation in the right PFC that was not 
seen in normal controls. Taken together, these findings suggest that 
schizophrenia patients and their relatives show altered brain function relative to 
healthy individuals during performance of the tasks requiring higher cognitive 
processes. 
What might explain such an alteration of brain activations in the functional 
studies? The findings of the present investigation suggest that the reduced 
volume of the structure might lead to the loss of its function. This may manifest 
as a reduced activation of this brain structure in functional imaging studies. Thus, 
the IFG volume was found to associate with learning and memory in normal 
controls, an association that would be expected from the data obtained by 
functional imaging studies. In patients, however, the IFG volume, which showed 
the greatest reduction, did not associate with performance on learning and 
memory tasks. Instead, better verbal learning in patients was associated with 
larger precuneus. Therefore, the underactivation in brain area in schizophrenia 
patients relative to healthy individuals might be due to the loss of the structural 
integrity in this area. Therefore, future studies of functional brain imaging in 
schizophrenia should correct for grey matter volume of the regions that show 
altered activation pattern, similarly to proposed correction for the brain atrophy 
for studying elderly and demented patients (Herscovitch et al., 1986; Schlageter 
et al., 1987). 
Another novel finding of the present investigation is that the deficit in the speed 
of information processing measured by the tasks involving visual processing 
(reading colour names and naming colours) was associated with the white matter 
reduction of the primary visual cortex, which might include the optic radiation of 
the optic tract, connecting lateral geniculate nucleus of the thalamus with the 
primary visual areas as well as white matter fibres inter-connecting different 
areas of the visual cortex. This finding challenges the assumption that cognitive 
deficits characteristic of schizophrenia arise primarily as a result of the integration 
failure in the heteromodal association cortices (e. g. Pearlson et al., 1996), and 
points to the abnormalities earlier on in the information transfer of the sensory 
information to the primary sensory cortex and/or an integration of the sensory 
input within the primary sensory cortex (visual in this case) contributing to the 
cognitive dysfunction in schizophrenia. 
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5.4.3. Structural Alterations and Treatment Response 
The investigation of the question as to whether structural alterations are 
predictive of treatment response with atypical antipsychotics produced more 
questions than answers. The present investigation was the first to address the 
predictive value of structural alterations in cognitive response to the atypical 
antipsychotic treatment. Previous research concentrated on predicting symptom 
improvement and found larger brain volumes to associate with greater clinical 
response (see Chapter 4). The present investigation tested the hypothesis that 
less alteration of structural volumes would be predictive of greater cognitive 
improvement with atypical antipsychotic treatment. The findings of the present 
investigation showed that smaller IFG and precuneus volumes were associated 
with greater improvement in verbal learning and memory. 
One thing to note is that the relationship between the volumes of IFG and the 
precuneus on the one hand and verbal learning and memory on the other hand in 
schizophrenia patients reoccurs in different contexts in the results of the present 
investigation. Larger precuneus was found to be related to verbal learning at the 
baseline, but it was patients with smaller precuneus who benefited most from the 
atypical antipsychotic treatment in terms of episodic memory function. This 
pattern of results could not be explained by the ceiling effect, as this possibility 
was refuted in the analysis of study 4 (Chapter 8). Moreover, patients with 
smaller precuneus had greater decrease in positive symptoms than patients 
whose precuneus was enlarged relative to normal controls. Related to that, there 
was a relationship between larger precuneus and the number of psychotic 
episodes (Study 1, Chapter 5). As has been speculated in the discussion of study 
4, patients with larger precuneus might experience treatment resistant, with both 
conventional and atypical antipsychotics, psychotic symptoms leading to a greater 
number of acute psychotic episodes, but better episodic memory due to the 
increased `vividness' of mental experiences afforded by larger precuneus. 
Patients with smaller, more 'normal' precuneus volume seem to benefit from 
atypical medication in terms of both reductions in reality distortion and improved 
verbal memory function. The mechanism of such action of atypical antipsychotics 
is not clear, since not much is known about the functional role of the precuneus 
and the effect of different neurotransmitters on the function of this structure. 
The relationship between smaller IFG volume and greater improvement in verbal 
memory is difficult to explain. A few possible explanations were offered in the 
discussion of Study 4 (Chapter 8), but none were deemed satisfactory. Studies 
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are needed to replicate or refute this finding before an understanding can be 
reached. 
Two other cognitive domains were found to be improved with atypical 
antipsychotics treatment in the present investigation, working memory and 
dexterity. There were no structural predictors of this improvement. Noteworthy, 
working memory was not predicted by any structural volumes at the baseline and 
did not have any structural predictors at 6 weeks, despite being a cognitive 
domain with the strongest differentiating power for the schizophrenia diagnosis. 
The improvement on working memory function was quite marked, over 1,5 sd. 
Most significantly from the therapeutic point of view, when differences in IQ 
between the patients and the controls were accounted for, patients' performance 
as a group did not differ from that of the control group. This suggests that 
although working memory is one of the most severely affected cognitive domains 
in schizophrenia, it can be dramatically improved by the treatment with atypical 
antipsychotics. This is a very encouraging finding indeed. Verbal working 
memory has been repeatedly found to predict occupational and independent living 
success in schizophrenia (review, Sharma and Antonova, 2003). Dexterity was 
found to predict patients with rehabilitation potential (Weaver and Brooks, 1964). 
The ameliorating effect of atypical antipsychotics on these functions will mean the 
reduction in the cost of this debilitating illness for an individual and the society. 
On the positive side, the fact that improvement in working memory and dexterity 
was not related to the severity of the structural alterations in the present 
investigation, at least not those that could be identified on the group level, does 
not limit the beneficial effects of atypical antipsychotics to patients with less 
severely affected neurophysiology. 
An important contribution of the present investigation to schizophrenia research is 
the finding that cognitive improvement with atypical antipsychotics could be 
observed despite relatively low doses of haloperidol as a comparator. As 
discussed in Chapter 8, one of the ongoing controversies in relation to atypical 
superiority on cognition relative to typical antipsychotics is whether these effects 
can be demonstrated relative to low doses of haloperidol. The initial findings of 
cognitive superiority of atypical antipsychotics relative to conventional ones where 
challenged by the fact that low doses of typical antipsychotics do not have 
detrimental effects on cognitive function. Moreover, it has been shown that 
atypical antipsychotics display no superiority over lower doses of typical 
antipsychotics (Green et al., 2002; Keefe et al., 2004). The results of the present 
study suggest that atypical antipsychotics effect on cognition could not be simply 
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explained by the typical antipsychotic dose, since patients in the present study 
were on low doses of conventional medications, which were comparable to those 
used in Keefe et al. study. Neither they can be explained by the reduction in 
motor disorders associated with conventional antipsychotics, since, as discussed 
before, the motor side effect ratings were initially low and no further 
ascertainable change occurred. The discontinuation of anticholinergic medication 
might have played a role, since none of the patients required anticholinergic 
medication with atypical antipsychotics at 6 weeks. However, anticholinergic 
medication was only found to associate with LM performance in Study 2 (Chapter 
6), but not with the tests that showed improvement in the present study. 
Although the present investigation cannot decisively answer the question as to 
whether the superior effect of atypical antipsychotics on cognitive function is due 
to their pharmacological properties or release from deleterious effects of 
conventional neuroleptics, it does show that better cognitive functioning can be 
achieved with atypical antipsychotics, particularly on the cognitive domains that 
have been consistently linked with functional outcome in schizophrenia. 
9.5. Methodological Considerations 
Methodological limitations of the individual studies have been listed in the 
discussion sections of these studies. There are, however, a few methodological 
considerations that limit overall genera Iisability of the findings of the present 
investigation. First, the sample of schizophrenia patients recruited for the studies 
consisted of predominantly paranoid patients; therefore, the present findings 
might not apply to other clinical sub-types. In addition, most patients were living 
in the community and thus relatively well functioning, which limits the 
generalisability of the present findings to the patients with relatively good 
outcome. 
Second, the possibility that there might be gender differences in the pattern of 
structural alterations and the relationship of these alterations to cognitive deficits 
and treatment response cannot be excluded. The sample size was not large 
enough to allow separate analyses for male and female patients. However, 
gender was controlled for in all analyses. Therefore, the observations reported in 
this thesis are applicable to schizophrenia patients regardless of gender. 
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Third, the groups were not perfectly matched on all demographic criteria, such as 
age. However, confounding effects of age were controlled for by performing 
ANCOVAs. 
Fourth, subtle abnormalities in cellular orientation, structural connectivity, 
receptor distribution and sensitivity, and neurotransmitter distribution, among 
other factors, are not detectable by MRI. Therefore, the power to identify 
structural alterations in the present cohort was limited by the chosen method of 
study, with all the obvious limitation for the rest of the findings. For example, 
cellular and neurotransmitter abnormalities that have been reported in the 
DLPFC, hippocampus, thalamus, anterior cingulate and other brain regions of 
schizophrenia patients could not be detected using methods utilised in the 
present investigation. Furthermore, the VBM may not detect very small grey 
matter reductions, grey matter reductions in areas of high variability in grey 
matter volume, or grey matter recutions with an inconsistent location, leading to 
type 2 errors. The structural alterations identified in the present investigation 
should be viewed as regional differences representing foci of maximal change, 
rather than regions that are exclusively or selectively affected. Therefore, there 
might be structural abnormalities that have a relationship to cognitive deficits in 
the present cohort of paitents, but could not be identified in the present 
investigation due to methodological limitations. 
A final issue concernes the assumption that structure/function relationship can be 
studied using standard neuropsychological tests. Since these tests were 
developed for the assessment of cognitive disturbances occurring due to brain 
lesions of either surgical or organic origin that tend to be quite extensive and 
generally involve several cognitive processes interacting with each other for the 
optimal task performance, it might be unreasonable to expect that they can be 
'mapped' accurately onto brain volumes with high spatial resolution as allowed 
with VBM. The future challenge lies in developing tests that might be more 
adequate for addressing research question posited by the present investigation. 
9.6. Future Directions 
The present thesis has identified a number of research questions for future 
investigations. Most intriguingly, present data suggest an emerging role of the 
precuneus in schizophrenia. This structure has not been previously considered in 
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theoretical accounts of schizophrenia pathology, and neglected by the ROI 
studies. It has only recently been implicated as a site of brain pathology in 
schizophrenia using VBM method, with increased availability of grey matter 
(however, Shapleske et al (2002) have found a decrease). The findings of the 
present investigation implicate the increased volume of the left precuneus as 
having a beneficial effect on verbal memory and learning in schizophrenia, the 
function that is most severely affected in the majority of the patients. 
Furthermore, increased volume of the precuneus appears to be related to the 
recurrent form of psychotic symptoms as well as treatment response with atypical 
antipsychotics. Yet, the role of the precuneus even in normal cognition is 
presently poorly understood. The activation of the precuneus is noted during 
wide variety of cognitive functions, for example, spatial learning (Parsons et al., 
2005), memory for time (Harrington et al., 2004), visual search and memory 
search (Makino et al., 2004), visuomotor tracking (Brown et al., 2004), and 
episodic memory retrieval (e. g. Mayes et al., 2004). There does not seem to be a 
full understanding of the conditions determining its activity. As has been 
discussed in Chapter 7 (Study 3), Fletcher and co-workers (1995) advanced a 
unifying theory of the precuneus function, i. e. that of a mind's eye. They have 
shown that the precuneus is a key part of the neural substrate of visual imagery 
serving the purpose of episodic memory retrieval. If this theory is correct, it is 
possible that an enlarged precuneus might manifest phenomenologically as the 
increased vividness of one's imagery, which can be pathologically expressed as 
the bluring of boundaries between what is real and what is imagined. In fact, 
Frith (1992) proposed that positive symptoms of schizophrenia such as 
hallucination, delusions of alien control, and thought insertions in patients with 
schizophrenia could stem from reality-monitoring deficits. Reality monitoring is 
defined as the discrimination between an event produced by oneself vs. external 
source, and the discrimination between an imagined vs. real event. Bental and 
Slade (1985) were first to demonstrate a relationship between hallucinations and 
a failure to discriminate imaged from real events in schizophrenia patients, and 
Rankin and O'Carroll (1995) replicated this result in healthy individuals prone to 
hallucinations. Frank et al. (2000) found that schizophrenia patients with auditory 
hallucinations had an increased tendency to report that words that had been read 
silently had been spoken aloud. Brebion and co-workers (2000) confirmed that 
patients with hallucinations and/or delusions prone to mistake mental images for 
perceived pictures. Interestingly, Bar et al. (2002) reported an fMRI investigation 
of a 53 year-old women diagnosed with schizophrenia, who showed elevated 
activity in medial parietal area, overlapping with precuneus, when experiencing 
tactile hallucinations, but not when similar tactile stimulation was applied to her 
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body by the experimenter. Therefore, it is possible that the role of the precuneus 
in hallucinatory experiences might arise due to it being a part of a network 
important for monitoring agency, i. e. whether actions are self-produced or 
generated by others. Enlarged precuneus might lead to reality-monitoring 
failures by producing an abnormal salience of imagined content (possibly 
independent of modality, as data seem to suggest). Abnormal precuneus might 
also be related to another positive symptom, formal thought disorder (FTD), since 
Erkworth et al. (2002) have observed significant activation in the right precuneus 
in patients with positive, but not negative, FTD during selective attention task 
using PET. The authors have speculated that schizophrenia patients with positive 
FTD may rely on the encoding process ascribed to the precuneus (comparison and 
response selection via the use of imagery). Further supporting the link between 
precuneus, positive symptoms, and memory, Kindermann and colleagues (2004) 
have recently observed that schizophrenia patients with more positive symptoms 
on the PANSS showed greater activation during spatial memory task in the right 
precuneus. It is also known that patients with predominantly positive symptoms, 
i. e. of paranoid type, show less severe impairment on the tests of episodic 
memory (review, Zalewsky et al., 1998). Finally, there is evidence suggesting 
that overactived precuneus is associated with the disease process itself rather 
than mere genetic predisposition. Spence et al. (2000) have observed 
significantly more activated precuneus during verbal fluency task in patients with 
schizophrenia than either in their unaffected obligate-carrier relatives or unrelated 
healthy controls. The tentative link between the volume of the precuneus, 
positive symptoms (e. g. hallucinations, delusions, and formal thought disorder), 
reality monitoring, and episodic memory should be addressed in future research 
comparing schizophrenia patients, their obligate-carrier relatives, and individuals 
with schizotypy. 
Future functional imaging studies will need to address the question of altered 
brain function in schizophrenia. In most fMRI studies using cognitive activation 
paradigms it is a 'peculiar' feature noted about brain function of schizophrenia 
patients. The brain regions activated in schizophrenia but not in controls are 
generally explained away as compensatory networks. It is possible that the 
existence of this 'altered' brain functioning might shed light on schizophrenia 
aetiology. Systematic investigation of the conditions under which differences in 
activation patterns emerge between schizophrenia patients and healthy 
individuals, as well as systematic investigation of the areas constituting these 
'alternative' networks may lead to new insights about the nature of schizophrenia. 
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Future investigation of the relationship between brain pathophysiology, cognitive 
(dys)function, and treatment response in schizophrenia should ideally combine 
different MR imaging modalities, such as functional, structural and chemical shift 
(a type of MR spectroscopy in which spatially localised spectra are obtained using 
techniques derived from MR imaging), in the same cohorts of patients and with 
longitudinal design in order to further address the issues raised by the present 
investigation and to advance our understanding of this complex disorder. 
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APPENDIX I 
""The Relationship between Brain Structure and Neurocognition in 
Schizophrenia: a Selective Review" 
Schizophrenia Research (2004), 70(2-3): 117-45. 
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ADDENDUM 
To reduce the multiple comparison problem in the analysis of the relationship 
between structural alterations and cognitive deficits performed in Study 3 
(Chapter 7), the data were reanalysed using stepwise multiple linear regressions 
with cognitive deficits as dependent variables and structural alterations as 
independent predictors to determine which global or regional structural volume 
alterations were the best predictors of cognitive deficits, adjusting for age and 
sex. To minimize the chance of false positive errors, the predictors were 
considered to be significant at p <. 025, as in Study 3. To examine the issue of 
altered structure/neurocognition relationship in schizophrenia, partial r 
coefficients, adjusted for age and sex, for each significant (at p<. 025) structural 
predictor of a neuropsychological variable were extracted from the stepwise 
multiple regression analysis and contrasted between the groups using Fisher z 
transformations (Fisher 1921), as in Study 3. This method produced the same 
results as reported in Study 3 (Chapter 7). 
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